news_id,ticker,ticker_url,title,link,published_date,company,event,reason,publisher,industry,publisher_topic,instrument_id,yf_ticker,published_date_gmt,timezone,publisher_summary,predicted_side,predicted_move,language
15439,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report,https://www.globenewswire.com/news-release/2020/12/17/2146815/0/en/Annovis-Bio-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html,2020-12-17 06:45:00+00:00,Annovis Bio,clinical_study,"The likely cause of the predicted upward move of +18.75% is increased visibility from the CEO's interview on The RedChip Money Report, enhancing investor interest. This could lead to increased trading volume and potentially attract new investors.",globenewswire_biotech,biotech,Company Announcement,296,ANVS,2020-12-17 11:45:00+00:00,US/Eastern,"BERWYN, Pa., Dec.  17, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.",UP,0.1874526724944866,en
15438,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio to Present at the BIO CEO & Investor Digital Conference,https://www.globenewswire.com/news-release/2021/02/16/2175895/0/en/Annovis-Bio-to-Present-at-the-BIO-CEO-Investor-Digital-Conference.html,2021-02-16 06:45:00+00:00,Annovis Bio,conference_call_webinar,"The predicted upward move of +0.07% for Annovis Bio Inc. is likely due to increased visibility from their presentation at the BIO CEO & Digital Conference. Such events can enhance investor interest and confidence, potentially positively impacting the stock's market perception.",globenewswire_biotech,biotech,Calendar of Events,296,ANVS,2021-02-16 11:45:00+00:00,US/Eastern,"BERWYN, Pa., Feb.  16, 2021  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021. Annovis Bio’s presentation will be accessible on demand during the virtual event for all registered attendees.",UP,0.0006896303971602915,en
15419,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer,https://www.globenewswire.com/news-release/2022/04/26/2429037/0/en/VBL-Therapeutics-Receives-FDA-Fast-Track-Designation-for-Ofra-Vec-for-the-Treatment-of-Platinum-Resistant-Ovarian-Cancer.html,2022-04-26 08:00:00+00:00,Vascular Biogenics,clinical_study,"The likely cause of the predicted upward move of +11.61% is the FDA granting Fast Track designation for VBL Therapeutics' treatment. This designation can accelerate drug development, potentially boosting investor confidence and increasing demand for VBLT shares.",globenewswire_biotech,biotech,Product / Services Announcement,295,VBLT,2022-04-26 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, April  26, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.",UP,0.11613714917301339,en
15418,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2022/04/28/2431973/0/en/VBL-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2022-04-28 16:05:00+00:00,Vascular Biogenics,corporate_action,"The predicted upward move of +0.28% likely stems from investor optimism regarding the strategic hiring and stock option grant by VBL Therapeutics. This action could enhance the company's operational capabilities, potentially boosting its prospects in the biotechnology market.",globenewswire_biotech,biotech,Stock Market News,295,VBLT,2022-04-28 20:05:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, April  28, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective April 24, 2022 of a non-qualified stock option to purchase an aggregate of 75,000 ordinary shares of VBL as an inducement material to the hiring of a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4).",UP,0.0027629736629412043,en
15417,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May,https://www.globenewswire.com/news-release/2022/05/03/2434479/0/en/VBL-Therapeutics-to-Participate-in-Upcoming-Scientific-and-Industry-Conferences-in-May.html,2022-05-03 08:00:00+00:00,Vascular Biogenics,clinical_study,"The predicted upward move of +18.41% is likely due to VBL Therapeutics presenting promising data on VB-601 and increased visibility at key industry events. Such advancements can drive investor interest, potentially boosting stock price and market confidence.",globenewswire_biotech,biotech,Calendar of Events,295,VBLT,2022-05-03 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, May  03, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022. In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 – May 26, 2022.",UP,0.18411712870449823,en
16403,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress,https://www.globenewswire.com/news-release/2022/05/04/2436067/0/en/Rain-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Progress.html,2022-05-04 16:01:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +17.27% is likely due to strong liquidity with a $123.2 million cash position. This robust cash runway could enhance investor confidence, potentially leading to increased stock demand and positive market sentiment.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,346,RAIN,2022-05-04 20:01:00+00:00,US/Eastern,– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 –,UP,0.172719702560049,en
15416,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17,https://www.globenewswire.com/news-release/2022/05/10/2439661/0/en/VBL-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-on-May-17.html,2022-05-10 08:00:00+00:00,Vascular Biogenics,financial_results,"1. The predicted downward move of -0.80% is likely due to investor anticipation or skepticism ahead of financial results. 2. This may lead to cautious trading or volatility, impacting investor sentiment and possibly affecting biotechnology sector valuations.",globenewswire_biotech,biotech,Calendar of Events,295,VBLT,2022-05-10 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, May  10, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.",UP,-0.00799097104843874,en
16623,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2022/05/12/2442407/0/en/NexImmune-Reports-First-Quarter-2022-Financial-Results-and-Provides-Business-Updates.html,2022-05-12 16:01:00+00:00,NexImmune,financial_results,The predicted downward move of -0.17% could be due to disappointing financial results or unmet market expectations for NexImmune. This minor decline might signal cautious investor sentiment but is unlikely to significantly impact broader market trends.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,357,NEXI,2022-05-12 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., May  12, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022.",UP,-0.0017106298486604923,en
15415,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2022/05/17/2444762/0/en/VBL-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html,2022-05-17 07:00:00+00:00,Vascular Biogenics,clinical_study,The likely cause of the predicted upward move of +7.98% is the anticipated submission of a BLA to the FDA following positive Phase 3 data. This could boost investor confidence and potentially increase market valuation for VBL's stock.,globenewswire_biotech,biotech,Calendar of Events,295,VBLT,2022-05-17 11:00:00+00:00,US/Eastern,"OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023",DOWN,0.07982150905528047,en
15414,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics to Participate in the Jefferies Healthcare Conference,https://www.globenewswire.com/news-release/2022/05/31/2453168/0/en/VBL-Therapeutics-to-Participate-in-the-Jefferies-Healthcare-Conference.html,2022-05-31 08:00:00+00:00,Vascular Biogenics,conference_call_webinar,"1. The predicted downward move of -0.09% could be due to investor skepticism about VBL Therapeutics' progress or recent announcements not meeting expectations. 2. This minor decline may indicate cautious sentiment, possibly affecting short-term investor confidence.",globenewswire_biotech,biotech,Trade Show,295,VBLT,2022-05-31 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, May  31, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.",UP,-0.0008570250707689343,en
16622,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers,https://www.globenewswire.com/news-release/2022/07/14/2480080/0/en/NexImmune-Announces-IND-Clearance-by-the-US-FDA-for-NEXI-003-for-the-Treatment-of-HPV-Related-Cancers.html,2022-07-14 16:09:00+00:00,NexImmune,clinical_study,"The predicted upward move of +3.23% is likely due to NexImmune receiving IND clearance for NEXI-003, boosting investor confidence. This development may increase market interest and potentially improve company's valuation, attracting more investment in biotechnology sector.",globenewswire_biotech,biotech,Clinical Study,357,NEXI,2022-07-14 20:09:00+00:00,US/Eastern,"GAITHERSBURG, Md., July  14, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors.  NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.",UP,0.032255402042383655,en
15413,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer,https://www.globenewswire.com/news-release/2022/07/19/2482252/0/en/VBL-Therapeutics-Announces-Top-Line-Data-from-Phase-3-OVAL-Trial-of-Ofra-Vec-in-Patients-with-Platinum-Resistant-Ovarian-Cancer.html,2022-07-19 16:01:00+00:00,Vascular Biogenics,clinical_study,The predicted downward move of -0.77% is likely due to the trial failing to achieve statistical significance in key endpoints like Progression Free Survival or Overall Survival. This outcome could weaken investor confidence and affect stock performance negatively.,globenewswire_biotech,biotech,Product / Services Announcement,295,VBLT,2022-07-19 20:01:00+00:00,US/Eastern,- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - - Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) -,DOWN,-0.0077351037911533495,en
15412,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Workforce Reduction,https://www.globenewswire.com/news-release/2022/08/02/2490344/0/en/VBL-Therapeutics-Announces-Workforce-Reduction.html,2022-08-02 08:00:00+00:00,Vascular Biogenics,corporate_action,"1. The predicted upward move of +0.26% is likely caused by VBL Therapeutics streamlining operations, reducing costs, and preserving capital. 2. This strategy could enhance financial stability, improving investor confidence and potentially boosting stock value.",globenewswire_biotech,biotech,Restructuring / Recapitalization,295,VBLT,2022-08-02 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, Aug.  02, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022.",UP,0.002617290797480741,en
16402,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma,https://www.globenewswire.com/news-release/2022/08/04/2492298/0/en/Rain-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-MANTRA-Trial-for-Milademetan-in-Liposarcoma.html,2022-08-04 08:00:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +0.82% is likely due to the Phase 3 MANTRA trial completing enrollment ahead of schedule, signaling strong execution. This may boost investor confidence, potentially increasing demand and enhancing the asset's market value.",globenewswire_biotech,biotech,Clinical Study,346,RAIN,2022-08-04 12:00:00+00:00,US/Eastern,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,UP,0.008180584952254903,en
16401,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma,https://www.globenewswire.com/news-release/2022/08/04/2492593/0/en/UPDATE-Rain-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-MANTRA-Trial-for-Milademetan-in-Liposarcoma.html,2022-08-04 10:47:00+00:00,Rain Therapeutics,clinical_study,The predicted downward move of -5.28% may be due to investor concerns about trial results or execution risks despite early enrollment completion. Market implications could include decreased investor confidence and potential volatility in related sector stocks.,globenewswire_biotech,biotech,Clinical Study,346,RAIN,2022-08-04 14:47:00+00:00,US/Eastern,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,UP,-0.052834474367508905,en
16400,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress,https://www.globenewswire.com/news-release/2022/08/04/2492761/0/en/Rain-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Progress.html,2022-08-04 16:05:00+00:00,Rain Therapeutics,financial_results,"The quarter-end cash position of $105.7 million suggests strong financial health, likely causing the predicted upward move of +0.35%. This may boost investor confidence, potentially attracting more investments and stabilizing future financial planning.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,346,RAIN,2022-08-04 20:05:00+00:00,US/Eastern,– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 –,UP,0.003468230253269011,en
15411,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options,https://www.globenewswire.com/news-release/2022/08/15/2498547/0/en/VBL-Therapeutics-Announces-Second-Quarter-2022-Financial-Results-and-Corporate-Process-to-Explore-Strategic-Options.html,2022-08-15 16:05:00+00:00,Vascular Biogenics,financial_results,"The predicted upward move of +0.05% is likely driven by investor optimism over strategic reviews to enhance shareholder value. Market implications may include increased investor interest and speculative buying, potentially stabilizing the asset's price in the short term.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,295,VBLT,2022-08-15 20:05:00+00:00,US/Eastern,Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor,UP,0.0005333480449482524,en
16621,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers,https://www.globenewswire.com/news-release/2022/08/15/2498560/0/en/NexImmune-Reports-Second-Quarter-2022-Financial-Results-and-Highlights-FDA-Clearance-of-IND-for-NEXI-003-for-the-Treatment-of-HPV-Related-Cancers.html,2022-08-15 16:05:00+00:00,NexImmune,financial_results,"NexImmune's positive Q2 2022 financial results likely sparked the predicted upward move of +1.29%. This suggests increased investor confidence, potentially enhancing the company's market position and attracting more investment in its immunotherapy innovations.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,357,NEXI,2022-08-15 20:05:00+00:00,US/Eastern,"GAITHERSBURG, Md., Aug.  15, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the second quarter of 2022.",UP,0.01294450706311369,en
16399,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference,https://www.globenewswire.com/news-release/2022/08/31/2507565/0/en/Rain-Therapeutics-to-Participate-in-Citi-s-17th-Annual-BioPharma-Conference.html,2022-08-31 08:00:00+00:00,Rain Therapeutics,conference_call_webinar,"The predicted downward move of -0.25% may be due to investor anticipation of negative outcomes or limited new information from Rain Therapeutics' participation in the BioPharma Conference. This could signal limited progress, impacting investor confidence. Expectations might readjust post-conference.",globenewswire_biotech,biotech,Calendar of Events,346,RAIN,2022-08-31 12:00:00+00:00,US/Eastern,"NEWARK, Calif., Aug.  31, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.",UP,-0.0024757115330582445,en
15410,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,https://www.globenewswire.com/news-release/2022/09/01/2508953/0/en/VBL-Therapeutics-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html,2022-09-01 16:30:00+00:00,Vascular Biogenics,observation_status,"1. VBL Therapeutics' predicted downward move of +nan% is likely due to non-compliance with Nasdaq's minimum bid price requirement. 2. This could lead to decreased investor confidence and increased selling pressure, affecting its market valuation and liquidity negatively.",globenewswire_biotech,biotech,Press releases,295,VBLT,2022-09-01 20:30:00+00:00,US/Eastern,"TEL AVIV, Israel and NEW YORK, Sept.  01, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 31, 2022, notifying VBL that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.",UP,-16.346660438108817,en
16620,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2022/09/09/2513482/0/en/NexImmune-to-Present-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html,2022-09-09 16:01:00+00:00,NexImmune,conference_call_webinar,"The predicted downward move of -1.05% for NexImmune may be due to investor anticipation ahead of Kristi Jones' presentation, signaling uncertainties about the company's strategic direction. Such movement implies cautious market sentiment impacting biotechnology stocks.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,357,NEXI,2022-09-09 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., Sept.  09, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.",DOWN,-0.01048476174921537,en
16423,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections,https://www.globenewswire.com/news-release/2022/09/12/2513917/0/en/ContraFect-Announces-Multiple-Publications-Highlighting-the-Potential-Utility-of-Lysins-for-the-Treatment-of-Bone-and-Joint-Infections.html,2022-09-12 07:32:00+00:00,ContraFect,clinical_study,"1. The predicted upward move of +1.60% is likely due to positive sentiment from the publication highlighting ContraFect's lysins' potential effectiveness against challenging infections. 2. This could lead to increased investor interest, anticipating future demand and potential market success.",globenewswire_biotech,biotech,Health,347,CFRX,2022-09-12 11:32:00+00:00,US/Eastern,"YONKERS, N.Y., Sept.  12, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of an editorial in the Journal of Bone and Joint Infection discussing the potential for each of the Company’s lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections (BJIs) due to their in vitro activity against coagulase-negative staphylococci (CoNS), the bacteria most frequently involved in implant-associated BJIs, and their potential for both local and systemic anti-biofilm activity. The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.",UP,0.016016879849298366,en
16619,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH),https://www.globenewswire.com/news-release/2022/10/06/2529360/0/en/NexImmune-Announces-Research-Collaboration-with-National-Institute-of-Neurological-Disorders-and-Stroke-NINDS-of-the-National-Institutes-of-Health-NIH.html,2022-10-06 07:00:00+00:00,NexImmune,partnerships,"The predicted upward move of +0.34% is likely due to positive market sentiment around the collaboration exploring EBV and HTLV-1 antigen-specific immune responses. This could lead to advancements in immunological disease treatments, positively impacting related assets.",globenewswire_biotech,biotech,Partnerships,357,NEXI,2022-10-06 11:00:00+00:00,US/Eastern,The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases,DOWN,0.003368196559790555,en
16398,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium,https://www.globenewswire.com/news-release/2022/10/26/2542176/0/en/Rain-Therapeutics-Announces-a-Poster-Presentation-at-the-34th-EORTC-AACR-NCI-Symposium.html,2022-10-26 14:04:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +12.20% likely stems from positive sentiment around Rain's presentation of milademetan's promising data at a key oncology symposium. This could enhance investor confidence, potentially leading to increased interest and investment in Rain Therapeutics.",globenewswire_biotech,biotech,Trade Show,346,RAIN,2022-10-26 18:04:00+00:00,US/Eastern,"NEWARK, Calif., Oct.  26, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.",UP,0.1220356408901599,en
16397,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022",https://www.globenewswire.com/news-release/2022/10/27/2542731/0/en/Rain-Therapeutics-to-Report-Third-Quarter-2022-Financial-Results-and-Highlights-of-Recent-Progress-on-November-10-2022.html,2022-10-27 08:00:00+00:00,Rain Therapeutics,earnings_releases_and_operating_results,"1. The predicted downward move of -1.00% could be due to investor uncertainty ahead of Rain Therapeutics' financial results announcement. 2. This may signal concerns about the company's financial health, potentially affecting investor confidence broadly in biotech stocks.",globenewswire_biotech,biotech,Calendar of Events,346,RAIN,2022-10-27 12:00:00+00:00,US/Eastern,"NEWARK, Calif., Oct.  27, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.",UP,-0.009986730634654512,en
16396,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2),https://www.globenewswire.com/news-release/2022/11/04/2548698/0/en/Rain-Therapeutics-Provides-Interim-Analysis-of-Phase-2-Basket-Trial-of-Milademetan-for-MDM2-Amplified-Advanced-Solid-Tumors-MANTRA-2.html,2022-11-04 07:55:00+00:00,Rain Therapeutics,clinical_study,"The predicted downward move of -3.13% is likely due to mixed clinical trial results, with only some patients showing positive responses. Market implications include potential reduced investor confidence and skepticism about milademetan's broader efficacy in MDM2-amplified patients.",globenewswire_biotech,biotech,Clinical Study,346,RAIN,2022-11-04 11:55:00+00:00,US/Eastern,"- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -",UP,-0.03127208508183879,en
16395,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Announces $50 Million Registered Offering of Common Stock,https://www.globenewswire.com/news-release/2022/11/04/2548723/0/en/Rain-Therapeutics-Announces-50-Million-Registered-Offering-of-Common-Stock.html,2022-11-04 08:00:00+00:00,Rain Therapeutics,shares_issue,"The predicted downward move of -0.87% is likely due to stock dilution from the new share offering. This could pressure existing stock prices down, impacting investor sentiment. It might also raise concerns over Rain's current cash burn rate and funding needs.",globenewswire_biotech,biotech,Other News,346,RAIN,2022-11-04 12:00:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  04, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per share, which is priced at the closing price on Nasdaq for Rain’s common stock on November 3, 2022. The shares of non-voting common stock are convertible into an equal number of shares of common stock, subject to beneficial ownership limitations. The gross proceeds to Rain, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50 million. The offering is expected to close on or about November 8, 2022, subject to customary closing conditions. Rain has granted the underwriters a 30-day overallotment option to purchase up to 1,286,449 additional shares of common stock at the offering price, less underwriting discounts and commissions.",DOWN,-0.008684299649057961,en
16394,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress,https://www.globenewswire.com/news-release/2022/11/10/2553752/0/en/Rain-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Progress.html,2022-11-10 16:05:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +17.27% is likely due to the strong cash position of $90.7 million and additional $50 million offering extending the cash runway into 2025. This strengthens investor confidence, potentially leading to increased stock demand.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,346,RAIN,2022-11-10 21:05:00+00:00,US/Eastern,"– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 –",UP,0.172719702560049,en
16422,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2022/11/14/2554922/0/en/ContraFect-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html,2022-11-14 08:00:00+00:00,ContraFect,financial_results,The predicted downward move of -0.07% likely results from uncertainty around clinical study progress for exebacase and CF-370. Market implications could include reduced investor confidence and pressure on the company's stock price due to potential delays or costs.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,347,CFRX,2022-11-14 13:00:00+00:00,US/Eastern,Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies,UP,-0.0006761915032107387,en
16393,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference,https://www.globenewswire.com/news-release/2022/11/14/2554961/0/en/Rain-Therapeutics-to-Participate-in-H-C-Wainwright-s-3rd-Annual-Precision-Oncology-Virtual-Conference.html,2022-11-14 08:00:00+00:00,Rain Therapeutics,conference_call_webinar,The predicted downward move of -0.69% in Rain Therapeutics Inc. may be due to investor reactions to conference announcements or perceived delays in product development. This could signal cautious market sentiment or concerns over competitive positioning.,globenewswire_biotech,biotech,Calendar of Events,346,RAIN,2022-11-14 13:00:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  14, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.",DOWN,-0.00689381968065741,en
16618,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update,https://www.globenewswire.com/news-release/2022/11/14/2555413/0/en/NexImmune-Reports-Third-Quarter-2022-Financial-Results-and-Announces-Strategic-Update.html,2022-11-14 16:01:00+00:00,NexImmune,financial_results,"1. The predicted downward move of -0.03% is likely due to NexImmune's reported third-quarter financial results and announced strategy shift, possibly signaling uncertainties about future performance. 2. This could affect investor confidence, potentially influencing broader market perceptions of the biotech sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,357,NEXI,2022-11-14 21:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., Nov.  14, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the third quarter of 2022 and announced a change in corporate strategy.",UP,-0.00033831123762243886,en
15409,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2022/11/14/2555443/0/en/VBL-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html,2022-11-14 16:05:00+00:00,Vascular Biogenics,earnings_releases_and_operating_results,"The predicted downward move of -1.90% likely results from market skepticism regarding the strategic process's effectiveness. Potential market implications include lowered investor confidence and reduced stock demand, impacting overall company valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,295,VBLT,2022-11-14 21:05:00+00:00,US/Eastern,Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value,DOWN,-0.01897101144169288,en
16392,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting,https://www.globenewswire.com/news-release/2022/11/17/2558602/0/en/Rain-Therapeutics-Announces-an-Oral-Presentation-at-the-Connective-Tissue-Oncology-Society-Annual-Meeting.html,2022-11-17 13:05:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +6.39% is likely due to positive sentiment surrounding Rain Therapeutics' presentation at the CTOS Annual Meeting, highlighting advances in their lead product. This could boost investor confidence and interest in potential partnerships or funding.",globenewswire_biotech,biotech,Calendar of Events,346,RAIN,2022-11-17 18:05:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  17, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.",UP,0.06390248151146455,en
16391,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference,https://www.globenewswire.com/news-release/2022/11/18/2559077/0/en/Rain-Therapeutics-to-Participate-in-Piper-Sandler-s-34th-Annual-Healthcare-Conference.html,2022-11-18 08:00:00+00:00,Rain Therapeutics,conference_call_webinar,"The predicted downward move of -0.28% for Rain Therapeutics may be due to investor anticipation of the conference not yielding significant new information. This could reflect cautious sentiment, potentially affecting other biotech stocks similarly focused on precision oncology.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,346,RAIN,2022-11-18 13:00:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  18, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.",DOWN,-0.0027559662542960763,en
16390,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium,https://www.globenewswire.com/news-release/2022/11/23/2561556/0/en/Rain-Therapeutics-Announces-a-Poster-Presentation-at-the-2022-San-Antonio-Breast-Cancer-Symposium.html,2022-11-23 08:00:00+00:00,Rain Therapeutics,clinical_study,"The predicted upward move of +8.97% is likely due to anticipation around Rain Therapeutics' presentation on milademetan, which could highlight promising developments. Success at the symposium could boost investor confidence and attract interest in precision oncology stocks.",globenewswire_biotech,biotech,Calendar of Events,346,RAIN,2022-11-23 13:00:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  23, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.",UP,0.08970435775198794,en
16421,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections,https://www.globenewswire.com/news-release/2022/11/28/2563081/0/en/ContraFect-Announces-ANSM-Approval-of-Clinical-Trial-Application-for-Exebacase-in-Prosthetic-Joint-Infections.html,2022-11-28 08:00:00+00:00,ContraFect,clinical_study,"ContraFect's predicted upward move of +2.78% is likely driven by positive news of French regulatory approval for their exebacase clinical trial, signaling progress in treating antibiotic-resistant infections. This could enhance investor confidence and potentially increase market interest in their innovative therapies.",globenewswire_biotech,biotech,Clinical Study,347,CFRX,2022-11-28 13:00:00+00:00,US/Eastern,"YONKERS, N.Y., Nov.  28, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase, in the setting of a minimally-invasive arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infection (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",UP,0.027842842412810178,en
16420,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement,https://www.globenewswire.com/news-release/2022/12/13/2572707/0/en/ContraFect-Announces-Pricing-of-7-0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html,2022-12-13 08:01:00+00:00,ContraFect,financing_agreements,"The predicted downward move of -4.39% likely stems from dilution concerns as ContraFect's securities purchase agreement increases shares. This may signal financial distress, undermining investor confidence. Market implications could include decreased stock value and cautious investor sentiment.",globenewswire_biotech,biotech,Management statements,347,CFRX,2022-12-13 13:01:00+00:00,US/Eastern,"YONKERS, N.Y., Dec.  13, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $0.129.",DOWN,-0.04390993154084313,en
16419,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase,https://www.globenewswire.com/news-release/2022/12/19/2576681/0/en/ContraFect-Provides-Update-from-the-Futility-Analysis-of-the-Phase-3-DISRUPT-Study-of-Exebacase.html,2022-12-19 16:30:00+00:00,ContraFect,clinical_study,"The predicted downward move of -5.81% may be due to negative sentiment or poor financial outlook discussed in the fireside chat. This could lead to decreased investor confidence, resulting in potential sell-offs and increased market volatility.",globenewswire_biotech,biotech,Product / Services Announcement,347,CFRX,2022-12-19 21:30:00+00:00,US/Eastern,Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023 Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023,DOWN,-0.058075786662937376,en
16617,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases,https://www.globenewswire.com/news-release/2023/01/18/2591310/0/en/NexImmune-Announces-Publication-in-Frontiers-in-Medicine-Highlighting-the-Company-s-AIM-Platform-to-Treat-Viral-Diseases.html,2023-01-18 16:01:00+00:00,NexImmune,press_releases,"1. The likely cause of the predicted downward move of -0.90% in NexImmune's stock could be investors' cautious reaction to the publication without immediate commercial application or revenue growth. 2. This may lead to short-term volatility and investor skepticism, impacting biotech innovation sentiment.",globenewswire_biotech,biotech,Health,357,NEXI,2023-01-18 21:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., Jan.  18, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the publication of an article highlighting the Company’s AIM platform as a new immunotherapy approach for viral diseases in Frontiers in Medicine. The article, titled “AIM Platform: A New Immunotherapy Approach for Viral Diseases,” focuses on the ability of AIM nanoparticles, which direct T cell response by mimicking the dendritic cell function, to consistently expand T cell populations with effector memory, central memory and self-renewing stem like memory phenotype directed at peptide-antigens from Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1) and human papillomavirus (HPV). Furthermore, T cells generated with the AIM platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.",UP,-0.008975124278902576,en
14658,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Initiates Process for Nasdaq Listing,https://www.globenewswire.com/news-release/2023/02/14/2607567/0/en/Radiopharm-Theranostics-Initiates-Process-for-Nasdaq-Listing.html,2023-02-14 08:00:00+00:00,Radiopharm Theranostics,regulatory_filings,"The predicted upward move of +0.13% is likely due to positive market sentiment surrounding the NASDAQ listing and regulatory compliance with Form 20-F. This could increase investor confidence and liquidity, potentially benefiting overall market perception of RADX.",globenewswire_biotech,biotech,Exchange announcement,256,RAD.AX,2023-02-14 13:00:00+00:00,US/Eastern,Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023,UP,0.001289427298344798,en
16616,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR,https://www.globenewswire.com/news-release/2023/02/16/2609548/0/en/NexImmune-Announces-Data-Showing-AIM-ACT-T-cells-Enhance-the-Response-to-Bispecific-T-cell-Engager-Therapy-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-.html,2023-02-16 07:00:00+00:00,NexImmune,clinical_study,"The predicted upward move of +8.59% is likely due to positive preclinical data from NexImmune, enhancing market confidence in its immunotherapy approach. This development may attract more investors, supporting potential growth and innovation within the biotechnology sector.",globenewswire_biotech,biotech,Trade Show,357,NEXI,2023-02-16 12:00:00+00:00,US/Eastern,"GAITHERSBURG, Md., Feb.  16, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.",UP,0.08585694675634092,en
15408,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash,https://www.globenewswire.com/news-release/2023/02/16/2609663/0/en/VBL-Therapeutics-Announces-Agreement-to-Sell-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html,2023-02-16 08:00:00+00:00,Vascular Biogenics,business_contracts,"The predicted upward move of +0.59% is likely due to VBL Therapeutics monetizing non-core assets, improving its cash position. This increase could enhance investor confidence, signaling strategic focus and potentially leading to higher market interest in VBL shares.",globenewswire_biotech,biotech,Other News,295,VBLT,2023-02-16 13:00:00+00:00,US/Eastern,"MODIIN, Israel and NEW YORK, Feb.  16, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today that it has entered into an agreement to monetize its manufacturing facility in Modiin, Israel and certain related assets, for $7.1 million in cash. VBL also has the right to sell certain equipment excluded from the agreement for additional cash consideration. The asset sale is subject to customary closing conditions and expected to close on or about March 9, 2023.",UP,0.005877711953782867,en
43581,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023",https://www.globenewswire.com/news-release/2023/02/16/2610246/0/en/Vir-Biotechnology-to-Provide-Corporate-Update-and-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-February-23-2023.html,2023-02-16 16:05:00+00:00,Vir Biotechnology,earnings_releases_and_operating_results,"The predicted upward move of +0.36% likely stems from positive anticipation of Vir Biotechnology's financial results and corporate update. This may boost investor confidence, potentially increasing stock demand and positively impacting the market sentiment for biotech stocks.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-02-16 21:05:00+00:00,US/Eastern,"SAN FRANCISCO, Feb.  16, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.",UP,0.3626206378014413,en
43580,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE),https://www.globenewswire.com/news-release/2023/02/22/2613242/0/en/Vir-Biotechnology-Announces-Positive-Final-Draft-Guidance-on-Sotrovimab-from-the-UK-s-National-Institute-for-Health-and-Care-Excellence-NICE.html,2023-02-22 08:30:00+00:00,Vir Biotechnology,advisory,"1. The predicted upward move of +0.63% is likely due to positive cost-effectiveness evaluation of sotrovimab. 2. This could increase investor confidence, potentially boosting demand and valuation for companies involved with sotrovimab.",globenewswire_biotech,biotech,Product / Services Announcement,272,VIR,2023-02-22 13:30:00+00:00,US/Eastern,Final draft guidance based on cost effectiveness evaluation of sotrovimab Final draft guidance based on cost effectiveness evaluation of sotrovimab,DOWN,0.6333427240775346,en
15407,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement,https://www.globenewswire.com/news-release/2023/02/23/2614116/0/en/VBL-Therapeutics-and-Notable-Labs-Announce-Definitive-Merger-Agreement.html,2023-02-23 07:00:00+00:00,Vascular Biogenics,mergers_acquisitions,"1. The predicted downward move of -0.07% likely reflects investor skepticism about merger synergies or integration challenges. 2. This minor decline suggests limited immediate impact, but long-term market implications depend on the successful development and commercialization of precision medicines.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,295,VBLT,2023-02-23 12:00:00+00:00,US/Eastern,"Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”)",UP,-0.000714007423142883,en
43579,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/02/23/2614817/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,2023-02-23 16:05:00+00:00,Vir Biotechnology,observation_status,"1. The predicted upward move of +0.73% likely stems from anticipated positive Phase 2 clinical trial results in hepatitis B, hepatitis D, and influenza programs. 2. Successful results could drive investor confidence, leading to increased valuations and strategic partnerships.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,272,VIR,2023-02-23 21:05:00+00:00,US/Eastern,"– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –",UP,0.7298993125650504,en
16418,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement,https://www.globenewswire.com/news-release/2023/02/28/2617103/0/en/ContraFect-Announces-Pricing-of-10-0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html,2023-02-28 08:30:00+00:00,ContraFect,financing_agreements,The predicted downward move of -4.95% is likely due to dilution concerns from ContraFect’s $10 million direct offering. Market implications may include reduced investor confidence and pressure on stock prices due to increased share supply.,globenewswire_biotech,biotech,Stock Market News,347,CFRX,2023-02-28 13:30:00+00:00,US/Eastern,"YONKERS, N.Y., Feb.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $4.00.",DOWN,-0.04950770157014936,en
43578,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference,https://www.globenewswire.com/news-release/2023/02/28/2617657/0/en/Vir-Biotechnology-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html,2023-02-28 16:05:00+00:00,Vir Biotechnology,observation_status,"The likely cause of the predicted upward move of +0.75% is Bolyn Hubby's participation in a health care conference panel, potentially increasing investor interest. This may enhance market perception of Vir Biotechnology's role in infectious diseases, positively impacting stock sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-02-28 21:05:00+00:00,US/Eastern,"SAN FRANCISCO, Feb.  28, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.",UP,0.745691099493522,en
14657,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Dr Ken Herrmann Appointed to RAD Scientific Advisory Board,https://www.globenewswire.com/news-release/2023/03/03/2620158/0/en/Dr-Ken-Herrmann-Appointed-to-RAD-Scientific-Advisory-Board.html,2023-03-03 07:30:00+00:00,Radiopharm Theranostics,advisory,1. The predicted downward move of +nan% could be due to market confusion or data error. 2. Potential market implications include investor skepticism or caution around the company's announcements.,globenewswire_biotech,biotech,Directors and Officers,256,RAD.AX,2023-03-03 12:30:00+00:00,US/Eastern,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB).",UP,-0.3742560813916459,en
14656,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals,https://www.globenewswire.com/news-release/2023/03/03/2620252/0/en/Radiopharm-Theranostics-Partners-With-Next-Generation-Preclinical-Platform-for-Therapeutic-Radiopharmaceuticals.html,2023-03-03 08:41:00+00:00,Radiopharm Theranostics,mergers_acquisitions,"The predicted downward move of -1.09% could be attributed to concerns over acquisition risks or integration costs related to buying Pharma15. This may lead to investor caution, potentially impacting Radiopharm's short-term market valuation and financial stability perceptions.",globenewswire_biotech,biotech,Mergers and Acquisitions,256,RAD.AX,2023-03-03 13:41:00+00:00,US/Eastern,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer. Pharma15 was founded by leading radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance.",UP,-0.010875523142207879,en
15406,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash,https://www.globenewswire.com/news-release/2023/03/09/2624072/0/en/VBL-Therapeutics-Announces-Closing-of-Sale-of-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html,2023-03-09 08:00:00+00:00,Vascular Biogenics,mergers_acquisitions,"The predicted downward move of -0.09% is likely due to market reactions to VBL Therapeutics' asset sale and merger plans. This suggests investor uncertainty about the strategic shift and its success, potentially impacting stock value temporarily.",globenewswire_biotech,biotech,Company Announcement,295,VBLT,2023-03-09 13:00:00+00:00,US/Eastern,"MODIIN, Israel and NEW YORK, March  09, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.",UP,-0.0008916846563873462,en
15405,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/14/2626587/0/en/VBL-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,2023-03-14 08:00:00+00:00,Vascular Biogenics,mergers_acquisitions,"The predicted downward move of -0.22% for VBL Therapeutics likely stems from disappointing financial results or corporate updates. This could negatively affect investor confidence, potentially leading to decreased stock demand and market valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,295,VBLT,2023-03-14 12:00:00+00:00,US/Eastern,"MODIIN, Israel and NEW YORK, March  14, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.",UP,-0.0021548041471435215,en
14655,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit,https://www.globenewswire.com/news-release/2023/03/28/2635541/0/en/Radiopharm-Theranostics-Invited-to-Participate-in-Jefferies-Radiopharma-Innovation-Summit.html,2023-03-28 07:30:00+00:00,Radiopharm Theranostics,trade_show,"The predicted downward move of -0.59% may be due to investor uncertainty regarding the impact of attending the summit on financial performance. This could lead to cautious sentiment, potentially affecting Radiopharm's market valuation and investor confidence temporarily.",globenewswire_biotech,biotech,Calendar of Events,256,RAD.AX,2023-03-28 11:30:00+00:00,US/Eastern,"SYDNEY, Australia, March  28, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023. Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, and Vittorio Puppo, Chief Operating Officer will be available for 1x1 meetings.",UP,-0.005907245108651117,en
16615,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/03/28/2636190/0/en/NexImmune-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Updates.html,2023-03-28 16:01:00+00:00,NexImmune,financial_results,"NexImmune's reported financial results likely drove the predicted upward move of +0.26%, reflecting investor optimism. This slight increase suggests potential market confidence in their innovative immunotherapy approach, possibly attracting more investor interest if momentum continues.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,357,NEXI,2023-03-28 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., March  28, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the fourth quarter and full year 2022.",UP,0.002574428544024377,en
15459,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/28/2636236/0/en/Adagene-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,2023-03-28 16:30:00+00:00,Adagene,clinical_study,"The predicted upward move of +9.60% likely stems from promising clinical data, indicating superior safety profiles for anti-CTLA-4 treatments. This enhances therapeutic potential, boosting investor confidence. Market implications include increased interest in combination therapies and potential competitive advantages.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,297,ADAG,2023-03-28 20:30:00+00:00,US/Eastern,"- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond -",UP,0.09599152369436674,en
16417,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/31/2638628/0/en/ContraFect-Reports-Fourth-Quarter-2022-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-31 08:30:00+00:00,ContraFect,clinical_study,"The predicted upward move of +8.26% for ContraFect is likely due to positive business updates and financial performance. This increase may signal investor confidence in their new medical modalities, potentially boosting stock interest in the biotech sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,347,CFRX,2023-03-31 12:30:00+00:00,US/Eastern,"YONKERS, N.Y., March  31, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.",UP,0.08264074028017854,en
16416,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee,https://www.globenewswire.com/news-release/2023/04/03/2639585/0/en/ContraFect-Announces-Initiation-of-a-Phase-1b-2-Study-of-Exebacase-in-Patients-with-Chronic-Prosthetic-Joint-Infections-of-the-Knee.html,2023-04-03 08:30:00+00:00,ContraFect,clinical_study,"The predicted upward move of +1.08% is likely caused by the announcement of the Phase 1b/2 trial initiation of exebacase, which represents progress in ContraFect's innovation pipeline. This could increase investor confidence and interest in biotechnology developments targeting antibiotic-resistant infections.",globenewswire_biotech,biotech,Product / Services Announcement,347,CFRX,2023-04-03 12:30:00+00:00,US/Eastern,"YONKERS, New York, April  03, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",DOWN,0.010789920393982879,en
16415,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting,https://www.globenewswire.com/news-release/2023/04/06/2642566/0/en/ContraFect-Announces-Multiple-Presentations-of-New-Data-at-the-33rd-Annual-ECCMID-Meeting.html,2023-04-06 08:30:00+00:00,ContraFect,clinical_study,"The predicted upward move of +3.83% is likely due to positive clinical data showing Lysin CF-370's effectiveness against XDR Pseudomonas aeruginosa. This could enhance investor confidence, potentially increasing market interest and investment in antibacterial solutions.",globenewswire_biotech,biotech,Calendar of Events,347,CFRX,2023-04-06 12:30:00+00:00,US/Eastern,Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa,UP,0.03828848899916261,en
14959,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2023/04/11/2644920/0/en/Vir-Biotechnology-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html,2023-04-11 16:05:00+00:00,Vir Biotechnology,conference_call_webinar,The predicted downward move of -0.12% could be due to investor anticipation of potential unfavorable news or lack of major updates at the fireside chat. This may signal cautious market sentiment and minor volatility for Vir Biotechnology.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-04-11 20:05:00+00:00,US/Eastern,"SAN FRANCISCO, April  11, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.",DOWN,-0.0011656654220342482,en
14654,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope,https://www.globenewswire.com/news-release/2023/04/17/2647815/0/en/Radiopharm-Theranostics-Enters-Into-Supply-Agreement-with-TerThera-for-Terbium-161-Isotope.html,2023-04-17 07:30:00+00:00,Radiopharm Theranostics,clinical_study,"The predicted upward move of +18.28% is likely due to optimism surrounding the agreement to supply Tb-161 for RAD 602, a promising new treatment for brain cancer. This could boost investor confidence and potentially lead to increased market interest in similar biotech stocks.",globenewswire_biotech,biotech,Product / Services Announcement,256,RAD.AX,2023-04-17 11:30:00+00:00,US/Eastern,"Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers",UP,0.18277892435372822,en
15458,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors,https://www.globenewswire.com/news-release/2023/04/18/2649190/0/en/Adagene-Presents-Clinical-Data-for-Anti-CTLA-4-SAFEbody-ADG126-Reinforcing-Best-in-Class-Safety-Profile-at-Repeat-Doses-and-Showing-Early-Efficacy-Profile-in-Advanced-Metastatic-So.html,2023-04-18 09:17:00+00:00,Adagene,clinical_study,"The predicted downward move of -0.22% likely stems from market skepticism about ADG126's preliminary trial results. Despite confirming clinical responses, such announcements can cause cautious investor reactions. This could imply short-term volatility and scrutiny for the asset.",globenewswire_biotech,biotech,Clinical Study,297,ADAG,2023-04-18 13:17:00+00:00,US/Eastern,"- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors -",UP,-0.0022000660042537402,en
16414,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens,https://www.globenewswire.com/news-release/2023/04/20/2650996/0/en/ContraFect-Data-Presentations-at-the-33rd-Annual-ECCMID-Meeting-Highlight-the-Potential-Efficacy-of-Lysin-CF-370-Against-Antibiotic-Resistant-Gram-negative-Pathogens.html,2023-04-20 08:30:00+00:00,ContraFect,clinical_study,"The likely cause of the predicted upward move of +3.32% in ContraFect Corporation's stock is the positive presentation data on CF-370's efficacy against XDR Pseudomonas aeruginosa, enhancing investor confidence. This could signal growth potential in combating drug-resistant infections.",globenewswire_biotech,biotech,Clinical Study,347,CFRX,2023-04-20 12:30:00+00:00,US/Eastern,"YONKERS, N.Y., April  20, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark.",UP,0.033152935815851714,en
16413,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee,https://www.globenewswire.com/news-release/2023/04/26/2655181/0/en/ContraFect-Announces-First-Patient-Dosed-in-the-Phase-1b-2-Study-of-Exebacase-in-Patients-with-Chronic-Prosthetic-Joint-Infections-of-the-Knee.html,2023-04-26 09:00:00+00:00,ContraFect,clinical_study,The predicted downward move of -0.38% for ContraFect shares may be due to investor caution about the experimental nature of the exebacase trial. This might indicate market uncertainty about clinical trial success and future revenue potential.,globenewswire_biotech,biotech,Health,347,CFRX,2023-04-26 13:00:00+00:00,US/Eastern,"YONKERS, N.Y., April  26, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",DOWN,-0.00377272655662266,en
16614,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting,https://www.globenewswire.com/news-release/2023/04/26/2655615/0/en/NexImmune-Announces-Presentation-of-Phase-1-2-Clinical-Data-at-the-2023-American-Society-of-Clinical-Oncology-Annual-Meeting.html,2023-04-26 16:01:00+00:00,NexImmune,clinical_study,"The predicted upward move of +0.78% for NexImmune, Inc. is likely due to the upcoming presentation of NEXI-001 data at the ASCO Annual Meeting, which may boost investor confidence. Positive clinical news could increase interest in biotech stocks.",globenewswire_biotech,biotech,Calendar of Events,357,NEXI,2023-04-26 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., April  26, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.",UP,0.007783176604676143,en
15379,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND,https://www.globenewswire.com/news-release/2023/04/26/2655685/35690/en/OpGen-s-Subsidiary-Curetis-Meets-All-Remaining-Key-Milestones-in-R-D-Collaboration-with-FIND.html,2023-04-26 16:30:00+00:00,OpGen,business_contracts,"The predicted upward move of +1.25% is likely due to OpGen's successful milestone achievements with Curetis GmbH, enhancing investor confidence. This strengthens OpGen's market positioning and could attract increased investment interest in their innovative R&D efforts.",globenewswire_biotech,biotech,Financing Agreements,293,OPGN,2023-04-26 20:30:00+00:00,US/Eastern,"ROCKVILLE, Md., April  26, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully. Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries. Completion of the deliverables triggered a milestone payment of approximately $0.3 million.",UP,0.01250174553544031,en
15457,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Announces Updates to its Board of Directors,https://www.globenewswire.com/news-release/2023/04/28/2657314/0/en/Adagene-Announces-Updates-to-its-Board-of-Directors.html,2023-04-28 07:00:00+00:00,Adagene,management_changes,"1. The predicted downward move of -0.02% is likely due to investor uncertainty following board updates, which may signal organizational changes. 2. Potential market implications include cautious investor sentiment and minor adjustments in stock valuations, reflecting the slight predicted movement.",globenewswire_biotech,biotech,Directors and Officers,297,ADAG,2023-04-28 11:00:00+00:00,US/Eastern,"SAN DIEGO and SUZHOU, China, April  28, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:",UP,-0.0001599880418543022,en
15378,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Announces Pricing of $3.5 Million Public Offering,https://www.globenewswire.com/news-release/2023/05/02/2658714/35690/en/OpGen-Announces-Pricing-of-3-5-Million-Public-Offering.html,2023-05-01 21:00:00+00:00,OpGen,shares_issue,The predicted downward move of -1.78% is likely due to dilution concerns from the new share issuance. This can affect existing shareholder value. Market implications include potential short-term volatility and investor hesitation pending the offering's closure.,globenewswire_biotech,biotech,Financing Agreements,293,OPGN,2023-05-02 01:00:00+00:00,US/Eastern,"ROCKVILLE, Md., May  01, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the pricing of a public offering of an aggregate of 4,495,825 shares of its common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share (or pre-funded warrant in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $0.7785 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years from the date of stockholder approval. The closing of the offering is expected to occur on or about May 4, 2023, subject to the satisfaction of customary closing conditions.",DOWN,-0.017803640000113828,en
14629,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013,https://www.globenewswire.com/news-release/2023/05/02/2659091/0/en/Eloxx-Pharmaceuticals-Announces-FDA-Clearance-to-Begin-Single-Ascending-Dose-Study-of-ZKN-013.html,2023-05-02 08:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"1. Positive clinical trial results or strategic partnerships may likely cause the predicted upward move of +17.52% for ZKN-013. 2. This could enhance investor confidence, increase funding opportunities, and boost the company's market valuation.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-05-02 12:00:00+00:00,US/Eastern,ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP),DOWN,0.17522034066334033,en
14958,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention,https://www.globenewswire.com/news-release/2023/05/02/2659283/0/en/Vir-Biotechnology-Receives-Expanded-Support-to-Develop-Its-Novel-T-Cell-Vaccine-Platform-with-New-10-Million-Grant-for-HIV-Prevention.html,2023-05-02 09:00:00+00:00,Vir Biotechnology,clinical_study,The predicted upward move of +2.68% likely results from increased investor optimism due to funding from the Bill & Melinda Gates Foundation. Market implications include potential advancements in HIV treatment and improved investor confidence in biotech innovation.,globenewswire_biotech,biotech,Health,272,VIR,2023-05-02 13:00:00+00:00,US/Eastern,"– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –",DOWN,0.026827296187763538,en
16683,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel,https://www.globenewswire.com/news-release/2023/05/03/2660288/0/en/RAPT-Therapeutics-Announces-the-Appointment-of-Michael-Listgarten-as-General-Counsel.html,2023-05-03 08:00:00+00:00,RAPT Therapeutics,management_changes,"The predicted downward move of -0.01% likely stems from the market's neutral response to the executive appointment, reflecting limited immediate impact. This suggests investor sentiment is stable, with minimal short-term market implications anticipated.",globenewswire_biotech,biotech,Directors and Officers,360,RAPT,2023-05-03 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., May  03, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel.",UP,-0.00010612929316597144,en
14957,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference,https://www.globenewswire.com/news-release/2023/05/03/2660796/0/en/Vir-Biotechnology-to-Participate-in-the-BofA-Securities-2023-Health-Care-Conference.html,2023-05-03 16:05:00+00:00,Vir Biotechnology,conference_call_webinar,"The predicted upward move of +0.08% is likely due to Vir Biotechnology's CEO presenting at a major healthcare conference, possibly boosting investor confidence. This minor rise may indicate stable investor sentiment and interest in the company's future prospects.",globenewswire_biotech,biotech,Calendar of Events,272,VIR,2023-05-03 20:05:00+00:00,US/Eastern,"SAN FRANCISCO, May  03, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.",DOWN,0.0007947354962511511,en
15319,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech - Notice of Annual General Meeting 2023,https://www.globenewswire.com/news-release/2023/05/04/2661123/0/en/PCI-Biotech-Notice-of-Annual-General-Meeting-2023.html,2023-05-04 04:04:00+00:00,PCI Biotech Holding,annual_general_meeting,"The predicted downward move of -0.90% might result from investor uncertainty ahead of PCI Biotech's annual meeting. Potential market implications include reduced short-term investor confidence, possibly impacting related biotech stocks.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-05-04 08:04:00+00:00,US/Eastern,"Oslo, Norway 4 May 2023 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2023 at 10:00am (CEST).",UP,-0.009012311546243497,en
15456,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate,https://www.globenewswire.com/news-release/2023/05/04/2661611/0/en/Adagene-Achieves-3-Million-Milestone-in-Collaboration-with-Exelixis-for-Successful-Nomination-of-Second-SAFEbody-Novel-Masked-Antibody-Drug-Conjugate.html,2023-05-04 09:00:00+00:00,Adagene,licensing_agreements,"The predicted upward move of +2.87% is likely caused by Adagene's achievement in its collaboration with Exelixis, highlighting progress in developing masked ADC candidates. This could improve investor confidence, leading to potential increases in market interest and investment in Adagene.",globenewswire_biotech,biotech,Product / Services Announcement,297,ADAG,2023-05-04 13:00:00+00:00,US/Eastern,"SAN DIEGO and SUZHOU, China, May  04, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.",UP,0.028725711094265936,en
14956,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/05/04/2662074/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results.html,2023-05-04 16:05:00+00:00,Vir Biotechnology,financial_results,1. The predicted downward move of -0.69% could be due to uncertainty surrounding the data readouts. 2. This may lead to cautious investor sentiment and potential volatility in related biotech stocks.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,272,VIR,2023-05-04 20:05:00+00:00,US/Eastern,"– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza –",UP,-0.0068623074062090636,en
15377,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Announces Closing of $3.5 Million Public Offering,https://www.globenewswire.com/news-release/2023/05/04/2662124/35690/en/OpGen-Announces-Closing-of-3-5-Million-Public-Offering.html,2023-05-04 16:30:00+00:00,OpGen,shares_issue,"The predicted downward move of -0.60% likely stems from investor dilution concerns due to the new share issuance. This could indicate reduced investor confidence or valuation pressure, possibly affecting the stock's attractiveness and future financing costs.",globenewswire_biotech,biotech,Warrants and Certificates,293,OPGN,2023-05-04 20:30:00+00:00,US/Eastern,"ROCKVILLE, Md., May  04, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share (or pre-funded warrant in lieu thereof) and accompanying warrant. The warrants have an exercise price of $0.7785 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years from the date of stockholder approval.",DOWN,-0.006011491991479779,en
15376,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time,https://www.globenewswire.com/news-release/2023/05/08/2663183/35690/en/OpGen-to-Provide-Business-Update-and-Financial-Results-for-the-First-Quarter-2023-on-May-15th-at-4-30-p-m-Eastern-Time.html,2023-05-08 07:30:00+00:00,OpGen,earnings_releases_and_operating_results,The predicted downward move of -0.91% is likely due to anticipated weak financial results or limited growth updates from OpGen's upcoming business report. This could result in decreased investor confidence and a potential dip in OpGen's stock price.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,293,OPGN,2023-05-08 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., May  08, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th, 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.",UP,-0.009129618208343807,en
14653,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer,https://www.globenewswire.com/news-release/2023/05/09/2664296/0/en/Radiopharm-Theranostics-Receives-FDA-Orphan-Drug-Designation-for-Trivehexin-RAD-301-in-Pancreatic-Cancer.html,2023-05-09 07:30:00+00:00,Radiopharm Theranostics,product_services_announcement,"The FDA's Orphan Drug Designation for Radiopharm's Ga68-Trivehexin likely caused the predicted upward move of +2.61%. This can boost investor confidence, potentially increasing investment in Radiopharm and enhancing the company's market position within the radiopharmaceutical sector.",globenewswire_biotech,biotech,Health,256,RAD.AX,2023-05-09 11:30:00+00:00,US/Eastern,"SYDNEY, Australia, May  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ga68-Trivehexin (RAD 301) radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma (PDAC).",UP,0.026145021483274536,en
15318,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: Invitation to Q1 2023 results presentation,https://www.globenewswire.com/news-release/2023/05/09/2664612/0/en/PCI-Biotech-Invitation-to-Q1-2023-results-presentation.html,2023-05-09 09:52:00+00:00,PCI Biotech Holding,interim_information,"The predicted downward move of +nan% could be due to poor financial performance or negative investor sentiment. This might lead to decreased investor confidence, possibly reducing demand for PCI Biotech shares and impacting overall market perception of the company's growth potential.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-05-09 13:52:00+00:00,US/Eastern,"Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time).",UP,-0.44042031245812086,en
16663,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products,https://www.globenewswire.com/news-release/2023/05/10/2665590/0/en/Celularity-Announces-Advisory-Guidance-From-Tamer-Group-Regarding-Anticipated-2023-Purchase-Orders-for-Celularity-Branded-Halal-Certified-Biomaterial-Products.html,2023-05-10 09:00:00+00:00,Celularity,product_services_announcement,"The predicted upward move of +0.13% is likely due to anticipated purchase orders from Tamer Group in Saudi Arabia, which signals increased revenue for Celularity. This could enhance investor confidence and potentially boost the stock's attractiveness.",globenewswire_biotech,biotech,Management statements,359,CELU,2023-05-10 13:00:00+00:00,US/Eastern,"FLORHAM PARK, N.J., May  10, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has been advised by Farouk, Maamoun Tamer & Co. (Tamer Group), the exclusive distributor for Celularity's branded Halal-Certified biomaterial products in the Kingdom of Saudi Arabia, that it expects to submit purchase orders through the end of 2023 in the range of $60 million to $80 million.",UP,0.0012722856971491342,en
15619,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Reports its 2023 Annual General Shareholders' Meeting Results,https://www.globenewswire.com/news-release/2023/05/10/2666042/0/en/Mydecine-Reports-its-2023-Annual-General-Shareholders-Meeting-Results.html,2023-05-10 16:05:00+00:00,Mydecine Innovations Group,annual_general_meeting,"The predicted downward move of -1.17% is likely due to low shareholder turnout, with only 11.25% participation, possibly indicating weak investor confidence. This could impact the stock negatively by reducing market trust and financial support.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,306,MYCO.CN,2023-05-10 20:05:00+00:00,US/Eastern,"VANCOUVER, British Columbia, May  10, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its annual general and special meeting (“AGSM”) of shareholders which was held on Friday, May 5, 2023, by conference call (the “Meeting”). There were 23 shareholders represented in person or by proxy at the Meeting, holding 2,423,009 common shares, representing 11.25% of the Company’s total issued and outstanding common shares as of the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:",UP,-0.011689931492044012,en
16682,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Reports First Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/05/11/2666661/0/en/RAPT-Therapeutics-Reports-First-Quarter-2023-Financial-Results.html,2023-05-11 08:00:00+00:00,RAPT Therapeutics,financial_results,"The predicted upward move of +0.19% is likely due to the company's strong cash position of $231.6 million, signaling financial stability and potential for growth. This may boost investor confidence and slightly increase demand for its assets.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,360,RAPT,2023-05-11 12:00:00+00:00,US/Eastern,Company maintains strong cash position of $231.6 million Company maintains strong cash position of $231.6 million,DOWN,0.0019110409948703924,en
14955,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI",https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html,2023-05-11 08:30:00+00:00,Vir Biotechnology,clinical_study,"1. The predicted downward move of -0.14% could be due to investor caution over trial risks and uncertainties. 2. Potential market implications include cautious sentiment around Vir's trial progress, possibly affecting stock volatility and investor confidence.",globenewswire_biotech,biotech,Product / Services Announcement,272,VIR,2023-05-11 12:30:00+00:00,US/Eastern,– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ,DOWN,-0.0013517097814385525,en
16179,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/05/11/2667375/0/en/Harpoon-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-05-11 16:30:00+00:00,Harpoon Therapeutics,financial_results,"The predicted upward move of +0.01% is likely due to steady enrollment and planned data updates for HPN217 and HPN328, suggesting progress. This could enhance investor confidence, though the modest increase indicates limited immediate market impact.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,334,HARP,2023-05-11 20:30:00+00:00,US/Eastern,"Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023",UP,5.571201411882235e-05,en
15317,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech interim Q1 2023 results,https://www.globenewswire.com/news-release/2023/05/12/2667502/0/en/PCI-Biotech-interim-Q1-2023-results.html,2023-05-12 01:00:00+00:00,PCI Biotech Holding,financial_results,"The predicted upward move of +0.49% for PCI Biotech likely stems from positive Q1 2023 results, boosting investor confidence. This may improve market sentiment around the company, attracting more investment and potentially enhancing its market position.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-05-12 05:00:00+00:00,US/Eastern,"Oslo (Norway), 12 May 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q1 2023 results. Please find enclosed the report and presentation.",UP,0.004890179209551373,en
16412,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2668702/0/en/ContraFect-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-05-15 08:00:00+00:00,ContraFect,clinical_study,"The predicted upward move of +8.24% for ContraFect might be due to positive business updates or strong first-quarter financial results, boosting investor confidence. This could increase market interest in biotechnology companies focused on antibiotic-resistant infections.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,347,CFRX,2023-05-15 12:00:00+00:00,US/Eastern,"YONKERS, N.Y., May  15, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023.",UP,0.0824155328788977,en
14954,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer",https://www.globenewswire.com/news-release/2023/05/15/2668713/0/en/Vir-Biotechnology-Appoints-Jeff-Calcagno-M-D-as-Executive-Vice-President-and-Chief-Business-Officer.html,2023-05-15 08:00:00+00:00,Vir Biotechnology,management_changes,The predicted downward move of -0.10% may result from investor uncertainty regarding the leadership change at Vir Biotechnology. Market implications include cautious trading as stakeholders await evidence of strategic impact under Jeff Calcagno's direction.,globenewswire_biotech,biotech,Directors and Officers,272,VIR,2023-05-15 12:00:00+00:00,US/Eastern,"SAN FRANCISCO, May  15, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir’s executive management team.",UP,-0.0009847589386439925,en
15404,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2669270/0/en/VBL-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-05-15 16:01:00+00:00,Vascular Biogenics,financial_results,The predicted downward move of -0.24% likely stems from uncertainty around SEC review and shareholder approvals. Market implications include potential increased volatility and investor caution as the merger process encounters regulatory and procedural hurdles.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,295,VBLT,2023-05-15 20:01:00+00:00,US/Eastern,"Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals",UP,-0.002372524217616076,en
16613,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/05/15/2669273/0/en/NexImmune-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,2023-05-15 16:01:00+00:00,NexImmune,financial_results,"The predicted downward move of -0.07% for NexImmune may be due to disappointing financial results or market reactions to their progress reported in Q1 2023. This slight decline might reflect investor uncertainty or skepticism, potentially influencing similar biotech stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,357,NEXI,2023-05-15 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., May  15, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the first quarter 2023.   ",UP,-0.0007111336429491896,en
15375,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2669334/35690/en/OpGen-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-05-15 16:15:00+00:00,OpGen,earnings_releases_and_operating_results,"The predicted downward move of -0.49% is likely due to underwhelming first quarter financial results from OpGen. This could indicate investor disappointment, potentially diminishing confidence in the company's short-term growth, impacting stock sentiment negatively.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,293,OPGN,2023-05-15 20:15:00+00:00,US/Eastern,"ROCKVILLE, Md., May  15, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.",UP,-0.004926134115139008,en
14628,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2669369/0/en/Eloxx-Pharmaceuticals-Reports-First-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,2023-05-15 16:30:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The likely cause of the predicted upward move of +8.24% is the encouraging biopsy results and observed protein reduction in a patient, suggesting potential efficacy of ELX-02 for Alport syndrome. This may boost investor confidence and increase the asset's valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,254,ELOX,2023-05-15 20:30:00+00:00,US/Eastern,Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date,UP,0.0824155328788977,en
15618,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023,https://www.globenewswire.com/news-release/2023/05/16/2670411/0/en/Mydecine-Reports-Financial-Results-for-the-First-Quarter-of-Fiscal-Year-2023.html,2023-05-16 16:01:00+00:00,Mydecine Innovations Group,financial_results,"The predicted upward move of +0.02% likely stems from Mydecine's announcement of innovative treatments for mental health and addiction, which could boost investor confidence. This slight increase suggests modest market optimism and potential for long-term growth in the biotechnology sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,306,MYCO.CN,2023-05-16 20:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, May  16, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (""Mydecine"" or the ""Company""), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the three months ended March 31, 2023.",UP,0.00018950429415791646,en
14953,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders,https://www.globenewswire.com/news-release/2023/05/17/2671486/0/en/Vir-Biotechnology-to-Host-a-Virtual-Only-2023-Annual-Meeting-of-Stockholders.html,2023-05-17 16:05:00+00:00,Vir Biotechnology,annual_general_meeting,"The predicted downward move of -1.13% for Vir Biotechnology may be due to investor concerns ahead of the virtual annual meeting, possibly reflecting unease about company performance or strategic direction. This may cause short-term volatility in the stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-05-17 20:05:00+00:00,US/Eastern,"SAN FRANCISCO, May  17, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.",DOWN,-0.011302046578748155,en
16662,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation,https://www.globenewswire.com/news-release/2023/05/19/2672795/0/en/Celularity-Announces-Phase-1-Data-Showing-That-MLASC-Therapy-in-Patients-With-Crohn-s-Disease-May-Be-a-Therapeutic-Option-to-Manage-Inflammatory-Bowel-Diseases-and-Prevent-Fistula-.html,2023-05-19 16:21:00+00:00,Celularity,clinical_study,1. The predicted downward move of -1.29% could be due to market skepticism regarding the early-stage data's effectiveness. 2. This may lead to cautious investor sentiment and re-evaluation of stock valuations in related biotech firms.,globenewswire_biotech,biotech,Health,359,CELU,2023-05-19 20:21:00+00:00,US/Eastern,Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy with placental-derived mesenchymal-like adherent stem cells (MLASCs) results in alterations in gene and protein signatures associated with inflammation and fistula formation in patients with Crohn’s disease,UP,-0.012924087800436485,en
16612,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting,https://www.globenewswire.com/news-release/2023/05/22/2673784/0/en/NexImmune-Announces-Poster-Presentation-at-the-2023-FOCIS-Annual-Meeting.html,2023-05-22 16:01:00+00:00,NexImmune,clinical_study,"The predicted upward move of +7.58% is likely due to positive sentiment around AIM's nanoparticle approach in treating multiple sclerosis by targeting EBV+ cells. Improved treatments may increase market confidence, boosting the company's valuation and attracting investors.",globenewswire_biotech,biotech,Health,357,NEXI,2023-05-22 20:01:00+00:00,US/Eastern,AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease,DOWN,0.07577068929939841,en
16661,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,"Celularity Announces $45 Million Purchase Order,  First Middle East Private Label Agreement For  Celularity’s Halal-Certified Biomaterial Products",https://www.globenewswire.com/news-release/2023/05/23/2674277/0/en/Celularity-Announces-45-Million-Purchase-Order-First-Middle-East-Private-Label-Agreement-For-Celularity-s-Halal-Certified-Biomaterial-Products.html,2023-05-23 08:10:00+00:00,Celularity,geographic_expansion,"The predicted downward move of -0.53% may be due to investor skepticism about Celularity's new market venture and its execution risk. This could affect investor confidence, despite potential growth in the Middle Eastern market.",globenewswire_biotech,biotech,Product / Services Announcement,359,CELU,2023-05-23 12:10:00+00:00,US/Eastern,"FLORHAM PARK, N.J., May  23, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has received a $45 million purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store (Jamjoom). Dr. Walid Swelim will serve as marketing manager for promotion and distribution of the products. This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity’s global market strategy.",UP,-0.005292264535844835,en
15316,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,Disclosure of voting rights for Chairman of the Board,https://www.globenewswire.com/news-release/2023/05/24/2674970/0/en/Disclosure-of-voting-rights-for-Chairman-of-the-Board.html,2023-05-24 04:43:00+00:00,PCI Biotech Holding,annual_general_meeting,The predicted downward move of -1.13% for PCI Biotech may likely stem from negative news or market sentiment surrounding the company. This movement could lead to investor caution and potential short-term selloffs impacting share value.,globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-05-24 08:43:00+00:00,US/Eastern,"Oslo, 24 May 2023. PCI Biotech Holding ASA (""PCI Biotech"" or the ""Company"") issue this notification on behalf of its chairman, Hans Peter Bøhn.",UP,-0.011344172581415355,en
14627,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study,https://www.globenewswire.com/news-release/2023/05/24/2675190/0/en/Eloxx-Pharmaceuticals-Intends-to-Advance-ELX-02-into-Pivotal-Trial-for-the-Treatment-of-Alport-Syndrome-with-Nonsense-Mutations-Following-Achievement-of-Remission-in-Patient-in-Pha.html,2023-05-24 08:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,1. The downward movement is likely due to market expectations already accounting for the trial results. 2. Potential implications include reduced investor confidence or profit-taking. 3. The asset's predicted downward move of -1.52% reflects this sentiment.,globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-05-24 12:00:00+00:00,US/Eastern,"Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria",UP,-0.015204499070363215,en
15315,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,Minutes from Annual General Meeting 2023,https://www.globenewswire.com/news-release/2023/05/25/2675891/0/en/Minutes-from-Annual-General-Meeting-2023.html,2023-05-25 05:38:00+00:00,PCI Biotech Holding,annual_general_meeting,"1. The predicted downward move of -1.17% could be due to disappointing outcomes or announcements at PCI Biotech Holding ASA's Annual General Meeting. 2. This could signal investor concern, potentially lowering confidence and reducing investment in biotech stocks.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-05-25 09:38:00+00:00,US/Eastern,"Oslo, 25 May 2023. The Annual General Meeting in PCI Biotech Holding ASA took place today, 25 May 2023.",DOWN,-0.011722717866872406,en
16681,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers,https://www.globenewswire.com/news-release/2023/05/25/2676755/0/en/RAPT-Therapeutics-to-Present-Biomarker-Data-Corroborating-Demonstrated-Clinical-Activity-and-Mechanism-of-Action-of-FLX475-in-Advanced-Cancers.html,2023-05-25 17:00:00+00:00,RAPT Therapeutics,clinical_study,The predicted downward move of -7.84% may be due to skepticism about the efficacy of FLX475. Market implications could include reduced investor confidence and potential funding challenges for future developments.,globenewswire_biotech,biotech,Clinical Study,360,RAPT,2023-05-25 21:00:00+00:00,US/Eastern,-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response,UP,-0.07836769281468343,en
15617,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,"Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors",https://www.globenewswire.com/news-release/2023/05/29/2677937/0/en/Mydecine-Innovations-Group-Files-Prospectus-Supplement-Announces-Closing-Under-Share-Subscription-Agreement-and-Provides-Update-on-Its-Board-of-Directors.html,2023-05-29 19:42:00+00:00,Mydecine Innovations Group,prospectus_announcement,"The predicted downward move of +nan% may stem from investor uncertainty due to financing developments and regulatory processes. This uncertainty could lead to decreased stock demand, impacting share value and potentially affecting Mydecine's market position and future financing capabilities.",globenewswire_biotech,biotech,Management statements,306,MYCO.CN,2023-05-29 23:42:00+00:00,US/Eastern,"VANCOUVER, British Columbia, May  29, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated March 10, 2023, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).",DOWN,-1.527531053179254,en
16389,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs,https://www.globenewswire.com/news-release/2023/05/30/2678353/0/en/Rain-Oncology-Provides-Company-Update-and-Outlines-Strategic-Priorities-of-Milademetan-Clinical-Programs.html,2023-05-30 08:30:00+00:00,Rain Therapeutics,clinical_study,"The predicted downward move of -2.29% is likely due to reduced investor confidence following the suspended trial and terminated plans, signaling potential setbacks. This may lead to decreased enthusiasm for the company's future growth prospects and product pipeline.",globenewswire_biotech,biotech,Management statements,346,RAIN,2023-05-30 12:30:00+00:00,US/Eastern,– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial –,UP,-0.022858713454590264,en
15579,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1),https://www.globenewswire.com/news-release/2023/05/30/2678819/0/en/PepGen-Inc-Announces-Clinical-Hold-in-the-U-S-on-IND-Application-to-Initiate-a-Phase-1-Study-of-PGN-EDODM1-for-Myotonic-Dystrophy-Type-1-DM1.html,2023-05-30 16:05:00+00:00,PepGen,clinical_study,"The predicted upward move of +2.16% might stem from investor optimism about resolving the FDA hold, signaling confidence in the long-term potential of PepGen's therapy. This suggests market belief in PepGen's innovation despite regulatory hurdles.",globenewswire_biotech,biotech,Health,303,PEPG,2023-05-30 20:05:00+00:00,US/Eastern,"BOSTON, May  30, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) to initiate a Phase 1 study of PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1). The FDA indicated its intention to provide an official clinical hold letter to PepGen stating the reasons for the clinical hold within 30 days.",UP,0.021557595188068067,en
16660,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability,https://www.globenewswire.com/news-release/2023/06/01/2680450/0/en/Celularity-Tissue-Factor-Gene-Knockout-of-Allogeneic-Stromal-Cells-Significantly-Lowers-Thrombotic-Effects-Study-Highlights-Critical-Importance-of-Gene-Editing-Capability.html,2023-06-01 09:15:00+00:00,Celularity,clinical_study,"1. The likely cause of the predicted upward move of +8.48% is the promising study results enhancing the safety of ASC-based therapies. 2. This could increase investor confidence and demand, potentially boosting valuations in the biotech sector.",globenewswire_biotech,biotech,Clinical Study,359,CELU,2023-06-01 13:15:00+00:00,US/Eastern,"Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy ",UP,0.08477470341707136,en
16611,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/06/05/2681928/0/en/NexImmune-Presents-Initial-Positive-Data-from-the-NEXI-001-Phase-1-Trial-for-Relapsed-Refractory-Post-Allo-HSCT-AML-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting.html,2023-06-05 08:01:00+00:00,NexImmune,clinical_study,"1. The predicted upward move of +0.35% is likely due to positive trial developments in treating high-risk AML patients. 2. This could boost investor confidence, suggesting potential success in a challenging medical area, impacting stock positively.",globenewswire_biotech,biotech,Clinical Study,357,NEXI,2023-06-05 12:01:00+00:00,US/Eastern,- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy,UP,0.0035106861527267504,en
14952,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/06/05/2682362/0/en/Vir-Biotechnology-to-Participate-in-the-44th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html,2023-06-05 16:05:00+00:00,Vir Biotechnology,conference_call_webinar,"1. The predicted downward move of -0.69% could be due to market anticipation of lackluster or unclear outcomes from the conference chat. 2. This may lead to short-term selling pressure, affecting investor confidence in Vir Biotechnology stock.",globenewswire_biotech,biotech,Trade Show,272,VIR,2023-06-05 20:05:00+00:00,US/Eastern,"SAN FRANCISCO, June  05, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.",DOWN,-0.00685372906599654,en
14626,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,https://www.globenewswire.com/news-release/2023/06/06/2682826/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html,2023-06-06 08:30:00+00:00,Eloxx Pharmaceuticals,exchange_announcement,"The predicted upward move of +4.24% is likely due to progress in pivotal clinical trials for ELX-02 and ZKN-013. This advancement may increase investor confidence, potentially leading to higher market valuations and expanded funding opportunities for the company.",globenewswire_biotech,biotech,Exchange Members,254,ELOX,2023-06-06 12:30:00+00:00,US/Eastern,"Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study",UP,0.04240811190051372,en
14951,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023,https://www.globenewswire.com/news-release/2023/06/07/2683460/0/en/Vir-Biotechnology-Announces-Multiple-Abstracts-Highlighting-New-Hepatitis-B-and-D-Data-Accepted-for-Presentation-at-EASL-Congress-2023.html,2023-06-07 02:13:00+00:00,Vir Biotechnology,clinical_study,"The predicted upward move of +2.49% is likely due to positive data on VIR-2218 and VIR-3434's impact on HBV and HDV, boosting confidence in a functional cure. This could enhance investor optimism and increase the company's market value.",globenewswire_biotech,biotech,Clinical Study,272,VIR,2023-06-07 06:13:00+00:00,US/Eastern,– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – – Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – ,DOWN,0.024914656909033637,en
16680,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/06/07/2683699/0/en/RAPT-Therapeutics-to-Participate-in-the-Goldman-Sachs-Global-Healthcare-Conference.html,2023-06-07 08:00:00+00:00,RAPT Therapeutics,conference_call_webinar,"The predicted upward move of +0.25% for RAPT Therapeutics is likely due to increased investor interest from their CEO's participation in the Goldman Sachs Global Healthcare Conference. This could enhance visibility and credibility, potentially leading to broader market interest.",globenewswire_biotech,biotech,Calendar of Events,360,RAPT,2023-06-07 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., June  07, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 1:20 p.m. PT.",UP,0.0024677267083596595,en
16411,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023,https://www.globenewswire.com/news-release/2023/06/08/2685182/0/en/ContraFect-to-Present-New-Data-Demonstrating-the-Potential-Efficacy-of-Its-Engineered-Lysins-Against-Antibiotic-Resistant-Pathogens-at-ASM-Microbe-2023.html,2023-06-08 16:01:00+00:00,ContraFect,clinical_study,"The predicted upward move of +3.44% for ContraFect is likely due to its promising data presentation on CF-370 at the ASM Microbe Conference, highlighting efficacy against drug-resistant infections. Successful outcomes could enhance clinical prospects and investor interest, boosting market value.",globenewswire_biotech,biotech,Calendar of Events,347,CFRX,2023-06-08 20:01:00+00:00,US/Eastern,"YONKERS, N.Y., June  08, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023. The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumoniae).",UP,0.03443426702499047,en
15578,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1,https://www.globenewswire.com/news-release/2023/06/13/2687642/0/en/PepGen-Inc-Provides-Update-on-Planned-Initiation-of-Phase-1-Study-of-PGN-EDODM1-in-Myotonic-Dystrophy-Type-1.html,2023-06-13 16:05:00+00:00,PepGen,clinical_study,"The predicted upward move of +2.82% for PepGen Inc. suggests investor optimism despite delayed trial timelines. Potentially, market confidence stems from anticipated resolution with the FDA. This could bolster future asset reliability and long-term growth prospects.",globenewswire_biotech,biotech,Health,303,PEPG,2023-06-13 20:05:00+00:00,US/Eastern,"BOSTON, June  13, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that while it awaits receipt of an official clinical hold letter from the U.S. Food and Drug Administration (FDA), the Company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023 in any geography.",UP,0.028247346860261,en
14625,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients,https://www.globenewswire.com/news-release/2023/06/14/2688488/0/en/Eloxx-Pharmaceuticals-Announces-Final-Data-Assessment-from-Phase-2-Combination-Clinical-Trial-of-ELX-02-in-Class-1-Cystic-Fibrosis-CF-Patients.html,2023-06-14 16:53:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted upward move of +1.36% may be due to strong earnings reports or positive economic data. This could boost investor confidence, leading to increased buying activity. Such movement indicates potential market optimism and could set a bullish tone.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-06-14 20:53:00+00:00,US/Eastern, ,DOWN,0.013563763076545101,en
16563,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics to Present at Upcoming June Investor Conferences,https://www.globenewswire.com/news-release/2023/06/15/2688829/0/en/Bionomics-to-Present-at-Upcoming-June-Investor-Conferences.html,2023-06-15 08:00:00+00:00,Bionomics,conference_call_webinar,"The predicted downward move of -0.08% in Bionomics' stock could be due to investor uncertainty or lack of impactful news announced at the conferences. This slight decline may indicate cautious sentiment, potentially affecting short-term investor confidence.",globenewswire_biotech,biotech,Calendar of Events,354,BNOX,2023-06-15 12:00:00+00:00,US/Eastern,"ADELAIDE, Australia and CAMBRIDGE, Mass., June  15, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:",UP,-0.0008111566910986339,en
15374,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference,https://www.globenewswire.com/news-release/2023/06/20/2690943/35690/en/OpGen-Presents-Unyvero-Urinary-Tract-Infection-Panel-Trial-Results-at-ASM-Microbe-2023-Conference.html,2023-06-20 07:30:00+00:00,OpGen,clinical_study,"OpGen’s predicted upward move of +15.36% likely stems from promising clinical trial results for its UTI diagnostic panel, which could enhance its market position. This advancement may attract investor interest, increasing stock demand and potentially boosting OpGen's valuation.",globenewswire_biotech,biotech,Clinical Study,293,OPGN,2023-06-20 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., June  20, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe’s In Depth Symposium session ‘The Year in Clinical Microbiology’ on June 17th in Houston, TX. Based on over 1,800 patient samples, the presentation titled “Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens” summarized the objectives of the clinical trial, the Unyvero UTI panel coverage and result evaluation recommendations based on multiple reference testing methods applied during the study.",UP,0.153574245113115,en
16410,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens,https://www.globenewswire.com/news-release/2023/06/20/2691115/0/en/ContraFect-Data-Presentations-at-ASM-Microbe-2023-Demonstrate-the-Power-of-the-Company-s-Proprietary-Platform-to-Discover-New-Agents-Targeting-Antibiotic-Resistant-Gram-negative-Pa.html,2023-06-20 08:59:00+00:00,ContraFect,clinical_study,"The predicted upward move of +0.28% is likely driven by ContraFect's promising data on its direct lytic agents' effectiveness against drug-resistant pathogens. This could boost investor confidence, indicating potential advancements in treating antibiotic-resistant infections, positively impacting market sentiment.",globenewswire_biotech,biotech,Product / Services Announcement,347,CFRX,2023-06-20 12:59:00+00:00,US/Eastern,"YONKERS, N.Y., June  20, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the presentation of data showing significant activity of its direct lytic agents against the most drug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Klebsiella pneumoniae (K. pneumoniae) and Burkholderia spp, at ASM Microbe 2023 held from June 15-19, 2023 in Houston, Texas.",UP,0.0027771718006151047,en
14624,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress,https://www.globenewswire.com/news-release/2023/06/21/2692112/0/en/Eloxx-Pharmaceuticals-Highlights-Recent-Alport-Syndrome-Natural-History-Data-Presented-at-60th-ERA-Congress.html,2023-06-21 09:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted upward move of +7.58% is likely due to increased awareness of Alport syndrome's severe progression in patients with specific mutations, prompting investment in related treatments. This could lead to higher market interest and funding in relevant biotech sectors.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-06-21 13:00:00+00:00,US/Eastern,"Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure",UP,0.07575821272884341,en
14623,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome,https://www.globenewswire.com/news-release/2023/06/21/2692434/0/en/Eloxx-Pharmaceuticals-to-Host-Investor-and-Analyst-Call-on-Alport-Syndrome.html,2023-06-21 13:30:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The upward move of +8.39% is likely driven by increased investor confidence in advancements related to Alport syndrome insights. This may lead to higher valuations for companies involved, potentially boosting research investments and market interest in related healthcare sectors.",globenewswire_biotech,biotech,Health,254,ELOX,2023-06-21 17:30:00+00:00,US/Eastern,Globally renowned Alport syndrome experts will provide key insights,DOWN,0.08385996851120242,en
14999,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,ImmuCell Appoints Bryan K. Gathagan to Board of Directors,https://www.globenewswire.com/news-release/2023/06/21/2692501/0/en/ImmuCell-Appoints-Bryan-K-Gathagan-to-Board-of-Directors.html,2023-06-21 16:05:00+00:00,ImmuCell Corporation,management_changes,"The predicted upward move of +0.01% is likely due to investor confidence in Bryan K. Gathagan's appointment, indicating potential strategic growth. This movement suggests stable optimism about ImmuCell's future performance and management direction.",globenewswire_biotech,biotech,Directors and Officers,274,ICCC,2023-06-21 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, June  21, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors.",UP,8.409641645977201e-05,en
15373,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments,https://www.globenewswire.com/news-release/2023/06/22/2692799/35690/en/OpGen-s-Subsidiary-Curetis-Receives-Batch-of-Ten-New-C-Series-Unyvero-A30-Instruments.html,2023-06-22 07:30:00+00:00,OpGen,product_services_announcement,"The predicted upward move of +0.32% for OpGen is likely due to the successful delivery and testing of the Unyvero A30 C-Series instruments. This advancement could enhance OpGen's market position in rapid molecular diagnostics, potentially increasing investor confidence.",globenewswire_biotech,biotech,Product / Services Announcement,293,OPGN,2023-06-22 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., June  22, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.",DOWN,0.0032177314455223687,en
14950,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D,https://www.globenewswire.com/news-release/2023/06/24/2693970/0/en/Vir-Biotechnology-Presents-New-Data-Evaluating-the-Potential-for-VIR-2218-and-VIR-3434-as-Therapies-for-Chronic-Hepatitis-B-and-Hepatitis-D.html,2023-06-24 05:30:00+00:00,Vir Biotechnology,clinical_study,1. The predicted upward move of +3.16% is likely due to promising trial results showing the combination therapy's superior efficacy in reducing HBsAg levels. 2. This could increase investor confidence and lead to higher demand for the company's stock.,globenewswire_biotech,biotech,Clinical Study,272,VIR,2023-06-24 09:30:00+00:00,US/Eastern,– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or immunomodulators alone –,UP,0.03160324925509647,en
15372,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe,https://www.globenewswire.com/news-release/2023/06/26/2694329/35690/en/OpGen-Subsidiary-Ares-Genetics-Successfully-Maintains-Key-Patent-under-Opposition-in-Europe.html,2023-06-26 07:30:00+00:00,OpGen,patents,"The likely cause of the predicted upward move of +1.89% is the successful maintenance of a key patent, enhancing OpGen's position in precision medicine. This may bolster investor confidence, potentially increasing market value and competitive advantage.",globenewswire_biotech,biotech,Patents,293,OPGN,2023-06-26 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., June  26, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.",UP,0.018930534625675156,en
15739,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering,https://www.globenewswire.com/news-release/2023/06/26/2694829/0/en/MoonLake-Immunotherapeutics-Announces-Proposed-Underwritten-Public-Offering.html,2023-06-26 16:01:00+00:00,MoonLake Immunotherapeutics,shares_issue,"The proposed underwritten public offering likely dilutes existing shares, causing the predicted downward move of -0.70%. This can signal weaker investor confidence and possibly increase volatility or pressure on MoonLake Immunotherapeutics' stock in the short term.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2023-06-26 20:01:00+00:00,US/Eastern,MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering ,DOWN,-0.006951287480593497,en
16178,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma,https://www.globenewswire.com/news-release/2023/06/27/2695191/0/en/Harpoon-Therapeutics-Announces-Completion-of-Planned-Patient-Enrollment-in-Phase-1-Study-of-HPN217-in-Relapsed-Refractory-Multiple-Myeloma.html,2023-06-27 07:30:00+00:00,Harpoon Therapeutics,clinical_study,"The likely cause of the predicted upward move of +0.32% is the completion of patient enrollment in Harpoon Therapeutics' Phase 1 study, signaling progress in their drug development efforts. This development could boost investor confidence and potentially attract interest, affecting market dynamics positively.",globenewswire_biotech,biotech,Clinical Study,334,HARP,2023-06-27 11:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma. Additional patients currently in screening will also be allowed to enroll.",UP,0.0031666516520566386,en
16409,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million,https://www.globenewswire.com/news-release/2023/06/27/2695308/0/en/ContraFect-Enters-Into-a-Warrant-Exercise-Transaction-for-Proceeds-of-9-6-Million.html,2023-06-27 08:30:00+00:00,ContraFect,warrants_and_certificates,1. The predicted downward move of +nan% might be due to the dilution of stock value as a result of issuing new warrants. 2. This could lead to decreased investor confidence and potential selling pressure in the market.,globenewswire_biotech,biotech,Stock Market News,347,CFRX,2023-06-27 12:30:00+00:00,US/Eastern,"YONKERS, N.Y., June  27, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In connection with the exercise, the company also agreed to reduce the exercise price of such existing warrants to $1.36, which is equal to the most recent closing price of the company's common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement.",DOWN,-7.277152994354506,en
15738,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares,https://www.globenewswire.com/news-release/2023/06/28/2695949/0/en/MoonLake-Immunotherapeutics-Announces-Pricing-of-400-Million-Upsized-Public-Offering-of-Class-A-Ordinary-Shares.html,2023-06-28 05:00:00+00:00,MoonLake Immunotherapeutics,shares_issue,The predicted downward move of -1.04% is likely due to dilution concerns from the upsized $400 million offering. This could signal market apprehension about current valuation. Investors might reassess growth prospects amidst increased share supply.,globenewswire_biotech,biotech,Press releases,312,MLTX,2023-06-28 09:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares,UP,-0.010378128097595817,en
14622,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02,https://www.globenewswire.com/news-release/2023/06/28/2696256/0/en/Eloxx-Pharmaceuticals-Key-Opinion-Leader-Event-Highlights-Significant-Unmet-Need-in-Treatment-of-Alport-Syndrome-Patients-with-Nonsense-Mutations-and-Additional-Positive-Results-fr.html,2023-06-28 09:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted downward move of -0.55% likely stems from the lack of disease-modifying treatments for Alport syndrome, highlighting unmet medical needs. This may dampen investor confidence, affecting related healthcare stocks negatively due to limited treatment innovation prospects.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-06-28 13:00:00+00:00,US/Eastern,"Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available",DOWN,-0.0054669985613636455,en
14998,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,ImmuCell Announces Change in Timing of Anticipated FDA Submission,https://www.globenewswire.com/news-release/2023/06/28/2696602/0/en/ImmuCell-Announces-Change-in-Timing-of-Anticipated-FDA-Submission.html,2023-06-28 16:05:00+00:00,ImmuCell Corporation,regulatory_filings,"The predicted upward move of +0.75% likely stems from optimism about ImmuCell's FDA submission schedule change, suggesting potential progress. This could enhance investor confidence in regulatory approvals, potentially leading to increased market interest in the company's shares.",globenewswire_biotech,biotech,Calendar of Events,274,ICCC,2023-06-28 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, June  28, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule.",UP,0.007539744864050839,en
14949,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer,https://www.globenewswire.com/news-release/2023/06/29/2697070/0/en/Vir-Biotechnology-Appoints-Sasha-Damouni-Ellis-as-Executive-Vice-President-and-Chief-Corporate-Affairs-Officer.html,2023-06-29 09:00:00+00:00,Vir Biotechnology,management_changes,1. The predicted downward move of -0.11% may be due to investor uncertainty about the leadership transition and its impact on corporate strategy. 2. This could lead to short-term volatility as the market assesses Ms. Damouni Ellis's influence.,globenewswire_biotech,biotech,Management Changes,272,VIR,2023-06-29 13:00:00+00:00,US/Eastern,"SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir’s corporate social responsibility and environmental, social and governance efforts. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.",DOWN,-0.0011481171923191872,en
16659,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces  Presentation at Upcoming  7th International Conference on Orthopedics,https://www.globenewswire.com/news-release/2023/06/29/2697429/0/en/Celularity-Announces-Presentation-at-Upcoming-7th-International-Conference-on-Orthopedics.html,2023-06-29 16:05:00+00:00,Celularity,product_services_announcement,"1. The predicted upward move of +0.10% is likely due to promising in vitro study results showing support for human tenocyte functions from the placental connective tissue matrix. 2. This could enhance investor confidence in related biotech firms, potentially impacting stock valuations positively.",globenewswire_biotech,biotech,Calendar of Events,359,CELU,2023-06-29 20:05:00+00:00,US/Eastern,Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human tenocytes Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human tenocytes,UP,0.0010101431090100243,en
16562,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth,https://www.globenewswire.com/news-release/2023/07/03/2698382/0/en/Bionomics-Announces-Key-Leadership-Updates-to-Drive-U-S-Focused-Transformation-and-Next-Stage-of-Strategic-Growth.html,2023-07-03 06:00:00+00:00,Bionomics,management_changes,"The predicted upward move of +0.26% is likely due to leadership updates signaling strategic U.S. focus and capital efficiency, boosting investor confidence. This could lead to increased interest and valuation, enhancing growth potential in the CNS disorder sector.",globenewswire_biotech,biotech,Management Changes,354,BNOX,2023-07-03 10:00:00+00:00,US/Eastern,"ADELAIDE, Australia and CAMBRIDGE, Mass., July  03, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth.",UP,0.002602639468169263,en
15616,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Reports its Special Meeting Results,https://www.globenewswire.com/news-release/2023/07/05/2699901/0/en/Mydecine-Reports-its-Special-Meeting-Results.html,2023-07-05 16:01:00+00:00,Mydecine Innovations Group,voting_rights,"The predicted downward move of -0.19% is likely due to low shareholder turnout at the meeting, reflecting limited investor engagement or confidence. This could signal potential market skepticism about the company's strategies, impacting its stock appeal and investor sentiment.",globenewswire_biotech,biotech,Warrants and Certificates,306,MYCO.CN,2023-07-05 20:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, July  05, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its special meeting of shareholders which was held on Tuesday, July 4, 2023, by conference call (the “Meeting”). There were 15 shareholders represented in person or by proxy at the Meeting, holding 3,670,377 common shares, representing 14.72% of the Company’s total issued and outstanding common shares as of the record date for the Meeting. The voting results for the Meeting are set out below:",UP,-0.0019248154349228142,en
14621,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit,https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html,2023-07-10 09:00:00+00:00,Eloxx Pharmaceuticals,research_analysis_and_reports,"1. The predicted downward move of +nan% is likely due to investor skepticism or uncertainty about the publication's findings. 2. Such skepticism may lead to decreased investor confidence in biotech stocks, impacting market volatility and sentiment.",globenewswire_biotech,biotech,Product / Services Announcement,254,ELOX,2023-07-10 13:00:00+00:00,US/Eastern,Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications,UP,1.1398670054264246,en
14997,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023",https://www.globenewswire.com/news-release/2023/07/11/2703133/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q2-2023.html,2023-07-11 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"The predicted downward move of -1.57% could be due to the preliminary, unaudited sales results indicating weaker than expected performance for ImmuCell. This may lead to reduced investor confidence, possibly affecting the company’s stock and shareholder value.",globenewswire_biotech,biotech,Pre-Release Comments,274,ICCC,2023-07-11 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, July  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.",DOWN,-0.015702606317935942,en
16658,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Human Placental-Derived  Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies,https://www.globenewswire.com/news-release/2023/07/18/2706479/0/en/Celularity-Human-Placental-Derived-Advanced-Biomaterials-Demonstrate-Superior-Biocompatibility-and-Better-Support-Differentiated-Cell-Functions-in-Studies.html,2023-07-18 09:00:00+00:00,Celularity,conference_call_webinar,"1. The predicted upward move of +0.15% is likely due to positive sentiment from Celularity's presentation on placental-derived biomaterials' potential. 2. This could increase investor interest and confidence, potentially boosting its stock value and visibility in biotech markets.",globenewswire_biotech,biotech,Clinical Study,359,CELU,2023-07-18 13:00:00+00:00,US/Eastern,"Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering",UP,0.0015212122583065804,en
15371,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND,https://www.globenewswire.com/news-release/2023/07/19/2707193/35690/en/OpGen-s-Subsidiary-Curetis-Meets-Milestones-of-Extended-and-Expanded-R-D-Collaboration-with-FIND.html,2023-07-19 07:30:00+00:00,OpGen,press_releases,"1. The predicted downward move of -0.29% could be due to investor expectations being fully priced in after OpGen's successful milestone achievements. 2. This suggests limited immediate upside potential, potentially dampening short-term investor enthusiasm and affecting trading volumes.",globenewswire_biotech,biotech,Product / Services Announcement,293,OPGN,2023-07-19 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., July  19, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.",UP,-0.002912404566631281,en
14948,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness,https://www.globenewswire.com/news-release/2023/07/20/2708142/0/en/Vir-Biotechnology-Announces-Topline-Data-from-Phase-2-PENINSULA-Trial-Evaluating-VIR-2482-for-the-Prevention-of-Seasonal-Influenza-A-Illness.html,2023-07-20 08:00:00+00:00,Vir Biotechnology,clinical_study,The predicted upward move of +0.46% may result from optimistic interpretations of VIR-2482's partial efficacy in reducing symptomatic influenza A. The market could view the tolerance and absence of safety issues as a foundation for future development.,globenewswire_biotech,biotech,Clinical Study,272,VIR,2023-07-20 12:00:00+00:00,US/Eastern,"SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.",UP,0.004633147901364143,en
15615,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Provides Corporate Update,https://www.globenewswire.com/news-release/2023/07/21/2709138/0/en/Mydecine-Innovations-Group-Provides-Corporate-Update.html,2023-07-21 17:30:00+00:00,Mydecine Innovations Group,management_changes,"The predicted upward move of +0.15% likely stems from confidence in leadership stability due to John Ross's expanded role. This could enhance investor trust, signaling strong governance and potentially boosting market sentiment for Mydecine Innovations Group.",globenewswire_biotech,biotech,Health,306,MYCO.CN,2023-07-21 21:30:00+00:00,US/Eastern,"VANCOUVER, British Columbia, July  21, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that John Ross, the Company’s current Chief Financial Officer has been appointed as Corporate Secretary, effective immediately.",UP,0.0014921182194532995,en
16561,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX),https://www.globenewswire.com/news-release/2023/07/25/2710183/0/en/Bionomics-Announces-Intention-to-Delist-from-the-Australian-Securities-Exchange-ASX.html,2023-07-25 06:00:00+00:00,Bionomics,exchange_announcement,"1. The likely cause of the predicted downward move of -0.59% is the ASX delisting, reducing share accessibility to primarily U.S. investors. 2. This could limit liquidity and investor base, impacting the stock's market perception and value.",globenewswire_biotech,biotech,Stock Market News,354,BNOX,2023-07-25 10:00:00+00:00,US/Eastern,"ADELAIDE, Australia and CAMBRIDGE, Mass., July  25, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has submitted a formal request to the Australian Securities Exchange (“ASX”) to be removed from the official list of the ASX, in keeping with the Company’s ongoing transformation to a U.S. focused organization. The main consequence of an ASX delisting for shareholders is that, from the time the proposed ASX delisting is scheduled to take effect on August 28, 2023, Bionomics Shares will no longer be quoted or traded on the ASX, and will only be tradable in the form of American Depositary Shares on the NASDAQ Global Market (NASDAQ) under the symbol BNOX.",DOWN,-0.00593346311333246,en
15737,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts,https://www.globenewswire.com/news-release/2023/07/25/2710350/0/en/MoonLake-completes-patient-randomization-ahead-of-schedule-for-its-Phase-2-trial-in-active-psoriatic-arthritis-PsA-and-provides-calendar-of-next-readouts.html,2023-07-25 08:00:00+00:00,MoonLake Immunotherapeutics,clinical_study,"The predicted downward move of -0.18% may be due to market concerns over the trial's outcomes. Potential uncertainty about the trial results could lead investors to sell, impacting MoonLake's stock negatively.",globenewswire_biotech,biotech,Press releases,312,MLTX,2023-07-25 12:00:00+00:00,US/Eastern,MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts,DOWN,-0.0017862545726126137,en
16388,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,"Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023",https://www.globenewswire.com/news-release/2023/07/26/2711254/0/en/Rain-Oncology-to-Report-Second-Quarter-2023-Financial-Results-and-Provide-a-Corporate-Update-on-August-10-2023.html,2023-07-26 08:00:00+00:00,Rain Therapeutics,earnings_releases_and_operating_results,1. The predicted downward move of -0.27% is likely due to investor anticipation of underwhelming financial results for Rain Oncology's second quarter. 2. This may lead to reduced investor confidence and lower trading volume in the short term.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,346,RAIN,2023-07-26 12:00:00+00:00,US/Eastern,"NEWARK, Calif., July  26, 2023  (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.",UP,-0.0027459201408170154,en
14947,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology to Provide Business Update and Report Second Quarter 2023  Financial Results on August 3, 2023",https://www.globenewswire.com/news-release/2023/07/26/2711662/0/en/Vir-Biotechnology-to-Provide-Business-Update-and-Report-Second-Quarter-2023-Financial-Results-on-August-3-2023.html,2023-07-26 16:05:00+00:00,Vir Biotechnology,conference_call_webinar,"The predicted upward move of +3.64% likely stems from investor optimism about Vir Biotechnology's upcoming financial report. Positive results could enhance market confidence, potentially increasing investment interest and supporting further gains in the company’s stock value.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-07-26 20:05:00+00:00,US/Eastern,"SAN FRANCISCO, July  26, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023.",UP,0.036359599656560875,en
16657,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications,https://www.globenewswire.com/news-release/2023/07/27/2712254/0/en/Celularity-and-Vers%C3%A9a-Ophthalmics-Announce-Exclusive-U-S-Commercialization-Agreement-to-Distribute-Biovance-and-Biovance-3l-Ocular-For-Ophthalmic-Applications.html,2023-07-27 09:00:00+00:00,Celularity,partnerships,"Celularity's predicted upward move of +2.77% is likely due to their exclusive U.S. commercialization agreement with Verséa Ophthalmics, enhancing market confidence. This partnership may increase Celularity's revenue and market presence in ocular treatments.",globenewswire_biotech,biotech,Product / Services Announcement,359,CELU,2023-07-27 13:00:00+00:00,US/Eastern,"FLORHAM PARK, N.J. and TAMPA, Fla., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.",UP,0.02771657488161137,en
16656,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Inc. Announces $3 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2023/07/27/2712276/0/en/Celularity-Inc-Announces-3-Million-Registered-Direct-Offering.html,2023-07-27 09:07:00+00:00,Celularity,shares_issue,"The predicted downward move of -0.57% likely stems from shareholder dilution due to issuing new shares. This could pressure share prices, impacting investor confidence and future financing options. The sale significantly increases the share count at a low price point.",globenewswire_biotech,biotech,Stock Market News,359,CELU,2023-07-27 13:07:00+00:00,US/Eastern,"FLORHAM PARK, N.J., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined purchase price of $0.35 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $3 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.35, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about July 31, 2023, subject to the satisfaction of customary closing conditions.",DOWN,-0.00574747588280104,en
16560,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Quarterly Activities and Cashflow Report,https://www.globenewswire.com/news-release/2023/07/31/2714666/0/en/Quarterly-Activities-and-Cashflow-Report.html,2023-07-31 06:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +18.65% for Bionomics may be attributed to positive developments reported in their Quarterly Cashflow Report, indicating progress in their CNS disorder treatments. This could boost investor confidence, potentially increasing demand and share prices.",globenewswire_biotech,biotech,Management statements,354,BNOX,2023-07-31 10:00:00+00:00,US/Eastern,"ADELAIDE, Australia, and CAMBRIDGE, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 30 June 2023 (Quarter) and up to the date of this announcement include:",DOWN,0.18648109180062036,en
14589,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer,https://www.globenewswire.com/news-release/2023/07/31/2715235/0/en/AnaptysBio-and-GSK-Partnered-Immuno-Oncology-Agent-JEMPERLI-dostarlimab-gxly-plus-Chemotherapy-Approved-in-the-U-S-for-dMMR-MSI-H-Primary-Advanced-or-Recurrent-Endometrial-Cancer.html,2023-07-31 13:34:00+00:00,AnaptysBio,clinical_study,"The predicted upward move of +10.22% is likely due to FDA approval of JEMPERLI, enhancing AnaptysBio's prospects. This approval could boost investor confidence and potentially increase market interest in AnaptysBio's innovative therapies.",globenewswire_biotech,biotech,Health,252,ANAB,2023-07-31 17:34:00+00:00,US/Eastern,"SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.",UP,0.10217795281096496,en
16177,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development,https://www.globenewswire.com/news-release/2023/08/01/2715708/0/en/Harpoon-Therapeutics-Appoints-Haibo-Wang-as-Senior-Vice-President-of-Business-Development.html,2023-08-01 07:30:00+00:00,Harpoon Therapeutics,management_changes,"The predicted downward move of -1.37% in Harpoon Therapeutics shares may stem from investor skepticism despite a positive leadership change. Potential market implications include short-term volatility, but strategic hires may bolster future growth prospects.",globenewswire_biotech,biotech,Management Changes,334,HARP,2023-08-01 11:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Aug.  01, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon.",UP,-0.013700413192559602,en
15370,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time,https://www.globenewswire.com/news-release/2023/08/03/2717888/35690/en/OpGen-to-Provide-Business-Update-and-Financial-Results-for-the-Second-Quarter-2023-on-August-10th-at-4-30-p-m-Eastern-Time.html,2023-08-03 07:30:00+00:00,OpGen,conference_call_webinar,"The predicted upward move of +3.92% likely stems from investor anticipation of positive financial results and business updates. Market implications could include increased investor confidence and potential stock buying, signaling optimism about OpGen's future performance.",globenewswire_biotech,biotech,Calendar of Events,293,OPGN,2023-08-03 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.",UP,0.03917671056404697,en
16176,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August,https://www.globenewswire.com/news-release/2023/08/03/2717893/0/en/Harpoon-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-in-August.html,2023-08-03 07:30:00+00:00,Harpoon Therapeutics,press_releases,The predicted downward move of -0.02% could be due to investor sentiment and mild skepticism regarding upcoming conference participation. Potential market implications include limited investor engagement and slight short-term volatility in Harpoon Therapeutics' stock price.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,334,HARP,2023-08-03 11:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences:",UP,-0.0002059248592778969,en
15369,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement,https://www.globenewswire.com/news-release/2023/08/03/2717968/35690/en/OpGen-s-Subsidiary-Curetis-and-FIND-Extend-R-D-Collaboration-Agreement.html,2023-08-03 08:00:00+00:00,OpGen,partnerships,"1. The predicted upward move of +0.12% is likely due to OpGen's successful R&D collaboration with FIND, enhancing anticipation for innovative AMR solutions. 2. This could increase interest from investors focused on emerging markets and infectious disease solutions.",globenewswire_biotech,biotech,Partnerships,293,OPGN,2023-08-03 12:00:00+00:00,US/Eastern,"ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.",UP,0.0011920661176586167,en
15219,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test,https://www.globenewswire.com/news-release/2023/08/03/2718011/0/en/CVS-Health-to-Begin-Nationwide-In-Store-Sales-of-Biomerica-s-EZ-Detect-Colorectal-Disease-Screening-Test.html,2023-08-03 08:19:00+00:00,Biomerica,product_services_announcement,"The likely cause of the predicted upward move of +3.74% is CVS Pharmacy's rollout of Biomerica's EZ Detect screening test in over 7,000 stores. This expanded distribution could boost Biomerica's revenue and market visibility, potentially increasing investor interest.",globenewswire_biotech,biotech,Product / Services Announcement,285,BMRA,2023-08-03 12:19:00+00:00,US/Eastern,"IRVINE, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to CVS Health distribution centers in the US, and the product is projected to be on store shelves in September. The Company is also working with CVS Health to introduce an additional Biomerica product to be sold in CVS pharmacies.  ",UP,0.03736736247931108,en
14620,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,https://www.globenewswire.com/news-release/2023/08/03/2718175/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html,2023-08-03 09:26:00+00:00,Eloxx Pharmaceuticals,regulatory_filings,"The predicted upward move of +0.13% is likely due to Eloxx Pharmaceuticals receiving an extension for Nasdaq compliance. The market may view this as a positive sign of potential stability, alleviating delisting concerns and possibly boosting investor confidence.",globenewswire_biotech,biotech,Stock Market News,254,ELOX,2023-08-03 13:26:00+00:00,US/Eastern,"WATERTOWN, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compliance with Listing Rule 5550(b)(2), which requires a listed company to have at least $35 million in market value of listed securities in order to qualify for continued listing on the Nasdaq Capital Market, until October 9, 2023, following a request for an extension and update submitted by the Company on July 27, 2023.",UP,0.001292215802813517,en
14946,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/08/03/2718588/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Second-Quarter-2023-Financial-Results.html,2023-08-03 16:05:00+00:00,Vir Biotechnology,financial_results,"1. The predicted downward move of -0.58% likely stems from investor uncertainty about the Phase 2 data's outcome. 2. Market implications include potential volatility and cautious investor sentiment, possibly affecting related sectors or similar biotech assets.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,272,VIR,2023-08-03 20:05:00+00:00,US/Eastern,– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 –,UP,-0.005822595024108038,en
15368,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering,https://www.globenewswire.com/news-release/2023/08/07/2719601/35690/en/OpGen-s-Subsidiary-Ares-Genetics-Releases-New-Features-to-its-AREScloud-Offering.html,2023-08-07 07:30:00+00:00,OpGen,product_services_announcement,"The predicted upward move of +0.32% for OpGen likely stems from the major feature upgrade of the AREScloud platform, enhancing capabilities in genomic surveillance. This could improve OpGen's market position, attracting more clients and investors.",globenewswire_biotech,biotech,Product / Services Announcement,293,OPGN,2023-08-07 11:30:00+00:00,US/Eastern,"ROCKVILLE, Md., Aug.  07, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.",UP,0.0032177314455223687,en
19257,MBX,,MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia,https://www.globenewswire.com/news-release/2023/08/07/2719652/0/en/MBX-Biosciences-Announces-U-S-FDA-Clearance-of-IND-Application-for-MBX-1416-for-the-Treatment-of-Post-Bariatric-Hypoglycemia.html,2023-08-07 08:00:00+00:00,MBX Biosciences,clinical_study,"The predicted upward move of +2.87% is likely due to investor optimism about the Phase 1 trial's initiation and future results. This could boost market confidence, potentially increasing investment interest and improving the asset's valuation.",globenewswire_biotech,biotech,Product / Services Announcement,749,MBX,2023-08-07 12:00:00+00:00,US/Eastern,Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024 Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024,UP,2.8710541644586582,en
14996,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023",https://www.globenewswire.com/news-release/2023/08/07/2719984/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2023.html,2023-08-07 12:00:00+00:00,ImmuCell Corporation,conference_call_webinar,1. The predicted upward move of +0.58% is likely due to positive expectations from the upcoming conference call. 2. Such a move could boost investor confidence and potentially lead to increased buying activity in the market.,globenewswire_biotech,biotech,Health,274,ICCC,2023-08-07 16:00:00+00:00,US/Eastern,"Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET",DOWN,0.005769812633569901,en
14588,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/07/2720158/0/en/AnaptysBio-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-07 16:15:00+00:00,AnaptysBio,clinical_study,"AnaptysBio's predicted upward move of +7.65% is likely due to positive operating results or promising developments in their immunology therapeutics. This may boost investor confidence, potentially leading to increased market interest and higher share demand.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,252,ANAB,2023-08-07 20:15:00+00:00,US/Eastern,"SAN DIEGO, Aug.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.",UP,0.0764988120304237,en
15577,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments,https://www.globenewswire.com/news-release/2023/08/08/2720622/0/en/PepGen-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html,2023-08-08 08:15:00+00:00,PepGen,clinical_study,"The upward move of +16.63% is likely due to investor optimism about the CONNECT1-EDO51 study advancing to Phase 2 in Canada. This could lead to increased value for the asset, attracting more investors and potentially boosting market confidence.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,303,PEPG,2023-08-08 12:15:00+00:00,US/Eastern,– Phase 2 open-label CONNECT1-EDO51 study open in Canada –,DOWN,0.166255090899218,en
16175,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/09/2722076/0/en/Harpoon-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-08-09 16:01:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +7.83% is likely due to increased investor confidence from the abstracts' acceptance at prestigious medical conferences, signaling promising developments. Market implications include potential growth in investment and interest in the company's medical advancements.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,334,HARP,2023-08-09 20:01:00+00:00,US/Eastern,Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall,UP,0.07826235870733514,en
15736,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update,https://www.globenewswire.com/news-release/2023/08/10/2722470/0/en/MoonLake-Immunotherapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html,2023-08-10 07:00:00+00:00,MoonLake Immunotherapeutics,financial_results,The predicted upward move of +0.15% is likely due to positive financial results and progress in creating therapies for inflammatory diseases. Market implications could include increased investor confidence and potential for further investment in biotechnology innovation.,globenewswire_biotech,biotech,Press releases,312,MLTX,2023-08-10 11:00:00+00:00,US/Eastern,"ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2023.",UP,0.0015270482035859825,en
16610,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/08/10/2723104/0/en/NexImmune-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,2023-08-10 16:01:00+00:00,NexImmune,financial_results,1. The predicted upward move of +0.00% likely reflects stable investor confidence following the financial results. 2. This stability could maintain current market positions without causing significant volatility or prompting major investment shifts.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,357,NEXI,2023-08-10 20:01:00+00:00,US/Eastern,"GAITHERSBURG, Md., Aug.  10, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the second quarter of 2023.",UP,2.16881490687618e-05,en
14995,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023",https://www.globenewswire.com/news-release/2023/08/10/2723136/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2023.html,2023-08-10 16:05:00+00:00,ImmuCell Corporation,financial_results,"ImmuCell's reported financial results may indicate strong performance or growth potential, driving investor confidence. This could lead to increased demand, causing the predicted upward move of +0.32%. Positive results might boost the company's market position and attract investments.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,274,ICCC,2023-08-10 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, Aug.  10, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.",UP,0.003193630303649206,en
16387,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/10/2723127/0/en/Rain-Oncology-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-08-10 16:05:00+00:00,Rain Therapeutics,earnings_releases_and_operating_results,The predicted downward move of -0.65% could be due to uncertainty over the success of diversification efforts in precision oncology. Market implications might include cautious investor sentiment and potential hesitancy in short-term investments in the asset.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,346,RAIN,2023-08-10 20:05:00+00:00,US/Eastern,– Evaluating a number of opportunities to diversify pipeline in precision oncology –,DOWN,-0.006468938564717636,en
15367,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/10/2723188/35690/en/OpGen-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-10 16:15:00+00:00,OpGen,financial_results,"The predicted downward move of -0.11% likely stems from OpGen's reported financial results, which may have underperformed market expectations. This slight dip might influence investor sentiment, potentially leading to cautious trading around the stock.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,293,OPGN,2023-08-10 20:15:00+00:00,US/Eastern,"ROCKVILLE, Md., Aug.  10, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.",UP,-0.0010637371142034442,en
16679,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Reports Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/08/11/2723503/0/en/RAPT-Therapeutics-Reports-Second-Quarter-2023-Financial-Results.html,2023-08-11 08:00:00+00:00,RAPT Therapeutics,financial_results,"The predicted upward move of +0.34% likely results from the company's strong cash position of $205 million, signaling financial stability. This may attract investors, boosting demand and potentially enhancing stock valuation and market confidence.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,360,RAPT,2023-08-11 12:00:00+00:00,US/Eastern,Company maintains strong cash position of $205 million Company maintains strong cash position of $205 million,DOWN,0.0033954578515460587,en
15403,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/14/2724325/0/en/VBL-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-14 08:00:00+00:00,Vascular Biogenics,mergers_acquisitions,The predicted downward move of -0.21% likely stems from uncertainty surrounding regulatory approval and shareholder consent. Market implications could include cautious investor sentiment and potential short-term volatility during the merger finalization period.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,295,VBLT,2023-08-14 12:00:00+00:00,US/Eastern,"Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval",UP,-0.002083645407935238,en
14619,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html,2023-08-14 08:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"Despite positive clinical results, the predicted downward move of -2.41% suggests concerns over ELX-02's commercial viability or broader market conditions. This could reflect skepticism about long-term profitability, affecting investor confidence and stock performance.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-08-14 12:00:00+00:00,US/Eastern,All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02,UP,-0.02409741948929237,en
16408,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/14/2724427/0/en/ContraFect-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-14 08:30:00+00:00,ContraFect,financial_results,"The predicted downward move of -0.11% may be due to investor concerns over ContraFect's financial performance or uncertainty about clinical progress. This could imply cautious investor sentiment around biotech stocks, potentially influencing sector volatility.",globenewswire_biotech,biotech,Company Announcement,347,CFRX,2023-08-14 12:30:00+00:00,US/Eastern,"YONKERS, N.Y., Aug.  14, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the second quarter ended June 30, 2023.",UP,-0.0010637371142034442,en
14618,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,2023-08-14 08:30:00+00:00,Eloxx Pharmaceuticals,clinical_study,The likely cause is the promising clinical results of ELX-02 showing a 100% positive response in patients. The predicted upward move of +8.13% reflects investor optimism. Market implications include increased interest in biotech innovations.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,254,ELOX,2023-08-14 12:30:00+00:00,US/Eastern,"Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02",UP,0.08128184826417523,en
15614,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023,https://www.globenewswire.com/news-release/2023/08/15/2725147/0/en/Mydecine-Reports-Financial-Results-for-the-Second-Quarter-of-Fiscal-Year-2023.html,2023-08-14 20:32:00+00:00,Mydecine Innovations Group,financial_results,"The predicted upward move of +0.11% could be due to Mydecine Innovations' focus on innovative mental health treatments, including for addiction and PTSD. This slight rise may indicate cautious investor optimism, potentially positively influencing broader biotechnology investment sentiments.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,306,MYCO.CN,2023-08-15 00:32:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Aug.  14, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) (""Mydecine"" or the ""Company""), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six months ended June 30, 2023.",UP,0.0011307106678997874,en
16559,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210,https://www.globenewswire.com/news-release/2023/08/23/2730217/0/en/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2b-ATTUNE-Study-for-Post-Traumatic-Stress-Disorder-PTSD-and-Confirms-Expected-2023-Milestones-with-its-Lead-Asset-BNC210.html,2023-08-23 06:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +2.25% for Bionomics is likely due to the completion of the Phase 2 ATTUNE study, signaling progress towards a Phase 3 program. This could increase investor confidence and potentially boost the biotech sector's market perception.",globenewswire_biotech,biotech,Product / Services Announcement,354,BNOX,2023-08-23 10:00:00+00:00,US/Eastern,"ADELAIDE, Australia, and CAMBRIDGE, Mass., Aug.  23, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD.",UP,0.022534731776846062,en
14652,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer,https://www.globenewswire.com/news-release/2023/08/24/2731100/0/en/Radiopharm-Theranostics-Expands-Supply-Agreement-With-TerThera-for-Terbium-161-Isotope-Use-in-Prostate-Cancer.html,2023-08-24 08:00:00+00:00,Radiopharm Theranostics,clinical_study,"The predicted upward move of +15.01% is likely due to the agreement to supply Tb-161 for RAD 402, a promising radiopharmaceutical for advanced prostate cancer treatment. This development could enhance market confidence and attract investor interest in related assets.",globenewswire_biotech,biotech,Business Contracts,256,RAD.AX,2023-08-24 12:00:00+00:00,US/Eastern,"Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer",UP,0.15009961430461263,en
15314,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: Invitation to first half interim 2023 results presentation,https://www.globenewswire.com/news-release/2023/08/25/2731830/0/en/PCI-Biotech-Invitation-to-first-half-interim-2023-results-presentation.html,2023-08-25 08:30:00+00:00,PCI Biotech Holding,interim_information,"The predicted downward move of +nan% may be due to investor concerns about the interim report or market conditions. Potential implications include decreased investor confidence and pressure on stock prices, affecting PCI Biotech's market position and investor sentiment.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-08-25 12:30:00+00:00,US/Eastern,"Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2023 interim report on Thursday 31 August 2023, 08:30am – 09:30am CEST (local time).",UP,0.03979470230707128,en
15218,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Reports Fiscal 2023 Year End Results,https://www.globenewswire.com/news-release/2023/08/25/2732165/0/en/Biomerica-Reports-Fiscal-2023-Year-End-Results.html,2023-08-25 17:00:00+00:00,Biomerica,financial_results,"The predicted upward move of +0.66% for Biomerica, Inc. likely stems from strong fiscal 2023 financial results, indicating improved business performance. This movement could boost investor confidence and enhance market perception of the company's growth potential.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,285,BMRA,2023-08-25 21:00:00+00:00,US/Eastern,"IRVINE, Calif., Aug.  25, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results.",UP,0.006558148763697138,en
16407,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect to Present at the World Anti-Microbial Resistance Congress 2023,https://www.globenewswire.com/news-release/2023/08/28/2732525/0/en/ContraFect-to-Present-at-the-World-Anti-Microbial-Resistance-Congress-2023.html,2023-08-28 08:00:00+00:00,ContraFect,clinical_study,"The likely cause of the predicted upward move of +16.63% is investor optimism over ContraFect's promising DLA programs targeting antibiotic-resistant pathogens, which will be highlighted at the AMR Congress. This could boost investor confidence, increasing stock demand.",globenewswire_biotech,biotech,Calendar of Events,347,CFRX,2023-08-28 12:00:00+00:00,US/Eastern,"YONKERS, N.Y., Aug.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.",UP,0.16634879684135873,en
15217,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors,https://www.globenewswire.com/news-release/2023/08/28/2732577/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Joins-Biomerica-s-Board-of-Directors.html,2023-08-28 08:19:00+00:00,Biomerica,management_changes,"The predicted upward move of +0.03% in Biomerica Inc.'s stock is likely due to the positive market sentiment following Jack Kenny's appointment, leveraging his expertise from Meridian Bioscience. This could enhance strategic direction and foster investor confidence.",globenewswire_biotech,biotech,Directors and Officers,285,BMRA,2023-08-28 12:19:00+00:00,US/Eastern,"NEWPORT BEACH, Calif., Aug.  28, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leading global provider of diagnostic testing solutions. Meridian Biosciences was acquired on January 31, 2023 by SD Biosensor, Inc. and SJL Partners LLC in an all-cash transaction valued at approximately $1.53 billion.",UP,0.0003152162275042135,en
15879,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,"Faron Reports Half-Year Financial Results, January 1 – June 30, 2023",https://www.globenewswire.com/news-release/2023/08/29/2733033/0/en/Faron-Reports-Half-Year-Financial-Results-January-1-June-30-2023.html,2023-08-29 00:01:00+00:00,Faron Pharmaceuticals,financial_results,"The predicted upward move of +0.36% is likely due to improved earnings or positive outlooks. This modest increase may boost investor confidence, leading to further investment. It could signal stability, attracting cautious investors seeking gradual gains.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,319,FARON.HE,2023-08-29 04:01:00+00:00,US/Eastern,Summary Highlights (including post-period events)  ,DOWN,0.0036494771867617735,en
14994,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,ImmuCell Announces Submission of CMC Technical Section to the FDA,https://www.globenewswire.com/news-release/2023/08/29/2733350/0/en/ImmuCell-Announces-Submission-of-CMC-Technical-Section-to-the-FDA.html,2023-08-29 08:00:00+00:00,ImmuCell Corporation,regulatory_filings,"The predicted upward move of +0.67% is likely due to ImmuCell's recent FDA submission of the CMC Technical Section for Re-Tain®. This progress could enhance investor confidence, potentially boosting stock value and advancing market position in animal health.",globenewswire_biotech,biotech,Government News,274,ICCC,2023-08-29 12:00:00+00:00,US/Eastern,"PORTLAND, Maine, Aug.  29, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA.",UP,0.0067331786157804,en
19256,MBX,,MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/08/29/2733337/0/en/MBX-Biosciences-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference.html,2023-08-29 08:00:00+00:00,MBX Biosciences,conference_call_webinar,"The predicted downward move of -0.13% might be due to investor skepticism about MBX Biosciences' market potential or upcoming announcements. Market implications could include short-term caution from investors, affecting overall confidence and stock performance.",globenewswire_biotech,biotech,Calendar of Events,749,MBX,2023-08-29 12:00:00+00:00,US/Eastern,"CARMEL, Ind., Aug.  29, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Richard Bartram, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12th, 2023, at 11:30 a.m. Eastern Time and will host 1-on-1 investor meetings.",UP,-0.13404619711753496,en
16655,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron,https://www.globenewswire.com/news-release/2023/08/29/2733451/0/en/Celularity-Announces-Multi-Year-Research-Collaboration-Services-Agreement-With-Regeneron.html,2023-08-29 09:00:00+00:00,Celularity,partnerships,"The predicted upward move of +0.05% is likely due to Celularity's collaboration with Regeneron, enhancing research credibility. This partnership could boost investor confidence, fostering potential growth in allogeneic cell therapy developments and increasing market interest in Celularity.",globenewswire_biotech,biotech,Calendar of Events,359,CELU,2023-08-29 13:00:00+00:00,US/Eastern,"FLORHAM PARK, N.J., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates.",UP,0.00048715950037557493,en
14945,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences,https://www.globenewswire.com/news-release/2023/08/29/2733902/0/en/Vir-Biotechnology-to-Participate-in-Upcoming-Investor-Healthcare-Conferences.html,2023-08-29 16:30:00+00:00,Vir Biotechnology,conference_call_webinar,"The predicted downward move of -0.06% for Vir Biotechnology may be due to neutral investor reactions to their participation in conferences, suggesting no immediate groundbreaking announcements. Market implications include minor adjustments in stock price without major volatility.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,272,VIR,2023-08-29 20:30:00+00:00,US/Eastern,"SAN FRANCISCO, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September:",DOWN,-0.000617841589508136,en
15613,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Announces Conditional Approval of CSE Listing,https://www.globenewswire.com/news-release/2023/08/30/2734773/0/en/Mydecine-Announces-Conditional-Approval-of-CSE-Listing.html,2023-08-30 16:01:00+00:00,Mydecine Innovations Group,exchange_announcement,"The predicted downward move of -0.15% could be due to uncertainty surrounding Mydecine's transition from the NEO Exchange to the CSE. This might signal instability to investors, impacting short-term market perception and potentially causing temporary volatility.",globenewswire_biotech,biotech,Product / Services Announcement,306,MYCO.CN,2023-08-30 20:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) (""Mydecine"" or the ""Company""), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the ""CSE"") subject to fulfilling customary CSE requirements. The Company anticipates that trading will commence immediately upon receipt of voluntarily delisting approval from the NEO Exchange with a trading date to be provided in due course. The Company’s trading symbol “MYCO” will remain the same.",UP,-0.0014721258078365662,en
16678,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September,https://www.globenewswire.com/news-release/2023/08/30/2734782/0/en/RAPT-Therapeutics-to-Participate-in-Several-Upcoming-Investor-Conferences-in-September.html,2023-08-30 16:05:00+00:00,RAPT Therapeutics,conference_call_webinar,"The predicted upward move of +0.63% for RAPT Therapeutics' stock is likely due to increased investor interest from their participation in upcoming conferences. This involvement could boost visibility and investor confidence, potentially enhancing market sentiment.",globenewswire_biotech,biotech,Calendar of Events,360,RAPT,2023-08-30 20:05:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:",DOWN,0.0063004100638373965,en
15313,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech first half 2023 interim results,https://www.globenewswire.com/news-release/2023/08/31/2734882/0/en/PCI-Biotech-first-half-2023-interim-results.html,2023-08-31 01:00:00+00:00,PCI Biotech Holding,earnings_releases_and_operating_results,"The predicted downward move of -1.11% for PCI Biotech likely stems from disappointing interim first-half 2023 results. This can lead to decreased investor confidence, impacting stock liquidity and possibly prompting a short-term sell-off in the market.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-08-31 05:00:00+00:00,US/Eastern,"Oslo (Norway), 31 August 2023 – PCI Biotech (OSE: PCIB), today announces its interim first half 2023 results. Please find enclosed the report and presentation.Highlights review",UP,-0.011147074670506239,en
15455,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/31/2735151/0/en/Adagene-Reports-Six-Month-Financial-Results-for-2023-and-Provides-Corporate-Update.html,2023-08-31 07:32:00+00:00,Adagene,clinical_study,"The predicted upward move of +5.13% is likely due to advancements in anti-CTLA-4 therapy, improving efficacy in critical patient groups. This could boost the asset's value, increasing interest in biotech investments focused on cancer treatment technologies.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,297,ADAG,2023-08-31 11:32:00+00:00,US/Eastern,"- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –",UP,0.05131033555841038,en
16609,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy,https://www.globenewswire.com/news-release/2023/08/31/2735724/0/en/NexImmune-Announces-Workforce-Reduction-to-Enable-Continued-AIMTM-Nanoparticle-Platform-Development-Strategy.html,2023-08-31 16:45:00+00:00,NexImmune,corporate_action,"The predicted downward move of -0.02% likely stems from NexImmune's significant workforce reduction, signaling financial strain. This move suggests cost-saving efforts might raise concern about future growth, affecting investor confidence and potentially influencing market perceptions of biotech resilience.",globenewswire_biotech,biotech,Product / Services Announcement,357,NEXI,2023-08-31 20:45:00+00:00,US/Eastern,"GAITHERSBURG, Md., Aug.  31, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company’s cash. The realignment will reduce the Company’s workforce from 47 to 22 full-time employees as of September 5, 2023.",UP,-0.00023027155563887943,en
15312,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: Write-down of share capital registered,https://www.globenewswire.com/news-release/2023/09/01/2735848/0/en/PCI-Biotech-Write-down-of-share-capital-registered.html,2023-09-01 05:04:00+00:00,PCI Biotech Holding,changes_in_share_capital_and_votes,"The likely cause of the downward movement is the significant write-down of share capital, reducing investor confidence. The predicted downward move of +nan% could lead to decreased stock liquidity and valuation concerns in the market.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-09-01 09:04:00+00:00,US/Eastern,"Oslo, Norway, 1 September 2023 – PCI Biotech Holding ASA (OSE: PCIB) Reference is made to the resolution made by the Annual General Meeting 25 May 2023, in respect of a write-down of share capital by reducing the par value of PCI Biotech Holding ASA’s shares from NOK 3.00 to NOK 0.03.",UP,-3.2696304733766834,en
15576,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,"PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference",https://www.globenewswire.com/news-release/2023/09/01/2735983/0/en/PepGen-Announces-Presentations-at-the-2023-Myotonic-Dystrophy-Foundation-Annual-Conference-Ottawa-Neuromuscular-Disease-Meeting-and-H-C-Wainwright-25th-Annual-Global-Investment-Con.html,2023-09-01 08:00:00+00:00,PepGen,clinical_study,The likely cause for the predicted upward move of +14.19% in PepGen's stock could be due to positive anticipation surrounding their presentation of promising PGN-EDODM1 data at key conferences. This can enhance investor confidence and potentially increase market interest in their treatments.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,303,PEPG,2023-09-01 12:00:00+00:00,US/Eastern,"BOSTON, Sept.  01, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at upcoming medical meetings and an investor conference. Ashling Holland, Director of Preclinical Development at PepGen, will be giving a talk titled “PGN-EDODM1 nonclinical data demonstrated mechanistic and meaningful activity for the potential treatment of myotonic dystrophy type 1 (DM1)”, at the 2023 Myotonic Dystrophy Foundation Annual Conference, on September 9, 2023, in Washington, D.C.",UP,0.14189664942043687,en
15311,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: Employee share option scheme,https://www.globenewswire.com/news-release/2023/09/04/2736503/0/en/PCI-Biotech-Employee-share-option-scheme.html,2023-09-04 04:14:00+00:00,PCI Biotech Holding,corporate_action,"The predicted upward move of +1.10% is likely due to increased investor confidence following the company's decision to grant share options to key employees. This could signal future growth potential, potentially leading to increased market interest in PCI Biotech.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-09-04 08:14:00+00:00,US/Eastern,"Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.        ",UP,0.011030792723632827,en
16174,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September,https://www.globenewswire.com/news-release/2023/09/05/2737304/0/en/Harpoon-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-in-September.html,2023-09-05 08:00:00+00:00,Harpoon Therapeutics,conference_call_webinar,"The predicted upward move of +0.63% is likely driven by Harpoon Therapeutics' participation in upcoming investor conferences, boosting investor interest. This could enhance market visibility and confidence in the firm's strategic endeavors.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,334,HARP,2023-09-05 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Sept.  05, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences in September.",DOWN,0.0063004100638373965,en
16173,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,"Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023",https://www.globenewswire.com/news-release/2023/09/05/2737319/0/en/Harpoon-Therapeutics-to-Host-KOL-Event-in-Person-and-via-Webcast-on-September-15-2023.html,2023-09-05 08:05:00+00:00,Harpoon Therapeutics,clinical_study,"1. The predicted upward move of +17.99% is likely due to KOLs highlighting HPN328's potential in treating SCLC, NEPC, and other neuroendocrine tumors. 2. This may increase investor interest and drive funding towards further development of HPN328.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,334,HARP,2023-09-05 12:05:00+00:00,US/Eastern,"KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors",DOWN,0.17985079465716583,en
15878,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2738005/0/en/Faron-Pharmaceuticals-Ltd-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,2023-09-06 02:00:00+00:00,Faron Pharmaceuticals,conference_call_webinar,"The predicted downward move of -0.76% for Faron Pharmaceuticals may be due to investor anticipation of unimpressive updates at the conference. This could indicate cautious sentiment, potentially affecting Faron's ability to attract new investment at the event.",globenewswire_biotech,biotech,Calendar of Events,319,FARON.HE,2023-09-06 06:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Sept.  06, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023. In addition to the presentation, company management will be available for one-on-one meetings with investors.",UP,-0.007595400568553279,en
15735,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,"MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11",https://www.globenewswire.com/news-release/2023/09/06/2738194/0/en/MoonLake-Immunotherapeutics-to-host-a-Capital-Markets-Day-on-Monday-September-11.html,2023-09-06 07:00:00+00:00,MoonLake Immunotherapeutics,conference_call_webinar,"The predicted upward move of +0.26% is likely due to positive investor sentiment ahead of MoonLake Immunotherapeutics' Capital Markets Day, where new developments or strategies might be revealed. This could enhance investor confidence and potentially boost stock demand.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2023-09-06 11:00:00+00:00,US/Eastern,"MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11",UP,0.002562539154723386,en
16172,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting,https://www.globenewswire.com/news-release/2023/09/06/2738263/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Poster-Presentation-at-the-20th-International-Myeloma-Society-Annual-Meeting.html,2023-09-06 07:30:00+00:00,Harpoon Therapeutics,clinical_study,The predicted upward move of +8.43% is likely due to investor optimism surrounding the encouraging preliminary data from Harpoon Therapeutics' Phase 1 study. This could lead to increased interest and investment in the company's innovative cancer treatment platform.,globenewswire_biotech,biotech,Calendar of Events,334,HARP,2023-09-06 11:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.",UP,0.08428782686671946,en
15575,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences,https://www.globenewswire.com/news-release/2023/09/06/2738306/0/en/PepGen-Inc-Presents-PGN-EDODM1-Preclinical-Data-Supporting-the-Company-s-Enhanced-Delivery-Oligonucleotide-Platform-and-PGN-EDODM1-Program-at-Two-Medical-Conferences.html,2023-09-06 08:00:00+00:00,PepGen,clinical_study,1. The EDO platform's enhanced delivery efficiency is driving investor confidence. 2. The predicted upward move of +6.19% might attract more investment and boost stock volatility. 3. Potential market implications include increased interest in oligonucleotide technologies and related sectors.,globenewswire_biotech,biotech,Clinical Study,303,PEPG,2023-09-06 12:00:00+00:00,US/Eastern,- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -,UP,0.06192302195704981,en
15402,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC,https://www.globenewswire.com/news-release/2023/09/06/2738347/0/en/VBL-Therapeutics-Announces-that-S-4-Registration-Statement-for-Proposed-Merger-with-Notable-Labs-Is-Declared-Effective-by-SEC.html,2023-09-06 08:00:00+00:00,Vascular Biogenics,mergers_acquisitions,"The predicted downward move of -0.06% likely stems from uncertainty surrounding the shareholder approval process. Market implications may include temporary hesitancy among investors, impacting short-term asset volatility and trading volumes.",globenewswire_biotech,biotech,Mergers and Acquisitions,295,VBLT,2023-09-06 12:00:00+00:00,US/Eastern,"Merger with Notable expected to close in mid-October, subject to shareholder approval",UP,-0.0006213041686172176,en
15574,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1,https://www.globenewswire.com/news-release/2023/09/06/2738854/0/en/PepGen-Inc-Announces-Clearance-of-CTA-by-Health-Canada-to-Begin-the-FREEDOM-DM1-Phase-1-Study-of-PGN-EDODM1-in-Patients-with-Myotonic-Dystrophy-Type-1.html,2023-09-06 16:05:00+00:00,PepGen,clinical_study,"The predicted upward move of +5.03% is likely due to the FDA granting Orphan Drug Designation to PGN-EDODM1, signaling potential market exclusivity and future revenue. This could increase investor interest and enhance the company's financial prospects.",globenewswire_biotech,biotech,Product / Services Announcement,303,PEPG,2023-09-06 20:05:00+00:00,US/Eastern,The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1),UP,0.050335223407659814,en
15454,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene to Present at Investor and Scientific Conferences in September,https://www.globenewswire.com/news-release/2023/09/07/2739093/0/en/Adagene-to-Present-at-Investor-and-Scientific-Conferences-in-September.html,2023-09-07 06:00:00+00:00,Adagene,conference_call_webinar,"The predicted upward move of +0.04% is likely due to investor optimism about Adagene's developments in Treg depletion for anti-CTLA-4 therapies. This innovation could enhance treatment efficacy, potentially increasing interest in the company's stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,297,ADAG,2023-09-07 10:00:00+00:00,US/Eastern,"– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –",DOWN,0.0004390783003304384,en
15310,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: European patent for mRNA delivery with fimaNAc,https://www.globenewswire.com/news-release/2023/09/07/2739127/0/en/PCI-Biotech-European-patent-for-mRNA-delivery-with-fimaNAc.html,2023-09-07 06:36:00+00:00,PCI Biotech Holding,patents,"The predicted upward move of +1.69% is likely due to the European Patent Office's intent to grant PCI Biotech a patent for mRNA delivery using fimaNAc technology. This could enhance PCI's market position, especially in dermatology applications, increasing investor confidence.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-09-07 10:36:00+00:00,US/Eastern,"Oslo (Norway), 7 September 2023 – PCI Biotech (OSE: PCIB), a biopharmaceutical company, today announces that the European Patent Office (EPO) has informed PCI Biotech that they intend to grant a new patent covering delivery of mRNA by use of PCI Biotech’s fimaNAc technology. This application is primarily foreseen to be used for dermatology.",DOWN,0.01688477444382867,en
14617,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013,https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html,2023-09-07 09:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted upward move of +18.11% likely stems from investor optimism about ELX-02's potential as a treatment for Alport syndrome. An FDA IND submission generally signals positive progress, potentially boosting the company's market value and competitive advantage.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-09-07 13:00:00+00:00,US/Eastern,Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations,UP,0.18107663346743877,en
16654,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,"Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors",https://www.globenewswire.com/news-release/2023/09/07/2739783/0/en/Celularity-Appoints-Geoffrey-Shiu-Fei-Ling-M-D-Ph-D-to-its-Board-of-Directors.html,2023-09-07 16:10:00+00:00,Celularity,management_changes,1. The predicted downward move of -0.35% likely stems from market skepticism about the new cellular therapies' commercial viability. 2. Potential market implications include reduced investor confidence and cautious trading behavior in related biotech stocks.,globenewswire_biotech,biotech,Directors and Officers,359,CELU,2023-09-07 20:10:00+00:00,US/Eastern,Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular Therapies Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular Therapies,DOWN,-0.003493558314805748,en
19255,MBX,,"MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults",https://www.globenewswire.com/news-release/2023/09/11/2740712/0/en/MBX-Biosciences-Announces-Positive-Phase-1-Multiple-Ascending-Dose-Data-for-MBX-2109-a-Long-Acting-Parathyroid-Hormone-Peptide-Prodrug-in-Healthy-Adults.html,2023-09-11 08:00:00+00:00,MBX Biosciences,clinical_study,"The predicted downward move of -6.13% is likely due to the lack of positive catalysts from ""generally well-tolerated"" findings, indicating potential investor disappointment. Market implications include decreased investor confidence, possible re-evaluation of company prospects, and increased volatility.",globenewswire_biotech,biotech,Product / Services Announcement,749,MBX,2023-09-11 12:00:00+00:00,US/Eastern,MBX 2109 was observed to be generally well-tolerated,DOWN,-6.1333062469906645,en
14587,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit,https://www.globenewswire.com/news-release/2023/09/12/2741776/0/en/AnaptysBio-to-Present-at-the-Stifel-2023-Immunology-and-Inflammation-Virtual-Summit.html,2023-09-12 09:15:00+00:00,AnaptysBio,conference_call_webinar,"The predicted downward move of -1.13% could be due to investor uncertainty surrounding the outcomes of AnaptysBio's presentation. This may impact market confidence, potentially leading to reduced short-term investment in the company's stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,252,ANAB,2023-09-12 13:15:00+00:00,US/Eastern,"SAN DIEGO, Sept.  12, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.",UP,-0.011320438298670812,en
14758,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,"Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023",https://www.globenewswire.com/news-release/2023/09/13/2742398/0/en/Science-37-Recognized-in-the-Gartner-Hype-Cycle-for-Life-Science-Clinical-Development-2023.html,2023-09-13 07:59:00+00:00,Science 37,contests_awards,"The predicted downward move of +nan% may be due to the ambiguity in growth expectations following the Gartner recognition. This uncertainty might lead to cautious investor sentiment, impacting market confidence and potentially limiting immediate investment inflows.",globenewswire_biotech,biotech,Contests/Awards,261,SNCE,2023-09-13 11:59:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stated by Gartner, “This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institutions, and contract research sectors.”",UP,0.7534656852406578,en
16171,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie,https://www.globenewswire.com/news-release/2023/09/13/2742865/0/en/Harpoon-Therapeutics-Provides-an-Update-on-the-HPN217-Development-and-Option-Agreement-with-AbbVie.html,2023-09-13 16:05:00+00:00,Harpoon Therapeutics,licensing_agreements,"1. The predicted upward move of +0.59% is likely due to Harpoon retaining full rights to its HPN217 program, which may increase future revenue potential. 2. This could strengthen investor confidence in Harpoon's autonomy and development capabilities.",globenewswire_biotech,biotech,Product / Services Announcement,334,HARP,2023-09-13 20:05:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. ​The Agreement, which will terminate effective October 12, 2023, granted AbbVie an option to a worldwide, exclusive license to the HPN217 program. The program has been and will remain exclusively owned by Harpoon, and the company plans to complete the ongoing Phase 1 clinical trial with data to support the next phase of development.",UP,0.005916507441833383,en
16558,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD,https://www.globenewswire.com/news-release/2023/09/14/2743067/0/en/Bionomics-Announces-Update-on-the-%CE%B17-Nicotinic-Acetylcholine-Receptor-nAChR-Positive-Allosteric-Modulator-PAM-Collaboration-with-MSD.html,2023-09-14 06:00:00+00:00,Bionomics,clinical_study,"1. The likely cause of the predicted upward move of +13.59% is the positive update on Bionomics' collaboration with MSD, showcasing progress with their α7 nAChR PAM candidate. 2. This could increase investor confidence and drive further investments in the biotechnology sector.",globenewswire_biotech,biotech,Product / Services Announcement,354,BNOX,2023-09-14 10:00:00+00:00,US/Eastern,"ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada). Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375), was recently presented at the Society for Chemical Industry (SCI) and Royal Society of Chemistry (RSC) 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13, 2023.",UP,0.13589429299746322,en
16170,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort,https://www.globenewswire.com/news-release/2023/09/15/2743899/0/en/Harpoon-Therapeutics-Announces-First-Patients-with-Small-Cell-Lung-Cancer-Dosed-in-HPN328-Combination-Cohort.html,2023-09-15 07:15:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +5.60% for Harpoon Therapeutics is likely due to the dosing of small cell lung cancer patients in their HPN328 trial and the strategic partnership with Roche. This development may increase investor confidence in Harpoon's pipeline, impacting market perception positively.",globenewswire_biotech,biotech,Clinical Study,334,HARP,2023-09-15 11:15:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial and Roche will supply atezolizumab. This announcement is being made in conjunction with Harpoon’s investor event, “DLL3 Market Opportunity and KOL Discussion of HPN328,” held virtually and in person today in New York beginning at 8 a.m. ET.",UP,0.05598426191407176,en
15612,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Files Prospectus Supplement,https://www.globenewswire.com/news-release/2023/09/15/2744268/0/en/Mydecine-Innovations-Group-Files-Prospectus-Supplement.html,2023-09-15 17:30:00+00:00,Mydecine Innovations Group,prospectus_announcement,"The predicted downward move of +nan% possibly stems from investor uncertainty related to the Prospectus Supplement filing, which may signal potential dilution. Market implications could include decreased investor confidence and share price volatility.",globenewswire_biotech,biotech,Prospectus/Announcement of Prospectus,306,MYCO.CN,2023-09-15 21:30:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Sept.  15, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with certain Common Share Subscription Agreements (the “Subscription Agreements”) entered into with third-party investors (collectively, the “Investors”) dated September 15, 2023, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus (the “Base Shelf Prospectus”) for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).",DOWN,0.5803194903506883,en
14616,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,https://www.globenewswire.com/news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html,2023-09-18 07:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted downward move of -3.47% is likely due to the confirmation of negative findings by the expert, reinforcing Mayo Clinic's assessment. This can erode market confidence, leading to potential divestment and decreased asset valuation.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2023-09-18 11:00:00+00:00,US/Eastern,Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans,UP,-0.03466309503983428,en
16406,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370,https://www.globenewswire.com/news-release/2023/09/18/2744662/0/en/ContraFect-Announces-Submission-of-IND-Application-to-the-FDA-for-its-Development-Candidate-CF-370.html,2023-09-18 07:30:00+00:00,ContraFect,clinical_study,"The likely cause of the predicted upward move of +7.14% is ContraFect's submission of an IND application for CF-370 to the FDA. This indicates progress in its drug pipeline, potentially increasing investor confidence and market valuation.",globenewswire_biotech,biotech,Regulatory information,347,CFRX,2023-09-18 11:30:00+00:00,US/Eastern,"YONKERS, N.Y., Sept.  18, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).",UP,0.07137519030130285,en
14586,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors,https://www.globenewswire.com/news-release/2023/09/18/2745192/0/en/AnaptysBio-Announces-Appointment-of-John-Orwin-as-Chairman-of-the-Board-of-Directors.html,2023-09-18 16:15:00+00:00,AnaptysBio,management_changes,The predicted downward move of -0.33% may be due to investor uncertainty regarding the leadership change. Market implications could include cautious trading and short-term volatility as stakeholders assess John Orwin's potential impact on AnaptysBio's strategic direction.,globenewswire_biotech,biotech,Directors and Officers,252,ANAB,2023-09-18 20:15:00+00:00,US/Eastern,"SAN DIEGO, Sept.  18, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.",UP,-0.0032906843804554266,en
14615,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2023-09-19 08:00:00+00:00,Eloxx Pharmaceuticals,shares_issue,"The predicted upward move of +0.08% is likely due to investor optimism from Eloxx's newly announced stock issuance and sale agreements. This move could increase liquidity and investor interest, signaling confidence in Eloxx's future potential within the market.",globenewswire_biotech,biotech,Prospectus/Announcement of Prospectus,254,ELOX,2023-09-19 12:00:00+00:00,US/Eastern,"WATERTOWN, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.",DOWN,0.0008350454113482472,en
16405,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development,https://www.globenewswire.com/news-release/2023/09/19/2745601/0/en/ContraFect-to-Present-at-the-ASM-ESCMID-Joint-Conference-on-Drug-Development.html,2023-09-19 08:30:00+00:00,ContraFect,conference_call_webinar,The predicted downward move of -0.70% for ContraFect Corporation may be due to investor skepticism surrounding the presentation at the conference. Market implications could include reduced short-term investor confidence and increased scrutiny on the company's clinical developments.,globenewswire_biotech,biotech,Calendar of Events,347,CFRX,2023-09-19 12:30:00+00:00,US/Eastern,"YONKERS, New York, Sept.  19, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023.",DOWN,-0.007013684108177856,en
15611,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Announces Closing of Prospectus Supplement Financing,https://www.globenewswire.com/news-release/2023/09/19/2746008/0/en/Mydecine-Innovations-Announces-Closing-of-Prospectus-Supplement-Financing.html,2023-09-19 16:01:00+00:00,Mydecine Innovations Group,shares_issue,"The predicted upward move of +1.18% is likely due to Mydecine closing its $3,750,000 offering, which strengthens its financial position. This may increase investor confidence, potentially leading to higher trading volumes and positive sentiment around Mydecine's stock.",globenewswire_biotech,biotech,Changes in company's own shares,306,MYCO.CN,2023-09-19 20:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Sept.  19, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,7500,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,7500,000.",DOWN,0.011757921147709006,en
14757,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,"Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List",https://www.globenewswire.com/news-release/2023/09/20/2746374/0/en/Science-37-Chief-Delivery-Officer-Darcy-Forman-Named-to-Prestigious-PharmaVoice-100-List.html,2023-09-20 07:59:00+00:00,Science 37,contests_awards,"1. The predicted downward move of +nan% could be due to a data error or analyst discrepancy that implies uncertainty around Science 37's valuation. 2. Such uncertainty might lead to short-term volatility, affecting investor confidence.",globenewswire_biotech,biotech,Contests/Awards,261,SNCE,2023-09-20 11:59:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Sept.  20, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that its Chief Delivery Officer, Darcy Forman, has been honored with a coveted spot on the prestigious PharmaVoice 100 list. This recognition not only underscores Darcy's leadership, it highlights the industry-wide impact of Science 37 and its positive contributions to patients, community providers, CROs, and clinical trial sponsors.",UP,-2.2140361153549826,en
14944,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV",https://www.globenewswire.com/news-release/2023/09/20/2746429/0/en/Vir-Biotechnology-Announces-First-Participant-Dosed-in-New-Phase-1-Trial-Evaluating-VIR-1388-an-Investigational-T-Cell-Vaccine-for-the-Prevention-of-HIV.html,2023-09-20 08:00:00+00:00,Vir Biotechnology,clinical_study,The predicted upward move of +2.08% is likely due to positive sentiment surrounding the innovative HIV vaccine development. This could enhance market optimism about future biotech advancements and increase investor interest in similar medical technology stocks.,globenewswire_biotech,biotech,Clinical Study,272,VIR,2023-09-20 12:00:00+00:00,US/Eastern,"– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –",DOWN,0.02079493759326012,en
15610,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing,https://www.globenewswire.com/news-release/2023/09/20/2746742/0/en/Mydecine-Innovations-Announces-Amended-Press-Release-Relating-to-the-Closing-of-Prospectus-Supplement-Financing.html,2023-09-20 12:12:00+00:00,Mydecine Innovations Group,shares_issue,"The likely cause of the predicted upward move of +1.18% is the successful closing of Mydecine's $3,750,000 share offering. This could improve investor confidence and enhance market positioning, potentially elevating stock value and increasing interest in mental health and addiction treatments.",globenewswire_biotech,biotech,Changes in company's own shares,306,MYCO.CN,2023-09-20 16:12:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.",DOWN,0.011757921147709006,en
15877,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,"Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer",https://www.globenewswire.com/news-release/2023/09/21/2746967/0/en/Faron-Appoints-Dr-Birge-Berns-MD-as-Interim-Chief-Medical-Officer.html,2023-09-21 02:00:00+00:00,Faron Pharmaceuticals,management_changes,The predicted downward move of -0.49% may be caused by leadership changes affecting investor confidence. Potential market implications include uncertainty regarding strategic direction and execution risks in bexmarilimab's development as investors assess the transition's impact.,globenewswire_biotech,biotech,Directors and Officers,319,FARON.HE,2023-09-21 06:00:00+00:00,US/Eastern,"• Dr. Marie-Louise Fjällskog, outgoing CMO, is proposed to continue key role in bexmarilimab’s development as a Board member",UP,-0.004896120832805798,en
16703,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/21/2747284/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html,2023-09-21 08:30:00+00:00,Checkpoint Therapeutics,conference_call_webinar,"The predicted upward move of +0.44% for Checkpoint Therapeutics likely results from increased investor interest due to CEO participation in the Cantor Global Healthcare Conference. This may enhance exposure and confidence, positively impacting market perception and trading activity.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,361,CKPT,2023-09-21 12:30:00+00:00,US/Eastern,"WALTHAM, Mass., Sept.  21, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City. The Company will also attend in-person one-on-one meetings during the conference.",DOWN,0.004400430986373098,en
15876,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting,https://www.globenewswire.com/news-release/2023/09/22/2747864/0/en/Faron-Pharmaceuticals-Ltd-Results-of-the-Extraordinary-General-Meeting.html,2023-09-22 06:33:00+00:00,Faron Pharmaceuticals,management_changes,"The predicted downward move of -0.05% likely stems from the market's muted reaction to routine EGM updates, where all proposals were already expected to pass. Such stability may imply limited immediate impact, suggesting no significant change in investor sentiment.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,319,FARON.HE,2023-09-22 10:33:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Sept.  22, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the ""EGM"") of the Company took place today, September 22, 2023 in Turku, Finland. The EGM approved all proposals of the Board of Directors (""Board"") as set out in the notice of the EGM published on September 1, 2023.",UP,-0.0004873962476455036,en
15875,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Pharmaceuticals Announces Board Changes,https://www.globenewswire.com/news-release/2023/09/22/2748072/0/en/Faron-Pharmaceuticals-Announces-Board-Changes.html,2023-09-22 11:00:00+00:00,Faron Pharmaceuticals,management_changes,"1. The predicted downward move of -0.08% is likely due to market participants' cautious reaction to new leadership appointments, as they may initially lead to uncertainty. 2. Potential market implications include short-term hesitation from investors, awaiting clarity on strategic direction.",globenewswire_biotech,biotech,Directors and Officers,319,FARON.HE,2023-09-22 15:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Sept.  22, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier today. ",DOWN,-0.0008092922746529944,en
15216,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test,https://www.globenewswire.com/news-release/2023/09/26/2749488/0/en/Dubai-Government-Grants-Insurance-Reimbursement-for-Biomerica-s-EZ-Detect-Colorectal-Disease-Screening-Test.html,2023-09-26 08:19:00+00:00,Biomerica,product_services_announcement,"The predicted upward move of +3.74% likely results from increased demand for the innovative colorectal cancer test. Market implications suggest heightened interest in healthcare stocks, potentially boosting investment in preventive medical solutions.",globenewswire_biotech,biotech,Clinical Study,285,BMRA,2023-09-26 12:19:00+00:00,US/Eastern,"Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide",UP,0.03736736247931108,en
15573,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology,https://www.globenewswire.com/news-release/2023/09/27/2750760/0/en/PepGen-Announces-Upcoming-Presentations-at-the-28th-Annual-Congress-of-the-World-Muscle-Society-and-the-World-Congress-of-Neurology.html,2023-09-27 16:16:00+00:00,PepGen,clinical_study,"PepGen Inc.'s predicted upward move of +12.36% is likely due to heightened investor interest ahead of its presentations at the World Muscle Society Congress. Successful presentations may boost market confidence, potentially attracting more investment in their therapies.",globenewswire_biotech,biotech,Calendar of Events,303,PEPG,2023-09-27 20:16:00+00:00,US/Eastern,"BOSTON, Sept.  27, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina. Details of the presentations can be found below: ",UP,0.12364529592779665,en
15609,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date,https://www.globenewswire.com/news-release/2023/09/27/2750787/0/en/Mydecine-Innovations-Group-Announces-Expected-U-K-Dual-Listing-Admission-Date.html,2023-09-27 17:18:00+00:00,Mydecine Innovations Group,exchange_announcement,"1. The predicted downward move of -0.15% is likely due to market anticipation of increased supply once Mydecine starts trading on the AQSE Growth Market. 2. This could signal tension between investor expectations and current performance, affecting market confidence.",globenewswire_biotech,biotech,Major shareholder announcements,306,MYCO.CN,2023-09-27 21:18:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Sept.  27, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce expected admission of its common shares to begin trading on the Access Segment of the AQSE Growth Market in the UK is expected to take place on October 10th, 2023. The AQSE Growth Market is a multilateral trading facility operated by Aquis Stock Exchange. A copy of the application announcement can be accessed at the following link: https://aqx-web-prod-s3-public-read.s3.eu-west-2.amazonaws.com/20230926_Application_Announcement_1_5533c9b702.pdf",UP,-0.0014721258078365662,en
15839,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer,https://www.globenewswire.com/news-release/2023/09/27/2750791/0/en/Elicio-Therapeutics-Presents-Updated-Preliminary-Data-Including-Promising-Relapse-Free-Survival-Data-from-the-Phase-1-Study-of-ELI-002-at-AACR-Special-Conference-Pancreatic-Cancer.html,2023-09-27 17:30:00+00:00,Elicio Therapeutics,clinical_study,"1. The predicted upward move of +3.57% is likely due to promising preliminary data on ELI-002, indicating potential effectiveness against mutant KRAS-driven tumors. 2. Market implications could include increased investor interest and confidence in Elicio Therapeutics' pipeline.",globenewswire_biotech,biotech,Calendar of Events,317,ELTX,2023-09-27 21:30:00+00:00,US/Eastern,"BOSTON, Sept.  27, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced promising preliminary relapse-free survival (RFS) data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002. This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS, as a monotherapy in patients with mutant KRAS-driven solid tumors. The data will be presented September 29th from 4:40pm – 6:40pm ET at the AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, taking place from September 27-30, 2023.",UP,0.035698967354852874,en
16169,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting,https://www.globenewswire.com/news-release/2023/09/28/2750912/0/en/Harpoon-Therapeutics-Presents-HPN217-Interim-Phase-1-Data-at-the-IMS-Annual-Meeting.html,2023-09-28 03:00:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +0.63% is likely due to the target dose's strong 63% ORR and manageable tolerability, including no ICANS. This suggests positive market reception and potential increased investor confidence, boosting the asset's attractiveness.",globenewswire_biotech,biotech,Clinical Study,334,HARP,2023-09-28 07:00:00+00:00,US/Eastern,"Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS –",UP,0.006294789556037903,en
16557,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD),https://www.globenewswire.com/news-release/2023/09/28/2751004/0/en/Bionomics-Announces-Positive-Topline-Results-from-the-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html,2023-09-28 06:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +1.47% is likely due to the successful ATTUNE trial, indicating BNC210's effectiveness in reducing PTSD symptoms. This positive clinical outcome could enhance investor confidence and improve market perceptions of the asset's future prospects.",globenewswire_biotech,biotech,Clinical Study,354,BNOX,2023-09-28 10:00:00+00:00,US/Eastern,ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.,UP,0.014652945612053056,en
15759,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine,https://www.globenewswire.com/news-release/2023/09/29/2752032/0/en/Renovaro-Biosciences-and-AI-Health-Company-GEDi-Cube-Sign-Definitive-Agreement-to-Combine.html,2023-09-29 09:15:00+00:00,Renovacor,mergers_acquisitions,"The predicted downward move of -1.31% could be due to market skepticism about integration challenges and execution risks. This may lead to increased investor caution, potentially affecting related biotech and AI sectors negatively.",globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2023-09-29 13:15:00+00:00,US/Eastern,"The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery",UP,-0.013124952382676643,en
15758,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine,https://www.globenewswire.com/news-release/2023/10/02/2752845/0/en/AI-Company-GEDiCube-and-Renovaro-Biosciences-Sign-Definitive-Agreement-to-Combine.html,2023-10-02 09:25:00+00:00,Renovacor,mergers_acquisitions,The predicted downward move of -0.88% for Renovaro Biosciences likely stems from investor concerns or negative news in the CEO's message. This dip could affect investor confidence and pressure the company's stock valuation in the short term.,globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2023-10-02 13:25:00+00:00,US/Eastern,"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD",UP,-0.008762839198704693,en
15757,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD",https://www.globenewswire.com/news-release/2023/10/02/2753011/0/en/Message-from-Renovaro-Biosciences-CEO-The-Hon-Mark-Dybul-MD.html,2023-10-02 12:05:00+00:00,Renovacor,mergers_acquisitions,"1. The predicted downward move of -0.68% could be due to investor uncertainty or integration risks. 2. Market implications may include short-term volatility and cautious sentiment, affecting related stocks.",globenewswire_biotech,biotech,Major shareholder announcements,313,RENB,2023-10-02 16:05:00+00:00,US/Eastern,AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine,UP,-0.006836298393574962,en
16702,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds,https://www.globenewswire.com/news-release/2023/10/02/2753067/36989/en/Checkpoint-Therapeutics-Announces-Exercise-of-Warrants-for-11-13-Million-in-Gross-Proceeds.html,2023-10-02 12:53:00+00:00,Checkpoint Therapeutics,warrants_and_certificates,1. The likely cause of the predicted downward move of +nan% is due to the dilution of shares from the exercise of warrants at a reduced price. 2. This could lead to decreased investor confidence and lower stock prices. 3. The predicted downward move of +nan% reflects anticipated market adjustment.,globenewswire_biotech,biotech,Financing Agreements,361,CKPT,2023-10-02 16:53:00+00:00,US/Eastern,"WALTHAM, Mass., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions.",DOWN,-11.247276893184539,en
15874,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide  Update on the Development Outlook for Next 6-9 Months,https://www.globenewswire.com/news-release/2023/10/03/2753302/0/en/Faron-to-Host-Webcast-to-Discuss-New-Data-From-Phase-I-II-BEXMAB-Study-of-Bexmarilimab-and-Provide-Update-on-the-Development-Outlook-for-Next-6-9-Months.html,2023-10-03 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,The predicted downward move of -0.17% likely stems from investor caution ahead of Faron Pharmaceuticals' data release on BEXMAB. Market implications include potential adjustments in stock value depending on the data's impact on the future AML and MDS therapies.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,319,FARON.HE,2023-10-03 06:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Oct.  03, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies, today announces it will host a virtual call for investors to provide an update on the most recent Phase I/II BEXMAB data in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on Wednesday, October 11 at 08.00 EST/13.00 BST/15.00 EEST.",UP,-0.001710182266115623,en
14943,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats,https://www.globenewswire.com/news-release/2023/10/03/2753536/0/en/Vir-Biotechnology-Awarded-BARDA-Funding-to-Support-Development-of-Antibody-Platform-Technologies-for-Global-Infectious-Disease-Threats.html,2023-10-03 07:59:00+00:00,Vir Biotechnology,government_news,"The predicted downward move of +nan% may be due to market skepticism about the efficacy or commercial potential of the funding. This uncertainty could lead to decreased investor confidence, impacting Vir Biotechnology's stock negatively despite the $50 million support.",globenewswire_biotech,biotech,Contests/Awards,272,VIR,2023-10-03 11:59:00+00:00,US/Eastern,Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19,UP,-0.04769555111395591,en
19254,MBX,,MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting,https://www.globenewswire.com/news-release/2023/10/03/2753591/0/en/MBX-Biosciences-to-Showcase-Results-from-Phase-1-Study-of-MBX-2109-in-Late-Breaking-Oral-Presentation-at-the-American-Society-for-Bone-and-Mineral-Research-Annual-Meeting.html,2023-10-03 08:00:00+00:00,MBX Biosciences,clinical_study,"The predicted upward move of +3.94% for MBX Biosciences is likely due to the positive anticipation surrounding the Phase 1 study results of MBX 2109. Successful outcomes can enhance investor confidence, potentially increasing stock value and market interest.",globenewswire_biotech,biotech,Calendar of Events,749,MBX,2023-10-03 12:00:00+00:00,US/Eastern,"CARMEL, Ind., Oct.  03, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that results from the Phase 1 Study of MBX 2109, the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP), will be featured in a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting being held in Vancouver, Canada October 13-16, 2023.",UP,3.9426502659483282,en
15734,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,https://www.globenewswire.com/news-release/2023/10/04/2754446/0/en/Phase-2-MIRA-primary-analysis-trial-results-12-week-for-MoonLake-s-Nanobody-sonelokimab-in-hidradenitis-suppurativa-to-be-presented-at-a-late-breaking-session-at-the-European-Acade.html,2023-10-04 07:01:00+00:00,MoonLake Immunotherapeutics,clinical_study,"The predicted upward move of +2.86% is likely due to positive Phase 2 trial results for sonelokimab, boosting investor confidence. Such news can increase market interest, potentially leading to higher demand and stock price appreciation for MoonLake.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2023-10-04 11:01:00+00:00,US/Eastern,Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,DOWN,0.028593657750542373,en
15401,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting,https://www.globenewswire.com/news-release/2023/10/04/2754511/0/en/VBL-Therapeutics-Reminds-Shareholders-to-Vote-in-the-Upcoming-Annual-and-Special-Shareholder-Meeting.html,2023-10-04 08:00:00+00:00,Vascular Biogenics,mergers_acquisitions,"The predicted downward move of -0.16% may stem from investor concerns over company direction or management decisions at the upcoming VBL Shareholder Meeting. Market implications could include decreased investor confidence, influencing short-term trading activity and potentially affecting stock liquidity.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,295,VBLT,2023-10-04 12:00:00+00:00,US/Eastern,"Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023",UP,-0.0016219758279754268,en
14993,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023",https://www.globenewswire.com/news-release/2023/10/05/2755774/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q3-2023.html,2023-10-05 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"The predicted downward move of -1.77% likely results from ImmuCell's preliminary, unaudited sales results not meeting market expectations. This could affect investor confidence and potentially lead to reduced stock demand, impacting future valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,274,ICCC,2023-10-05 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, Oct.  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.",DOWN,-0.01766734636268162,en
14942,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,"Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023",https://www.globenewswire.com/news-release/2023/10/05/2755808/0/en/Vir-Biotechnology-to-Provide-Business-Update-and-Report-Third-Quarter-2023-Financial-Results-on-November-2-2023.html,2023-10-05 16:30:00+00:00,Vir Biotechnology,earnings_releases_and_operating_results,"The predicted upward move of +0.09% may be due to investor optimism ahead of Vir Biotechnology's third-quarter financial results. Market implications include potential increased interest in their stock if results exceed expectations, leading to minor positive investor sentiment.",globenewswire_biotech,biotech,Calendar of Events,272,VIR,2023-10-05 20:30:00+00:00,US/Eastern,"Vir Biotechnology will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.",UP,0.0009011369082261866,en
15608,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO,https://www.globenewswire.com/news-release/2023/10/05/2755826/0/en/Mydecine-Innovations-Group-Announces-Listing-on-the-Canadian-Securities-Exchange-and-Delisting-from-the-NEO.html,2023-10-05 17:01:00+00:00,Mydecine Innovations Group,exchange_announcement,The predicted downward move of -0.09% is likely due to investor uncertainty surrounding Mydecine's transition from the NEO Exchange to the Canadian Securities Exchange. This move could imply potential volatility or lack of confidence in market stability.,globenewswire_biotech,biotech,Advisory,306,MYCO.CN,2023-10-05 21:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has received approval to have the common shares (""Common Shares"") of the Company listed on the Canadian Securities Exchange (the ""CSE""). Consequently, the Company has also submitted a request to the NEO Exchange Inc., operating as Cboe Canada (the ""NEO"") to delist the Common Shares NEO.",UP,-0.0009282491717165192,en
14859,ADTX,https://www.google.com/finance/quote/ADTX:NASDAQ,"Aditxt, Inc. to Present at 8th Annual Dawson James Conference",https://www.globenewswire.com/news-release/2023/10/06/2756039/0/en/Aditxt-Inc-to-Present-at-8th-Annual-Dawson-James-Conference.html,2023-10-06 08:00:00+00:00,Aditxt,conference_call_webinar,"The predicted downward move of -0.38% might stem from anticipated negative news or market sentiment expected during Amro Albanna's presentation. This could impact investor confidence, potentially causing a temporary dip in the company's stock price.",globenewswire_biotech,biotech,Advisory,267,ADTX,2023-10-06 12:00:00+00:00,US/Eastern,"Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023",DOWN,-0.0037968952383798525,en
14756,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2023/10/06/2756321/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,2023-10-06 16:41:00+00:00,Science 37,corporate_action,"The predicted upward move of +0.27% is likely due to investor confidence in Science 37’s strategic hiring initiatives. This could positively impact market sentiment and enhance the company's operational capabilities, potentially improving future performance and shareholder value.",globenewswire_biotech,biotech,Financing Agreements,261,SNCE,2023-10-06 20:41:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Oct.  06, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",UP,0.0026910097428583645,en
14738,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio,https://www.globenewswire.com/news-release/2023/10/06/2756329/0/en/Talaris-Therapeutics-Declares-Special-Dividend-In-Connection-with-Proposed-Merger-with-Tourmaline-Bio.html,2023-10-06 17:09:00+00:00,Talaris Therapeutics,dividend_reports_and_estimates,The predicted downward move of +nan% might result from the asset price adjusting for the special dividend payout. Market implications could include decreased share price due to the dividend adjustment and potential reevaluation by investors focused on long-term gains.,globenewswire_biotech,biotech,Mergers and Acquisitions,260,TALS,2023-10-06 21:09:00+00:00,US/Eastern,Special dividend estimated to be $1.5118 per share,DOWN,-5.872585742155114,en
14651,RAD.AX,https://www.google.com/finance/quote/RAD.AX:NASDAQ,RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer,https://www.globenewswire.com/news-release/2023/10/09/2756594/0/en/RAD-receives-approval-for-Phase-1-therapeutic-study-of-PDL1-nanobody-in-Non-Small-Cell-Lung-Cancer.html,2023-10-09 07:27:00+00:00,Radiopharm Theranostics,clinical_study,"The predicted upward move of +2.48% is likely due to the Human Research Ethics Committee approval for Radiopharm Theranostics' Phase I study. This approval potentially increases investor confidence and enhances the company's market position, especially in the NSCLC treatment space.",globenewswire_biotech,biotech,Clinical Study,256,RAD.AX,2023-10-09 11:27:00+00:00,US/Eastern,"SYDNEY, Australia, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC).",UP,0.024785829704188463,en
19253,MBX,,MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia,https://www.globenewswire.com/news-release/2023/10/09/2756617/0/en/MBX-Biosciences-Doses-First-Participant-in-Phase-1-2-Clinical-Trial-of-MBX-1416-for-the-Treatment-of-Post-Bariatric-Hypoglycemia.html,2023-10-09 08:00:00+00:00,MBX Biosciences,clinical_study,The anticipated topline results in the second half of 2024 likely drive the predicted upward move of +2.64% as expectations for positive financial performance grow. This movement may increase investor confidence and potentially boost market valuations for related assets.,globenewswire_biotech,biotech,Clinical Study,749,MBX,2023-10-09 12:00:00+00:00,US/Eastern,Topline results expected in 2H 2024 Topline results expected in 2H 2024,UP,2.6423237973664975,en
14614,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria,https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html,2023-10-09 08:00:00+00:00,Eloxx Pharmaceuticals,clinical_study,"The predicted upward move of +0.33% likely results from positive clinical results for ELX-02 treatment in improving podocyte conditions. This may boost investor confidence, leading to increased demand for related assets.",globenewswire_biotech,biotech,Health,254,ELOX,2023-10-09 12:00:00+00:00,US/Eastern,ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH,UP,0.0032543943118143737,en
14585,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP),https://www.globenewswire.com/news-release/2023/10/09/2756638/0/en/Anaptys-Announces-Positive-Top-Line-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html,2023-10-09 08:00:00+00:00,AnaptysBio,clinical_study,"The predicted downward move of -0.14% could be due to the market's tempered reaction despite AnaptysBio's positive trial results, possibly reflecting concerns about future commercialization hurdles or competition. This suggests moderate investor enthusiasm, impacting the stock slightly.",globenewswire_biotech,biotech,Product / Services Announcement,252,ANAB,2023-10-09 12:00:00+00:00,US/Eastern,"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.",UP,-0.0013809839702939469,en
14584,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,"Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25",https://www.globenewswire.com/news-release/2023/10/09/2756658/0/en/Anaptys-to-Provide-Overview-of-Rosnilimab-a-PD-1-Agonist-at-Virtual-R-D-Event-on-Wednesday-Oct-25.html,2023-10-09 08:15:00+00:00,AnaptysBio,conference_call_webinar,"The predicted upward move of +0.10% is likely due to investor interest in AnaptysBio's virtual R&D event, showcasing their PD-1 agonist antibody. Increased visibility could enhance market confidence, potentially leading to slight positive shifts in their stock value.",globenewswire_biotech,biotech,Product / Services Announcement,252,ANAB,2023-10-09 12:15:00+00:00,US/Eastern,"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.",DOWN,0.0010414712811035258,en
16168,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023,https://www.globenewswire.com/news-release/2023/10/09/2757043/0/en/Harpoon-Therapeutics-to-Present-Interim-Tolerability-and-Response-Data-from-Phase-1-2-Clinical-Trial-of-T-Cell-Engager-HPN328-at-ESMO-Congress-2023.html,2023-10-09 16:17:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted downward move of -0.54% in Harpoon Therapeutics' stock may be due to market anticipation of the Phase 1/2 trial results. Negative or underwhelming data could impact investor confidence, possibly leading to further stock volatility or investment shifts.",globenewswire_biotech,biotech,Clinical Study,334,HARP,2023-10-09 20:17:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Oct.  09, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place in Madrid, Spain from October 20-24, 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.",UP,-0.00544530379830238,en
15607,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,"Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings",https://www.globenewswire.com/news-release/2023/10/10/2757124/0/en/Mydecine-Innovations-Group-Announces-Admission-to-Trading-on-the-AQSE-Growth-Market-in-London-UK-and-First-Day-of-Dealings.html,2023-10-10 02:00:00+00:00,Mydecine Innovations Group,exchange_announcement,"The predicted downward move of -0.56% may be due to initial investor skepticism or market adjustment after the company's admission. This could signal cautious investor sentiment, impacting liquidity and market perception temporarily as trading begins.",globenewswire_biotech,biotech,Exchange announcement,306,MYCO.CN,2023-10-10 06:00:00+00:00,US/Eastern,"The Company has completed its admission to the Access segment of the AQSE Growth Market and trading will commence at 8:00 A.M. GM - Oct 10, 2023 - ""MYIG""",UP,-0.005589174640415564,en
15999,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit,https://www.globenewswire.com/news-release/2023/10/10/2757419/0/en/Ovid-Therapeutics-to-Present-at-the-Jefferies-Biotech-CNS-Neuro-Summit.html,2023-10-10 08:00:00+00:00,Ovid Therapeutics,conference_call_webinar,The predicted downward move of -0.79% for Ovid Therapeutics may be due to investor uncertainty or skepticism regarding their presentation at the Jefferies Summit. Market implications could include reduced short-term investor confidence or selloffs.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,325,OVID,2023-10-10 12:00:00+00:00,US/Eastern,"NEW YORK, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York.",DOWN,-0.007947182326870233,en
15756,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors,https://www.globenewswire.com/news-release/2023/10/10/2757407/0/en/Renovaro-Biosciences-Appoints-Two-Finance-Industry-Experts-to-Board-of-Directors.html,2023-10-10 08:00:00+00:00,Renovacor,management_changes,"The predicted upward move of +0.06% is likely due to positive market reception of Leni Boeren and Ruud Hendriks' appointments, enhancing governance credibility. This may signal strategic confidence, potentially attracting cautious investors seeking stability in biotech sectors.",globenewswire_biotech,biotech,Directors and Officers,313,RENB,2023-10-10 12:00:00+00:00,US/Eastern,"LOS ANGELES, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, is pleased to announce the appointment of Leni Boeren and Ruud Hendriks as Independent Directors.",DOWN,0.0006468728713177241,en
15873,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients,https://www.globenewswire.com/news-release/2023/10/11/2758195/0/en/Inside-information-Faron-Announces-Positive-BEXMAB-Study-Update-in-Relapsed-Refractory-AML-and-HMA-Refractory-MDS-Patients.html,2023-10-11 07:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +4.20% is likely due to positive insider information, indicating improved company performance or future growth. This can boost investor confidence, leading to increased demand and potential rise in stock prices.",globenewswire_biotech,biotech,Health,319,FARON.HE,2023-10-11 11:00:00+00:00,US/Eastern,"Company announcement, Inside Information",UP,0.04201024056389304,en
14698,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule,https://www.globenewswire.com/news-release/2023/10/11/2758188/0/en/PolyPid-Regains-Compliance-with-Nasdaq-Minimum-Closing-Bid-Price-Rule.html,2023-10-11 07:00:00+00:00,PolyPid,exchange_announcement,"The predicted downward move of -0.03% might be due to investor sentiment aligning with compliance news already being priced in, resulting in minimal impact. Market implications could involve slight volatility or reassessment of the company's stock stability by investors.",globenewswire_biotech,biotech,Changes in company's own shares,258,PYPD,2023-10-11 11:00:00+00:00,US/Eastern,"PETACH TIKVA, Israel, Oct.  11, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC (""Nasdaq"") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.",DOWN,-0.00025131475742072584,en
14941,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023,https://www.globenewswire.com/news-release/2023/10/11/2758321/0/en/Vir-Biotechnology-Announces-Multiple-Abstracts-Highlighting-New-Chronic-Hepatitis-B-and-Hepatitis-Delta-Data-Accepted-for-Presentation-at-AASLD-s-The-Liver-Meeting-2023.html,2023-10-11 08:00:00+00:00,Vir Biotechnology,clinical_study,"1. The likely cause of the predicted upward move of +2.44% is the positive reception of new data from Vir's hepatitis B and delta programs at AASLD. 2. This could enhance investor confidence, potentially boosting stock demand and valuation.",globenewswire_biotech,biotech,Calendar of Events,272,VIR,2023-10-11 12:00:00+00:00,US/Eastern,Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.,DOWN,0.02437338734463167,en
15859,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023,https://www.globenewswire.com/news-release/2023/10/11/2758282/0/en/NKGen-Announces-Poster-Presentation-at-the-XXVI-World-Congress-of-Neurology-WCN-Annual-Meeting-2023.html,2023-10-11 08:00:00+00:00,NKGen Biotech,clinical_study,"1. The predicted upward move of +8.10% is likely due to positive expectations from the Phase I study interim report of SNK01 for Alzheimer’s Disease. 2. This might boost investor confidence, increasing market interest in NKGen Biotech's innovative therapies.",globenewswire_biotech,biotech,Calendar of Events,318,NKGN,2023-10-11 12:00:00+00:00,US/Eastern,"SANTA ANA, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on an interim report of a Phase I study of SNK01 in patients with Alzheimer’s Disease, at the XXVI World Congress of Neurology (WCN) Annual Meeting to be held in Montreal, QC, Canada and online between October 15–19, 2023.",UP,0.08096183111713945,en
15838,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting,https://www.globenewswire.com/news-release/2023/10/11/2758314/0/en/Elicio-Therapeutics-Announces-Upcoming-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-2023-Annual-Meeting.html,2023-10-11 08:00:00+00:00,Elicio Therapeutics,clinical_study,"The predicted upward move of +10.03% for Elicio Therapeutics likely stems from positive investor sentiment regarding their updated preliminary data on ELI-002 and promising preclinical data on ELI-007 and ELI-008. This could increase interest in their cancer therapies, potentially boosting stock value and attracting new investors.",globenewswire_biotech,biotech,Research Analysis and Reports,317,ELTX,2023-10-11 12:00:00+00:00,US/Eastern,"BOSTON, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008. ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, are being evaluated in studies funded by a grant from the Gastro-Intestinal (GI) Research Foundation with the aim of developing multivalent cancer vaccines targeting several mutations.",UP,0.10029691327937625,en
14583,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,"Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress",https://www.globenewswire.com/news-release/2023/10/11/2758455/0/en/Anaptys-to-Present-Phase-1-Data-on-ANB032-its-BTLA-Agonist-Antibody-at-the-32nd-EADV-Congress.html,2023-10-11 09:15:00+00:00,AnaptysBio,clinical_study,"The likely cause of the predicted upward move of +0.96% is AnaptysBio's presentations at the EADV Congress, highlighting promising trial data for ANB032. This may boost investor confidence, potentially leading to increased stock valuation and heightened interest from partners.",globenewswire_biotech,biotech,Clinical Study,252,ANAB,2023-10-11 13:15:00+00:00,US/Eastern,"SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.",DOWN,0.009575634919625355,en
15755,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,"Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors",https://www.globenewswire.com/news-release/2023/10/11/2758464/0/en/Avram-Miller-Co-Founder-of-Intel-Capital-Joins-Renovaro-Biosciences-Board-of-Directors.html,2023-10-11 09:25:00+00:00,Renovacor,mergers_acquisitions,"1. The predicted downward move of -0.59% may be due to investor uncertainty regarding the integration of GEDiCube. 2. Market implications could include skepticism about the merger's potential synergies, impacting investor confidence in Renovaro's future growth.",globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2023-10-11 13:25:00+00:00,US/Eastern,"LOS ANGELES, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors. Beyond this board position, Mr. Miller will also take on an advisory role, contributing to the company's strategy and business development efforts. Renovaro Biosciences has recently signed a definitive agreement to combine with GEDiCube, a UK-based medical AI company specializing in early detection and remissions of cancer, and expedited drug discovery (Renovaro Press Release) (GEDiCube press release). GEDiCube intends to rebrand as Renovaro.AI.",DOWN,-0.005904763874111893,en
15733,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress,https://www.globenewswire.com/news-release/2023/10/11/2758532/0/en/MoonLake-Immunotherapeutics-presents-positive-12-week-data-from-the-Phase-2-MIRA-trial-with-Nanobody-Sonelokimab-for-Hidradenitis-Suppurativa-at-the-European-Academy-of-Dermatology.html,2023-10-11 10:15:00+00:00,MoonLake Immunotherapeutics,clinical_study,"The predicted upward move of +2.36% is likely due to positive trial data enhancing investor confidence. Market implications include increased interest in MoonLake’s potential, boosting their competitive position in dermatological treatments, and possibly attracting further investments or partnerships.",globenewswire_biotech,biotech,Press releases,312,MLTX,2023-10-11 14:15:00+00:00,US/Eastern,MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress,DOWN,0.02364761666672276,en
15659,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,"Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference",https://www.globenewswire.com/news-release/2023/10/11/2758816/0/en/Certara-to-Report-Third-Quarter-2023-Financial-Results-on-November-8th-2023-and-participate-in-the-Stephens-Annual-Investment-Conference.html,2023-10-11 16:15:00+00:00,Certara,earnings_releases_and_operating_results,"The predicted upward move of +0.44% is likely due to investor optimism ahead of Certara’s financial results announcement. This could boost investor confidence. If results exceed expectations, it may signal further positive momentum for the stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,308,CERT,2023-10-11 20:15:00+00:00,US/Eastern,"PRINCETON, N.J, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.",UP,0.0044149936342174735,en
15606,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,"Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK",https://www.globenewswire.com/news-release/2023/10/12/2758940/0/en/Mydecine-Innovations-Group-Announces-Admission-to-Trading-on-the-AQSE-Growth-Market-in-London-UK.html,2023-10-12 02:00:00+00:00,Mydecine Innovations Group,exchange_announcement,"The predicted downward move of -0.56% may be attributed to investor uncertainty or profit-taking following Mydecine's admission to the AQSE Growth Market. This could lead to short-term volatility, impacting investor confidence and influencing trading activity.",globenewswire_biotech,biotech,Changes in company's own shares,306,MYCO.CN,2023-10-12 06:00:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access segment of the AQSE Growth Market (“AQSE”) and that trading commenced at 8:00 A.M. GMT on Tuesday, 10 October 2023 (""Admission"") under the ticker ""MYIG"".",UP,-0.005589174640415564,en
15572,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1),https://www.globenewswire.com/news-release/2023/10/12/2759094/0/en/PepGen-Inc-Announces-FDA-has-Lifted-the-Clinical-Hold-on-its-Investigational-New-Drug-Application-for-FREEDOM-DM1-Phase-1-Study-of-PGN-EDODM1-for-Myotonic-Dystrophy-Type-1-DM1.html,2023-10-12 07:00:00+00:00,PepGen,clinical_study,"The predicted upward move of +1.47% is likely due to the FDA lifting the hold, allowing the FREEDOM-DM1 study to proceed. This improves market confidence and potential future revenue, positively impacting the asset's valuation.",globenewswire_biotech,biotech,Product / Services Announcement,303,PEPG,2023-10-12 11:00:00+00:00,US/Eastern,"– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –",DOWN,0.014691648249715255,en
15452,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,https://www.globenewswire.com/news-release/2023/10/12/2759194/0/en/Adagene-Announces-Poster-Presentation-on-Optimal-Dose-Selection-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-Upcoming-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html,2023-10-12 08:00:00+00:00,Adagene,clinical_study,"1. The likely cause of the upward movement is positive data on pembrolizumab's dosing regimen efficacy in MSS CRC. 2. The predicted upward move of +4.43% may boost investor confidence, potentially increasing investment and interest in related therapeutics.",globenewswire_biotech,biotech,Calendar of Events,297,ADAG,2023-10-12 12:00:00+00:00,US/Eastern,- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –,UP,0.044324652683841004,en
15453,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果,https://www.globenewswire.com/news-release/2023/10/12/2759195/0/zh-hans/%E5%A4%A9%E6%BC%94%E8%8D%AF%E4%B8%9A%E5%B0%86%E5%9C%A8%E7%AC%AC38%E5%B1%8ASITC%E5%B9%B4%E4%BC%9A%E4%B8%8A%E4%BB%A5%E6%B5%B7%E6%8A%A5%E5%BD%A2%E5%BC%8F%E5%85%AC%E5%B8%83%E5%85%B6%E7%B2%BE%E5%87%86%E6%8E%A9%E8%94%BD%E5%9E%8B%E6%8A%97CTLA-4%E5%AE%89%E5%85%A8%E6%8A%97%E4%BD%93SAFEbody-ADG126%E5%89%82%E9%87%8F%E4%BC%98%E5%8C%96%E8%AF%95%E9%AA%8C%E7%BB%93%E6%9E%9C.html,2023-10-12 08:00:00+00:00,Adagene,clinical_study,"1. The predicted upward move of +18.28% is likely due to promising data on ADG126, its mechanism, and its combined dosing with pembrolizumab in clinical studies. 2. This could boost investor confidence, potentially leading to increased investment and higher stock valuations.",globenewswire_biotech,biotech,Calendar of Events,297,ADAG,2023-10-12 12:00:00+00:00,US/Eastern,-数据将展示ADG126的作用机制及与帕博利珠单抗联用连续给药的剂量优化，10 mg/kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究,UP,0.18277892435372822,zh
15437,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study,https://www.globenewswire.com/news-release/2023/10/12/2759203/0/en/Annovis-Bio-Announces-Positive-Interim-Independent-Analysis-for-Statistical-Power-in-Its-Alzheimer-s-Study.html,2023-10-12 08:02:00+00:00,Annovis Bio,clinical_study,"The predicted upward move of +9.83% is likely due to positive interim analysis results, signaling confidence in the study's effectiveness without needing additional patients. Market implications include increased investor confidence and potential upward valuation of related assets.",globenewswire_biotech,biotech,Clinical Study,296,ANVS,2023-10-12 12:02:00+00:00,US/Eastern,"Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients",UP,0.09832988524605629,en
15400,VBLT,https://www.google.com/finance/quote/VBLT:NASDAQ,VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting,https://www.globenewswire.com/news-release/2023/10/12/2759289/0/en/VBL-Therapeutics-Announces-Results-of-Annual-and-Special-Shareholder-Meeting.html,2023-10-12 09:00:00+00:00,Vascular Biogenics,mergers_acquisitions,The predicted downward move of -0.17% likely results from investor concerns over integration challenges or unfavorable terms in the merger with Notable Labs. Market implications could include reduced confidence in future growth or strategic direction.,globenewswire_biotech,biotech,Mergers and Acquisitions,295,VBLT,2023-10-12 13:00:00+00:00,US/Eastern,Approved Merger with Notable Labs and All Other Proposals,UP,-0.0017112994642299697,en
15366,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds,https://www.globenewswire.com/news-release/2023/10/12/2759527/35690/en/OpGen-Enters-Into-Warrant-Inducement-Transaction-for-up-to-11-2-Million-in-Gross-Proceeds.html,2023-10-12 12:32:00+00:00,OpGen,warrants_and_certificates,"The predicted downward move of +nan% could be due to potential market dilution from issuing 10.9 million shares. This may lead to reduced earnings per share. Investors might react negatively, impacting OpGen's stock value in the near term.",globenewswire_biotech,biotech,Stock Market News,293,OPGN,2023-10-12 16:32:00+00:00,US/Eastern,"ROCKVILLE, Md., Oct.  12, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.",DOWN,-9.014823135743574,en
14940,VIR,https://www.google.com/finance/quote/VIR:NASDAQ,Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference,https://www.globenewswire.com/news-release/2023/10/12/2759641/0/en/Vir-Biotechnology-to-Participate-in-the-H-C-Wainwright-4th-Annual-Hepatitis-B-Virus-HBV-Conference.html,2023-10-12 16:05:00+00:00,Vir Biotechnology,conference_call_webinar,"The predicted downward move of -0.69% may result from anticipated negative sentiment or lack of impactful news at the HBV Conference. This could lead to cautious investor behavior, potentially affecting Vir Biotechnology's short-term stock volatility and market confidence.",globenewswire_biotech,biotech,Health,272,VIR,2023-10-12 20:05:00+00:00,US/Eastern,"Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th",DOWN,-0.006891297750003467,en
15309,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing,https://www.globenewswire.com/news-release/2023/10/13/2759790/0/en/PCI-Biotech-initiates-field-testing-of-its-proprietary-technology-for-gene-therapy-manufacturing.html,2023-10-13 04:17:00+00:00,PCI Biotech Holding,partnerships,PCI Biotech's research collaboration likely drives the predicted upward move of +0.30% by addressing production issues in gene therapies. Market implications include potential growth opportunities and increased investor confidence in future successes.,globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2023-10-13 08:17:00+00:00,US/Eastern,"Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies.",UP,0.002975923744802723,en
15215,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Reports First Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2023/10/13/2759856/0/en/Biomerica-Reports-First-Quarter-2024-Financial-Results.html,2023-10-13 06:39:00+00:00,Biomerica,financial_results,"The predicted upward move of +0.49% is likely due to Biomerica's 16.3% revenue growth excluding Covid test sales, indicating strong core business performance. This could boost investor confidence, potentially leading to increased stock demand and a positive market perception.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,285,BMRA,2023-10-13 10:39:00+00:00,US/Eastern,Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,UP,0.004924496704469272,en
15214,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,REPEAT - Biomerica Reports First Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2023/10/13/2760118/0/en/REPEAT-Biomerica-Reports-First-Quarter-2024-Financial-Results.html,2023-10-13 13:10:00+00:00,Biomerica,financial_results,"The predicted upward move of +0.49% is likely due to Biomerica's 16.3% revenue growth excluding Covid test sales, indicating underlying business strength. This suggests positive investor sentiment and potential increased confidence in the company's long-term growth prospects.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,285,BMRA,2023-10-13 17:10:00+00:00,US/Eastern,Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,UP,0.004924496704469272,en
15732,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,"MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa",https://www.globenewswire.com/news-release/2023/10/15/2760245/0/en/MoonLake-Immunotherapeutics-announces-the-full-dataset-from-its-24-week-MIRA-clinical-trial-establishing-the-Nanobody-sonelokimab-as-a-highly-promising-and-differentiated-therapeut.html,2023-10-15 09:03:00+00:00,MoonLake Immunotherapeutics,clinical_study,"1. The predicted upward move of +4.38% is likely due to positive clinical trial results, showcasing sonelokimab's promise for Hidradenitis Suppurativa. 2. This could enhance MoonLake's market position, attracting investor interest and increasing demand for shares.",globenewswire_biotech,biotech,Press releases,312,MLTX,2023-10-15 13:03:00+00:00,US/Eastern,"MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS)",UP,0.04384137912555218,en
16404,CFRX,https://www.google.com/finance/quote/CFRX:NASDAQ,ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study,https://www.globenewswire.com/news-release/2023/10/16/2760540/0/en/ContraFect-Announces-FDA-Clearance-of-CF-370-IND-Application-to-Proceed-With-Phase-1-Clinical-Study.html,2023-10-16 07:30:00+00:00,ContraFect,clinical_study,"The predicted upward move of +13.40% is likely due to CF-370 entering human trials as the first lysin therapeutic targeting Gram-negative pathogens, indicating strong market interest and potential success. This could boost investor confidence and influence related biotech stocks.",globenewswire_biotech,biotech,Product / Services Announcement,347,CFRX,2023-10-16 11:30:00+00:00,US/Eastern,CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial,DOWN,0.1339539520806529,en
16556,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder,https://www.globenewswire.com/news-release/2023/10/16/2760586/0/en/Bionomics-Announces-Successful-End-of-Phase-2-Meeting-with-the-FDA-and-Solidifies-Plans-to-Initiate-the-Registrational-Program-for-BNC210-in-Social-Anxiety-Disorder.html,2023-10-16 08:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +3.86% is likely due to Bionomics' successful End-of-Phase 2 meeting with the FDA for BNC210, signaling advancement into Phase 3 trials. This could boost investor confidence and interest in the biotechnology sector.",globenewswire_biotech,biotech,Product / Services Announcement,354,BNOX,2023-10-16 12:00:00+00:00,US/Eastern,"ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.",UP,0.03863039536364006,en
16543,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/10/16/2760611/0/en/Entera-Bio-Reports-Rapid-Pharmacodynamic-PD-Response-and-Consistent-Pharmacokinetic-PK-Data-for-its-First-in-Class-Oral-PTH-1-34-Mini-Tablets-at-the-ASBMR-2023-Annual-Meeting.html,2023-10-16 08:00:00+00:00,Entera Bio,clinical_study,"The predicted upward move of +7.46% for Entera Bio Ltd. likely stems from positive reception to their presentations at the ASBMR 2023 meeting. This could increase investor confidence, possibly leading to heightened interest and investment in the company's stock.",globenewswire_biotech,biotech,Health,353,ENTX,2023-10-16 12:00:00+00:00,US/Eastern,"JERUSALEM, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com.",UP,0.0745967764215197,en
16483,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,"Inotiv, Inc. Announces Changes to its Board Composition",https://www.globenewswire.com/news-release/2023/10/16/2760610/0/en/Inotiv-Inc-Announces-Changes-to-its-Board-Composition.html,2023-10-16 08:00:00+00:00,Inotiv,management_changes,"1. The predicted upward move of +0.16% is likely due to investor confidence in Terry Coelho's expertise enhancing board leadership. 2. Potential market implications include strengthened corporate governance and strategic direction, which could boost investor trust and long-term growth expectations.",globenewswire_biotech,biotech,Directors and Officers,350,NOTV,2023-10-16 12:00:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board’s succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board.",UP,0.0015867019213426637,en
16386,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences,https://www.globenewswire.com/news-release/2023/10/16/2760579/0/en/Rain-Oncology-Confirms-Receipt-of-Unsolicited-Proposal-from-Concentra-Biosciences.html,2023-10-16 08:00:00+00:00,Rain Therapeutics,mergers_acquisitions,"The predicted upward move of +8.57% is likely due to the takeover offer from Tang Capital, enhancing shareholder value. This could attract more investor interest, increase trading volume, and possibly spur additional bids, positively impacting Rain Oncology's market perception.",globenewswire_biotech,biotech,Management statements,346,RAIN,2023-10-16 12:00:00+00:00,US/Eastern,"NEWARK, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.",UP,0.08570369894630693,en
16303,PHIL.MI,https://www.google.com/finance/quote/PHIL.MI:NASDAQ,Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma,https://www.globenewswire.com/news-release/2023/10/16/2760644/0/en/Nidlegy-Phase-III-PIVOTAL-trial-meets-the-study-s-primary-objective-demonstrating-statistically-significant-and-clinically-meaningful-improvement-in-Recurrence-Free-Survival-for-pa.html,2023-10-16 08:21:00+00:00,PharmaNutra,clinical_study,"Successful Phase III results for Nidlegy™ likely cause the predicted upward move of +8.98%, increasing investor confidence. This may drive higher valuation and investment interest in the company, impacting the broader biotech market positively.",globenewswire_biotech,biotech,Product / Services Announcement,341,PHIL.MI,2023-10-16 12:21:00+00:00,US/Eastern,Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective for patients with locally advanced fully resectable melanoma,UP,0.08981192246592523,en
14489,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1,https://www.globenewswire.com/news-release/2023/10/16/2760729/28889/en/Fortress-Biotech-Subsidiary-Helocyte-Announces-Option-Agreement-with-City-of-Hope-for-Exclusive-Worldwide-Rights-to-use-a-Novel-Bispecific-CMV-HIV-CAR-T-Cell-Therapy-optionally-in-.html,2023-10-16 09:00:00+00:00,Fortress Biotech,clinical_study,"The predicted downward move of -3.30% may result from investor concerns over clinical trial risks and extended timelines. Market implications include potential short-term volatility, while long-term effects depend on trial outcomes and future funding successes.",globenewswire_biotech,biotech,Product / Services Announcement,247,FBIO,2023-10-16 13:00:00+00:00,US/Eastern,Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration,UP,-0.0330021562697931,en
19252,MBX,,MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting,https://www.globenewswire.com/news-release/2023/10/16/2761040/0/en/MBX-Biosciences-Presents-Positive-Results-from-Phase-1-Study-of-MBX-2109-in-Late-Breaking-Oral-Presentation-at-the-American-Society-for-Bone-and-Mineral-Research-Annual-Meeting.html,2023-10-16 16:00:00+00:00,MBX Biosciences,clinical_study,"The predicted downward move of -6.18% suggests market concerns despite MBX 2109 being well-tolerated, possibly due to efficacy doubts. This may lead to decreased investor confidence, impacting funding and partnership opportunities for further development.",globenewswire_biotech,biotech,Company Announcement,749,MBX,2023-10-16 20:00:00+00:00,US/Eastern,MBX 2109 was generally well-tolerated across all dosing cohorts,DOWN,-6.1833739682149,en
16167,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,"Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023",https://www.globenewswire.com/news-release/2023/10/16/2761060/0/en/Harpoon-Therapeutics-to-Host-Webcast-Reviewing-HPN328-Interim-Data-Presented-at-ESMO-Congress-2023-on-October-23-2023.html,2023-10-16 16:05:00+00:00,Harpoon Therapeutics,clinical_study,The predicted upward move of +11.26% for Harpoon Therapeutics is likely due to anticipated positive results from their HPN328 trial data. This could boost investor confidence and elevate the company's market standing within the immunotherapy sector.,globenewswire_biotech,biotech,Clinical Study,334,HARP,2023-10-16 20:05:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncology Congress (ESMO) 2023.",UP,0.11263697969878425,en
15858,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Presents Interim Phase I Trial Data at the  XXVI World Congress of Neurology (WCN) Annual Meeting 2023,https://www.globenewswire.com/news-release/2023/10/17/2761460/0/en/NKGen-Biotech-Presents-Interim-Phase-I-Trial-Data-at-the-XXVI-World-Congress-of-Neurology-WCN-Annual-Meeting-2023.html,2023-10-17 08:00:00+00:00,NKGen Biotech,clinical_study,The predicted upward move of +0.75% for NKGen Biotech Inc. is likely due to positive reception of interim Phase I trial data for SNK01 at the WCN meeting. Successful trial progress could enhance investor confidence and potentially lead to increased investment in the company's Alzheimer's research.,globenewswire_biotech,biotech,Health,318,NKGN,2023-10-17 12:00:00+00:00,US/Eastern,"SANTA ANA, Calif., Oct.  17, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.",UP,0.007531229708602008,en
14737,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio,https://www.globenewswire.com/news-release/2023/10/17/2761965/0/en/Talaris-Therapeutics-Announces-Stockholder-Approval-of-Merger-with-Tourmaline-Bio.html,2023-10-17 17:47:00+00:00,Talaris Therapeutics,mergers_acquisitions,"The predicted downward move of -0.12% likely results from the announcement of the 1-for-10 reverse stock split, which can signal financial instability. This may lead to reduced investor confidence and potentially lower trading volumes.",globenewswire_biotech,biotech,Mergers and Acquisitions,260,TALS,2023-10-17 21:47:00+00:00,US/Eastern,Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock,UP,-0.001154042660126827,en
15998,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026,https://www.globenewswire.com/news-release/2023/10/18/2762278/0/en/Ovid-Therapeutics-and-Ligand-Pharmaceuticals-Enter-into-a-30-Million-Agreement-for-a-13-Interest-in-Soticlestat-Royalties-and-Milestones-Extending-Ovid-s-Cash-Runway-into-2026.html,2023-10-18 08:00:00+00:00,Ovid Therapeutics,partnerships,The predicted downward move of -0.24% could be due to investor concerns over Ovid receiving less future revenue from soticlestat royalties. Market implications might include a reevaluation of Ovid's long-term revenue prospects and potential investor caution.,globenewswire_biotech,biotech,Partnerships,325,OVID,2023-10-18 12:00:00+00:00,US/Eastern,"NEW YORK and SAN DIEGO, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.",DOWN,-0.002390777935948209,en
16701,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer,https://www.globenewswire.com/news-release/2023/10/18/2762378/36989/en/Checkpoint-Therapeutics-Announces-Publication-of-Cosibelimab-Pivotal-Trial-Results-in-the-Journal-for-ImmunoTherapy-of-Cancer.html,2023-10-18 08:30:00+00:00,Checkpoint Therapeutics,clinical_study,"The upward move of +8.72% is likely due to Cosibelimab's successful trial results showing effectiveness and safety, boosting investor confidence. This may lead to increased stock valuation and competitive positioning in the oncology market.",globenewswire_biotech,biotech,Clinical Study,361,CKPT,2023-10-18 12:30:00+00:00,US/Eastern,"Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma",UP,0.08723865819054943,en
16653,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification,https://www.globenewswire.com/news-release/2023/10/18/2762428/0/en/Celularity-Announces-Commercial-Biomaterial-Products-Receive-Saudi-Food-and-Drug-Authority-SFDA-Product-Classification.html,2023-10-18 09:00:00+00:00,Celularity,regulatory_filings,"The predicted upward move of +8.86% is likely due to regulatory approval easing product entry into Saudi Arabia, expanding market access. This could increase revenue and investor confidence, impacting market dynamics positively and encouraging further investments.",globenewswire_biotech,biotech,Regulatory information,359,CELU,2023-10-18 13:00:00+00:00,US/Eastern,SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia,DOWN,0.08864398840646935,en
16677,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/10/18/2762443/0/en/RAPT-Therapeutics-Announces-Two-FLX475-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-SITC-2023-Annual-Meeting.html,2023-10-18 09:00:00+00:00,RAPT Therapeutics,clinical_study,"1. The likely cause of the predicted upward move of +9.77% for RAPT Therapeutics is the anticipated presentation of promising data on their oncology drug candidate FLX475 at a major industry conference. 2. This could boost investor confidence, enhancing market interest and potential funding opportunities.",globenewswire_biotech,biotech,Calendar of Events,360,RAPT,2023-10-18 13:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Oct.  18, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475, its oncology drug candidate, at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 3-5, 2023 in San Diego, CA.",DOWN,0.09766346256700217,en
16608,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces 1-for-25 Reverse Stock Split,https://www.globenewswire.com/news-release/2023/10/18/2762610/0/en/NexImmune-Announces-1-for-25-Reverse-Stock-Split.html,2023-10-18 11:30:00+00:00,NexImmune,corporate_action,"The predicted downward move of -4.05% is likely due to the reverse stock split, which can signal financial distress to investors. This may lead to decreased investor confidence and potential short-term volatility in NexImmune's stock value.",globenewswire_biotech,biotech,Health,357,NEXI,2023-10-18 15:30:00+00:00,US/Eastern,"GAITHERSBURG, Md., Oct.  18, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company’s common stock will open for trading under a new CUSIP number 65344D 208 on The Nasdaq Capital Market on October 19, 2023, on a split-adjusted basis under the current ticker symbol ""NEXI."" The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.",UP,-0.040491799564515166,en
15857,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference,https://www.globenewswire.com/news-release/2023/10/19/2763130/0/en/NKGen-Biotech-Announces-Poster-Presentation-at-the-16th-Annual-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html,2023-10-19 08:00:00+00:00,NKGen Biotech,clinical_study,"The likely cause of the predicted upward move of +7.81% is NKGen's announcement of promising research results presented at a significant Alzheimer's conference. This may boost investor confidence, leading to increased investment interest and potential market growth for NKGen.",globenewswire_biotech,biotech,Health,318,NKGN,2023-10-19 12:00:00+00:00,US/Eastern,"SANTA ANA, Calif., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with Alzheimer’s Disease, at the 16th Clinical Trials on Alzheimer’s Disease Annual Meeting to be held in Boston, MA, USA from October 24–27, 2023.",UP,0.07813469393946885,en
16607,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting,https://www.globenewswire.com/news-release/2023/10/19/2763112/0/en/NexImmune-Announces-Presentations-at-The-Society-for-Immunotherapy-of-Cancer-s-38th-Annual-Meeting.html,2023-10-19 08:00:00+00:00,NexImmune,conference_call_webinar,"The predicted upward move of +0.58% is likely due to the positive reception of NexImmune's accepted abstracts at SITC, indicating progress in their immunotherapy pipeline. This could boost investor confidence and increase interest in biotech innovation.",globenewswire_biotech,biotech,Calendar of Events,357,NEXI,2023-10-19 12:00:00+00:00,US/Eastern,"GAITHERSBURG, Md., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.",DOWN,0.005809365407568204,en
14736,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million,https://www.globenewswire.com/news-release/2023/10/19/2763751/0/en/Tourmaline-Bio-Announces-Closing-of-Merger-with-Talaris-Therapeutics-and-Concurrent-Private-Placement-of-75-Million.html,2023-10-19 17:37:00+00:00,Talaris Therapeutics,mergers_acquisitions,The predicted downward move of -0.12% may be due to investor caution about TOUR006's development risks and market competition. This slight decline could signal skepticism about its impact on Tourmaline's growth in the TED and ASCVD markets.,globenewswire_biotech,biotech,Mergers and Acquisitions,260,TALS,2023-10-19 21:37:00+00:00,US/Eastern,"Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases",UP,-0.001167357231533001,en
16166,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023,https://www.globenewswire.com/news-release/2023/10/21/2764299/0/en/Harpoon-Therapeutics-Announces-Updated-Interim-Tolerability-and-Response-Data-from-Phase-1-2-Clinical-Trial-of-T-Cell-Engager-HPN328-at-ESMO-Congress-2023.html,2023-10-21 11:31:00+00:00,Harpoon Therapeutics,clinical_study,The likely cause of the predicted downward move of -0.16% is investor reaction to the interim data from Harpoon’s trial at ESMO 2023. This might indicate uncertainty about HPN328's efficacy. Market implications include potential caution in biotech investments.,globenewswire_biotech,biotech,Research Analysis and Reports,334,HARP,2023-10-21 15:31:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Oct.  21, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO) 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.",UP,-0.001613296747208316,en
16165,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Announces Up to $150 Million Private Placement,https://www.globenewswire.com/news-release/2023/10/23/2764595/0/en/Harpoon-Therapeutics-Announces-Up-to-150-Million-Private-Placement.html,2023-10-23 07:17:00+00:00,Harpoon Therapeutics,financing_agreements,The predicted downward move of -0.31% may be due to investor dilution concerns from the PIPE financing. Market implications include potential short-term pressure on share prices despite long-term growth prospects supported by significant investor backing.,globenewswire_biotech,biotech,Financing Agreements,334,HARP,2023-10-23 11:17:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Oct.  23, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.",DOWN,-0.003076160633373437,en
14755,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,"Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023",https://www.globenewswire.com/news-release/2023/10/24/2765384/0/en/Science-37-to-Report-Third-Quarter-2023-Financial-Results-on-November-7-2023.html,2023-10-24 06:00:00+00:00,Science 37,earnings_releases_and_operating_results,The predicted downward move of -0.39% could be due to anticipated weak financial results or market sentiment ahead of the earnings report. This may lead to cautious investor behavior and impact overall market confidence in Science 37 Holdings' growth prospects.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,261,SNCE,2023-10-24 10:00:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Oct.  24, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023.",UP,-0.003864079352908621,en
16606,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes",https://www.globenewswire.com/news-release/2023/10/24/2765592/0/en/NexImmune-Yale-and-JDRF-Extend-Research-Partnership-for-Type-1-Diabetes.html,2023-10-24 08:00:00+00:00,NexImmune,partnerships,"The predicted upward move of +0.36% is likely due to the extended research partnership, signaling confidence in innovative diabetes therapies. Market implications include potential advancements in type 1 diabetes prevention, enhancing investor interest in NexImmune.",globenewswire_biotech,biotech,Partnerships,357,NEXI,2023-10-24 12:00:00+00:00,US/Eastern,"GAITHERSBURG, Md., Oct.  24, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).",UP,0.0036303973746740644,en
15856,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/10/24/2765577/0/en/NKGen-Biotech-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-SNK01-NK-Cell-Therapy-to-Treat-Alzheimer-s-Disease.html,2023-10-24 08:00:00+00:00,NKGen Biotech,clinical_study,"The predicted upward move of +11.96% is likely driven by positive sentiment around NKGen's advancing neurodegenerative program. This may signal confidence in future growth prospects, attracting investor interest and potentially strengthening market positioning.",globenewswire_biotech,biotech,Health,318,NKGN,2023-10-24 12:00:00+00:00,US/Eastern,NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023,UP,0.11957090544862956,en
15605,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Provides Q4 2023 Business Update,https://www.globenewswire.com/news-release/2023/10/26/2767127/0/en/Mydecine-Provides-Q4-2023-Business-Update.html,2023-10-26 02:00:00+00:00,Mydecine Innovations Group,corporate_action,"The predicted upward move of +0.34% likely stems from positive company updates boosting shareholder confidence. This minor increase suggests stable investor sentiment, potentially driving moderate interest and more trading activity in the asset.",globenewswire_biotech,biotech,Management statements,306,MYCO.CN,2023-10-26 06:00:00+00:00,US/Eastern,Mydecine is pleased to address its shareholders and provide a general update on the company's progress.,UP,0.0034285705847373698,en
15855,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Presented Phase I Clinical Trial Data at the  16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference,https://www.globenewswire.com/news-release/2023/10/26/2767459/0/en/NKGen-Biotech-Presented-Phase-I-Clinical-Trial-Data-at-the-16th-Annual-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html,2023-10-26 08:00:00+00:00,NKGen Biotech,clinical_study,"The predicted upward move of +4.96% is likely due to positive clinical trial results showing 90% of patients improved or maintained cognitive function in Alzheimer's treatment. This could enhance investor confidence, potentially boosting the asset's market valuation and attractiveness.",globenewswire_biotech,biotech,Clinical Study,318,NKGN,2023-10-26 12:00:00+00:00,US/Eastern,90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks,UP,0.049571843020955776,en
15939,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria,https://www.globenewswire.com/news-release/2023/10/27/2768137/7767/en/MediciNova-s-Collaborator-Initiates-Clinical-Development-of-a-Gene-Therapy-Product-for-the-Treatment-of-Phenylketonuria.html,2023-10-27 01:00:00+00:00,MediciNova,clinical_study,The predicted upward move of +2.32% for MediciNova is likely due to positive investor sentiment following the initiation of a clinical trial with Genzyme. This collaboration could enhance MediciNova's market position and attract further investment interest.,globenewswire_biotech,biotech,Health,322,MNOV,2023-10-27 05:00:00+00:00,US/Eastern,"LA JOLLA, Calif., Oct.  26, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.",UP,0.023214208581120693,en
15872,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,"Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register",https://www.globenewswire.com/news-release/2023/10/27/2768168/0/en/Inside-Information-Announcement-of-the-Results-of-Placing-the-Issue-Price-and-registration-of-Placing-Shares-with-the-Trade-Register.html,2023-10-27 02:05:00+00:00,Faron Pharmaceuticals,shares_issue,"1. The announcement likely contains restricted information impacting investor sentiment. 2. A predicted downward move of -1.99% may signal regulatory concerns or decreased investor confidence, potentially affecting market stability and prompting cautious trading.",globenewswire_biotech,biotech,Stock Market News,319,FARON.HE,2023-10-27 06:05:00+00:00,US/Eastern,"THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.",UP,-0.019903055304821938,en
15604,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,"Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements",https://www.globenewswire.com/news-release/2023/10/31/2769817/0/en/Mydecine-Innovations-Group-Files-Prospectus-Supplement-Announces-Closing-Under-Share-Subscription-Agreements.html,2023-10-31 02:00:00+00:00,Mydecine Innovations Group,financing_agreements,"1. The likely cause of the predicted upward move of +0.14% in Mydecine's asset is the positive reception of its recent funding agreements and the filing of the Prospectus Supplement. 2. This could enhance investor confidence and liquidity, potentially driving market demand.",globenewswire_biotech,biotech,Financing Agreements,306,MYCO.CN,2023-10-31 06:00:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Oct.  31, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with: (i) its previously announced Common Share Subscription Agreement (the “Opensky Subscription Agreement”) with OpenSky Opportunities Fund Ltd. (“Opensky”) dated 10 March 2023; and (ii) a Common Share Subscription Agreement dated 25 October 2023 (the “Standalone Subscription Agreement”, and collectively with the Opensky Subscription Agreement, the “Subscription Agreements”) between the Company and an arms-length investor (the “Standalone Investor” and collectively with Opensky, the “Investors”), the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated 28 January 2022 (together, the “Shelf Prospectus”).",DOWN,0.0013625491957128058,en
19251,MBX,,MBX Biosciences to Participate in Stifel 2023 Healthcare Conference,https://www.globenewswire.com/news-release/2023/10/31/2770118/0/en/MBX-Biosciences-to-Participate-in-Stifel-2023-Healthcare-Conference.html,2023-10-31 08:00:00+00:00,MBX Biosciences,conference_call_webinar,"The predicted downward move of -0.51% could be attributed to investors anticipating limited short-term growth prospects after the presentation announcement. This may indicate potential volatility or muted enthusiasm among investors, impacting market perception and investment decisions.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,749,MBX,2023-10-31 12:00:00+00:00,US/Eastern,"CARMEL, Ind., Oct.  31, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time and will host 1-on-1 investor meetings.",UP,-0.5094608000313788,en
15799,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land,https://www.globenewswire.com/news-release/2023/10/31/2770199/34378/en/Yield10-Bioscience-and-BioMar-Aim-to-Grow-Fish-Oil-on-Land.html,2023-10-31 08:31:00+00:00,Yield10 Bioscience,partnerships,"1. The predicted upward move of +0.73% is likely due to the partnership, advancing Omega-3 technology toward market readiness. 2. This could alleviate supply constraints of marine fatty acids, enhancing Yield10's market position.",globenewswire_biotech,biotech,Partnerships,315,YTEN,2023-10-31 12:31:00+00:00,US/Eastern,"Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of research, this Omega-3 Camelina technology is now advancing toward market availability and has the potential to become another important, high-quality supplement to the scarce supply of marine long-chain fatty acids.",UP,0.0073254604030556884,en
15679,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023,https://www.globenewswire.com/news-release/2023/10/31/2770244/0/en/Akoya-Biosciences-to-Showcase-New-Spatial-Biology-2-0-Solutions-and-Spatial-Phenotyping-Data-at-SITC-2023.html,2023-10-31 09:00:00+00:00,Akoya Biosciences,trade_show,"1. The predicted downward move of -0.59% might result from market skepticism about the adoption speed of Spatial Biology 2.0 solutions. 2. This could imply cautious investor sentiment, potentially affecting broader biotech sector valuations.",globenewswire_biotech,biotech,Calendar of Events,309,AKYA,2023-10-31 13:00:00+00:00,US/Eastern,Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale,UP,-0.0058774582554403775,en
15179,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,"Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023",https://www.globenewswire.com/news-release/2023/10/31/2770619/0/en/Mineralys-Therapeutics-to-Announce-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-Tuesday-November-7-2023.html,2023-10-31 16:05:00+00:00,Mineralys Therapeutics,earnings_releases_and_operating_results,The predicted upward move of +0.04% may be due to investor anticipation of positive financial results or developments in Mineralys' clinical programs. This modest increase suggests stable investor confidence with limited immediate market impact.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,283,MLYS,2023-10-31 20:05:00+00:00,US/Eastern,"RADNOR, Pa., Oct.  31, 2023  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.",UP,0.00037131762899711424,en
14697,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,"PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023",https://www.globenewswire.com/news-release/2023/11/01/2770972/0/en/PolyPid-to-Report-Third-Quarter-2023-Financial-Results-and-Operational-Highlights-on-November-8-2023.html,2023-11-01 07:00:00+00:00,PolyPid,conference_call_webinar,"The predicted upward move of +0.70% for PolyPid likely stems from anticipated positive third-quarter financial results and operational updates. Improved investor confidence could enhance the stock's appeal, potentially boosting market interest and driving the stock price higher.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,258,PYPD,2023-11-01 11:00:00+00:00,US/Eastern,"PETACH TIKVA, Israel, Nov.  01, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.",UP,0.007015979102802942,en
16482,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,"Inotiv, Inc. to Participate in Upcoming Investor Conferences",https://www.globenewswire.com/news-release/2023/11/01/2771067/0/en/Inotiv-Inc-to-Participate-in-Upcoming-Investor-Conferences.html,2023-11-01 08:00:00+00:00,Inotiv,conference_call_webinar,"The predicted upward move of +0.24% for Inotiv, Inc. may result from increased investor visibility as executives participate in November conferences. This could enhance investor confidence and potentially attract new investors, positively impacting market perception and trading volume.",globenewswire_biotech,biotech,Calendar of Events,350,NOTV,2023-11-01 12:00:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Nov.  01, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.",UP,0.0024047582074323095,en
19250,MBX,,MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer,https://www.globenewswire.com/news-release/2023/11/01/2771084/0/en/MBX-Biosciences-Announces-Appointment-of-Michelle-Graham-as-Chief-Human-Resources-Officer.html,2023-11-01 08:00:00+00:00,MBX Biosciences,management_changes,"The predicted downward move of -0.31% may result from market skepticism about the new HR leadership's impact on MBX Biosciences. This could indicate concerns about execution risk during leadership transitions, potentially affecting investor confidence.",globenewswire_biotech,biotech,Directors and Officers,749,MBX,2023-11-01 12:00:00+00:00,US/Eastern,"CARMEL, Ind., Nov.  01, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer. Ms. Graham is a seasoned global executive with 25+ years of experience leading human resources across a broad range of companies in the biopharmaceutical and healthcare industries.",UP,-0.31099791865998844,en
14735,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/11/01/2771076/0/en/Tourmaline-Bio-to-Present-at-Upcoming-Investor-Conferences.html,2023-11-01 08:00:00+00:00,Talaris Therapeutics,conference_call_webinar,"The participation of CEO Sandeep Kulkarni in investor conferences likely boosts investor confidence, leading to a predicted upward move of +0.14%. This could attract more investor interest, potentially enhancing liquidity and valuation.",globenewswire_biotech,biotech,Calendar of Events,260,TALS,2023-11-01 12:00:00+00:00,US/Eastern,"NEW YORK, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in November:",DOWN,0.0013869549798464814,en
14582,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Announces Participation in November Investor Conferences,https://www.globenewswire.com/news-release/2023/11/01/2771329/0/en/Anaptys-Announces-Participation-in-November-Investor-Conferences.html,2023-11-01 09:15:00+00:00,AnaptysBio,conference_call_webinar,The predicted downward move of -0.03% for AnaptysBio might result from anticipated expenses or lack of new data from investor conferences. This slight dip suggests limited immediate impact on investor sentiment but highlights market caution.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,252,ANAB,2023-11-01 13:15:00+00:00,US/Eastern,"SAN DIEGO, Nov.  01, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November:",DOWN,-0.0003321046716595598,en
15599,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23,https://www.globenewswire.com/news-release/2023/11/01/2771630/0/en/InspireMD-Presents-Positive-30-Day-Follow-Up-Results-from-the-C-GUARDIANS-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial-at-VIVA23.html,2023-11-01 14:19:00+00:00,InspireMD,clinical_study,The predicted downward move of -0.36% is likely due to market reactions considering the adverse event rate higher than expected. Potential implications include decreased investor confidence and potential reassessment of future returns for this asset.,globenewswire_biotech,biotech,Clinical Study,304,NSPR,2023-11-01 18:19:00+00:00,US/Eastern,Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure,UP,-0.0035587627548510155,en
15119,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,"scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023",https://www.globenewswire.com/news-release/2023/11/01/2771701/0/en/scPharmaceuticals-to-Announce-Third-Quarter-2023-Financial-Results-on-Wednesday-November-8-2023.html,2023-11-01 16:05:00+00:00,scPharmaceuticals,conference_call_webinar,"The predicted upward move of +0.47% likely stems from anticipated positive news in the conference call. This could boost investor confidence, potentially increasing buying interest and positively impacting stock value short-term. Further gains depend on detailed revelations.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,280,SCPH,2023-11-01 20:05:00+00:00,US/Eastern,Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,DOWN,0.00473260368365055,en
16676,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November,https://www.globenewswire.com/news-release/2023/11/01/2771696/0/en/RAPT-Therapeutics-to-Participate-in-Several-Upcoming-Investor-Conferences-in-November.html,2023-11-01 16:05:00+00:00,RAPT Therapeutics,conference_call_webinar,"The predicted upward move of +0.61% for RAPT Therapeutics is likely due to increased investor interest from upcoming investor conference participation. This can enhance visibility and confidence, potentially leading to higher demand and positive sentiment in the market.",globenewswire_biotech,biotech,Calendar of Events,360,RAPT,2023-11-01 20:05:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November:",UP,0.006087661728170493,en
15598,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD to Participate in Upcoming November Investor Conferences,https://www.globenewswire.com/news-release/2023/11/02/2772201/0/en/InspireMD-to-Participate-in-Upcoming-November-Investor-Conferences.html,2023-11-02 08:00:00+00:00,InspireMD,conference_call_webinar,The predicted downward move of -0.51% could be due to investor uncertainty about InspireMD's growth or competition in the stent market. This may lead to reduced investor confidence and impact short-term stock performance and market sentiment.,globenewswire_biotech,biotech,Calendar of Events,304,NSPR,2023-11-02 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and MIAMI, Fla., Nov.  02, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:",UP,-0.005145784867942402,en
15678,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya to Participate at Three Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/11/02/2772246/0/en/Akoya-to-Participate-at-Three-Upcoming-Investor-Conferences.html,2023-11-02 08:00:00+00:00,Akoya Biosciences,conference_call_webinar,"1. The anticipated participation of Akoya in three investor conferences likely leads to increased investor interest, causing a predicted upward move of +0.21%. 2. This could enhance visibility and investor confidence, potentially attracting more investment.",globenewswire_biotech,biotech,Calendar of Events,309,AKYA,2023-11-02 12:00:00+00:00,US/Eastern,"MARLBOROUGH, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.",UP,0.002140747658265008,en
15871,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting,https://www.globenewswire.com/news-release/2023/11/02/2772399/0/en/Faron-to-Present-Phase-1-2-Data-From-BEXMAB-Study-of-Bexmarilimab-in-Combination-with-Standard-of-Care-in-Myeloid-Malignancies-at-the-65th-American-Society-of-Hematology-Annual-Mee.html,2023-11-02 09:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +1.62% likely stems from investor optimism about Faron Pharmaceuticals' promising Phase 1/2 BEXMAB study results. Market implications could include increased interest in their innovative cancer treatments, enhancing shareholder value and future funding opportunities.",globenewswire_biotech,biotech,Calendar of Events,319,FARON.HE,2023-11-02 13:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Nov.  02, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs), at the 65th American Society of Hematology (ASH) Annual Meeting.",UP,0.016205593052886165,en
16164,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition,https://www.globenewswire.com/news-release/2023/11/02/2772457/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Presentation-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html,2023-11-02 09:15:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +8.35% is likely due to investor optimism following the abstract acceptance and upcoming oral presentation of positive Phase 1 study results. This could increase market confidence in Harpoon Therapeutics' potential, possibly boosting share value.",globenewswire_biotech,biotech,Calendar of Events,334,HARP,2023-11-02 13:15:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.",UP,0.08348605949183074,en
15178,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting,https://www.globenewswire.com/news-release/2023/11/02/2772515/0/en/Mineralys-Therapeutics-Presents-New-Post-Hoc-Analysis-from-Target-HTN-Phase-2-Trial-of-Lorundrostat-in-Late-Breaking-Poster-Session-at-ASN-Kidney-Week-2023-Meeting.html,2023-11-02 10:00:00+00:00,Mineralys Therapeutics,clinical_study,"1. The analysis highlights lorundrostat's effectiveness in treating specific hypertension cases, boosting investor confidence. 2. A predicted upward move of +2.46% may increase interest in healthcare stocks. 3. Positive sentiment could drive further investment in related sectors.",globenewswire_biotech,biotech,Trade Show,283,MLYS,2023-11-02 14:00:00+00:00,US/Eastern,– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension –,DOWN,0.02457695637036689,en
15239,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,"Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study",https://www.globenewswire.com/news-release/2023/11/02/2772786/0/en/Kronos-Bio-Announces-Plan-to-Optimize-Resource-Allocation-Restructure-and-Contain-Costs-Following-Positive-Preliminary-Clinical-Data-from-its-KB-0742-Phase-1-2-Study.html,2023-11-02 16:05:00+00:00,Kronos Bio,clinical_study,"The likely cause of the predicted upward move of +0.79% is increased investor confidence due to strategic resource allocation in KB-0742's study. This may enhance market interest and investment, potentially boosting future valuations and stock performance.",globenewswire_biotech,biotech,Product / Services Announcement,286,KRON,2023-11-02 20:05:00+00:00,US/Eastern,Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study,UP,0.007879066266204887,en
14581,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/02/2772847/0/en/Anaptys-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-02 16:15:00+00:00,AnaptysBio,earnings_releases_and_operating_results,"The predicted downward move of -0.67% likely stems from disappointing financial results or negative business developments reported by AnaptysBio. This could impact investor confidence, leading to potential selling pressure and influencing broader market sentiment in biotech stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,252,ANAB,2023-11-02 20:15:00+00:00,US/Eastern,"SAN DIEGO, Nov.  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.",UP,-0.006687598260084554,en
16383,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine Announces Third Quarter 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html,2023-11-03 07:00:00+00:00,Editas Medicine,clinical_study,"1. Positive clinical updates for EDIT-301 and EdiTHAL could boost investor confidence, driving the predicted upward move of +27.83%. 2. This may enhance the company's market valuation and attract increased investor interest, impacting stock performance.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,345,EDIT,2023-11-03 11:00:00+00:00,US/Eastern,Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar,UP,0.2782817148553247,en
15997,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates,https://www.globenewswire.com/news-release/2023/11/03/2773136/0/en/Ovid-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Corporate-Updates.html,2023-11-03 08:00:00+00:00,Ovid Therapeutics,financial_results,The predicted upward move of +0.15% for Ovid Therapeutics may result from positive business updates and financial results. Market implications could include increased investor confidence and potential interest in the firm's growth prospects in rare epilepsy treatments.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,325,OVID,2023-11-03 12:00:00+00:00,US/Eastern,"NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.",UP,0.001531836931574598,en
15451,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023,https://www.globenewswire.com/news-release/2023/11/03/2773331/0/en/Adagene-Presents-Data-Demonstrating-the-Best-in-Class-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-SITC-2023.html,2023-11-03 12:00:00+00:00,Adagene,clinical_study,"The predicted upward move of +6.97% is likely due to positive clinical data showing a confirmed partial response with ADG126 and pembrolizumab, indicating potential efficacy. This could increase investor confidence and boost the asset's perceived value in the market.",globenewswire_biotech,biotech,Product / Services Announcement,297,ADAG,2023-11-03 16:00:00+00:00,US/Eastern,"- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab –",UP,0.06968224355381447,en
16675,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,"RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC",https://www.globenewswire.com/news-release/2023/11/03/2773329/0/en/RAPT-Therapeutics-Announces-Positive-Data-Including-Objective-Response-Rates-and-Progression-Free-Survival-from-its-Phase-2-Trial-of-FLX475-in-Combination-with-a-Checkpoint-Inhibit.html,2023-11-03 12:00:00+00:00,RAPT Therapeutics,clinical_study,"The likely cause of the predicted upward move of +1.32% is the strong 40% ORR in PD-L1 positive patients, indicating effective therapy potential. This could boost investor confidence and increase stock demand, positively impacting market valuation.",globenewswire_biotech,biotech,Product / Services Announcement,360,RAPT,2023-11-03 16:00:00+00:00,US/Eastern,- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI),UP,0.013156302060272882,en
14509,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting,https://www.globenewswire.com/news-release/2023/11/03/2773425/0/en/Kineta-Presents-New-Preclinical-Data-on-Lead-Anti-CD27-Monoclonal-Antibody-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-38th-Annual-Meeting.html,2023-11-03 16:00:00+00:00,Kineta,clinical_study,"1. The upward move is likely due to positive clinical data for the Anti-CD27 Monoclonal Antibody, boosting investor confidence. 2. This predicted upward move of +5.36% may attract increased investment, enhancing interest in biotech.",globenewswire_biotech,biotech,Calendar of Events,248,KA,2023-11-03 20:00:00+00:00,US/Eastern,Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity ,UP,0.0535777632707243,en
14508,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/03/2773432/0/en/Kineta-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-11-03 16:01:00+00:00,Kineta,clinical_study,"The likely cause of the predicted upward move of +8.11% is the positive safety data announcement for KVA12123 from its VISTA-101 clinical trial, boosting investor confidence. This may increase interest and investment in the asset, enhancing its market position.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,248,KA,2023-11-03 20:01:00+00:00,US/Eastern,Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial,UP,0.08112745283447317,en
15837,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting,https://www.globenewswire.com/news-release/2023/11/03/2773455/0/en/Elicio-Therapeutics-Presents-Updated-Preliminary-Immunogenicity-Data-from-the-Ongoing-Phase-1-Study-of-ELI-002-and-New-Preclinical-Data-on-ELI-007-and-ELI-008-at-the-Society-for-Im.html,2023-11-03 16:30:00+00:00,Elicio Therapeutics,clinical_study,"The predicted upward move of +2.90% likely stems from Elicio Therapeutics' promising preliminary data on its cancer vaccine, ELI-002, and new preclinical insights on ELI-007 and ELI-008. This progress may boost investor confidence and enhance market interest in their biotechnology advancements.",globenewswire_biotech,biotech,Clinical Study,317,ELTX,2023-11-03 20:30:00+00:00,US/Eastern,"BOSTON, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced promising updated preliminary translational data from the ongoing Phase 1 (AMPLIFY-201) study of its lead cancer vaccine candidate, ELI-002, in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers, and new preclinical data on vaccine candidates, ELI-007 and ELI-008.",UP,0.029034019581130867,en
15731,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis,https://www.globenewswire.com/news-release/2023/11/05/2773591/0/en/MoonLake-Immunotherapeutics-announces-landmark-Phase-2-results-for-Nanobody-sonelokimab-in-active-psoriatic-arthritis.html,2023-11-05 11:00:00+00:00,MoonLake Immunotherapeutics,clinical_study,"The predicted upward move of +5.63% likely stems from positive Phase 2 results for sonelokimab, boosting investor confidence. Market implications include increased interest in MoonLake Immunotherapeutics for potentially transformative psoriatic arthritis treatments.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2023-11-05 16:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis,UP,0.056256207285717785,en
43510,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,"MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation",https://www.globenewswire.com/news-release/2023/11/06/2773704/0/en/MDxHealth-Announces-the-Approval-by-its-Shareholders-of-the-Proposed-Transition-to-a-Sole-Listing-of-Shares-on-Nasdaq-and-Details-of-the-Share-Consolidation.html,2023-11-06 01:00:00+00:00,MDxHealth,corporate_action,The predicted upward move of +0.14% is likely due to the release of favorable regulated or inside information. This modest increase could indicate a positive market sentiment but might not significantly impact trading volumes or investor strategies.,globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-06 06:00:00+00:00,US/Eastern,"NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET",UP,0.13966916818423122,en
15870,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS,https://www.globenewswire.com/news-release/2023/11/06/2773717/0/en/Insider-information-Faron-Initiates-Phase-2-Part-of-BEXMAB-Study-of-Bexmarilimab-in-HMA-failed-MDS.html,2023-11-06 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The upward movement may be due to positive news or developments within the company. This predicted upward move of +1.30% could boost investor confidence, potentially increasing trading volumes and enhancing market sentiment towards the company.",globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2023-11-06 07:00:00+00:00,US/Eastern,"Company announcement, Inside Information",UP,0.013025669427650998,en
16343,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023,https://www.globenewswire.com/news-release/2023/11/06/2773808/0/en/CRISPR-Therapeutics-Announces-Preclinical-Data-at-the-American-Heart-Association-AHA-Scientific-Sessions-2023.html,2023-11-06 05:01:00+00:00,CRISPR Therapeutics,clinical_study,"The predicted upward move of +9.12% is likely due to successful CTX310™ trials showing significant reductions in ANGPTL3 and triglycerides in primates. This suggests strong therapeutic potential, boosting investor confidence and possibly increasing pharmaceutical market interest.",globenewswire_biotech,biotech,Product / Services Announcement,343,CRSP,2023-11-06 10:01:00+00:00,US/Eastern,-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose-,UP,0.09119576945618305,en
15597,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Reports Third Quarter 2023 Financial Results and Provides  Business Update,https://www.globenewswire.com/news-release/2023/11/06/2773922/0/en/InspireMD-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-06 07:00:00+00:00,InspireMD,clinical_study,"The predicted upward move of +8.24% is likely due to positive clinical trial results showing a low major adverse events rate of 0.95%, enhancing investor confidence. This could lead to increased investor interest and potential future market expansion for the company.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,304,NSPR,2023-11-06 12:00:00+00:00,US/Eastern,- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –,DOWN,0.0824155328788977,en
65637,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test,https://www.globenewswire.com/news-release/2023/11/06/2774002/0/en/Revive-Therapeutics-Enters-into-Worldwide-Exclusive-Agreement-with-Lawson-Health-Research-Institute-to-Develop-and-Commercialize-a-Novel-Long-COVID-Rapid-Test.html,2023-11-06 07:45:00+00:00,Revive Therapeutics,patents,"The predicted upward move of +0.28% is likely due to the novelty and potential efficacy of the biomarker, which could attract investment and partnerships in the healthcare sector. This could lead to increased market confidence and drive stock prices higher, potentially indicating a growing interest in long COVID treatments and diagnostics.",globenewswire_biotech,biotech,Health,314,RVVTF,2023-11-06 12:45:00+00:00,US/Eastern,Potential world-first patented biomarker for long COVID,UP,0.27510172212909767,en
14507,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting,https://www.globenewswire.com/news-release/2023/11/06/2774113/0/en/Kineta-Unveils-Positive-New-Data-from-VISTA-101-Clinical-Trial-of-KVA12123-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-38th-Annual-Meeting.html,2023-11-06 08:30:00+00:00,Kineta,clinical_study,"The upward move of +2.15% is likely due to positive clinical safety results, reducing investment risk. This can boost investor confidence, potentially increasing demand and share price, while enhancing the asset's market reputation.",globenewswire_biotech,biotech,Clinical Study,248,KA,2023-11-06 13:30:00+00:00,US/Eastern,Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines,UP,0.021517109350949384,en
16342,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/06/2774541/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-06 16:15:00+00:00,CRISPR Therapeutics,clinical_study,"The predicted upward move of +8.23% is likely due to the positive outcome of the advisory committee meeting for exa-cel. This suggests potential FDA approval, boosting investor confidence. Successful approval could expand market opportunities and enhance company valuation.",globenewswire_biotech,biotech,Health,343,CRSP,2023-11-06 21:15:00+00:00,US/Eastern,"-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD-",UP,0.08229234828960635,en
14754,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/07/2774824/0/en/Science-37-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-07 06:00:00+00:00,Science 37,financial_results,"The predicted upward move of +0.19% for Science 37 likely stems from positive financial results for Q3 2023. This could enhance investor confidence, possibly leading to increased stock demand. Market implications include potential short-term stock appreciation and enhanced company valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,261,SNCE,2023-11-07 11:00:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023.",UP,0.0019428266171337845,en
14696,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors,https://www.globenewswire.com/news-release/2023/11/07/2774914/0/en/PolyPid-Announces-the-Addition-of-Dr-Nurit-Tweezer-Zaks-to-its-Board-of-Directors.html,2023-11-07 07:00:00+00:00,PolyPid,management_changes,"1. The predicted upward move of +0.18% likely results from investor confidence in Nurit Tweezer-Zaks' industry experience. 2. This appointment could enhance strategic direction and operational growth, potentially boosting investor sentiment and share value beyond the surface level change.",globenewswire_biotech,biotech,Directors and Officers,258,PYPD,2023-11-07 12:00:00+00:00,US/Eastern,"Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal",DOWN,0.0018344728348428456,en
14992,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023",https://www.globenewswire.com/news-release/2023/11/07/2775408/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-Ended-September-30-2023.html,2023-11-07 12:15:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,The predicted downward move of -0.82% likely stems from negative information expected in the upcoming conference call. Market implications could include reduced investor confidence and potential selling pressure on the asset post-announcement.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,274,ICCC,2023-11-07 17:15:00+00:00,US/Eastern,"Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET",UP,-0.008222974568671762,en
15177,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/07/2775613/0/en/Mineralys-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-11-07 16:05:00+00:00,Mineralys Therapeutics,clinical_study,The upward movement of +8.10% is likely due to investor optimism about the Phase 3 trial initiation of lorundrostat. Successful progression could enhance market confidence in the asset and potentially increase its valuation prospects.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,283,MLYS,2023-11-07 21:05:00+00:00,US/Eastern,– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –,UP,0.08100426824518182,en
14580,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Named a BioSpace 2024 Best Places to Work Winner,https://www.globenewswire.com/news-release/2023/11/07/2775654/0/en/Anaptys-Named-a-BioSpace-2024-Best-Places-to-Work-Winner.html,2023-11-07 16:15:00+00:00,AnaptysBio,contests_awards,"1. The predicted downward move of +nan% is likely due to data input errors or anomalies in analysis models. 2. Such inconsistencies can create uncertainty, potentially affecting investor confidence and market valuation.",globenewswire_biotech,biotech,Contests/Awards,252,ANAB,2023-11-07 21:15:00+00:00,US/Eastern,"SAN DIEGO, Nov.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category.",DOWN,1.6875011644886533,en
14695,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/08/2776036/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-08 07:00:00+00:00,PolyPid,clinical_study,"The likely cause of the predicted upward move of +8.11% is the expansion and progress of the SHIELD II Phase 3 trial, suggesting market confidence in D-PLEX100's potential. This could imply increased investor interest and heightened expectations for successful trial outcomes.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,258,PYPD,2023-11-08 12:00:00+00:00,US/Eastern,Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,UP,0.08112745283447317,en
16481,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™,https://www.globenewswire.com/news-release/2023/11/08/2776113/0/en/Inotiv-Ranked-Number-127-Fastest-Growing-Company-in-North-America-on-the-2023-Deloitte-Technology-Fast-500.html,2023-11-08 07:30:00+00:00,Inotiv,contests_awards,"The predicted downward move of +nan% may result from market skepticism about the sustainability of its 1156% revenue growth attributed to strategic initiatives. Potential market implications include investor caution, impacting stock valuations and future growth expectations.",globenewswire_biotech,biotech,Feature Article,350,NOTV,2023-11-08 12:30:00+00:00,US/Eastern,"Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint",UP,5.09561503448911,en
15571,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments,https://www.globenewswire.com/news-release/2023/11/08/2776169/0/en/PepGen-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html,2023-11-08 08:00:00+00:00,PepGen,financial_results,"The predicted upward move of +0.17% is likely due to increased investor confidence from expanding trial sites in Canada, which could enhance clinical development prospects. This may lead to improved market sentiment and potential long-term value growth.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,303,PEPG,2023-11-08 13:00:00+00:00,US/Eastern,- Continuing to open CONNECT1-EDO51 trial sites in Canada -,DOWN,0.0016595511192965989,en
15213,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups,https://www.globenewswire.com/news-release/2023/11/08/2776231/0/en/Biomerica-Expands-inFoods-IBS-Reach-with-Addition-of-Several-New-GI-Groups.html,2023-11-08 08:19:00+00:00,Biomerica,product_services_announcement,"The likely cause of the predicted upward move of +0.28% in Biomerica's stock is the increased adoption of their inFoods IBS product by new GI groups, indicating enhanced market acceptance. This could lead to expanded revenue streams, potentially boosting investor confidence.",globenewswire_biotech,biotech,Health,285,BMRA,2023-11-08 13:19:00+00:00,US/Eastern,"IRVINE, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revolutionary inFoods® IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for Irritable Bowel Syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company's first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.",UP,0.002825659787531173,en
15798,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,"Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023",https://www.globenewswire.com/news-release/2023/11/08/2776271/34378/en/Yield10-Bioscience-to-Announce-Third-Quarter-2023-Financial-Results-and-Host-a-Conference-Call-on-Tuesday-November-14-2023.html,2023-11-08 08:31:00+00:00,Yield10 Bioscience,financial_results,"The predicted upward move of +1.62% for Yield10 Bioscience likely stems from anticipation of positive financial results and a promising corporate update. This could increase investor confidence, potentially boosting stock demand and enhancing market perception of agricultural bioscience.",globenewswire_biotech,biotech,Company Announcement,315,YTEN,2023-11-08 13:31:00+00:00,US/Eastern,"WOBURN, Mass., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.",UP,0.016174016176598444,en
15677,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance,https://www.globenewswire.com/news-release/2023/11/08/2776648/0/en/Akoya-Reports-Record-Revenue-in-the-Third-Quarter-of-2023-and-Reiterates-Full-Year-2023-Revenue-Guidance.html,2023-11-08 16:00:00+00:00,Akoya Biosciences,earnings_releases_and_operating_results,The predicted downward move of -0.90% despite strong Q3 revenue growth likely stems from market expectations already pricing in the guidance range. Potential market implications include short-term profit-taking or concerns about future growth sustainability.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,309,AKYA,2023-11-08 21:00:00+00:00,US/Eastern,"Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million",UP,-0.008975110192901595,en
43509,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth communique ses résultats pour le troisième trimestre et la période de neuf mois clôturée le 30 septembre 2023,https://www.globenewswire.com/news-release/2023/11/08/2776644/0/fr/MDxHealth-communique-ses-r%C3%A9sultats-pour-le-troisi%C3%A8me-trimestre-et-la-p%C3%A9riode-de-neuf-mois-cl%C3%B4tur%C3%A9e-le-30-septembre-2023.html,2023-11-08 16:00:00+00:00,MDxHealth,earnings_releases_and_operating_results,"The predicted downward move of -1.63% could be due to a regulatory announcement causing investor concern. Market implications may include reduced investor confidence and potential sell-off sentiment, potentially impacting related securities or sectors.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-08 21:00:00+00:00,US/Eastern,"COMMUNIQUÉ DE PRESSE — INFORMATIONS RÉGLEMENTÉES8 NOVEMBRE 2023, 16 h 00 EDT/22 h 00 CET",DOWN,-1.6327286187315828,fr
43508,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,"MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023",https://www.globenewswire.com/news-release/2023/11/08/2776644/0/en/MDxHealth-Reports-Results-for-the-Third-Quarter-and-Nine-Month-Period-Ended-September-30-2023.html,2023-11-08 16:00:00+00:00,MDxHealth,earnings_releases_and_operating_results,"The predicted downward move of -0.98% may be due to negative financial results or regulatory issues. Such a decline could lead to decreased investor confidence, potentially impacting trading volumes and liquidity in the short term.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-08 21:00:00+00:00,US/Eastern,"NEWS RELEASE – REGULATED INFORMATION8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET",UP,-0.981561780897807,en
15118,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/08/2776650/0/en/scPharmaceuticals-Inc-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-08 16:01:00+00:00,scPharmaceuticals,financial_results,"The predicted downward move of -0.20% might result from market expectations exceeding the reported $3.8 million revenue for FUROSCIX®. This could signal weaker-than-anticipated growth, causing investor concerns and potential short-term stock volatility.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,280,SCPH,2023-11-08 21:01:00+00:00,US/Eastern,Generated net FUROSCIX® revenue of $3.8 million,UP,-0.0019594497756575983,en
15658,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,Certara Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/08/2776728/0/en/Certara-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-08 16:10:00+00:00,Certara,financial_results,"The predicted upward move of +0.19% is likely due to the company's confidence in meeting its financial targets, reflecting stability. This could boost investor confidence, fostering potential increased investment and supporting further stock price stability or growth.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,308,CERT,2023-11-08 21:10:00+00:00,US/Eastern,Reiterates Full Year 2023 Financial Guidance Reiterates Full Year 2023 Financial Guidance,UP,0.0019428266171337845,en
15436,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/08/2776799/0/en/Annovis-Bio-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-11-08 17:00:00+00:00,Annovis Bio,earnings_releases_and_operating_results,"The predicted downward move of -0.73% for Annovis Bio might be due to underwhelming third-quarter financial results or unmet expectations. This could signal to investors potential challenges in the company's drug development pipeline, affecting market confidence.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,296,ANVS,2023-11-08 22:00:00+00:00,US/Eastern,"BERWYN, Pa., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.",UP,-0.007275550443828559,en
14506,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit,https://www.globenewswire.com/news-release/2023/11/09/2777372/0/en/Kineta-to-Present-at-the-5th-Annual-Macrophage-Directed-Therapies-Summit.html,2023-11-09 08:30:00+00:00,Kineta,clinical_study,"1. The predicted upward move of +12.30% is likely due to the anticipation surrounding Kineta's presentation of promising preclinical data on KVA12123 and its ongoing clinical trials. 2. Positive data could boost investor confidence, leading to increased stock demand and valuation.",globenewswire_biotech,biotech,Calendar of Events,248,KA,2023-11-09 13:30:00+00:00,US/Eastern,"SEATTLE, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the 5th Annual Macrophage-Directed Therapies Summit, to be held on November 13-15, 2023 in Boston, MA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present preclinical data on KVA12123, the company’s VISTA blocking immunotherapy, as well as an overview of the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.",DOWN,0.12299204327631022,en
16542,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis,https://www.globenewswire.com/news-release/2023/11/09/2777730/0/en/Entera-Bio-Reports-Key-Milestone-Relating-to-Oral-PTH-1-34-Peptide-EB613-Phase-3-Program-ASBMR-SABRE-Has-Submitted-to-FDA-the-Full-Qualification-Plan-to-Approve-BMD-as-a-Surrogate-.html,2023-11-09 14:30:00+00:00,Entera Bio,clinical_study,"1. The predicted upward move of +2.56% is likely due to Entera Bio's involvement with the SABRE project, signalling progress in drug development. 2. This could enhance investor confidence and potentially increase valuation in the osteoporosis drug market.",globenewswire_biotech,biotech,Clinical Study,353,ENTX,2023-11-09 19:30:00+00:00,US/Eastern,"JERUSALEM, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.",UP,0.025631053973809638,en
14838,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/11/09/2777760/0/en/ARS-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,2023-11-09 16:00:00+00:00,ARS Pharmaceuticals,clinical_study,"The predicted upward move of +16.81% is likely due to the company's progress in the FDA-requested study, signaling positive potential outcomes. Market implications include increased investor confidence and potential valuation growth if results meet expectations.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,265,SPRY,2023-11-09 21:00:00+00:00,US/Eastern,Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024,UP,0.16812003355902308,en
15019,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/09/2777775/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-Third-Quarter-2023-Financial-Results.html,2023-11-09 16:01:00+00:00,Oncternal Therapeutics,financial_results,1. The predicted downward move of -0.34% likely stems from weak financial results in Oncternal's third quarter. 2. Market implications may include reduced investor confidence and potential decreased funding for ongoing research and development.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,275,ONCT,2023-11-09 21:01:00+00:00,US/Eastern,"SAN DIEGO, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.",UP,-0.0033808892969134745,en
16163,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/09/2777780/0/en/Harpoon-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,2023-11-09 16:01:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +8.10% is likely due to increased investor confidence from financing of late-stage clinical trials for HPN328, indicating potential market approval. This could enhance the company's value and attract more investment, impacting the biotech sector positively.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,334,HARP,2023-11-09 21:01:00+00:00,US/Eastern,October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types,UP,0.08100426824518182,en
16385,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/09/2777781/0/en/Rain-Oncology-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-09 16:01:00+00:00,Rain Therapeutics,financial_results,"The predicted downward move of -0.18% could be due to disappointing third-quarter financial results or unfavorable updates on key developments. This slight decline may affect investor sentiment, leading to cautious trading for Rain Oncology Inc.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,346,RAIN,2023-11-09 21:01:00+00:00,US/Eastern,"NEWARK, Calif., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.",UP,-0.0017949393743137538,en
15176,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics to Participate in Three Upcoming Conferences,https://www.globenewswire.com/news-release/2023/11/09/2777850/0/en/Mineralys-Therapeutics-to-Participate-in-Three-Upcoming-Conferences.html,2023-11-09 16:05:00+00:00,Mineralys Therapeutics,conference_call_webinar,"The predicted upward move of +0.74% for Mineralys Therapeutics may be driven by increased investor interest due to the company's participation in multiple high-profile healthcare conferences. This could enhance visibility and attract potential partnerships or investments, positively impacting market sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,283,MLYS,2023-11-09 21:05:00+00:00,US/Eastern,"RADNOR, Pa., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.",UP,0.007393836180032669,en
15539,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates,https://www.globenewswire.com/news-release/2023/11/09/2777880/0/en/Windtree-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Key-Business-Updates.html,2023-11-09 16:15:00+00:00,Windtree Therapeutics,financial_results,"The predicted upward move of +0.20% for Windtree Therapeutics may be driven by positive financial results and business updates. This can improve investor confidence, potentially leading to increased stock interest and a slight positive shift in the biotechnology market.",globenewswire_biotech,biotech,Health,301,WINT,2023-11-09 21:15:00+00:00,US/Eastern,"WARRINGTON, Pa., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.",UP,0.001987741056581834,en
15836,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates,https://www.globenewswire.com/news-release/2023/11/09/2777902/0/en/Elicio-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Updates.html,2023-11-09 16:30:00+00:00,Elicio Therapeutics,clinical_study,"The predicted upward move of +17.03% for Elicio Therapeutics is likely driven by positive financial results or promising clinical updates. This optimism could enhance investor confidence, potentially increasing demand and share prices in the biotechnology sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,317,ELTX,2023-11-09 21:30:00+00:00,US/Eastern,"BOSTON, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX)(“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate and clinical updates.",UP,0.17034322168197297,en
14488,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Announces Launch of Proposed Public Offering,https://www.globenewswire.com/news-release/2023/11/09/2777951/28889/en/Fortress-Biotech-Announces-Launch-of-Proposed-Public-Offering.html,2023-11-09 17:05:00+00:00,Fortress Biotech,shares_issue,"The predicted downward move of -0.52% likely results from potential dilution due to Fortress Biotech's public offering. Market implications may include reduced stock value perception as new shares or warrants increase supply, affecting shareholder equity.",globenewswire_biotech,biotech,Financing Agreements,247,FBIO,2023-11-09 22:05:00+00:00,US/Eastern,"MIAMI, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has commenced a public offering, subject to market and other conditions, to offer and sell units, consisting of (i) one share of common stock (or pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock. All of the shares of common stock, pre-funded warrants and accompanying warrants are being offered by Fortress.",DOWN,-0.00519689077451941,en
14487,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Announces Pricing of $10.0 Million Public Offering,https://www.globenewswire.com/news-release/2023/11/10/2778298/28889/en/Fortress-Biotech-Announces-Pricing-of-10-0-Million-Public-Offering.html,2023-11-10 08:15:00+00:00,Fortress Biotech,shares_issue,The predicted downward move of -1.31% for Fortress Biotech is likely due to dilution concerns from the new public offering. Market implications might include decreased investor confidence and potential volatility as the company raises additional capital.,globenewswire_biotech,biotech,Management statements,247,FBIO,2023-11-10 13:15:00+00:00,US/Eastern,"MIAMI, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the pricing of its public offering of an aggregate of 5,885,000 units, at a public offering price of $1.70 per unit, consisting of (i) one share of common stock (or one pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock, immediately exercisable at a price of $1.70 per share and expiring five years from the date of issuance.",DOWN,-0.013123887140347174,en
15212,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16,https://www.globenewswire.com/news-release/2023/11/10/2778299/0/en/Biomerica-to-Participate-in-14th-Annual-Craig-Hallum-Alpha-Select-Conference-on-November-16.html,2023-11-10 08:19:00+00:00,Biomerica,conference_call_webinar,"1. The predicted downward move of -0.16% likely stems from investor expectations surrounding the conference, where no significant news or breakthroughs may be anticipated. 2. This could impact short-term investor sentiment, leading to cautious trading and muted stock activity.",globenewswire_biotech,biotech,Calendar of Events,285,BMRA,2023-11-10 13:19:00+00:00,US/Eastern,"IRVINE, Calif., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.",UP,-0.0015662457207599703,en
14753,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2023/11/10/2778526/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,2023-11-10 16:39:00+00:00,Science 37,corporate_action,"The predicted upward move of +0.27% is likely due to positive investor sentiment following inducement equity awards, signaling confidence in future growth. This move may enhance investor interest and stability in Science 37’s stock performance.",globenewswire_biotech,biotech,Financing Agreements,261,SNCE,2023-11-10 21:39:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2023. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",UP,0.0026910097428583645,en
15175,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,"Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023",https://www.globenewswire.com/news-release/2023/11/11/2778607/0/en/Mineralys-Therapeutics-Further-Defines-Endotype-Specific-Targeted-Approach-to-Treatment-of-Uncontrolled-or-Resistant-Hypertension-with-Lorundrostat-Data-at-AHA-Scientific-Sessions-.html,2023-11-11 11:30:00+00:00,Mineralys Therapeutics,clinical_study,"1. Positive trial results linking obesity, leptin, and aldosterone likely caused the predicted upward move of +1.76%. 2. This could enhance investor confidence, potentially increasing stock value and attracting more investments in obesity-related therapies.",globenewswire_biotech,biotech,Clinical Study,283,MLYS,2023-11-11 16:30:00+00:00,US/Eastern,"– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –",UP,0.017615957876554875,en
16059,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/13/2778893/0/en/Akero-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-13 07:00:00+00:00,Akero Therapeutics,clinical_study,"The predicted upward move of +8.23% is likely due to positive news about Akero Therapeutics' progress in the Phase 3 SYNCHRONY studies. This could increase investor confidence, potentially boosting market interest and affecting share price dynamics positively.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,328,AKRO,2023-11-13 12:00:00+00:00,US/Eastern,"-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.",UP,0.08229234828960635,en
16674,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/13/2779017/0/en/RAPT-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-13 08:00:00+00:00,RAPT Therapeutics,financial_results,"The predicted upward move of +0.19% is likely driven by the company's strong cash position of $184.8 million, indicating financial stability. This could enhance investor confidence, potentially leading to increased stock investments and positive market sentiment.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,360,RAPT,2023-11-13 13:00:00+00:00,US/Eastern,Company maintains strong cash position of $184.8 million Company maintains strong cash position of $184.8 million,DOWN,0.0019110409948703924,en
16198,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,"MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights",https://www.globenewswire.com/news-release/2023/11/13/2779410/0/en/MDxHealth-Announces-Completion-of-Share-Consolidation-and-Update-of-Outstanding-Shares-and-Voting-Rights.html,2023-11-13 16:00:00+00:00,MDxHealth,changes_in_share_capital_and_votes,"1. The predicted downward move of +nan% indicates a data error or unavailable forecast rather than a real expectation. 2. Such errors can cause investor uncertainty, potentially increasing market volatility as traders react to incomplete or unclear information.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-13 21:00:00+00:00,US/Eastern,"           NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET",DOWN,-4.242379424003494,en
16199,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,"MDxHealth annonce la réalisation de son regroupement d'actions, et la mise à jour des actions et des droits de vote en circulation",https://www.globenewswire.com/news-release/2023/11/13/2779410/0/fr/MDxHealth-annonce-la-r%C3%A9alisation-de-son-regroupement-d-actions-et-la-mise-%C3%A0-jour-des-actions-et-des-droits-de-vote-en-circulation.html,2023-11-13 16:00:00+00:00,MDxHealth,changes_in_share_capital_and_votes,"The predicted downward move of +nan% likely signals data or calculation error. Potential market implications include increased volatility and uncertainty. Investors may react cautiously, awaiting clarification or corrections to adjust their strategies accordingly.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-13 21:00:00+00:00,US/Eastern,"COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE13 NOVEMBRE 2023, 16:00 ET / 22:00 CET",DOWN,-8.694876693782007,fr
15238,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/13/2779455/0/en/Kronos-Bio-Reports-Recent-Business-Progress-and-Third-Quarter-2023-Financial-Results.html,2023-11-13 16:05:00+00:00,Kronos Bio,clinical_study,"The predicted upward move of +17.09% is likely driven by the positive preliminary data presentation, indicating favorable trial progress. This could boost investor confidence, potentially increasing demand and elevating the company's stock value in the market.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,286,KRON,2023-11-13 21:05:00+00:00,US/Eastern,Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences,UP,0.17093368658114413,en
16480,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,Inotiv Provides Business Updates and Upcoming Investor Conferences Update,https://www.globenewswire.com/news-release/2023/11/13/2779445/0/en/Inotiv-Provides-Business-Updates-and-Upcoming-Investor-Conferences-Update.html,2023-11-13 16:05:00+00:00,Inotiv,press_releases,"The predicted upward move of +0.81% for Inotiv, Inc. likely stems from positive business updates and upcoming investor conference participation. This could boost investor confidence, potentially leading to increased demand and stock price.",globenewswire_biotech,biotech,Calendar of Events,350,NOTV,2023-11-13 21:05:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provides business updates related to Inotiv’s operations and an update regarding its participation in upcoming investor conferences.",UP,0.008064209991141776,en
14991,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023",https://www.globenewswire.com/news-release/2023/11/13/2779424/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-Ended-September-30-2023.html,2023-11-13 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"1. The predicted downward move of -0.99% may be due to underwhelming financial results for the quarter. 2. This could lead to reduced investor confidence, impacting stock valuations.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,274,ICCC,2023-11-13 21:05:00+00:00,US/Eastern,"PORTLAND, Maine, Nov.  13, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.",UP,-0.00987578291481819,en
14613,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/13/2779493/0/en/Eloxx-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,2023-11-13 16:15:00+00:00,Eloxx Pharmaceuticals,clinical_study,"1. The likely cause of the predicted upward move of +8.24% is the positive Phase 2 trial results showing improved kidney morphology and protein re-expression in Alport Syndrome treatment. 2. This suggests strong therapeutic potential, possibly increasing investor confidence and demand for shares.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,254,ELOX,2023-11-13 21:15:00+00:00,US/Eastern,Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome,UP,0.0824155328788977,en
16700,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2023/11/13/2779566/36989/en/Checkpoint-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,2023-11-13 17:00:00+00:00,Checkpoint Therapeutics,regulatory_filings,"The predicted downward move of -0.01% likely results from uncertainty surrounding the cosibelimab approval process. Markets may perceive regulatory hurdles or competitive pressures, potentially affecting biotech valuations and investor sentiment. However, the minimal decrease suggests stability remains.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,361,CKPT,2023-11-13 22:00:00+00:00,US/Eastern,"Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 ",DOWN,-7.885532371121887e-05,en
16541,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,"Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development",https://www.globenewswire.com/news-release/2023/11/14/2779971/0/en/Entera-Bio-Reports-Q3-2023-Financial-Results-Highlights-Transformational-Steps-and-Unveils-Vision-as-Premier-Oral-Peptide-Company-with-Five-Potential-Programs-in-Development.html,2023-11-14 07:30:00+00:00,Entera Bio,financial_results,"The predicted upward move of +0.43% in Entera Bio's stock is likely due to positive corporate updates and strong financial results for Q3 2023. This could boost investor confidence, potentially leading to increased market interest and stock demand.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,353,ENTX,2023-11-14 12:30:00+00:00,US/Eastern,"JERUSALEM, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023.",UP,0.0043024734599580354,en
15730,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,https://www.globenewswire.com/news-release/2023/11/14/2780026/0/en/MoonLake-Immunotherapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html,2023-11-14 08:00:00+00:00,MoonLake Immunotherapeutics,financial_results,"The predicted downward move of -0.04% likely stems from underwhelming financial results or updates. Market implications include reduced investor confidence, possibly affecting short-term stock demand and slight volatility changes as traders reassess MoonLake’s financial health and future prospects.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2023-11-14 13:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,UP,-0.00038813949439379513,en
16197,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/14/2780474/0/en/MDxHealth-to-Participate-in-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html,2023-11-14 16:00:00+00:00,MDxHealth,conference_call_webinar,"The predicted downward move of -0.75% might be due to weak earnings reports or geopolitical tensions. This decline could impact investor confidence and deter new investments, potentially increasing market volatility.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-14 21:00:00+00:00,US/Eastern,       ,UP,-0.00751501786010739,en
14486,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Announces Closing of $10.0 Million Public Offering,https://www.globenewswire.com/news-release/2023/11/14/2780484/28889/en/Fortress-Biotech-Announces-Closing-of-10-0-Million-Public-Offering.html,2023-11-14 16:01:00+00:00,Fortress Biotech,shares_issue,The predicted upward move of +0.05% likely results from investor optimism following Fortress Biotech's successful public offering. Market implications may include increased trading activity as investors respond to potential future growth and stock liquidity.,globenewswire_biotech,biotech,Financing Agreements,247,FBIO,2023-11-14 21:01:00+00:00,US/Eastern,"MIAMI, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced public offering of an aggregate of 5,885,000 units, consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $1.70 per unit. The warrants are immediately exercisable at a price of $1.70 per share and expire five years from the date of issuance.",DOWN,0.00045839800853745725,en
15797,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Announces Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/14/2780485/34378/en/Yield10-Bioscience-Announces-Third-Quarter-2023-Financial-Results.html,2023-11-14 16:01:00+00:00,Yield10 Bioscience,financial_results,"The predicted upward move of +0.06% is likely due to advances in herbicide-tolerant camelina varieties and securing a global license for Omega-3 technology. This could enhance market competitiveness and drive investor interest, suggesting positive long-term growth potential.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,315,YTEN,2023-11-14 21:01:00+00:00,US/Eastern,"-Establishes ""Camelina Seed Genetics to Biofuel"" Platform-Advances Herbicide Tolerant Camelina Varieties toward Commercialization-Exercises Option to Finalize Exclusive, Global Commercial License to Advanced Omega-3 Technology-Management will host a conference call today at 4:30 pm (ET)",UP,0.000643491641510321,en
14485,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2023/11/14/2780529/28889/en/Fortress-Biotech-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,2023-11-14 16:10:00+00:00,Fortress Biotech,earnings_releases_and_operating_results,"Despite a 100% revenue increase to $34.8 million in Q3 2023 from Q2, investor expectations or earnings forecasts might not have been met, causing a predicted downward move of -0.62%. This suggests caution or potential overvaluation concerns.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,247,FBIO,2023-11-14 21:10:00+00:00,US/Eastern,"Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023",UP,-0.006163416988118425,en
15365,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/14/2780555/35690/en/OpGen-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-14 16:30:00+00:00,OpGen,financial_results,"1. The predicted downward move of -0.21% may result from disappointing financials or unmet market expectations. 2. This could signal investor concerns, potentially leading to reduced confidence or selling pressure in OpGen's stock.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,293,OPGN,2023-11-14 21:30:00+00:00,US/Eastern,"ROCKVILLE, Md., Nov.  14, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.",UP,-0.0021002643506977518,en
15854,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,"NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights",https://www.globenewswire.com/news-release/2023/11/14/2780588/0/en/NKGen-Biotech-Inc-Reports-Third-Quarter-2023-Financial-Results-and-Business-Highlights.html,2023-11-14 16:48:00+00:00,NKGen Biotech,clinical_study,The reported improvement in neuroinflammation and cognitive function in Alzheimer's patients from the SNK01 Phase I program likely drives the predicted upward move of +16.21%. This success could attract investor interest and increase funding potential for further studies.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,318,NKGN,2023-11-14 21:48:00+00:00,US/Eastern,"– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase I/IIa by year end",UP,0.16208274355457558,en
19249,MBX,,MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/15/2780957/0/en/MBX-Biosciences-to-Participate-in-Piper-Sandler-35th-Annual-Healthcare-Conference.html,2023-11-15 08:00:00+00:00,MBX Biosciences,conference_call_webinar,"The predicted downward move of -0.75% for MBX Biosciences may be due to uncertainty around upcoming announcements or perceived risks in clinical developments. This could indicate cautious investor sentiment, possibly impacting short-term stock performance and confidence.",globenewswire_biotech,biotech,Calendar of Events,749,MBX,2023-11-15 13:00:00+00:00,US/Eastern,"CARMEL, Ind., Nov.  15, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th, 2023, at 9:10 a.m. Eastern Time and will host 1-on-1 investor meetings.",UP,-0.7545165586137261,en
15570,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,"PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors",https://www.globenewswire.com/news-release/2023/11/15/2780968/0/en/PepGen-Announces-Appointment-of-Howard-Mayer-M-D-to-Board-of-Directors.html,2023-11-15 08:00:00+00:00,PepGen,management_changes,1. The predicted downward move of -0.01% is likely due to minor investor uncertainty following the board appointment news. 2. Market implications might include short-term volatility as investors assess Dr. Mayer's impact on company strategy.,globenewswire_biotech,biotech,Directors and Officers,303,PEPG,2023-11-15 13:00:00+00:00,US/Eastern,"BOSTON, Nov.  15, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.",DOWN,-8.833539848866305e-05,en
15796,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States,https://www.globenewswire.com/news-release/2023/11/15/2781049/34378/en/USDA-APHIS-Determines-that-Yield10-Bioscience-s-Glufosinate-Tolerant-Camelina-May-Be-Planted-and-Bred-in-the-United-States.html,2023-11-15 08:31:00+00:00,Yield10 Bioscience,product_services_announcement,"The predicted downward move of -0.36% may stem from investor concerns about commercial viability or market reception of Camelina as a biofuel crop. This could imply cautious market sentiment, affecting investment decisions and future market positioning.",globenewswire_biotech,biotech,Product / Services Announcement,315,YTEN,2023-11-15 13:31:00+00:00,US/Eastern,-Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils,DOWN,-0.003604432522587084,en
15795,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States,https://www.globenewswire.com/news-release/2023/11/15/2781050/34378/en/USDA-APHIS-Determines-that-Yield10-Bioscience-s-Stacked-Herbicide-Tolerant-Camelina-May-Be-Planted-and-Bred-in-the-United-States.html,2023-11-15 08:32:00+00:00,Yield10 Bioscience,regulatory_filings,"The predicted upward move of +26.98% likely stems from improved herbicide technology, which boosts camelina cultivation. This advancement positions camelina as a viable large-acreage crop, attracting investment and potentially increasing market demand and agricultural innovation.",globenewswire_biotech,biotech,Regulatory information,315,YTEN,2023-11-15 13:32:00+00:00,US/Eastern,-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America,DOWN,0.26983221716879396,en
15538,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent,https://www.globenewswire.com/news-release/2023/11/16/2781791/0/en/Windtree-Therapeutics-Announces-Issuance-of-New-Pure-SERCA2a-Activator-Patent.html,2023-11-16 08:00:00+00:00,Windtree Therapeutics,patents,The predicted upward move of +1.74% is likely due to positive sentiment around the potential of SERCA2a activators to innovate heart failure therapies. Market implications include increased investor interest and potential for long-term growth in biotech stocks.,globenewswire_biotech,biotech,Product / Services Announcement,301,WINT,2023-11-16 13:00:00+00:00,US/Eastern,This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program,UP,0.01744426433024239,en
15819,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day,https://www.globenewswire.com/news-release/2023/11/17/2782535/0/en/Rezolute-to-Participate-in-BTIG-s-3rd-Annual-Ophthalmology-Day.html,2023-11-17 08:00:00+00:00,Rezolute,conference_call_webinar,"1. The predicted downward move of -0.00% suggests negligible market impact from Rezolute's participation announcement. 2. This indicates investor expectations remain unchanged, potentially signaling stable current valuations without significant new developments affecting the stock.",globenewswire_biotech,biotech,Calendar of Events,316,RZLT,2023-11-17 13:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG’s 3rd Annual Ophthalmology Day, taking place virtually on November 27th.",DOWN,-4.293835584441921e-07,en
15938,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology,https://www.globenewswire.com/news-release/2023/11/19/2782852/7767/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Presented-at-the-28th-Annual-Meeting-of-the-Society-for-Neuro-Oncology.html,2023-11-19 18:00:00+00:00,MediciNova,clinical_study,"The predicted upward move of +0.34% for MediciNova is likely due to positive Phase 2 trial results of MN-166 in glioblastoma, showcasing promising data. This could boost investor confidence, potentially enhancing MediciNova's market position and collaborations in oncology.",globenewswire_biotech,biotech,Clinical Study,322,MNOV,2023-11-19 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., Nov.  19, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.",UP,0.0034068183766574277,en
15359,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/20/2783587/0/en/Immuneering-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html,2023-11-20 16:05:00+00:00,Immuneering,conference_call_webinar,"The predicted downward move of -1.11% for Immuneering Corporation likely stems from investor skepticism about the company's pipeline and strategies, leading to cautious sentiment. This could impact market confidence and potentially influence other biotech stocks negatively.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,292,IMRX,2023-11-20 21:05:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Nov.  20, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.",UP,-0.011131651516310504,en
14649,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,"MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer",https://www.globenewswire.com/news-release/2023/11/21/2783924/30505/en/MediWound-Announces-Appointment-of-Shmulik-Hess-Ph-D-as-Chief-Operating-Officer-and-Chief-Commercial-Officer.html,2023-11-21 07:00:00+00:00,MediWound,management_changes,"1. The predicted downward move of -0.70% may be due to investor uncertainty about leadership changes at MediWound. 2. This change could impact operational efficiency and commercial strategy, leading to temporary market hesitation.",globenewswire_biotech,biotech,Directors and Officers,255,MDWD,2023-11-21 12:00:00+00:00,US/Eastern,"YAVNE, Israel, Nov.  21, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound.",DOWN,-0.007039765222961226,en
14648,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update,https://www.globenewswire.com/news-release/2023/11/21/2783933/30505/en/MediWound-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Company-Update.html,2023-11-21 07:02:00+00:00,MediWound,financial_results,The predicted downward move of -0.04% may stem from concerns about the costs of resource allocation to meet global demand. Market implications include potential short-term instability before possible future gains as the company adjusts.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,255,MDWD,2023-11-21 12:02:00+00:00,US/Eastern,NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand,DOWN,-0.00037490284863858745,en
15779,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development,https://www.globenewswire.com/news-release/2023/11/21/2783948/0/en/Revive-Therapeutics-Provides-Update-of-Novel-Bucillamine-Formulation-Development.html,2023-11-21 07:30:00+00:00,Revive Therapeutics,product_services_announcement,"The predicted downward move of -0.59% may result from perceived delays or high competition in Revive Therapeutics' R&D. This could impact investor confidence, potentially reducing stock attractiveness and affecting future funding opportunities.",globenewswire_biotech,biotech,Company Announcement,314,RVVTF,2023-11-21 12:30:00+00:00,US/Eastern,"TORONTO, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.",DOWN,-0.0058601263827041585,en
15657,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development,https://www.globenewswire.com/news-release/2023/11/21/2784437/0/en/Certara-introduces-Simcyp-Biopharmaceutics-software-to-increase-efficiency-of-novel-and-generic-drug-formulation-development.html,2023-11-21 16:30:00+00:00,Certara,product_services_announcement,"The predicted downward move of -0.64% for Certara might be due to market competition or pricing pressures. This could lead to decreased investor confidence, potentially affecting its stock valuation, and influencing similar companies in the biopharma sector.",globenewswire_biotech,biotech,Product / Services Announcement,308,CERT,2023-11-21 21:30:00+00:00,US/Eastern,"Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.",UP,-0.006407467090562216,en
16652,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing,https://www.globenewswire.com/news-release/2023/11/24/2785689/0/en/Celularity-Inc-Announces-Receipt-of-Nasdaq-Notice-Regarding-Late-Form-10-Q-Filing.html,2023-11-24 13:15:00+00:00,Celularity,company_regulatory_filings,The predicted upward move of +0.33% despite non-compliance with Nasdaq listing requirements may be driven by investor optimism regarding the company's underlying technologies or future filings. This could indicate confidence in their long-term potential despite current setbacks.,globenewswire_biotech,biotech,Exchange Members,359,CELU,2023-11-24 18:15:00+00:00,US/Eastern,"FLORHAM PARK, N.J., Nov.  24, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for the third quarter of 2023.",UP,0.00334335568084988,en
16195,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq,https://www.globenewswire.com/news-release/2023/11/27/2785832/0/en/MDxHealth-Announces-Completion-of-Mandatory-ADS-Exchange-and-Commencement-of-Transition-Period-to-Single-Listing-on-Nasdaq.html,2023-11-27 01:00:00+00:00,MDxHealth,exchange_announcement,"The predicted downward move of -0.22% might be due to anticipated negative financial results or adverse economic news. This could lead to decreased investor confidence, causing slight pressure on asset prices and a cautious market sentiment.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-27 06:00:00+00:00,US/Eastern,"NEWS RELEASE – REGULATED INFORMATIONNOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET",DOWN,-0.002167859796700301,en
16196,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth annonce la réalisation de l'échange obligatoire d'ADS et le début de la période de transition vers une cotation unique sur le Nasdaq,https://www.globenewswire.com/news-release/2023/11/27/2785832/0/fr/MDxHealth-annonce-la-r%C3%A9alisation-de-l-%C3%A9change-obligatoire-d-ADS-et-le-d%C3%A9but-de-la-p%C3%A9riode-de-transition-vers-une-cotation-unique-sur-le-Nasdaq.html,2023-11-27 01:00:00+00:00,MDxHealth,exchange_announcement,"The predicted downward move of -4.73% likely stems from unfavorable regulatory news affecting investor sentiment. Potential market implications include reduced investor confidence and potential asset sell-offs, impacting overall market stability and potentially causing broader index declines.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-11-27 06:00:00+00:00,US/Eastern,"COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE27 NOVEMBRE 2023, 1:00 EDT / 7:00 CET",DOWN,-0.047332977244580465,fr
15596,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions,https://www.globenewswire.com/news-release/2023/11/27/2786025/0/en/InspireMD-Announces-Strategic-Agreement-with-Jacobs-Institute-to-Execute-Early-Feasibility-Study-of-CGuard-EPS-for-the-Treatment-of-Acute-Stroke-Patients-with-Tandem-Lesions.html,2023-11-27 07:00:00+00:00,InspireMD,clinical_study,The predicted upward move of +1.57% is likely due to optimism surrounding the stroke study's potential breakthrough. This could boost investor confidence in the associated medical company. Successful trial results may drive further gains and increased market interest.,globenewswire_biotech,biotech,Health,304,NSPR,2023-11-27 12:00:00+00:00,US/Eastern,Study to enroll 15 acute stroke patients across three U.S. sites Study to enroll 15 acute stroke patients across three U.S. sites,UP,0.015742068433450357,en
15435,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,"Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections",https://www.globenewswire.com/news-release/2023/11/27/2786071/0/en/Annovis-Bio-Announces-Full-Enrollment-of-Its-Phase-II-III-Alzheimer-s-Disease-Trial-Exceeding-Original-Projections.html,2023-11-27 07:30:00+00:00,Annovis Bio,clinical_study,The likely cause of the predicted downward move of -2.04% could be investor concerns over trial results or higher expectations already priced in. Market implications could include decreased investor confidence and potential short-term stock volatility.,globenewswire_biotech,biotech,Clinical Study,296,ANVS,2023-11-27 12:30:00+00:00,US/Eastern,"BERWYN, Pa., Nov.  27, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment. ",UP,-0.02035571290274712,en
16673,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy,https://www.globenewswire.com/news-release/2023/11/27/2786122/0/en/RAPT-Therapeutics-Announces-Publication-of-Phase-1a-1b-Clinical-Trial-of-Zelnecirnon-RPT193-to-Treat-Atopic-Dermatitis-in-Allergy.html,2023-11-27 08:00:00+00:00,RAPT Therapeutics,clinical_study,"The predicted upward move of +1.52% is likely due to positive results from RAPT Therapeutics' Phase 1a/1b trial of zelnecirnon, highlighting potential advancements in atopic dermatitis treatment. This could enhance investor confidence and support RAPT's market position in immunology therapies.",globenewswire_biotech,biotech,Clinical Study,360,RAPT,2023-11-27 13:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Nov.  27, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that results from its previously disclosed Phase 1a/1b clinical trial of zelnecirnon (formerly RPT193) were published in Allergy. The Phase 1a portion of the trial was a standard single and multiple dose-escalation study in 72 healthy volunteers. The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining zelnecirnon as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).",DOWN,0.015176850110386417,en
16479,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,"Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023",https://www.globenewswire.com/news-release/2023/11/27/2786522/0/en/Inotiv-Inc-to-Report-Fiscal-2023-Fourth-Quarter-and-Full-Year-Results-and-Host-Conference-Call-on-Monday-December-11-2023.html,2023-11-27 16:05:00+00:00,Inotiv,financial_results,"The predicted downward move of -0.48% likely stems from uncertainty ahead of Inotiv's earnings release. Market implications include potential investor caution and reassessment of positions, reflecting broader sentiment on the company's financial health and future prospects.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,350,NOTV,2023-11-27 21:05:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Nov.  27, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, on Monday, December 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.",UP,-0.004791417448976877,en
15237,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/27/2786515/0/en/Kronos-Bio-Announces-Participation-in-35th-Annual-Piper-Sandler-Healthcare-Conference.html,2023-11-27 16:05:00+00:00,Kronos Bio,conference_call_webinar,"The predicted downward move of -0.25% may result from investor anticipation of limited immediate news from the fireside chat. Such a slight dip suggests moderate investor uncertainty, potentially signaling restrained short-term confidence in Kronos Bio's strategic plans.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,286,KRON,2023-11-27 21:05:00+00:00,US/Eastern,"SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov.  27, 2023  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN Mapping will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 4:00 p.m. ET.",UP,-0.002464595856698078,en
14579,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals,https://www.globenewswire.com/news-release/2023/11/27/2786530/0/en/Anaptys-Expands-Immune-Cell-Modulator-Pipeline-with-Exclusive-License-to-BDCA2-Modulator-Antibody-Portfolio-from-Centessa-Pharmaceuticals.html,2023-11-27 16:15:00+00:00,AnaptysBio,licensing_agreements,"The predicted upward move of +2.69% is likely due to AnaptysBio's exclusive license agreement for promising BDCA2 modulator assets. This agreement may enhance Anaptys' pipeline, potentially improving competitive positioning and investor confidence in future autoimmune treatments.",globenewswire_biotech,biotech,Licensing Agreements,252,ANAB,2023-11-27 21:15:00+00:00,US/Eastern,"SAN DIEGO, Nov.  27, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.",UP,0.026895775010460938,en
14505,KA,https://www.google.com/finance/quote/KA:NASDAQ,"Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023",https://www.globenewswire.com/news-release/2023/11/28/2786945/0/en/Kineta-to-Host-KOL-Event-to-Review-New-Data-from-VISTA-101-Clinical-Trial-of-KVA12123-in-Patients-with-Advanced-Solid-Tumors-on-December-5-2023.html,2023-11-28 08:30:00+00:00,Kineta,clinical_study,"The predicted upward move of +0.99% for Kineta, Inc. likely stems from anticipation surrounding the virtual KOL event discussing VISTA-101 trial data. This suggests positive developments, potentially boosting investor confidence and interest in Kineta's oncology advancements.",globenewswire_biotech,biotech,Calendar of Events,248,KA,2023-11-28 13:30:00+00:00,US/Eastern,"SEATTLE, Nov.  28, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors. Details are as follows:",DOWN,0.009932897596045718,en
16643,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,"Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409",https://www.globenewswire.com/news-release/2023/11/28/2787049/0/en/Candel-Therapeutics-Announces-Restructuring-to-Prioritize-Resources-on-Key-Value-Drivers-for-Expanded-Development-of-CAN-3110-the-enLIGHTEN-Discovery-Platform-and-Key-Clinical-Read.html,2023-11-28 09:00:00+00:00,Candel Therapeutics,clinical_study,1. The predicted upward move of +5.56% is likely due to Candel Therapeutics' strategic restructuring to focus on promising drug development and cost reduction. 2. The market may view this as increasing the potential for future growth and profitability.,globenewswire_biotech,biotech,Clinical Study,358,CADL,2023-11-28 14:00:00+00:00,US/Eastern,"NEEDHAM, Mass., Nov.  28, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN™ Discovery Platform, while reducing the Company’s workforce and expenses associated with enabling commercial readiness of CAN-2409. The Company expects to present initial activity and biomarker data for repeated injections of CAN-3110 in recurrent high-grade glioma in the second half of 2024 and new data for the second drug candidate based on the enLIGHTEN™ Discovery Platform in Q3 2024. The Company plans to continue to collect clinical data for key readouts for CAN-2409 in non-small cell lung cancer (NSCLC), with topline overall survival data of the open label phase 2 clinical trial expected in Q2 2024; pancreatic cancer, with an update on overall survival based on an interim analysis of the randomized, open label clinical trial in Q2 2024; and prostate cancer, with topline data for both fully enrolled randomized, blinded, placebo-controlled phase 2 and phase 3 clinical trials in Q4 2024.",UP,0.055627223924658374,en
15603,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Announces Update Regarding the Special Access Program,https://www.globenewswire.com/news-release/2023/11/28/2787361/0/en/Mydecine-Announces-Update-Regarding-the-Special-Access-Program.html,2023-11-28 16:05:00+00:00,Mydecine Innovations Group,press_releases,"The predicted upward move of +1.09% is likely due to Mydecine's clarification on their program for psychedelic-assisted psychotherapy, indicating progress or renewed interest. This may enhance investor confidence, potentially increasing market interest in mental health innovations.",globenewswire_biotech,biotech,Product / Services Announcement,306,MYCO.CN,2023-11-28 21:05:00+00:00,US/Eastern,"DENVER, Nov.  28, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company’s news release of January 13, 2022 (the “Prior Release”) wherein the Company announced it would be launching the Special Access Support and Supply Program (“SASSP”) to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.",UP,0.01087472251000333,en
16540,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform,https://www.globenewswire.com/news-release/2023/11/29/2787754/0/en/Interim-Results-from-Ongoing-Clinical-Study-Confirm-EB613-Optimized-Profile-for-Osteoporosis-Treatment-and-Potential-for-Entera-s-Next-Generation-Oral-Peptide-Platform.html,2023-11-29 08:30:00+00:00,Entera Bio,clinical_study,"The predicted upward move of +1.37% for Entera Bio Ltd. likely results from positive interim data from their ongoing Phase 1 study. This suggests potential advancements in their oral peptide platform, potentially boosting investor confidence and interest in biotech innovations.",globenewswire_biotech,biotech,Health,353,ENTX,2023-11-29 13:30:00+00:00,US/Eastern,"JERUSALEM, Nov.  29, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167).",UP,0.013671380402013539,en
15434,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Appoints Andrew Walsh as Vice President Finance,https://www.globenewswire.com/news-release/2023/12/01/2789245/0/en/Annovis-Bio-Appoints-Andrew-Walsh-as-Vice-President-Finance.html,2023-12-01 07:30:00+00:00,Annovis Bio,management_changes,"The predicted upward move of +0.24% is likely due to the strategic appointment of Andrew Walsh as VP, Finance, potentially boosting investor confidence. This could enhance operational effectiveness, possibly leading to better financial outcomes and increased stockholder value.",globenewswire_biotech,biotech,Directors and Officers,296,ANVS,2023-12-01 12:30:00+00:00,US/Eastern,"BERWYN, Pa., Dec.  01, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. ",UP,0.002364670295835167,en
15996,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023),https://www.globenewswire.com/news-release/2023/12/01/2789250/0/en/Ovid-Therapeutics-to-Present-Five-Abstracts-Supporting-its-Epilepsy-Programs-at-the-77th-American-Epilepsy-Society-Annual-Meeting-2023.html,2023-12-01 07:30:00+00:00,Ovid Therapeutics,clinical_study,"The predicted upward move of +10.01% for Ovid Therapeutics is likely due to the positive reception of their data presentations at the AES Annual Meeting. This could increase investor confidence, potentially boosting interest and investment in their epilepsy treatments.",globenewswire_biotech,biotech,Health,325,OVID,2023-12-01 12:30:00+00:00,US/Eastern,"NEW YORK, Dec.  01, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.",UP,0.10009302178604275,en
16302,PHIL.MI,https://www.google.com/finance/quote/PHIL.MI:NASDAQ,Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors,https://www.globenewswire.com/news-release/2023/12/04/2789729/0/en/Philochem-and-Blue-Earth-Diagnostics-Announce-First-Three-Patients-Imaged-in-Phase-1-Clinical-Trial-of-68Ga-OncoFAP-68Ga-OncoFAP-DOTAGA-for-Diagnostic-Imaging-in-Solid-Tumors.html,2023-12-04 03:00:00+00:00,PharmaNutra,licensing_agreements,The predicted upward move of +1.86% is likely due to positive sentiment from the successful imaging of initial patients in the Phase I trial with 68Ga-OncoFAP. This progress could enhance investor confidence and attention in the biotech market.,globenewswire_biotech,biotech,Clinical Study,341,PHIL.MI,2023-12-04 08:00:00+00:00,US/Eastern,Philochem (Philogen) and Blue Earth Diagnostic (Bracco) announce the three first patients in the Phase I trial have been imaged with 68Ga-OncoFAP,UP,0.01856100189941813,en
15835,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference,https://www.globenewswire.com/news-release/2023/12/04/2789966/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-4th-Annual-Precision-Oncology-Virtual-Conference.html,2023-12-04 08:00:00+00:00,Elicio Therapeutics,conference_call_webinar,The predicted downward move of -0.75% for Elicio Therapeutics may be due to investor skepticism about the impact of the upcoming presentation. Market implications might include cautious trading and potential reassessment of Elicio's growth prospects.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,317,ELTX,2023-12-04 13:00:00+00:00,US/Eastern,"BOSTON, Dec.  04, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET.",UP,-0.007504051449833609,en
15236,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference,https://www.globenewswire.com/news-release/2023/12/04/2789938/0/en/Kronos-Bio-Announces-Participation-in-H-C-Wainwright-4th-Annual-Precision-Oncology-Virtual-Conference.html,2023-12-04 08:00:00+00:00,Kronos Bio,conference_call_webinar,The predicted downward move of -1.12% for Kronos Bio is likely due to investor anticipation or lack of immediate announcements from the upcoming conference. Such a decline may impact investor sentiment and short-term stock trading strategies.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,286,KRON,2023-12-04 13:00:00+00:00,US/Eastern,"SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec.  04, 2023  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:00 a.m. ET.",UP,-0.011191070317162917,en
16341,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease,https://www.globenewswire.com/news-release/2023/12/04/2790468/0/en/CRISPR-Therapeutics-Announces-Updates-to-Immuno-Oncology-Pipeline-and-Expansion-into-Autoimmune-Disease.html,2023-12-04 16:15:00+00:00,CRISPR Therapeutics,clinical_study,"The predicted upward move of +11.69% is likely due to promising clinical trial results for CTX112™ and CTX131™. This could boost investor confidence, increasing demand and valuation, potentially influencing biotech markets positively by driving interest in similar innovations.",globenewswire_biotech,biotech,Clinical Study,343,CRSP,2023-12-04 21:15:00+00:00,US/Eastern,"-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70-",UP,0.11691616616806687,en
16301,PHIL.MI,https://www.google.com/finance/quote/PHIL.MI:NASDAQ,"Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities",https://www.globenewswire.com/news-release/2023/12/05/2790613/0/en/Philogen-S-p-A-announces-receipt-of-the-Good-Manufacturing-Practice-Certificate-for-its-new-Production-facility-in-Rosia-Siena-Italy-by-Competent-Authorities.html,2023-12-05 02:30:00+00:00,PharmaNutra,company_regulatory_filings,"The upward move of +0.05% is likely due to the GMP certification, indicating quality compliance, boosting investor confidence. Market implications include potential for increased production efficiency and revenue, further enhancing Philogen's competitive position and investor interest.",globenewswire_biotech,biotech,Warrants and Certificates,341,PHIL.MI,2023-12-05 07:30:00+00:00,US/Eastern,Philogen new production facility in Rosia has received the GMP certificate by Competent Authorities,DOWN,0.0005279907026758877,en
14752,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,"Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023",https://www.globenewswire.com/news-release/2023/12/05/2790764/0/en/Science-37-Holdings-Inc-Announces-1-for-20-Reverse-Stock-Split-effective-December-8-2023.html,2023-12-05 07:00:00+00:00,Science 37,corporate_action,"The predicted downward move of -0.35% is likely due to the reverse stock split, which can signal financial challenges or an attempt to meet Nasdaq listing requirements. It could lead to reduced investor confidence and lower trading volumes.",globenewswire_biotech,biotech,Stock Market News,261,SNCE,2023-12-05 12:00:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Dec.  05, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time. Science 37’s Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existing symbol “SNCE” and will begin trading on a split-adjusted basis when the market opens on December 8, 2023. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 808644207.",UP,-0.003522855601695238,en
15433,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease,https://www.globenewswire.com/news-release/2023/12/05/2790799/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-III-Study-of-Buntanetap-in-Parkinson-s-Disease.html,2023-12-05 07:30:00+00:00,Annovis Bio,clinical_study,1. The predicted downward move of -12.18% likely stems from investor skepticism about successfully achieving positive results in the phase III study. 2. This may lead to decreased investor confidence and a potential sell-off of Annovis Bio shares.,globenewswire_biotech,biotech,Health,296,ANVS,2023-12-05 12:30:00+00:00,US/Eastern,"BERWYN, Pa., Dec.  05, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024.",UP,-0.12178249805826152,en
16699,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance,https://www.globenewswire.com/news-release/2023/12/05/2790924/36989/en/Checkpoint-Therapeutics-Strengthens-Intellectual-Property-Protection-for-Cosibelimab-with-New-U-S-Patent-Issuance.html,2023-12-05 08:30:00+00:00,Checkpoint Therapeutics,patents,The predicted upward move of +1.69% likely results from investor optimism about a favorable FDA decision on the PDUFA date. Market implications include increased investor interest and potential volatility in the asset's value post-announcement.,globenewswire_biotech,biotech,Patents,361,CKPT,2023-12-05 13:30:00+00:00,US/Eastern,"Upcoming PDUFA goal date of January 3, 2024",DOWN,0.016943008410949367,en
16555,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting,https://www.globenewswire.com/news-release/2023/12/06/2791725/0/en/Bionomics-Presents-Detailed-Data-on-the-Validity-and-Reliability-of-the-Subjective-Units-of-Distress-Scale-at-the-2023-American-College-of-Neuropsychopharmacology-Annual-Meeting.html,2023-12-06 08:00:00+00:00,Bionomics,clinical_study,"Bionomics' presentation of positive clinical data at a major conference likely spurred the predicted upward move of +7.23%. This suggests increased investor confidence in their CNS treatments, potentially boosting interest and investment in the biotech sector.",globenewswire_biotech,biotech,Health,354,BNOX,2023-12-06 13:00:00+00:00,US/Eastern,"ADELAIDE, Australia and CAMBRIDGE, Mass., Dec.  06, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida.",UP,0.0723456598708076,en
14484,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,"Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.",https://www.globenewswire.com/news-release/2023/12/06/2791767/28889/en/Cyprium-Therapeutics-a-Fortress-Biotech-Subsidiary-Company-Completes-Asset-Transfer-of-CUTX-101-Copper-Histidinate-Product-Candidate-for-Treatment-of-Menkes-Disease-to-Sentynl-Ther.html,2023-12-06 08:30:00+00:00,Fortress Biotech,licensing_agreements,1. The predicted upward move of +3.50% is likely due to the $4.5 million payment and potential for substantial future royalties and milestone earnings. 2. Market implications include increased investor confidence and potential stock price growth.,globenewswire_biotech,biotech,Health,247,FBIO,2023-12-06 13:30:00+00:00,US/Eastern,Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones,UP,0.035035293587448835,en
16478,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,"Inotiv, Inc. Announces Plan to Insource North American Transportation Operations",https://www.globenewswire.com/news-release/2023/12/06/2792120/0/en/Inotiv-Inc-Announces-Plan-to-Insource-North-American-Transportation-Operations.html,2023-12-06 16:30:00+00:00,Inotiv,partnerships,"The predicted upward move of +2.02% is likely driven by Inotiv's strategic integration with Vanguard Supply Chain Solutions, enhancing operational efficiency. This may increase investor confidence and boost profitability, influencing similar partnerships in the sector.",globenewswire_biotech,biotech,Management statements,350,NOTV,2023-12-06 21:30:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Dec.  06, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will be partnering with Vanguard Supply Chain Solutions LLC, the Company’s current provider of transportation services, to enable the in-house integration of Inotiv’s North American transportation operations.",UP,0.020156392961062513,en
15937,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe,https://www.globenewswire.com/news-release/2023/12/06/2792155/7767/en/MediciNova-Receives-a-Notice-of-Decision-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Progressive-MS-in-Europe.html,2023-12-06 18:00:00+00:00,MediciNova,patents,"The predicted upward move of +0.78% is likely due to the granting of a European patent for MediciNova's MS treatment, enhancing its intellectual property portfolio. This patent could increase market confidence and potential partnerships, affecting the company's valuation positively.",globenewswire_biotech,biotech,Patents,322,MNOV,2023-12-06 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., Dec.  06, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).",UP,0.007846440621834375,en
15869,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine,https://www.globenewswire.com/news-release/2023/12/07/2792226/0/en/Faron-Announces-Publication-of-Full-Analysis-from-Phase-1-2-MATINS-Trial-of-Bexmarilimab-in-Solid-Tumors-in-Cell-Reports-Medicine.html,2023-12-07 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +15.10% is likely due to positive safety and efficacy results from Faron Pharmaceuticals' Phase 1/2 trial of bexmarilimab. This success could enhance investor confidence, possibly boosting the company's market valuation and attracting further investment interest.",globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2023-12-07 07:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Dec.  07, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage reprogramming for effective anticancer immunotherapies, today announces the publication of the full safety and anti-tumor efficacy results from the first-in-human Phase 1/2 MATINS trial of bexmarilimab in patients with treatment-refractory late-stage solid tumors in Cell Reports Medicine.",UP,0.15098219869515617,en
14751,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2023/12/07/2792922/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,2023-12-07 16:59:00+00:00,Science 37,corporate_action,"The predicted upward move of +0.27% is likely due to increased investor confidence following the equity awards granted as inducements. This may signal growth or stability, potentially attracting more investors and positively impacting the stock's future performance.",globenewswire_biotech,biotech,Product / Services Announcement,261,SNCE,2023-12-07 21:59:00+00:00,US/Eastern,"RESEARCH TRIANGLE PARK, N.C., Dec.  07, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2023. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",UP,0.0026910097428583645,en
15868,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting,https://www.globenewswire.com/news-release/2023/12/11/2793556/0/en/Inside-information-Faron-Presents-Phase-1-Data-from-BEXMAB-in-Myeloid-Malignancies-Trial-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting.html,2023-12-11 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +1.29% could be driven by positive earnings reports, favorable economic data, or increased investor sentiment. This may boost market confidence and encourage more investments, potentially leading to further asset appreciation across related sectors.",globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2023-12-11 07:00:00+00:00,US/Eastern, ,DOWN,0.012873698086875869,en
16382,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,"Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar",https://www.globenewswire.com/news-release/2023/12/11/2794110/0/en/Editas-Medicine-Announces-New-EDIT-301-Safety-and-Efficacy-Data-in-17-Patients-Presented-Today-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-and-in-a-Company-sponsored-W.html,2023-12-11 12:00:00+00:00,Editas Medicine,clinical_study,"The upward move of +14.33% is likely due to successful clinical trial results for RUBY, boosting investor confidence. This could lead to increased investment and valuation, impacting related healthcare stocks positively.",globenewswire_biotech,biotech,Clinical Study,345,EDIT,2023-12-11 17:00:00+00:00,US/Eastern,All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%,DOWN,0.143297291364829,en
15432,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio to Participate in the 139th Yale CEO Summit,https://www.globenewswire.com/news-release/2023/12/11/2794161/0/en/Annovis-Bio-to-Participate-in-the-139th-Yale-CEO-Summit.html,2023-12-11 13:00:00+00:00,Annovis Bio,press_releases,"The predicted downward move of -1.26% for Annovis Bio may stem from investor focus on management activities instead of clinical progress. This could signal concerns over immediate business growth, impacting investor confidence and potentially affecting stock valuation.",globenewswire_biotech,biotech,Calendar of Events,296,ANVS,2023-12-11 18:00:00+00:00,US/Eastern,"BERWYN, Pa., Dec.  11, 2023  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023. ",DOWN,-0.012610383539615806,en
16477,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/12/11/2794268/0/en/Inotiv-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-Fiscal-2023-and-Provides-Business-Update.html,2023-12-11 16:05:00+00:00,Inotiv,financial_results,The predicted upward move of +0.43% is likely due to increased revenue and strategic expansions in DSA capacity. Market implications include potential investor confidence and positive momentum for fiscal 2024 if expense reductions are achieved as anticipated.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,350,NOTV,2023-12-11 21:05:00+00:00,US/Eastern,"— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing expected to drive continued growth of fiscal 2024 DSA revenues— Anticipate achieving the balance of expected expense reductions in fiscal 2024— Conference call begins today at 4:30 pm ET",UP,0.004313224269422056,en
16162,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D),https://www.globenewswire.com/news-release/2023/12/12/2794338/0/en/Harpoon-Therapeutics-Presents-HPN217-Phase-1-Clinical-Data-in-Relapsed-Refractory-Multiple-Myeloma-RRMM-at-ASH-2023-and-Announces-Selection-of-Recommended-Phase-2-Dose-RP2D.html,2023-12-11 20:15:00+00:00,Harpoon Therapeutics,clinical_study,The predicted downward move of -1.17% is likely due to tempered expectations despite positive clinical results. Investors may have concerns about market competition or regulatory hurdles. This could impact investor confidence and short-term stock valuation.,globenewswire_biotech,biotech,Product / Services Announcement,334,HARP,2023-12-12 01:15:00+00:00,US/Eastern,"• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy",UP,-0.011719855238804889,en
16299,HUMA,https://www.google.com/finance/quote/HUMA:NASDAQ,Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma,https://www.globenewswire.com/news-release/2023/12/12/2794704/0/en/Humacyte-Submits-Biologics-License-Application-BLA-to-U-S-FDA-Seeking-Approval-of-Human-Acellular-Vessel-HAV-for-the-Treatment-of-Vascular-Trauma.html,2023-12-12 08:00:00+00:00,Humacyte,clinical_study,"The predicted upward move of +1.94% is likely due to the positive results from the Phase 2/3 clinical trial and successful real-world outcomes in Ukraine, suggesting efficacy and market confidence. This could boost investor interest and increase asset demand.",globenewswire_biotech,biotech,Regulatory information,340,HUMA,2023-12-12 13:00:00+00:00,US/Eastern,– BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine –,UP,0.019390888280260563,en
15358,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,https://www.globenewswire.com/news-release/2023/12/12/2794706/0/en/Immuneering-Announces-FDA-Clearance-of-IND-Application-for-Phase-1-2a-Trial-of-IMM-6-415-to-Treat-Advanced-Solid-Tumors-with-RAF-or-RAS-Mutations.html,2023-12-12 08:00:00+00:00,Immuneering,clinical_study,"1. FDA clearance boosts investor confidence, likely causing Immuneering's predicted upward move of +4.27%. 2. Positive trial developments can increase investor interest and funding opportunities, driving further asset growth potential.",globenewswire_biotech,biotech,Clinical Study,292,IMRX,2023-12-12 13:00:00+00:00,US/Eastern,Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,UP,0.04265710728401832,en
16642,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer,https://www.globenewswire.com/news-release/2023/12/12/2794671/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Pancreatic-Cancer.html,2023-12-12 08:00:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +14.35% is likely due to FDA Fast Track Designation for Candel's CAN-2409, potentially accelerating its PDAC treatment approval. This enhances investor optimism, potentially increasing stock liquidity and attracting strategic partnerships.",globenewswire_biotech,biotech,Product / Services Announcement,358,CADL,2023-12-12 13:00:00+00:00,US/Eastern,"NEEDHAM, Mass., Dec.  12, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.",UP,0.14354683752145894,en
14750,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Receives Top Honors in Everest PEAK Matrix®,https://www.globenewswire.com/news-release/2023/12/12/2794676/0/en/Science-37-Receives-Top-Honors-in-Everest-PEAK-Matrix.html,2023-12-12 08:00:00+00:00,Science 37,contests_awards,"1. The predicted downward move of +nan% suggests data or analytical errors. 2. Such errors could undermine investor confidence, potentially affecting stock valuation and causing market volatility, impacting stakeholder decision-making.",globenewswire_biotech,biotech,Contests/Awards,261,SNCE,2023-12-12 13:00:00+00:00,US/Eastern,Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical Trials Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical Trials,UP,5.767747746423457,en
16099,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,"CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone",https://www.globenewswire.com/news-release/2023/12/13/2795390/0/en/CENTOGENE-s-Frontotemporal-Dementia-FTD-Genetic-Study-EFRONT-Reaches-Initial-Patient-Enrollment-Milestone.html,2023-12-13 06:30:00+00:00,Centogene,clinical_study,"Centogene's achievement in reaching a key milestone in the EFRONT Study likely caused the predicted upward move of +2.98%. This progress could enhance investor confidence and attract attention to advances in genetic research for frontotemporal dementia, potentially elevating market interest.",globenewswire_biotech,biotech,Clinical Study,330,CNTG,2023-12-13 11:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec.  13, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD).",DOWN,0.02984171471336567,en
15818,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”),https://www.globenewswire.com/news-release/2023/12/13/2795495/0/en/Rezolute-Completes-Enrollment-of-its-Phase-2-Study-in-Diabetic-Macular-Edema-DME.html,2023-12-13 08:00:00+00:00,Rezolute,clinical_study,"The predicted upward move of +1.55% is likely due to anticipation of positive topline data forthcoming in mid-second quarter 2024. This might enhance investor confidence, potentially leading to increased market interest and higher valuation of the asset.",globenewswire_biotech,biotech,Clinical Study,316,RZLT,2023-12-13 13:00:00+00:00,US/Eastern,Plans to report topline data mid-second quarter 2024 Plans to report topline data mid-second quarter 2024,UP,0.015499460350620036,en
14504,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer,https://www.globenewswire.com/news-release/2023/12/13/2795564/0/en/Kineta-Publishes-Preclinical-Data-Demonstrating-the-Potential-of-Anti-VISTA-Antibody-KVA12123-as-an-Immunomodulatory-Therapy-for-Cancer.html,2023-12-13 08:30:00+00:00,Kineta,clinical_study,The predicted upward move of +5.66% is likely due to positive clinical data showing strong anti-tumor activity with reduced side effects. Market implications include increased investor interest and potential competitive advantage in oncology treatments.,globenewswire_biotech,biotech,Clinical Study,248,KA,2023-12-13 13:30:00+00:00,US/Eastern,VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events,UP,0.05655082113274134,en
16381,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9,https://www.globenewswire.com/news-release/2023/12/13/2795602/0/en/Editas-Medicine-and-Vertex-Pharmaceuticals-Enter-into-Non-exclusive-License-Agreement-for-Cas9.html,2023-12-13 09:00:00+00:00,Editas Medicine,licensing_agreements,1. The upward movement likely results from positive market sentiment regarding Vertex Pharmaceuticals' strategic expansion in gene-editing technology. 2. This predicted upward move of +1.82% may increase investor confidence and strengthen the company's market position.,globenewswire_biotech,biotech,Licensing Agreements,345,EDIT,2023-12-13 14:00:00+00:00,US/Eastern,Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel),UP,0.018196508052763006,en
15656,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies,https://www.globenewswire.com/news-release/2023/12/13/2795886/0/en/Certara-Acquires-Applied-BioMath-Expanding-Its-Biosimulation-Portfolio-to-Industrialize-New-Capabilities-for-Optimal-Dosing-for-Novel-Therapies.html,2023-12-13 16:30:00+00:00,Certara,mergers_acquisitions,"1. The predicted downward move of -0.96% could be due to market skepticism about integration challenges. 2. This may lead to short-term investor caution, affecting share prices and broader sector confidence.",globenewswire_biotech,biotech,Mergers and Acquisitions,308,CERT,2023-12-13 21:30:00+00:00,US/Eastern,Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center.,UP,-0.009575651753347052,en
16384,RAIN,https://www.google.com/finance/quote/RAIN:NASDAQ,Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights,https://www.globenewswire.com/news-release/2023/12/13/2795922/0/en/Rain-Oncology-Enters-into-Agreement-to-be-Acquired-by-Pathos-AI-for-1-16-in-Cash-per-Share-Plus-Contingent-Value-Rights.html,2023-12-13 18:05:00+00:00,Rain Therapeutics,mergers_acquisitions,"The predicted upward move of +7.62% is likely due to Rain Oncology's acquisition by Pathos AI, offering $1.16 per share and a potential $0.17 CVR. This may heighten investor interest, implying confidence in future value realization and potential market realignment.",globenewswire_biotech,biotech,Stock Market News,346,RAIN,2023-12-13 23:05:00+00:00,US/Eastern,"NEWARK, Calif., Dec.  13, 2023  (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share.",UP,0.07617610023514752,en
14734,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board,https://www.globenewswire.com/news-release/2023/12/14/2796170/0/en/Tourmaline-Bio-Appoints-Dr-Clay-Siegall-as-Chairman-of-the-Board.html,2023-12-14 07:30:00+00:00,Talaris Therapeutics,management_changes,The predicted downward move of -0.34% might result from uncertainty following the new appointment of Clay Siegall as Chairman. Market implications include short-term investor apprehension but potential long-term strategic shifts for Tourmaline Bio.,globenewswire_biotech,biotech,Directors and Officers,260,TALS,2023-12-14 12:30:00+00:00,US/Eastern,"NEW YORK, Dec.  14, 2023  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board.",UP,-0.003372022566553677,en
15817,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism,https://www.globenewswire.com/news-release/2023/12/14/2796213/0/en/Rezolute-Initiates-Phase-3-Clinical-Study-for-RZ358-in-Congenital-Hyperinsulinism.html,2023-12-14 08:00:00+00:00,Rezolute,clinical_study,"The predicted upward move of +0.67% is likely due to anticipated completion of enrollment and timeline for results, signaling progress and potential success. This could enhance investor confidence, affecting market trends positively and possibly attracting further investments.",globenewswire_biotech,biotech,Clinical Study,316,RZLT,2023-12-14 13:00:00+00:00,US/Eastern,Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025,UP,0.006706574144340396,en
14733,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio added to the NASDAQ Biotechnology Index,https://www.globenewswire.com/news-release/2023/12/15/2797271/0/en/Tourmaline-Bio-added-to-the-NASDAQ-Biotechnology-Index.html,2023-12-15 16:00:00+00:00,Talaris Therapeutics,exchange_announcement,The predicted downward move of -0.66% for Tourmaline Bio may be due to profit-taking following the news of its inclusion in the NASDAQ Biotechnology Index. This could indicate some investor uncertainty despite the positive news. Market implications include potential short-term volatility.,globenewswire_biotech,biotech,Exchange Members,260,TALS,2023-12-15 21:00:00+00:00,US/Eastern,"NEW YORK, Dec.  15, 2023  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Tourmaline has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 18, 2023.",UP,-0.006585494619497527,en
16193,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth Announces Completion of Transition to Single Listing on Nasdaq,https://www.globenewswire.com/news-release/2023/12/18/2797458/0/en/MDxHealth-Announces-Completion-of-Transition-to-Single-Listing-on-Nasdaq.html,2023-12-18 01:00:00+00:00,MDxHealth,exchange_announcement,"The predicted downward move of -0.22% may be due to negative news or regulatory developments. This could lead to reduced investor confidence, impacting the asset's short-term demand and potentially influencing broader market sentiment.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-12-18 06:00:00+00:00,US/Eastern,"NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET",DOWN,-0.002167859796700301,en
16194,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth annonce la réalisation de sa transition vers une cotation unique sur le Nasdaq,https://www.globenewswire.com/news-release/2023/12/18/2797458/0/fr/MDxHealth-annonce-la-r%C3%A9alisation-de-sa-transition-vers-une-cotation-unique-sur-le-Nasdaq.html,2023-12-18 01:00:00+00:00,MDxHealth,exchange_announcement,"The predicted downward move of -3.34% might result from disappointing earnings or negative regulatory news. This could erode investor confidence, potentially leading to broader selling pressure in related sectors, affecting overall market sentiment.",globenewswire_biotech,biotech,European Regulatory News,335,MDXH,2023-12-18 06:00:00+00:00,US/Eastern,"COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE18 DECEMBRE 2023, 01:00 ET / 07:00 CET",DOWN,-0.03336219162769045,fr
15602,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound,https://www.globenewswire.com/news-release/2023/12/18/2797495/0/en/Mydecine-Innovations-Group-Receives-Notice-of-Allowance-from-USPTO-for-its-MYCO-005-Compound.html,2023-12-18 02:00:00+00:00,Mydecine Innovations Group,patents,"The likely cause of the predicted upward move of +2.02% is investor optimism about MYCO's patent progress for MYCO-005, indicating possible future revenue growth. This development could enhance MYCO's competitive edge, positively impacting market perception and investment interest.",globenewswire_biotech,biotech,Product / Services Announcement,306,MYCO.CN,2023-12-18 07:00:00+00:00,US/Eastern,MYCO announces it has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office for MYCO-005 compound,UP,0.020194214707128535,en
16698,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer,https://www.globenewswire.com/news-release/2023/12/18/2797694/36989/en/U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Cosibelimab-Solely-Due-to-Inspection-Findings-at-Third-Party-Manufacturer.html,2023-12-18 07:00:00+00:00,Checkpoint Therapeutics,regulatory_filings,The predicted downward move of -2.74% likely stems from market uncertainty despite no FDA concerns about cosibelimab. Traders might anticipate regulatory delays or competitive threats. This decline could affect investor confidence and future drug pricing strategies.,globenewswire_biotech,biotech,Clinical Study,361,CKPT,2023-12-18 12:00:00+00:00,US/Eastern,"FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab",DOWN,-0.027432186041358816,en
16058,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program,https://www.globenewswire.com/news-release/2023/12/18/2797681/0/en/Akero-Therapeutics-Announces-First-Patients-Dosed-in-Efruxifermin-Phase-3-SYNCHRONY-Program.html,2023-12-18 07:00:00+00:00,Akero Therapeutics,clinical_study,"1. The predicted upward move of +1.09% likely stems from positive market anticipation of the HARMONY trial results. 2. Success may boost investor confidence, potentially raising asset value and interest in related NASH/MASH treatments.",globenewswire_biotech,biotech,Clinical Study,328,AKRO,2023-12-18 12:00:00+00:00,US/Eastern,Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024,DOWN,0.010899701163792873,en
15778,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine,https://www.globenewswire.com/news-release/2023/12/18/2797682/0/en/Revive-Therapeutics-Collaborates-with-Attwill-Medical-Solutions-for-the-Clinical-and-Commercial-Development-of-a-Novel-Lyophilized-Formulation-of-Bucillamine.html,2023-12-18 07:00:00+00:00,Revive Therapeutics,partnerships,"The predicted downward move of -0.66% may result from investor skepticism about the collaboration's immediate financial impact. Market implications could include caution in the life sciences sector, affecting perceptions of similar partnerships.",globenewswire_biotech,biotech,Partnerships,314,RVVTF,2023-12-18 12:00:00+00:00,US/Eastern,"TORONTO, Dec.  18, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s next-generation lyophilized formulation of Bucillamine.",UP,-0.006594267744504725,en
15211,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population,https://www.globenewswire.com/news-release/2023/12/18/2797746/0/en/Biomerica-Received-US-FDA-510-k-Clearance-for-Their-Hp-Detect-ELISA-Test-Product-Designed-to-Detect-the-Presence-of-the-H-pylori-Bacteria-That-infects-Approximately-35-of-the-U-S-P.html,2023-12-18 07:47:00+00:00,Biomerica,product_services_announcement,The announced FDA clearance for Biomerica's Hp Detect™ Stool Antigen ELISA test likely drives the predicted upward move of +5.24%. This clearance could enhance market confidence and expand Biomerica's market share in medical diagnostics.,globenewswire_biotech,biotech,Product / Services Announcement,285,BMRA,2023-12-18 12:47:00+00:00,US/Eastern,"IRVINE, Calif., Dec.  18, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test (K232892), a new product that is designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. H. pylori infection is a disease which affects half the population of the world.",UP,0.05243920645805149,en
15569,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1),https://www.globenewswire.com/news-release/2023/12/18/2797798/0/en/PepGen-Announces-First-Patient-Dosed-in-Phase-1-FREEDOM-DM1-Clinical-Trial-of-PGN-EDODM1-for-Myotonic-Dystrophy-Type-1-DM1.html,2023-12-18 08:00:00+00:00,PepGen,clinical_study,The predicted upward move of +0.52% likely stems from anticipated positive trial results at the 5 mg/kg dose level in the FREEDOM-DM1 trial. This could boost investor confidence and enhance the company's valuation in the market.,globenewswire_biotech,biotech,Clinical Study,303,PEPG,2023-12-18 13:00:00+00:00,US/Eastern,"- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical trial expected in 2024 -",UP,0.005212395735739509,en
15537,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock,https://www.globenewswire.com/news-release/2023/12/18/2797777/0/en/Windtree-Therapeutics-Announces-the-Start-of-Patient-Dosing-In-Phase-2-SEISMiC-Extension-Study-of-Istaroxime-in-Early-Cardiogenic-Shock.html,2023-12-18 08:00:00+00:00,Windtree Therapeutics,clinical_study,"The predicted downward move of -2.48% likely reflects investor uncertainty about the SEISMiC Extension Study's outcome. Market implications may include reduced confidence in future drug development, affecting the company’s valuation and potential strategic decisions.",globenewswire_biotech,biotech,Product / Services Announcement,301,WINT,2023-12-18 13:00:00+00:00,US/Eastern,SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3,UP,-0.024793881665187416,en
16239,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,"Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board",https://www.globenewswire.com/news-release/2023/12/18/2797934/0/en/Immix-Biopharma-Announces-Dr-Marko-Radic-Autoimmune-CAR-T-Pioneer-and-Associate-Professor-at-the-University-of-Tennessee-Health-Science-Center-Joins-Scientific-Advisory-Board.html,2023-12-18 09:39:00+00:00,Immix Biopharma,advisory,The predicted downward move of +nan% may result from data errors or market uncertainty. This can lead to incorrect market assumptions and volatility. Investors should verify data accuracy to prevent misguided decisions and potential losses.,globenewswire_biotech,biotech,Company Announcement,337,IMMX,2023-12-18 14:39:00+00:00,US/Eastern, ,DOWN,-3.595839583024258,en
15235,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate,https://www.globenewswire.com/news-release/2023/12/18/2798137/0/en/Kronos-Bio-Announces-Pipeline-Update-and-p300-KAT-Inhibitor-Development-Candidate.html,2023-12-18 16:06:00+00:00,Kronos Bio,clinical_study,The predicted upward move of +3.66% may be due to positive sentiment from cost-saving measures by halting the trial. Investors might anticipate strategic reallocations of resources. Potential market implications include increased focus on more promising pipelines.,globenewswire_biotech,biotech,Clinical Study,286,KRON,2023-12-18 21:06:00+00:00,US/Eastern,Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2,UP,0.036614069918929355,en
16098,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Announces Voting Results of Extraordinary General Meeting,https://www.globenewswire.com/news-release/2023/12/19/2798385/0/en/CENTOGENE-Announces-Voting-Results-of-Extraordinary-General-Meeting.html,2023-12-19 06:30:00+00:00,Centogene,voting_rights,"The predicted downward move of -0.63% is likely due to investor concerns despite passing agenda items, possibly signaling uncertainty about future prospects. This minor decline suggests limited market impact but may reflect cautious investor sentiment toward Centogene's performance.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,330,CNTG,2023-12-19 11:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec.  19, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. All voting items on the agenda, which included the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, were passed by the requisite majority.",DOWN,-0.006344483078641427,en
16161,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium,https://www.globenewswire.com/news-release/2023/12/19/2798452/0/en/Harpoon-Therapeutics-Abstract-for-HPN328-Accepted-for-Rapid-Oral-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium.html,2023-12-19 07:30:00+00:00,Harpoon Therapeutics,clinical_study,"The predicted upward move of +1.53% is likely due to the positive reception of Harpoon's Phase 1/2 trial data and its presentation at a major oncology symposium. This could boost investor confidence, signaling progress in their immunotherapy pipeline and potential market success.",globenewswire_biotech,biotech,Calendar of Events,334,HARP,2023-12-19 12:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Dec.  19, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.",UP,0.015271549850621308,en
15595,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System,https://www.globenewswire.com/news-release/2023/12/20/2799146/0/en/InspireMD-Announces-Issuance-of-Key-U-S-Patent-Covering-Its-SwitchGuard-Neuroprotection-System.html,2023-12-20 07:00:00+00:00,InspireMD,patents,"The predicted upward move of +1.92% likely stems from the company's enhanced intellectual property, supporting its strategic direction in treating carotid artery disease. This may boost investor confidence, increasing market valuation and competitive positioning in the healthcare sector.",globenewswire_biotech,biotech,Patents,304,NSPR,2023-12-20 12:00:00+00:00,US/Eastern,Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke,UP,0.019221719718210767,en
19248,MBX,,MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/20/2799216/0/en/MBX-Biosciences-to-Participate-in-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2023-12-20 08:00:00+00:00,MBX Biosciences,conference_call_webinar,"The predicted upward move of +0.07% is likely due to MBX Biosciences' participation in the high-profile J.P. Morgan Healthcare Conference, which may increase visibility and investor confidence. Long-term, this could enhance investor relations and funding opportunities.",globenewswire_biotech,biotech,Calendar of Events,749,MBX,2023-12-20 13:00:00+00:00,US/Eastern,"CARMEL, Ind., Dec.  20, 2023  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024, at 11:30 a.m. PST and the Company will host one-on-one investor meetings during the conference.",UP,0.07074734940208999,en
15676,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/20/2799236/0/en/Akoya-to-Participate-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2023-12-20 08:05:00+00:00,Akoya Biosciences,conference_call_webinar,The predicted downward move of -0.22% for Akoya Biosciences could be due to investor anticipation or uncertainty regarding upcoming presentations. Potential market implications might include short-term price volatility as investors react to disclosed information.,globenewswire_biotech,biotech,Calendar of Events,309,AKYA,2023-12-20 13:05:00+00:00,US/Eastern,"MARLBOROUGH, Mass., Dec.  20, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J.P. Morgan Healthcare Conference.",DOWN,-0.002161442110719252,en
15777,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders,https://www.globenewswire.com/news-release/2023/12/20/2799564/0/en/Revive-Therapeutics-Announces-Results-of-Annual-General-and-Special-Meeting-of-Shareholders.html,2023-12-20 12:54:00+00:00,Revive Therapeutics,annual_general_meeting,"The predicted downward move of -0.92% may stem from limited shareholder engagement, as only 40% of shares were voted. This could indicate low investor confidence or interest, potentially impacting future equity financing or strategic decisions.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,314,RVVTF,2023-12-20 17:54:00+00:00,US/Eastern,"TORONTO, Dec.  20, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholders held Tuesday, December 19, 2023 (the “Meeting”) in Toronto, Ontario. All matters presented to the shareholders of the Company (the “Shareholders”) for approval as set out in the Company's Notice of Meeting and Information Circular, dated November 10, 2023 respectively, were approved by an overwhelming majority of votes cast at the Meeting. Of the 357,646,841 shares issued and outstanding on the record date for the Meeting, 143,297,862 shares, being 40% of the shares, were voted.",UP,-0.009243964703418029,en
14647,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads,https://www.globenewswire.com/news-release/2023/12/21/2799949/30505/en/MediWound-Announces-Peer-Reviewed-Publication-of-EscharEx-Mechanism-of-Action-Study-Assessing-Its-Effects-on-Biofilm-and-Microbial-Loads.html,2023-12-21 08:00:00+00:00,MediWound,clinical_study,The predicted upward move of +8.73% likely results from positive clinical results indicating EscharEx's safety and effectiveness beyond traditional enzymatic debridement. This increase may enhance investor confidence and potentially boost funding and partnerships in the biotech sector.,globenewswire_biotech,biotech,Product / Services Announcement,255,MDWD,2023-12-21 13:00:00+00:00,US/Eastern,"Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement",DOWN,0.08729406996769351,en
15174,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,"Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension",https://www.globenewswire.com/news-release/2023/12/21/2800342/0/en/Mineralys-Therapeutics-Announces-First-Subject-Dosed-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html,2023-12-21 16:05:00+00:00,Mineralys Therapeutics,clinical_study,"The anticipated topline data release from the Launch-HTN trial in 2H 2025 likely causes interest, leading to the predicted upward move of +1.68%. This may signal positive trial expectations, potentially boosting investor confidence in the asset.",globenewswire_biotech,biotech,Clinical Study,283,MLYS,2023-12-21 21:05:00+00:00,US/Eastern,– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 –,UP,0.01677071044658656,en
15936,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology,https://www.globenewswire.com/news-release/2023/12/21/2800380/7767/en/MediciNova-Announces-Abstract-Regarding-MN-166-ibudilast-in-Chlorine-Gas-induced-Lung-Injury-Accepted-for-Presentation-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html,2023-12-21 18:00:00+00:00,MediciNova,clinical_study,"The predicted upward move of +8.43% is likely due to positive investor sentiment following MediciNova's abstract acceptance at the SOT Annual Meeting, indicating promising MN-166 data. This could boost investor interest and potentially enhance market valuation.",globenewswire_biotech,biotech,Calendar of Events,322,MNOV,2023-12-21 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., Dec.  21, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah. The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.",UP,0.08432829613434091,en
15834,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Announces $7.0 Million Private Placement Financing,https://www.globenewswire.com/news-release/2023/12/22/2800613/0/en/Elicio-Therapeutics-Announces-7-0-Million-Private-Placement-Financing.html,2023-12-22 09:00:00+00:00,Elicio Therapeutics,shares_issue,"The predicted upward move of +1.27% in Elicio Therapeutics' stock is likely due to investor confidence from the $7 million investment by GKCC, LLC. This influx suggests strong insider support, potentially increasing market interest and perceived stability in the company's financial health.",globenewswire_biotech,biotech,Financing Agreements,317,ELTX,2023-12-22 14:00:00+00:00,US/Eastern,"BOSTON, Dec.  22, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC. GKCC, LLC is an entity controlled by a member of Elicio’s Board of Directors. Gross proceeds of the private placement are expected to be approximately $7.0 million, before deducting expenses. The private placement is expected to close on December 22, 2023, subject to the satisfaction of customary closing conditions.",DOWN,0.012719752865195529,en
16160,HARP,https://www.google.com/finance/quote/HARP:NASDAQ,Harpoon Therapeutics Strengthens Leadership Team,https://www.globenewswire.com/news-release/2023/12/26/2801063/0/en/Harpoon-Therapeutics-Strengthens-Leadership-Team.html,2023-12-26 07:30:00+00:00,Harpoon Therapeutics,management_changes,"The predicted upward move of +0.37% likely stems from investor confidence in James Bucher's legal expertise enhancing company governance. This could improve risk management, positively influencing the company's market perception and potentially increasing shareholder value.",globenewswire_biotech,biotech,Directors and Officers,334,HARP,2023-12-26 12:30:00+00:00,US/Eastern,"James Bucher, J.D. joins as Chief Legal Officer",DOWN,0.0036695989172311093,en
16539,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025,https://www.globenewswire.com/news-release/2023/12/26/2801081/0/en/Entera-Bio-Announces-Closing-of-Private-Placement-Extends-Cash-Runway-into-2025.html,2023-12-26 08:00:00+00:00,Entera Bio,financing_agreements,"The predicted upward move of +0.77% is likely caused by Entera Bio's successful $6.6 million fundraising, which extends its cash runway into 2025. This financial stability could boost investor confidence, potentially improving market perception and liquidity for the company.",globenewswire_biotech,biotech,Management statements,353,ENTX,2023-12-26 13:00:00+00:00,US/Eastern,"JERUSALEM, Dec.  26, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors. The Company issued and sold 7,916,879 units at a price of $0.835 per unit, each consisting of one ordinary share of Entera (or one pre-funded warrant in lieu thereof), and one five-year warrant. Gross proceeds to Entera, before offering expenses, were approximately $6.6 million, extending the Company’s cash runway into 2025.",UP,0.007694978471656974,en
15018,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,"Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma",https://www.globenewswire.com/news-release/2023/12/26/2801088/0/en/Oncternal-Therapeutics-Updates-the-Status-of-its-Phase-1-2-Study-of-ONCT-808-a-ROR1-Targeting-Autologous-CAR-T-in-Patients-with-Relapsed-or-Refractory-Aggressive-B-cell-Lymphoma.html,2023-12-26 09:00:00+00:00,Oncternal Therapeutics,clinical_study,"1. The predicted downward move of -3.31% is likely due to uncertainties or concerns about Oncternal Therapeutics' ongoing Phase 1/2 study results. 2. This could impact investor confidence, leading to broader market unease regarding biotech investment risks.",globenewswire_biotech,biotech,Clinical Study,275,ONCT,2023-12-26 14:00:00+00:00,US/Eastern,"SAN DIEGO, Dec.  26, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.",UP,-0.033098446052114545,en
15853,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/12/27/2801339/0/en/NKGen-Biotech-Announces-Clearance-of-Clinical-Trial-Application-by-Health-Canada-for-SNK01-NK-Cell-Therapy-to-Treat-Alzheimer-s-Disease.html,2023-12-27 08:00:00+00:00,NKGen Biotech,clinical_study,"The upward move of +13.05% is likely due to positive regulatory milestones in NKGen's SNK01 program, including FDA IND and Health Canada CTA clearances. This progress boosts investor confidence, potentially increasing asset value and market interest.",globenewswire_biotech,biotech,Clinical Study,318,NKGN,2023-12-27 13:00:00+00:00,US/Eastern,"NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients",UP,0.13049339123406722,en
14646,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army,https://www.globenewswire.com/news-release/2023/12/28/2801651/30505/en/MediWound-Secures-Additional-U-S-Department-of-Defense-Funding-to-Advance-NexoBrid-Development-for-the-U-S-Army.html,2023-12-28 07:00:00+00:00,MediWound,financing_agreements,"The likely cause of the predicted upward move of +0.97% is the additional $6.7 million funding, boosting NexoBrid's development. This increased R&D budget could enhance market competitiveness, potentially improving investor confidence and attracting further investments.",globenewswire_biotech,biotech,Financing Agreements,255,MDWD,2023-12-28 12:00:00+00:00,US/Eastern,Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million,UP,0.00969276957210337,en
15852,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,"NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease",https://www.globenewswire.com/news-release/2023/12/28/2801852/0/en/NKGen-Biotech-Inc-Announces-Dosing-of-First-Patient-in-its-Phase-1-2a-Trial-with-Autologous-NK-Cell-Product-SNK01-for-the-Treatment-of-Moderate-Alzheimer-s-Disease.html,2023-12-28 16:05:00+00:00,NKGen Biotech,clinical_study,The predicted upward move of +10.00% is likely due to positive trial results showing SNK01's effectiveness in improving neuroinflammation and cognitive function in Alzheimer's patients. This breakthrough could boost investor confidence and attract more investment in NKGen Biotech.,globenewswire_biotech,biotech,Clinical Study,318,NKGN,2023-12-28 21:05:00+00:00,US/Eastern,"NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1 dose-escalation safety trial.",UP,0.10002379478267154,en
14483,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/12/29/2802052/28889/en/Fortress-Biotech-Announces-Pricing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2023-12-29 08:20:00+00:00,Fortress Biotech,shares_issue,"The likely cause of the predicted downward move of -2.23% is shareholder dilution from issuing new shares and warrants. This may increase supply and decrease existing share value, potentially influencing investor sentiment and short-term market perception negatively.",globenewswire_biotech,biotech,Financing Agreements,247,FBIO,2023-12-29 13:20:00+00:00,US/Eastern,"MIAMI, Dec.  29, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into a definitive agreement for the issuance and sale of 3,303,305   shares of its common stock and warrants to purchase up to 3,303,305   shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, are immediately exercisable, and will expire five years following the date of issuance.",DOWN,-0.022265733561903703,en
16672,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/02/2802642/0/en/RAPT-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-02 08:00:00+00:00,RAPT Therapeutics,conference_call_webinar,"The predicted downward move of -0.07% might be due to market anticipation of the presentation lacking new, positive data. This slight decrease suggests limited investor excitement, potentially impacting short-term stock interest and trading volumes.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,360,RAPT,2024-01-02 13:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Jan.  02, 2024  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 a.m. Pacific Time.",UP,-0.0007166988604415639,en
15017,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/01/02/2802711/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-01-02 09:00:00+00:00,Oncternal Therapeutics,management_changes,"The predicted upward move of +0.12% is likely due to the positive sentiment from strengthening Oncternal's team with Rebecca Nolan-Olson as Safety Manager. This move indicates investor confidence in improved safety management, potentially enhancing operational efficiency and long-term growth.",globenewswire_biotech,biotech,Stock Market News,275,ONCT,2024-01-02 14:00:00+00:00,US/Eastern,"SAN DIEGO, Jan.  02, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager.",UP,0.001168855336421617,en
15536,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator,https://www.globenewswire.com/news-release/2024/01/02/2802918/0/en/Windtree-Therapeutics-Announces-Reduction-In-Arrythmias-In-A-New-Study-With-Istaroxime-And-A-Pure-SERCA2a-Activator.html,2024-01-02 16:05:00+00:00,Windtree Therapeutics,clinical_study,"The predicted upward move of +3.11% is likely due to positive preclinical data supporting istaroxime's effectiveness from three Phase 2 studies. This could boost investor confidence, increase demand, and enhance the asset's valuation in the market.",globenewswire_biotech,biotech,Clinical Study,301,WINT,2024-01-02 21:05:00+00:00,US/Eastern,The new preclinical data further supports istaroxime clinical data from three Phase 2 studies,UP,0.031120668494644534,en
15867,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803031/0/en/Faron-Pharmaceuticals-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-03 02:00:00+00:00,Faron Pharmaceuticals,conference_call_webinar,1. The predicted downward move of -0.67% for Faron Pharmaceuticals may be due to investor anticipation of the company's presentation lacking significant new developments. 2. Market implications could include reduced investor confidence and a potential decrease in share demand.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,319,FARON.HE,2024-01-03 07:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Jan.  03, 2024  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (“Faron” or “Company”) (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate immunity in hematological and solid tumor microenvironments, today announces that Dr. Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday January 11, 2024, at 12pm PT, in San Francisco.",DOWN,-0.006691099974466982,en
16380,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803160/0/en/Editas-Medicine-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-03 07:00:00+00:00,Editas Medicine,conference_call_webinar,"1. The predicted downward move of -0.60% might be caused by investor anticipation of announcements or updates lacking positive surprises. 2. A minor decrease could signal cautious sentiment, potentially influencing short-term trading strategies and stock valuations.",globenewswire_biotech,biotech,Calendar of Events,345,EDIT,2024-01-03 12:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Jan.  03, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.",DOWN,-0.006044739234295577,en
15594,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America,https://www.globenewswire.com/news-release/2024/01/03/2803154/0/en/InspireMD-Announces-Appointment-of-Medical-Technology-Executive-Pete-Ligotti-as-Executive-Vice-President-and-General-Manager-of-North-America.html,2024-01-03 07:00:00+00:00,InspireMD,management_changes,"The predicted upward move of +0.38% is likely due to the value of experienced leadership enhancing strategic capabilities. This may boost investor confidence, potentially leading to increased investment and a stronger competitive position in the medical tech market.",globenewswire_biotech,biotech,Management Changes,304,NSPR,2024-01-03 12:00:00+00:00,US/Eastern,Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team,DOWN,0.0037699185869363183,en
16538,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule,https://www.globenewswire.com/news-release/2024/01/03/2803257/0/en/Entera-Bio-Receives-Extension-from-Nasdaq-to-Regain-Compliance-with-Minimum-Bid-Price-Rule.html,2024-01-03 08:00:00+00:00,Entera Bio,exchange_announcement,"The predicted upward move of +0.06% is likely due to Entera Bio regaining time to meet Nasdaq's listing standards, boosting investor confidence. This could stabilize its stock price short-term, though the market remains cautious about long-term compliance.",globenewswire_biotech,biotech,Management statements,353,ENTX,2024-01-03 13:00:00+00:00,US/Eastern,"JERUSALEM, Jan.  03, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 27, 2023, it received an extension of 180 calendar days from the Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”). The Nasdaq determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement.",UP,0.0005514345489294419,en
16057,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803286/0/en/Akero-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-03 08:15:00+00:00,Akero Therapeutics,conference_call_webinar,"The predicted downward move of -0.07% may result from limited investor enthusiasm due to lack of groundbreaking news. Market implications include cautious sentiment pending Akero's conference presentation, potentially affecting investor confidence in its pipeline.",globenewswire_biotech,biotech,Calendar of Events,328,AKRO,2024-01-03 13:15:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Jan.  03, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 09:45 a.m. P.T. in San Francisco, CA.",DOWN,-0.0007166988604415639,en
16340,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803326/0/en/CRISPR-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2024-01-03 08:30:00+00:00,CRISPR Therapeutics,conference_call_webinar,"1. The predicted downward move of -0.07% might be due to investor anticipation or profit-taking ahead of the conference. 2. This could signal cautious sentiment, potentially impacting short-term investor confidence and trading volumes in CRISPR Therapeutics' stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,343,CRSP,2024-01-03 13:30:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, Jan.  03, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.",DOWN,-0.0007166988604415639,en
16651,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023,https://www.globenewswire.com/news-release/2024/01/03/2803517/0/en/Celularity-Announces-Net-Sales-and-Total-Revenue-Expectations-for-Fourth-Quarter-2023-and-Full-Year-2023.html,2024-01-03 12:00:00+00:00,Celularity,earnings_releases_and_operating_results,"The predicted upward move of +0.45% is likely due to Celularity's strong anticipated sales growth in biomaterial products and biobanking, reflecting triple-digit increases from 2022. This could boost investor confidence, potentially leading to increased market interest and investment appeal.",globenewswire_biotech,biotech,Pre-Release Comments,359,CELU,2024-01-03 17:00:00+00:00,US/Eastern,"Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include revenue from other sources, including research contracts such as the Company’s previously announced multi-year research collaboration services agreement with Regeneron.",UP,0.004470371744862552,en
14482,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2024/01/03/2803604/28889/en/Fortress-Biotech-Announces-Closing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2024-01-03 16:01:00+00:00,Fortress Biotech,shares_issue,"1. The predicted downward move of -0.64% is likely caused by potential dilution from issuing new shares and warrants, which can lower stock value. 2. This could lead to cautious investor sentiment and short-term volatility in the market.",globenewswire_biotech,biotech,Warrants and Certificates,247,FBIO,2024-01-03 21:01:00+00:00,US/Eastern,"MIAMI, Jan.  03, 2024  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering. The company issued 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, are immediately exercisable, and will expire five years following the date of issuance.",DOWN,-0.006386728361511876,en
15450,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium,https://www.globenewswire.com/news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html,2024-01-04 05:00:00+00:00,Adagene,clinical_study,"The predicted upward move of +11.46% is likely due to MSS CRC's promising interim results, showcasing SAFEbody's ability to enhance anti-CTLA-4 therapy. This advancement could lead to increased adoption and investment, impacting the immunotherapy market positively.",globenewswire_biotech,biotech,Health,297,ADAG,2024-01-04 10:00:00+00:00,US/Eastern,"- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -",UP,0.11460593791051178,en
14879,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions,https://www.globenewswire.com/news-release/2024/01/04/2803925/0/en/Ocuphire-Pharma-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-for-LYNX-2-Phase-3-Trial-of-Phentolamine-Ophthalmic-Solution-for-the-Treatment-of-Decreased-Visual-Acuity-u.html,2024-01-04 08:00:00+00:00,Ocuphire Pharma,clinical_study,"The predicted upward move of +0.15% is likely due to investor optimism about the Phase 3 trial initiating in Q1 2024. This progress could increase asset value, improving investor confidence and potentially boosting market interest in related sectors.",globenewswire_biotech,biotech,Clinical Study,268,OCUP,2024-01-04 13:00:00+00:00,US/Eastern,"Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024 Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024",UP,0.0014503991106177996,en
14503,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event,https://www.globenewswire.com/news-release/2024/01/04/2803997/0/en/Kineta-to-Participate-in-the-13th-Annual-LifeSci-Partners-Corporate-Access-Event.html,2024-01-04 08:30:00+00:00,Kineta,press_releases,"The predicted upward move of +0.81% for Kineta, Inc. is likely due to increased investor interest from their participation in a major event. This could enhance visibility and credibility, potentially attracting more investment and partnerships in the biotechnology sector.",globenewswire_biotech,biotech,Calendar of Events,248,KA,2024-01-04 13:30:00+00:00,US/Eastern,"SEATTLE, Jan.  04, 2024  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.",UP,0.008102852695340956,en
15016,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Announces Reverse Stock Split,https://www.globenewswire.com/news-release/2024/01/04/2804028/0/en/Oncternal-Therapeutics-Announces-Reverse-Stock-Split.html,2024-01-04 09:00:00+00:00,Oncternal Therapeutics,corporate_action,"The predicted downward move of -3.80% for Oncternal Therapeutics likely stems from the 1-for-20 reverse stock split, often viewed negatively as it suggests potential financial difficulties. Market implications could include reduced liquidity and investor confidence.",globenewswire_biotech,biotech,Changes in company's own shares,275,ONCT,2024-01-04 14:00:00+00:00,US/Eastern,"SAN DIEGO, Jan.  04, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on January 8, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the same symbol (ONCT) when the market opens on January 8, 2024 with the new CUSIP number 68236P206.",UP,-0.03798697820652341,en
16238,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,"Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board",https://www.globenewswire.com/news-release/2024/01/04/2804098/0/en/Immix-Biopharma-Announces-Dr-Vaishali-Sanchorawala-AL-Amyloidosis-Thought-Leader-Director-of-the-Amyloidosis-Center-at-Boston-University-and-Boston-Medical-Center-Joins-Scientific-.html,2024-01-04 09:34:00+00:00,Immix Biopharma,advisory,The predicted downward move of +nan% could be due to data entry error or software glitch. Such inaccuracies may cause temporary investor confusion. Immediate clarification is crucial to restore market confidence and prevent undue volatility.,globenewswire_biotech,biotech,Company Announcement,337,IMMX,2024-01-04 14:34:00+00:00,US/Eastern,"Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care",DOWN,-0.6756734811986819,en
16650,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare,https://www.globenewswire.com/news-release/2024/01/04/2804245/0/en/Celularity-Confirms-Commercialization-Agreement-with-BioCellgraft-for-the-Manufacture-and-Distribution-of-Advanced-Biomaterial-Products-for-Use-in-Oral-Healthcare.html,2024-01-04 13:00:00+00:00,Celularity,partnerships,1. The predicted downward move of -0.32% might be due to market uncertainty surrounding the new agreement and its impact on Celularity's financial outlook. 2. This could temporarily affect investor confidence and trading patterns.,globenewswire_biotech,biotech,Partnerships,359,CELU,2024-01-04 18:00:00+00:00,US/Eastern,"FLORHAM PARK, N.J., Jan.  04, 2024  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html.",DOWN,-0.0031945977990023248,en
16443,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise,https://www.globenewswire.com/news-release/2024/01/04/2804307/0/en/Vaxcyte-Provides-Clinical-and-Regulatory-Progress-Update-on-Potential-Best-in-Class-Pneumococcal-Conjugate-Vaccine-PCV-Franchise.html,2024-01-04 16:01:00+00:00,Vaxcyte,clinical_study,"The predicted downward move of -0.81% is likely due to the long timeline for data release and market uncertainty around clinical trial outcomes. This could lead to cautious investor sentiment, affecting the company's immediate stock performance.",globenewswire_biotech,biotech,Clinical Study,348,PCVX,2024-01-04 21:01:00+00:00,US/Eastern,"-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following Successful End-of-Phase 2 Meeting with FDA, Company Planning for Initiation of VAX-24 Adult Phase 3 Pivotal, Non-Inferiority Study in Second Half of 2024; Topline Data Expected in Second Half of 2025 --",UP,-0.00808267114955233,en
15899,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals,https://www.globenewswire.com/news-release/2024/01/04/2804301/0/en/C4-Therapeutics-Announces-Closing-of-25-Million-Equity-Investment-by-Betta-Pharmaceuticals.html,2024-01-04 16:01:00+00:00,C4 Therapeutics,financing_agreements,"The predicted upward move of +0.20% is likely due to C4 Therapeutics closing a $25 million stock purchase agreement at a 25% premium, which signals investor confidence. This could attract increased market interest and boost share demand for C4T.",globenewswire_biotech,biotech,Financing Agreements,320,CCCC,2024-01-04 21:01:00+00:00,US/Eastern,"WATERTOWN, Mass., Jan.  04, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China. This investment was completed at $4.49 per share. The purchase price represents a 25% premium over the 60-trading-day volume weighted average through the date that was two business days prior to the entry into the stock purchase agreement on May 29, 2023.",UP,0.0019516001667700704,en
15173,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,"Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer",https://www.globenewswire.com/news-release/2024/01/04/2804310/0/en/Mineralys-Therapeutics-Appoints-Minji-Kim-Ph-D-as-Chief-Business-Officer.html,2024-01-04 16:05:00+00:00,Mineralys Therapeutics,management_changes,"The predicted downward move of -0.72% may stem from potential uncertainties linked to leadership changes at Mineralys Therapeutics. Markets could react nervously to shifts in company strategy, although the effect might be minor given stable financial leadership.",globenewswire_biotech,biotech,Directors and Officers,283,MLYS,2024-01-04 21:05:00+00:00,US/Eastern,"RADNOR, Pa., Jan.  04, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer.",UP,-0.007235068197976413,en
15117,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue,https://www.globenewswire.com/news-release/2024/01/04/2804315/0/en/scPharmaceuticals-Announces-Preliminary-Unaudited-Q4-and-Full-Year-2023-Net-FUROSCIX-Revenue.html,2024-01-04 16:05:00+00:00,scPharmaceuticals,earnings_releases_and_operating_results,"The predicted downward move of -0.40% likely stems from revenue expectations not meeting stronger forecasts. This may suggest weaker-than-expected business performance, potentially influencing market sentiment negatively and impacting investor confidence.",globenewswire_biotech,biotech,Health,280,SCPH,2024-01-04 21:05:00+00:00,US/Eastern,Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million,UP,-0.004021352993023729,en
14694,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Announces Private Placement for $16 Million in Gross Proceeds,https://www.globenewswire.com/news-release/2024/01/04/2804359/0/en/PolyPid-Announces-Private-Placement-for-16-Million-in-Gross-Proceeds.html,2024-01-04 16:32:00+00:00,PolyPid,financing_agreements,1. The likely cause of the predicted upward move of +0.84% is investor confidence fueled by financing from top U.S. life sciences-focused investors. 2. This could lead to increased interest and investment in life sciences assets.,globenewswire_biotech,biotech,Financing Agreements,258,PYPD,2024-01-04 21:32:00+00:00,US/Eastern,Financing Led by Leading U.S. Life Sciences-focused Investors Financing Led by Leading U.S. Life Sciences-focused Investors,UP,0.008371206482461514,en
16554,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics to Present at Biotech Showcase™ 2024,https://www.globenewswire.com/news-release/2024/01/05/2804526/0/en/Bionomics-to-Present-at-Biotech-Showcase-2024.html,2024-01-05 06:00:00+00:00,Bionomics,press_releases,"The predicted downward move of -0.50% may be caused by uncertainty regarding BNC210's performance and partnership strategy. This could signal potential investor concern, possibly affecting market confidence and leading to a minor decrease in stock value.",globenewswire_biotech,biotech,Calendar of Events,354,BNOX,2024-01-05 11:00:00+00:00,US/Eastern,The Company will provide an update on its leading asset BNC210 and their partnership strategy The Company will provide an update on its leading asset BNC210 and their partnership strategy,UP,-0.004990494623562437,en
15299,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,"Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024",https://www.globenewswire.com/news-release/2024/01/05/2804707/0/en/Tiziana-Life-Sciences-to-Present-at-Biotech-Showcase-Conference-in-San-Francisco-January-8-10-2024.html,2024-01-05 09:30:00+00:00,Tiziana Life Sciences,clinical_study,The predicted upward move of +4.94% for Tiziana Life Sciences is likely due to heightened investor interest and potential positive announcements at the Biotech Showcase Conference. This can enhance visibility and attract new investment in the biotech sector.,globenewswire_biotech,biotech,Calendar of Events,289,TLSA,2024-01-05 14:30:00+00:00,US/Eastern,"Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024",UP,0.049366528798955436,en
15675,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow,https://www.globenewswire.com/news-release/2024/01/07/2805001/0/en/Akoya-Biosciences-and-Thermo-Fisher-Scientific-Announce-a-License-and-Distribution-Agreement-to-Deliver-Spatial-Multiomics-Workflow.html,2024-01-07 08:00:00+00:00,Akoya Biosciences,licensing_agreements,The predicted upward move of +1.42% is likely due to the strategic partnership between Thermo Fisher and Akoya enhancing imaging of RNA and protein biomarkers. This innovation may drive increased demand and strengthen market position.,globenewswire_biotech,biotech,Licensing Agreements,309,AKYA,2024-01-07 13:00:00+00:00,US/Eastern,"The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers",UP,0.01415584639468697,en
15673,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform,https://www.globenewswire.com/news-release/2024/01/07/2804998/0/en/Akoya-Biosciences-Deploys-the-MaxFuse-Algorithm-Co-Developed-by-Dr-Garry-Nolan-and-His-Laboratory-at-Stanford-University-for-Multiomic-Integration-of-Spatial-and-Single-cell-Data-o.html,2024-01-07 08:00:00+00:00,Akoya Biosciences,product_services_announcement,"MaxFuse's innovation in integrating diverse datasets likely drives the predicted upward move of +0.95%. This could enhance research capabilities in biotech, attracting investor interest and possibly boosting similar tech adoption in the market.",globenewswire_biotech,biotech,Clinical Study,309,AKYA,2024-01-07 13:00:00+00:00,US/Eastern,"MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities",UP,0.009531747294099346,en
15674,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook,https://www.globenewswire.com/news-release/2024/01/07/2804999/0/en/Akoya-Biosciences-Announces-Preliminary-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023-and-Provides-2024-Outlook.html,2024-01-07 08:00:00+00:00,Akoya Biosciences,earnings_releases_and_operating_results,"The predicted downward move of -0.09% may stem from investor caution over Akoya announcing unaudited, preliminary financial figures. Market implications include potential investor uncertainty, affecting stock performance, until audited results provide a clearer financial picture.",globenewswire_biotech,biotech,Stock Market News,309,AKYA,2024-01-07 13:00:00+00:00,US/Eastern,"MARLBOROUGH, Mass., Jan.  07, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited.",UP,-0.0009324037128349099,en
14732,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,"Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)",https://www.globenewswire.com/news-release/2024/01/08/2805285/0/en/Tourmaline-Bio-Announces-Expected-Upcoming-Key-Milestones-for-the-Clinical-Development-of-TOUR006-a-Long-Acting-Subcutaneous-Inhibitor-of-IL-6-with-Best-in-Class-Potential-in-Thyro.html,2024-01-08 07:00:00+00:00,Talaris Therapeutics,clinical_study,"The predicted upward move of +3.70% is likely due to Tourmaline accelerating its Phase 3 trial for TOUR006, signaling confidence in its potential success. This move could enhance market confidence, potentially leading to increased investments in the company.",globenewswire_biotech,biotech,Product / Services Announcement,260,TALS,2024-01-08 12:00:00+00:00,US/Eastern,"Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026",UP,0.03697518974488079,en
16339,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook,https://www.globenewswire.com/news-release/2024/01/08/2805274/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-2024-Outlook.html,2024-01-08 07:00:00+00:00,CRISPR Therapeutics,press_releases,"1. The predicted downward move of -0.58% is likely due to investor skepticism about CRISPR's execution of strategic priorities. 2. This could reflect concerns about potential challenges in advancing gene-based therapies, impacting investor confidence in the biotech sector.",globenewswire_biotech,biotech,Clinical Study,343,CRSP,2024-01-08 12:00:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, Jan.  08, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.",DOWN,-0.005814814812410213,en
15568,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping,https://www.globenewswire.com/news-release/2024/01/08/2805272/0/en/PepGen-Announces-First-Patient-Dosed-in-CONNECT1-EDO51-Phase-2-Clinical-Trial-of-PGN-EDO51-for-Duchenne-Muscular-Dystrophy-Patients-Amenable-to-Exon-51-Skipping.html,2024-01-08 07:00:00+00:00,PepGen,clinical_study,"The predicted upward move of +0.42% likely stems from investor optimism about positive mid-2024 trial results for the 5 mg/kg PGN-EDO51 dose, focusing on safety and efficacy. Successful outcomes could enhance market confidence and potential market opportunities.",globenewswire_biotech,biotech,Product / Services Announcement,303,PEPG,2024-01-08 12:00:00+00:00,US/Eastern,"- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data -",DOWN,0.004222540719806716,en
15298,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients,https://www.globenewswire.com/news-release/2024/01/08/2805251/0/en/Tiziana-Life-Sciences-Announces-Updated-Clinical-and-PET-Scan-Findings-for-Intranasal-Foralumab-in-Two-New-Multiple-Sclerosis-Patients.html,2024-01-08 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The predicted upward move of +7.03% is likely due to the positive findings in six out of eight patients showing improved fatigue scores and reduced microglial activation. This could increase market confidence in Tiziana's therapies, potentially boosting investor interest and share value.",globenewswire_biotech,biotech,Clinical Study,289,TLSA,2024-01-08 12:00:00+00:00,US/Eastern,"NEW YORK, Jan.  08, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.",UP,0.07028825112569029,en
16379,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html,2024-01-08 08:15:00+00:00,Editas Medicine,clinical_study,"The predicted upward move of +23.92% is likely driven by positive milestones including clinical data updates and new trials. Market implications could include increased investor confidence and potential partnerships, enhancing the asset's market position.",globenewswire_biotech,biotech,Calendar of Events,345,EDIT,2024-01-08 13:15:00+00:00,US/Eastern,"Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP",UP,0.23919524328795702,en
15794,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil,https://www.globenewswire.com/news-release/2024/01/08/2805469/34378/en/Yield10-Bioscience-Files-Request-for-Regulatory-Status-Review-with-USDA-APHIS-for-Camelina-Designed-to-Produce-the-EPA-and-DHA-Components-of-Omega-3-Oil.html,2024-01-08 08:31:00+00:00,Yield10 Bioscience,regulatory_filings,"Yield10 Bioscience's filing signals a significant advancement in biotech, likely driving the predicted upward move of +10.16%. Market implications include increased investor interest and potential expansion in omega-3 oil markets, boosting the company's strategic position.",globenewswire_biotech,biotech,Product / Services Announcement,315,YTEN,2024-01-08 13:31:00+00:00,US/Eastern,Yield10 Bioscience files RSR with USDA-APHIS for elite Camelina designed to produce EPA/DHA omega-3 oils,DOWN,0.1016202396199988,en
15015,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer,https://www.globenewswire.com/news-release/2024/01/08/2805505/0/en/Oncternal-Therapeutics-Enrolls-Patients-into-the-Third-Dosing-Cohort-of-its-Phase-1-2-Study-of-ONCT-534-for-the-Treatment-of-R-R-Metastatic-Castration-Resistant-Prostate-Cancer.html,2024-01-08 09:00:00+00:00,Oncternal Therapeutics,clinical_study,"1. The enrollment of the fourth patient and progression to a higher dosing cohort in Oncternal's Phase 1/2 study likely spurred the predicted upward move of +0.83%. 2. This could indicate confidence in the drug's development, potentially boosting investor interest.",globenewswire_biotech,biotech,Clinical Study,275,ONCT,2024-01-08 14:00:00+00:00,US/Eastern,"SAN DIEGO, Jan.  08, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). The last two patients were enrolled into the third dosing cohort, to receive ONCT-534 at a dose of 160 mg taken orally each day. The study utilizes an adaptive Bayesian Optimal Interval (BOIN) design, under which the first two dosing cohorts treated one patient each at 40 mg ONCT-534 per day and 80 mg ONCT-534 per day, respectively. The decision to proceed to dose level 3 was confirmed by the study’s Safety Review Committee (SRC).",UP,0.008284383402653065,en
16192,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance,https://www.globenewswire.com/news-release/2024/01/08/2805835/0/en/MDxHealth-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-Revenues-and-Issues-2024-Revenue-Guidance.html,2024-01-08 16:00:00+00:00,MDxHealth,earnings_releases_and_operating_results,The predicted downward move of -0.04% could be due to minor market fluctuations or reduced investor confidence. This slight decrease might discourage marginal investments but is unlikely to significantly impact broader market sentiment or long-term trends.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,335,MDXH,2024-01-08 21:00:00+00:00,US/Eastern,           ,DOWN,-0.0003975721534316114,en
14990,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023",https://www.globenewswire.com/news-release/2024/01/08/2805851/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q4-2023.html,2024-01-08 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"The predicted downward move of -1.57% for ImmuCell Corporation likely stems from lower than expected sales results. This could signal potential challenges in demand or production, possibly affecting market confidence and reducing investor interest in the short term.",globenewswire_biotech,biotech,Pre-Release Comments,274,ICCC,2024-01-08 21:05:00+00:00,US/Eastern,"PORTLAND, Maine, Jan.  08, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023.",DOWN,-0.015702606317935942,en
14818,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex to Present at the Swiss Equities Baader Conference,https://www.globenewswire.com/news-release/2024/01/09/2805955/0/en/Addex-to-Present-at-the-Swiss-Equities-Baader-Conference.html,2024-01-09 01:00:00+00:00,Addex Therapeutics,conference_call_webinar,"The predicted downward move of -0.27% might be due to lack of major announcements or market sentiment. This could signal muted investor enthusiasm, potentially impacting Addex's stock and broader interest in biotech innovations at the conference.",globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-01-09 06:00:00+00:00,US/Eastern,"Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.",UP,-0.0027394142059510855,en
15866,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial,https://www.globenewswire.com/news-release/2024/01/09/2805980/0/en/Inside-information-Faron-Announces-First-HMA-failed-MDS-Patient-Dosed-with-Bexmarilimab-as-part-of-Phase-2-of-BEXMAB-Trial.html,2024-01-09 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +0.13% is likely due to positive insider information or company developments. This could boost investor confidence, potentially increasing demand for the asset, leading to slight market optimism and increased trading activity.",globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2024-01-09 07:00:00+00:00,US/Eastern,"Company Announcement, Inside Information",UP,0.0012646976122847407,en
15833,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002,https://www.globenewswire.com/news-release/2024/01/09/2806073/0/en/Nature-Medicine-Publishes-Updated-Preliminary-Phase-1-Data-From-Elicio-Therapeutic-s-AMPLIFY-201-Phase-1-Solid-Tumor-Study-of-ELI-002.html,2024-01-09 06:00:00+00:00,Elicio Therapeutics,clinical_study,"The likely cause of the predicted upward move of +14.95% is the positive data from Elicio Therapeutics' Phase 1 trial published in Nature Medicine, showcasing promising results in cancer treatment. This may boost investor confidence, potentially increasing biotech sector interest.",globenewswire_biotech,biotech,Health,317,ELTX,2024-01-09 11:00:00+00:00,US/Eastern,"BOSTON, Jan.  09, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of data from the Phase 1 (AMPLIFY-201) study of ELI-002 2P in Nature Medicine. The paper, “Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The phase 1 AMPLIFY-201 Trial”, details expanded and updated results originally presented at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer.",UP,0.14949775125077752,en
14645,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns,https://www.globenewswire.com/news-release/2024/01/09/2806137/30505/en/MediWound-Announces-that-FDA-has-Accepted-for-Review-the-Supplement-to-the-NexoBrid-BLA-to-Include-Pediatric-Patients-with-Severe-Thermal-Burns.html,2024-01-09 07:00:00+00:00,MediWound,regulatory_filings,"The predicted upward move of +1.34% likely stems from market optimism over NexoBrid's approval, enhancing treatment options for burn patients. This approval could boost NexoBrid's market penetration and revenues, positively impacting investor sentiment and stock performance.",globenewswire_biotech,biotech,Product / Services Announcement,255,MDWD,2024-01-09 12:00:00+00:00,US/Eastern,"If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.",UP,0.013448916139987041,en
15898,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines,https://www.globenewswire.com/news-release/2024/01/09/2806663/0/en/C4-Therapeutics-Announces-2024-Priorities-and-Extended-Cash-Runway-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html,2024-01-09 16:01:00+00:00,C4 Therapeutics,clinical_study,"The predicted upward move of +1.56% is likely due to anticipated positive clinical updates, increasing investor optimism. These updates could enhance confidence in the asset's potential, possibly leading to heightened interest and investment in the related sector.",globenewswire_biotech,biotech,Product / Services Announcement,320,CCCC,2024-01-09 21:01:00+00:00,US/Eastern,"Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials",UP,0.015620260112699721,en
15776,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine,https://www.globenewswire.com/news-release/2024/01/10/2806975/0/en/Revive-Therapeutics-Successfully-Completes-Development-of-a-Novel-Lyophilized-Formulation-of-Bucillamine.html,2024-01-10 07:00:00+00:00,Revive Therapeutics,product_services_announcement,"The predicted downward move of -0.45% may result from market skepticism about Revive Therapeutics' ability to commercialize its New Bucillamine effectively. This could impact investor confidence, potentially limiting short-term stock performance amid broader market uncertainties.",globenewswire_biotech,biotech,Clinical Study,314,RVVTF,2024-01-10 12:00:00+00:00,US/Eastern,"TORONTO, Jan.  10, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo. The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.",DOWN,-0.004493514573627874,en
15672,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,"Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board",https://www.globenewswire.com/news-release/2024/01/10/2807080/0/en/Akoya-Biosciences-Announces-that-Garry-Nolan-Ph-D-James-Allison-Ph-D-and-Padmanee-Sharma-M-D-Ph-D-Join-Newly-Created-Scientific-Advisory-Board.html,2024-01-10 08:00:00+00:00,Akoya Biosciences,advisory,"The likely cause of the predicted downward move of +nan% could be market uncertainty or a lack of investor confidence in Akoya's leadership or strategic direction. Potential market implications might involve reduced investment interest, affecting overall share prices.",globenewswire_biotech,biotech,Directors and Officers,309,AKYA,2024-01-10 13:00:00+00:00,US/Eastern,"Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions",DOWN,-0.9212687964494589,en
16697,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference,https://www.globenewswire.com/news-release/2024/01/11/2807906/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-B-Riley-Securities-4th-Annual-Oncology-Conference.html,2024-01-11 08:15:00+00:00,Checkpoint Therapeutics,conference_call_webinar,"The predicted downward move of -0.60% may be due to investor caution ahead of the conference, potentially reflecting concerns about Checkpoint's clinical-stage progress. This could imply reduced short-term investor confidence, impacting trading volumes and short-term stock volatility.",globenewswire_biotech,biotech,Health,361,CKPT,2024-01-11 13:15:00+00:00,US/Eastern,"WALTHAM, Mass., Jan.  11, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.",UP,-0.005995165593005278,en
15832,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study,https://www.globenewswire.com/news-release/2024/01/11/2807912/0/en/Elicio-Therapeutics-Announces-First-Patient-Dosed-in-Randomized-Phase-2-Pancreatic-Cancer-Study.html,2024-01-11 08:30:00+00:00,Elicio Therapeutics,clinical_study,"1. The upward move is likely due to positive investor sentiment from dosing the first patient in a significant Phase 2 trial. 2. The predicted upward move of +1.04% suggests optimism for Elicio's treatment potential against KRAS mutated pancreatic cancer, potentially attracting more investor interest.",globenewswire_biotech,biotech,Health,317,ELTX,2024-01-11 13:30:00+00:00,US/Eastern,"BOSTON, Jan.  11, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).",UP,0.010424175827346411,en
15775,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada,https://www.globenewswire.com/news-release/2024/01/16/2809707/0/en/Revive-Therapeutics-Provides-Update-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-with-Defence-Research-and-Development-Canada.html,2024-01-16 07:00:00+00:00,Revive Therapeutics,clinical_study,The predicted upward move of +9.76% is likely due to Revive Therapeutics' progress with Bucillamine's research agreement with DRDC. Market implications could include increased investor confidence and heightened interest in Revive's future developments.,globenewswire_biotech,biotech,Product / Services Announcement,314,RVVTF,2024-01-16 12:00:00+00:00,US/Eastern,"TORONTO, Jan.  16, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.",UP,0.09759099385861385,en
15754,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,"Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD",https://www.globenewswire.com/news-release/2024/01/16/2809826/0/en/Message-from-Renovaro-Bioscience-Inc-s-CEO-The-Hon-Mark-Dybul-MD.html,2024-01-16 08:00:00+00:00,Renovacor,partnerships,"1. The predicted upward move of +1.63% is likely driven by advancements in AI technology enhancing healthcare efficiency. 2. This could increase investor confidence, fueling growth in healthcare-related stocks and sectors, positively impacting market trends.",globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2024-01-16 13:00:00+00:00,US/Eastern,Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024 Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024,UP,0.016292737385118904,en
15210,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Reports Second Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2024/01/16/2809870/0/en/Biomerica-Reports-Second-Quarter-2024-Financial-Results.html,2024-01-16 08:19:00+00:00,Biomerica,financial_results,"The predicted downward move of -0.14% could be caused by underwhelming financial results for the second quarter. This minor decline may suggest investor caution, potentially reducing short-term trading volume and affecting the stock's liquidity and price stability.",globenewswire_biotech,biotech,Company Announcement,285,BMRA,2024-01-16 13:19:00+00:00,US/Eastern,"IRVINE, Calif., Jan.  16, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2024 ended November 30, 2023.",UP,-0.001379802268251083,en
15831,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference,https://www.globenewswire.com/news-release/2024/01/16/2809883/0/en/Elicio-Therapeutics-to-Present-at-the-B-Riley-Securities-4th-Annual-Oncology-Conference.html,2024-01-16 08:30:00+00:00,Elicio Therapeutics,conference_call_webinar,"The predicted downward move of -0.86% for Elicio Therapeutics may be due to investor uncertainty ahead of the conference. This could imply cautious market sentiment towards upcoming announcements, potentially impacting investor confidence temporarily.",globenewswire_biotech,biotech,Calendar of Events,317,ELTX,2024-01-16 13:30:00+00:00,US/Eastern,"BOSTON, Jan.  16, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.",UP,-0.008569847727163724,en
16219,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management,https://www.globenewswire.com/news-release/2024/01/16/2810011/25416/en/Vaxart-Announces-10-0-Million-Registered-Direct-Offering-with-RA-Capital-Management.html,2024-01-16 09:25:00+00:00,Vaxart,shares_issue,"The predicted upward move of +2.67% is likely due to Vaxart's new capital infusion from the stock sale to RA Capital Management. This could enhance liquidity, supporting growth initiatives, potentially inspiring investor confidence in Vaxart's future prospects.",globenewswire_biotech,biotech,Financing Agreements,336,VXRT,2024-01-16 14:25:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Jan.  16, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.",DOWN,0.026711727695330943,en
16442,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Appoints Whitney Jones as Chief People Officer,https://www.globenewswire.com/news-release/2024/01/16/2810301/0/en/Vaxcyte-Appoints-Whitney-Jones-as-Chief-People-Officer.html,2024-01-16 16:01:00+00:00,Vaxcyte,management_changes,"1. The predicted downward move of -0.24% might be due to market uncertainty as investors assess the impact of Ms. Jones' leadership on Vaxcyte's human resources strategy. 2. This could lead to cautious trading, impacting short-term stock volatility.",globenewswire_biotech,biotech,Directors and Officers,348,PCVX,2024-01-16 21:01:00+00:00,US/Eastern,"-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan.  16, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte’s human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement.",DOWN,-0.002409775709369927,en
16338,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia,https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html,2024-01-16 16:01:00+00:00,CRISPR Therapeutics,product_services_announcement,"1. The likely cause is approval of a one-time treatment for 1,000 U.S. patients, increasing revenue prospects. 2. Market implications include investor optimism and potential stock price gains. 3. This results in a predicted upward move of +32.68%.",globenewswire_biotech,biotech,Product / Services Announcement,343,CRSP,2024-01-16 21:01:00+00:00,US/Eastern,"- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment-",UP,0.32680055058822965,en
15449,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC),https://www.globenewswire.com/news-release/2024/01/16/2810362/0/en/Adagene-Presents-Interim-Results-Reinforcing-Best-in-Class-Profile-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-Metastatic-Microsatellite-s.html,2024-01-16 17:01:00+00:00,Adagene,clinical_study,"1. The upward movement is likely due to positive clinical data showing confirmed responses with ADG126, indicating promising therapy potential. 2. This predicted upward move of +7.36% suggests increased investor confidence, possibly boosting sector interest.",globenewswire_biotech,biotech,Clinical Study,297,ADAG,2024-01-16 22:01:00+00:00,US/Eastern,"- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy -",UP,0.07361958542690264,en
15935,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China,https://www.globenewswire.com/news-release/2024/01/17/2810539/7767/en/MediciNova-Receives-a-Notice-of-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-China.html,2024-01-17 06:00:00+00:00,MediciNova,patents,"The likely cause of the predicted upward move of +0.80% is the grant of a new patent by the Chinese Patent Office for MediciNova's MN-166. This strengthens the company's intellectual property, potentially increasing investor confidence and long-term market opportunities.",globenewswire_biotech,biotech,Patents,322,MNOV,2024-01-17 11:00:00+00:00,US/Eastern,"LA JOLLA, Calif., Jan.  17, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Grant from the Chinese Patent Office for a new patent which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",UP,0.0080002497376353,en
15567,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,Mary Beth DeLena Joins PepGen as General Counsel and Secretary,https://www.globenewswire.com/news-release/2024/01/17/2810588/0/en/Mary-Beth-DeLena-Joins-PepGen-as-General-Counsel-and-Secretary.html,2024-01-17 07:00:00+00:00,PepGen,management_changes,"1. The likely cause of the predicted upward move of +0.13% is the strategic hire of Mary Beth DeLena, enhancing PepGen's leadership. 2. Her extensive experience may improve corporate governance and investor confidence, potentially leading to increased stock value.",globenewswire_biotech,biotech,Directors and Officers,303,PEPG,2024-01-17 12:00:00+00:00,US/Eastern,"BOSTON, Jan.  17, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law.",DOWN,0.0012823053321428556,en
15535,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,"Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region",https://www.globenewswire.com/news-release/2024/01/17/2810651/0/en/Windtree-Therapeutics-Announces-License-Agreement-with-Lee-s-Pharmaceuticals-to-Develop-and-Commercialize-Istaroxime-Dual-Mechanism-SERCA2a-Activators-and-Rostafuroxin-for-Greater-.html,2024-01-17 08:00:00+00:00,Windtree Therapeutics,licensing_agreements,"The predicted upward move of +0.93% is likely due to Windtree's favorable financial terms, including significant milestone payments and royalties, lessening financial burden. This could increase investor confidence, potentially enhancing market perception and boosting share value.",globenewswire_biotech,biotech,Licensing Agreements,301,WINT,2024-01-17 13:00:00+00:00,US/Eastern,"Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory",UP,0.00927644535446206,en
15830,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium,https://www.globenewswire.com/news-release/2024/01/17/2810706/0/en/Elicio-Therapeutics-to-Present-ELI-002-7P-AMPLIFY-7P-Trial-in-Progress-Poster-on-Phase-1-2-Study-of-Lymph-Node-Targeted-Vaccine-at-ASCO-GI-Symposium.html,2024-01-17 08:30:00+00:00,Elicio Therapeutics,clinical_study,"The predicted upward move of +2.20% is likely due to Elicio Therapeutics' presentation of their AMPLIFY-7P study at ASCO GI, indicating potential advancements in cancer treatment. This may attract investor interest, boosting share value and potentially enhancing market confidence.",globenewswire_biotech,biotech,Calendar of Events,317,ELTX,2024-01-17 13:30:00+00:00,US/Eastern,"BOSTON, Jan.  17, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced a Trial in Progress poster presentation on the Phase 1/2 (AMPLIFY-7P) study design at the ASCO Gastrointestinal Cancers (“ASCO GI”) Symposium being held January 18-20, 2024 in San Francisco, CA.",UP,0.02201475929362244,en
14502,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors,https://www.globenewswire.com/news-release/2024/01/17/2810707/0/en/Kineta-Provides-Update-on-its-Ongoing-Phase-1-2-VISTA-101-Clinical-Trial-of-KVA12123-in-Patients-with-Advanced-Solid-Tumors.html,2024-01-17 08:30:00+00:00,Kineta,clinical_study,"The predicted upward move of +1.06% likely results from successful clinical trial outcomes, signaling strong drug safety. This could boost investor confidence, potentially increasing stock value and enhancing the company's competitive position in the pharmaceutical market.",globenewswire_biotech,biotech,Clinical Study,248,KA,2024-01-17 13:30:00+00:00,US/Eastern,Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level,DOWN,0.01056941474553065,en
16097,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Announces Preliminary Full Year 2023 Revenue,https://www.globenewswire.com/news-release/2024/01/18/2811370/0/en/CENTOGENE-Announces-Preliminary-Full-Year-2023-Revenue.html,2024-01-18 06:30:00+00:00,Centogene,earnings_releases_and_operating_results,"The predicted downward move of -0.49% is likely due to Centogene's modest mid-single digit revenue growth, which may have fallen short of market expectations. This suggests investor skepticism, potentially affecting confidence and causing slight pressure on share prices.",globenewswire_biotech,biotech,Management statements,330,CNTG,2024-01-18 11:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan.  18, 2024  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits.",UP,-0.004859351993132716,en
15671,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases,https://www.globenewswire.com/news-release/2024/01/18/2811486/0/en/Akoya-Biosciences-Technology-Enables-Queensland-Spatial-Biology-Centre-to-Revolutionize-the-Diagnosis-and-Treatment-of-Cancer-and-Other-Diseases.html,2024-01-18 08:00:00+00:00,Akoya Biosciences,product_services_announcement,"1. The likely cause of the predicted upward move of +1.48% is the PhenoCycler-Fusion system's selection for advanced spatial biology studies, enhancing its perceived market value. 2. This could attract increased investment interest and boost the company's competitive edge.",globenewswire_biotech,biotech,Health,309,AKYA,2024-01-18 13:00:00+00:00,US/Eastern,PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies,UP,0.014815866909891172,en
16463,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering,https://www.globenewswire.com/news-release/2024/01/18/2811872/0/en/TransCode-Therapeutics-Announces-Pricing-of-7-25-Million-Public-Offering.html,2024-01-18 13:27:00+00:00,TransCode Therapeutics,shares_issue,"The predicted downward move of -1.11% is likely due to dilution concerns from the new $7.25 million public offering. This could signal market apprehension, potentially affecting investor sentiment and impacting short-term stock performance.",globenewswire_biotech,biotech,Financing Agreements,349,RNAZ,2024-01-18 18:27:00+00:00,US/Eastern,TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering,DOWN,-0.011072094677139979,en
16649,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Releases CEO Letter to Shareholders,https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html,2024-01-18 13:40:00+00:00,Celularity,press_releases,"The predicted downward move of -0.56% for Celularity Inc. likely stems from negative investor sentiment or financial outlook in the letter. It may lead to decreased investor confidence, potentially affecting stock liquidity and valuation.",globenewswire_biotech,biotech,Major shareholder announcements,359,CELU,2024-01-18 18:40:00+00:00,US/Eastern,"FLORHAM PARK, N.J., Jan.  18, 2024  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here.",UP,-0.005565364340627035,en
16218,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate,https://www.globenewswire.com/news-release/2024/01/19/2812305/25416/en/Vaxart-Receives-9-27-Million-BARDA-Project-NextGen-Award-to-Prepare-for-Phase-2b-Clinical-Study-Evaluating-Its-COVID-19-Oral-Pill-Vaccine-Candidate.html,2024-01-19 08:30:00+00:00,Vaxart,clinical_study,"The predicted upward move of +1.03% is likely due to market optimism about Vaxart's Phase 2b study, which could enhance their competitive position. This potential success might increase investor confidence and interest, impacting Vaxart's stock positively.",globenewswire_biotech,biotech,Clinical Study,336,VXRT,2024-01-19 13:30:00+00:00,US/Eastern,"- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -",UP,0.010296551736550856,en
15079,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal,https://www.globenewswire.com/news-release/2024/01/22/2812687/33333/en/Coherus-Announces-Agreement-to-Divest-Ophthalmology-Franchise-to-Sandoz-in-170-Million-Upfront-All-Cash-Deal.html,2024-01-22 01:15:00+00:00,Coherus BioSciences,mergers_acquisitions,"The predicted downward move of -0.11% likely reflects market skepticism about the transaction's impact on Coherus' financials. This could lead to cautious investor sentiment, potentially impacting stock performance and creating short-term volatility in the oncology sector.",globenewswire_biotech,biotech,Financing Agreements,278,CHRS,2024-01-22 06:15:00+00:00,US/Eastern,"– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –",UP,-0.001065755556929962,en
16553,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Provides a Review of 2023 and of 2024 Plans,https://www.globenewswire.com/news-release/2024/01/22/2812832/0/en/Bionomics-Provides-a-Review-of-2023-and-of-2024-Plans.html,2024-01-22 06:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +5.01% is likely due to positive Phase 2b data for BNC210 in PTSD. This could boost investor confidence, signaling potential FDA approval and increased market competitiveness for the company's future offerings.",globenewswire_biotech,biotech,Clinical Study,354,BNOX,2024-01-22 11:00:00+00:00,US/Eastern,"Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24.",UP,0.05014778771095453,en
16462,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics Announces Closing of $7.25 Million Public Offering,https://www.globenewswire.com/news-release/2024/01/22/2813502/0/en/TransCode-Therapeutics-Announces-Closing-of-7-25-Million-Public-Offering.html,2024-01-22 16:45:00+00:00,TransCode Therapeutics,shares_issue,The predicted upward move of +0.50% is likely due to investor optimism following TransCode Therapeutics' successful public offering. Market implications include increased investor confidence and potential for improved liquidity and funding for the company's future operations.,globenewswire_biotech,biotech,Financing Agreements,349,RNAZ,2024-01-22 21:45:00+00:00,US/Eastern,TransCode Therapeutics closes public offering,DOWN,0.004963767038376646,en
16096,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics,https://www.globenewswire.com/news-release/2024/01/23/2813910/0/en/CENTOGENE-and-The-Michael-J-Fox-Foundation-Announce-Research-Project-to-Validate-Genetic-Risk-Factors-of-Parkinson-s-Disease-Using-Multiomics.html,2024-01-23 06:30:00+00:00,Centogene,research_analysis_and_reports,The predicted downward move of +nan% might be due to market uncertainty surrounding the research outcomes or skepticism about its impact. Market implications could include cautious investor sentiment and potential volatility in related biotech stocks.,globenewswire_biotech,biotech,Clinical Study,330,CNTG,2024-01-23 11:30:00+00:00,US/Eastern,Collaboration to accelerate research to determine role of GBA gene Collaboration to accelerate research to determine role of GBA gene,UP,-1.4116832840515006,en
15816,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism,https://www.globenewswire.com/news-release/2024/01/23/2814018/0/en/Rezolute-Receives-Innovation-Passport-Designation-from-the-U-K-Innovative-Licensing-and-Access-Pathway-Steering-Group-for-RZ358-in-the-Treatment-of-Hypoglycemia-Due-to-Congenital-H.html,2024-01-23 08:00:00+00:00,Rezolute,clinical_study,"The predicted upward move of +9.41% for Rezolute, Inc. is likely caused by the Innovation Passport designation for RZ358, indicating potential treatment success for congenital hyperinsulinism. This news could boost investor confidence and enhance market interest in the company's future prospects.",globenewswire_biotech,biotech,Contests/Awards,316,RZLT,2024-01-23 13:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Jan.  23, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase 2 RIZE study in congenital HI, which safely demonstrated significant improvements in hypoglycemia events.",UP,0.09413817086690045,en
15209,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica,https://www.globenewswire.com/news-release/2024/01/23/2814070/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Appointed-as-Chairman-of-the-Board-at-Biomerica.html,2024-01-23 08:19:00+00:00,Biomerica,management_changes,"The predicted downward move of -0.14% is likely due to market uncertainty over leadership changes at Biomerica. Investors might be cautious, impacting short-term sentiment. This move may lead to temporary volatility but could stabilize as confidence in new leadership builds.",globenewswire_biotech,biotech,Directors and Officers,285,BMRA,2024-01-23 13:19:00+00:00,US/Eastern,"IRVINE, Calif., Jan.  23, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Directors in August 2023 as an independent director.",UP,-0.001355761234279025,en
16095,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Receives French Research Tax Credit Accreditation,https://www.globenewswire.com/news-release/2024/01/24/2815050/0/en/CENTOGENE-Receives-French-Research-Tax-Credit-Accreditation.html,2024-01-24 06:30:00+00:00,Centogene,government_news,"1. The predicted downward move of +nan% likely indicates data retrieval or calculation errors. 2. This could lead to uncertainty, affecting investor confidence and market volatility.",globenewswire_biotech,biotech,Management statements,330,CNTG,2024-01-24 11:30:00+00:00,US/Eastern,Partners able to claim up to 30% tax relief Partners able to claim up to 30% tax relief,DOWN,-2.4013799461078746,en
15815,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,"Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer",https://www.globenewswire.com/news-release/2024/01/24/2815219/0/en/Rezolute-Expands-Leadership-Team-with-Appointment-of-Daron-Evans-MS-MBA-as-Chief-Financial-Officer.html,2024-01-24 08:00:00+00:00,Rezolute,management_changes,"The predicted upward move of +0.29% is likely due to investor optimism about Daron Evans' appointment as CFO, potentially enhancing financial strategy. This confidence could lead to increased investor interest and stability in stock performance.",globenewswire_biotech,biotech,Directors and Officers,316,RZLT,2024-01-24 13:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Jan.  24, 2024  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the “Inducement Grant”).",UP,0.00292611960155432,en
15431,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement,https://www.globenewswire.com/news-release/2024/01/24/2815216/0/en/Annovis-Bio-Refines-Timeline-for-Parkinson-s-Phase-III-Study-Data-Announcement.html,2024-01-24 08:00:00+00:00,Annovis Bio,clinical_study,"The likely cause of the predicted downward move of -11.81% is the postponement of Phase III data for buntanetap in Parkinson's Disease. This delay could undermine investor confidence, impacting short-term market perception and potentially affecting Annovis Bio's stock value.",globenewswire_biotech,biotech,Clinical Study,296,ANVS,2024-01-24 13:00:00+00:00,US/Eastern,"MALVERN, Pa., Jan.  24, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.",UP,-0.11813686920819765,en
16237,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products,https://www.globenewswire.com/news-release/2024/01/24/2815328/0/en/Immix-Biopharma-Statement-On-January-2024-FDA-Labeling-Change-Notification-For-Approved-CAR-T-Products.html,2024-01-24 08:35:00+00:00,Immix Biopharma,clinical_study,"The predicted downward move of -0.45% is likely due to concerns over Immix Biopharma's statement about FDA labeling changes for CAR-T products, potentially impacting future sales or development. Market implications may include reduced investor confidence in the company's growth prospects.",globenewswire_biotech,biotech,Company Announcement,337,IMMX,2024-01-24 13:35:00+00:00,US/Eastern,"LOS ANGELES, CA, Jan.  24, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products:",DOWN,-0.004506674385016153,en
14731,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio Announces Proposed Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/01/24/2816077/0/en/Tourmaline-Bio-Announces-Proposed-Public-Offering-of-Common-Stock.html,2024-01-24 16:05:00+00:00,Talaris Therapeutics,shares_issue,"The predicted downward move of -0.25% is likely due to the dilution effect from issuing new shares. Market implications include potential decreased stock value, reflecting investor uncertainty regarding the offering's impact on Tourmaline's financial health and future growth prospects.",globenewswire_biotech,biotech,Financing Agreements,260,TALS,2024-01-24 21:05:00+00:00,US/Eastern,"NEW YORK, Jan.  24, 2024  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Tourmaline. In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",DOWN,-0.0025455088370532415,en
14878,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/01/24/2816080/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-01-24 16:10:00+00:00,Ocuphire Pharma,corporate_action,"The predicted upward move of +0.23% likely results from the market's positive reception of Ocuphire Pharma's strategic employee incentives, signaling growth potential. This could enhance investor confidence, potentially increasing demand and supporting a positive market outlook for Ocuphire.",globenewswire_biotech,biotech,Stock Market News,268,OCUP,2024-01-24 21:10:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., Jan.  24, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to two new employees in connection with their employment with the Company effective on January 18, 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.",UP,0.002310372947825854,en
15774,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Ltd. Announces Offering of Up to $3 Million,https://www.globenewswire.com/news-release/2024/01/24/2816162/0/en/Revive-Therapeutics-Ltd-Announces-Offering-of-Up-to-3-Million.html,2024-01-24 17:55:00+00:00,Revive Therapeutics,financing_agreements,"The predicted downward move of -3.24% may stem from regulatory issues or market sentiment concerns regarding the U.S. market exclusion. This could lead to reduced investor confidence and lower liquidity, potentially impacting overall market stability.",globenewswire_biotech,biotech,Financing Agreements,314,RVVTF,2024-01-24 22:55:00+00:00,US/Eastern,NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN,UP,-0.032356639417287225,en
15865,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population,https://www.globenewswire.com/news-release/2024/01/25/2816292/0/en/Detailed-Analysis-of-BEXMAB-Data-Provides-Insights-into-Patient-Profiles-of-Responding-HMA-Failed-MDS-Population.html,2024-01-25 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +2.23% is likely due to the positive analysis of Phase 1 BEXMAB trial data. This could boost investor confidence in Faron Pharmaceuticals, potentially leading to increased market interest and higher stock demand.",globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2024-01-25 07:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, Jan.  25, 2024  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided details from its further analysis of data from the completed Phase 1 part of the ongoing BEXMAB trial.",UP,0.022345053020033853,en
16094,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration,https://www.globenewswire.com/news-release/2024/01/25/2816524/0/en/CENTOGENE-and-the-Laboratory-of-Human-Genetics-of-Infectious-Diseases-at-Institut-Imagine-Announce-Rare-Disease-Research-Collaboration.html,2024-01-25 06:30:00+00:00,Centogene,partnerships,"The predicted upward move of +3.71% likely results from optimism about leveraging diversified data to enhance drug discovery and development. This could boost investor confidence, potentially increasing investment in data-driven biotech approaches and impacting related stocks positively.",globenewswire_biotech,biotech,Health,330,CNTG,2024-01-25 11:30:00+00:00,US/Eastern,Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development,UP,0.03714656772468909,en
14730,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio Announces Pricing of Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/01/25/2816562/0/en/Tourmaline-Bio-Announces-Pricing-of-Public-Offering-of-Common-Stock.html,2024-01-25 07:00:00+00:00,Talaris Therapeutics,shares_issue,"The predicted downward move of -1.21% is likely due to market concern over share dilution from Tourmaline Bio's public offering. This could lead to decreased investor confidence and short-term impact on share price, affecting market perception of company value.",globenewswire_biotech,biotech,Changes in company's own shares,260,TALS,2024-01-25 12:00:00+00:00,US/Eastern,"NEW YORK, Jan.  25, 2024  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share. The gross proceeds to Tourmaline from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million. All of the common stock is being offered by Tourmaline. In addition, Tourmaline has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on January 29, 2024, subject to satisfaction of customary closing conditions.",DOWN,-0.012108668300880426,en
15234,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement,https://www.globenewswire.com/news-release/2024/01/25/2816694/0/en/Kronos-Bio-Implements-New-Leadership-Structure-to-Drive-Pipeline-Advancement.html,2024-01-25 08:00:00+00:00,Kronos Bio,management_changes,1. The upward movement is likely due to anticipated efficiency gains and strategic realignment from the reshuffling of leadership. 2. The predicted upward move of +0.29% suggests investor optimism. 3. This could improve market confidence and attract more investments.,globenewswire_biotech,biotech,Management Changes,286,KRON,2024-01-25 13:00:00+00:00,US/Eastern,Company eliminates three executive officer roles and appoints new Executive Leadership team Company eliminates three executive officer roles and appoints new Executive Leadership team,UP,0.0028562378065492633,en
15534,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company,https://www.globenewswire.com/news-release/2024/01/25/2816759/0/en/Windtree-Eliminates-15-Million-Contingent-Liability-to-Deerfield-Management-Company.html,2024-01-25 08:30:00+00:00,Windtree Therapeutics,exchange_announcement,"1. The predicted downward move of -0.79% is likely due to Windtree Therapeutics terminating milestone payment rights, signaling potential challenges with AEROSURF®. 2. This may affect investor confidence and lead to decreased valuation, impacting future funding opportunities.",globenewswire_biotech,biotech,Management statements,301,WINT,2024-01-25 13:30:00+00:00,US/Eastern,"WARRINGTON, Pa., Jan.  25, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that the Company entered an Exchange and Termination Agreement with affiliates of Deerfield Management Company (collectively, “Deerfield”) pursuant to which Deerfield has agreed to terminate its rights under the Company’s 2017 Exchange and Termination Agreement to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®, an acute pulmonary drug/device combination intended to treat premature infants with respiratory distress syndrome. Windtree out-licensed global rights to AEROSURF® in 2022.",UP,-0.007864572938810602,en
16648,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions,https://www.globenewswire.com/news-release/2024/01/25/2816813/0/en/Celularity-and-Genting-Leaders-Comments-on-Closing-21-Million-Financing-Transactions.html,2024-01-25 09:00:00+00:00,Celularity,financing_agreements,"The predicted upward move of +0.29% is likely due to Celularity securing $21 million in financing, enhancing liquidity. This could boost investor confidence, potentially improving the company's strategic position and market presence.",globenewswire_biotech,biotech,Financing Agreements,359,CELU,2024-01-25 14:00:00+00:00,US/Eastern,"Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million amended and restated senior secured loan agreement with an existing lender, Resorts World Inc Pte Ltd. Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million amended and restated senior secured loan agreement with an existing lender, Resorts World Inc Pte Ltd.",DOWN,0.0029019825596264064,en
15829,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors,https://www.globenewswire.com/news-release/2024/01/25/2816830/0/en/Elicio-Therapeutics-Announces-Publication-of-Preclinical-Data-Demonstrating-TCR-T-Cell-Therapy-in-Combination-with-Lymph-Node-Targeted-Amphiphile-Immunotherapy-Enhanced-Anti-Tumor-.html,2024-01-25 09:00:00+00:00,Elicio Therapeutics,clinical_study,"The likely cause of the predicted upward move of +7.94% is the publication of promising preclinical data on Elicio's innovative immunotherapy platform. This may increase investor confidence, potentially leading to heightened interest and increased valuation in the biotechnology sector.",globenewswire_biotech,biotech,Clinical Study,317,ELTX,2024-01-25 14:00:00+00:00,US/Eastern,"BOSTON, Jan.  25, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (“AACR”). These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.",UP,0.07944876486283749,en
15753,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Renovaro Biosciences Announces Results of Special Meeting of Shareholders,https://www.globenewswire.com/news-release/2024/01/25/2817258/0/en/Renovaro-Biosciences-Announces-Results-of-Special-Meeting-of-Shareholders.html,2024-01-25 12:45:00+00:00,Renovacor,voting_rights,"The predicted downward move of -0.19% likely stems from shareholder decisions or announcements at Renovaro Biosciences' meeting. Market implications could include reduced investor confidence, possibly affecting stock performance and future investment interest.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,313,RENB,2024-01-25 17:45:00+00:00,US/Eastern,"LOS ANGELES, Jan.  25, 2024  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.",UP,-0.0019248154349228142,en
14749,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,"Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment",https://www.globenewswire.com/news-release/2024/01/29/2818796/0/en/Science-37-to-be-Acquired-by-eMed-Expanding-Access-to-Patients-and-Accelerating-Enrollment.html,2024-01-29 07:30:00+00:00,Science 37,mergers_acquisitions,"The predicted downward move of -0.14% likely reflects market adjustments to the fixed cash offer of $5.75 per share for Science 37 stockholders. The market may perceive limited upside potential, impacting investor sentiment and trading decisions.",globenewswire_biotech,biotech,Mergers and Acquisitions,261,SNCE,2024-01-29 12:30:00+00:00,US/Eastern,Science 37 stockholders to receive $5.75 per share in cash Science 37 stockholders to receive $5.75 per share in cash,UP,-0.001409661893168272,en
16696,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market,https://www.globenewswire.com/news-release/2024/01/29/2818873/36989/en/Checkpoint-Therapeutics-Announces-14-Million-Registered-Direct-Offering-Priced-At-the-Market.html,2024-01-29 08:00:00+00:00,Checkpoint Therapeutics,financing_agreements,"1. The predicted downward move of -3.96% is likely due to share dilution from issuing new stock. 2. This could reduce investor confidence, pressure stock prices, and lead to short-term volatility in Checkpoint's market valuation.",globenewswire_biotech,biotech,Financing Agreements,361,CKPT,2024-01-29 13:00:00+00:00,US/Eastern,"WALTHAM, Mass., Jan.  29, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 7,756,233 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.805 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock. The warrants will have an exercise price of $1.68 per share, will be exercisable immediately upon issuance and will expire five years following the issuance date.",DOWN,-0.03956977002718065,en
16441,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older,https://www.globenewswire.com/news-release/2024/01/29/2818922/0/en/Vaxcyte-Completes-Enrollment-of-Phase-1-2-Study-Evaluating-VAX-31-for-the-Prevention-of-Invasive-Pneumococcal-Disease-IPD-in-Adults-Aged-50-and-Older.html,2024-01-29 08:30:00+00:00,Vaxcyte,clinical_study,"The predicted upward move of +5.00% is likely due to anticipated positive results from VAX-31, addressing 95% of IPD in U.S. adults. This could boost investor confidence and increase demand, potentially advancing public health initiatives.",globenewswire_biotech,biotech,Product / Services Announcement,348,PCVX,2024-01-29 13:30:00+00:00,US/Eastern,"-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S. Adult Population --",UP,0.04998700505532119,en
16461,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer,https://www.globenewswire.com/news-release/2024/01/29/2818904/0/en/TransCode-Therapeutics-and-Debiopharm-Announce-Collaboration-to-Develop-Targeted-Nucleic-Acid-Therapeutics-for-Cancer.html,2024-01-29 08:30:00+00:00,TransCode Therapeutics,partnerships,"The predicted upward move of +9.66% likely stems from the collaborative potential to advance cancer therapeutics. This could attract investor interest and confidence, potentially boosting market valuations and enhancing both companies' competitive positions.",globenewswire_biotech,biotech,Product / Services Announcement,349,RNAZ,2024-01-29 13:30:00+00:00,US/Eastern,TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer,UP,0.09664862275298453,en
14729,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,"Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares",https://www.globenewswire.com/news-release/2024/01/29/2819419/0/en/Tourmaline-Bio-Announces-Closing-of-172-5-Million-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html,2024-01-29 16:01:00+00:00,Talaris Therapeutics,shares_issue,"The predicted upward move of +1.17% is likely due to the successful completion of Tourmaline Bio's public offering, raising substantial capital of $172.5 million. This increases investor confidence and may enhance the company's ability to fund its late-stage clinical trials.",globenewswire_biotech,biotech,Stock Market News,260,TALS,2024-01-29 21:01:00+00:00,US/Eastern,"NEW YORK, Jan.  29, 2024  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the closing of its previously-announced underwritten public offering of 5,307,691 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 692,307 additional shares, at a public offering price of $32.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $172.5 million. All shares of common stock were offered by Tourmaline. Following the closing of the offering, Tourmaline has 25,645,262 shares of common stock issued and outstanding as of January 29, 2024.",DOWN,0.01174755403267987,en
16476,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,"Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024",https://www.globenewswire.com/news-release/2024/01/29/2819424/0/en/Inotiv-Inc-to-Report-Fiscal-2024-First-Quarter-Financial-Results-and-Host-Conference-Call-on-Wednesday-February-7-2024.html,2024-01-29 16:05:00+00:00,Inotiv,earnings_releases_and_operating_results,"The predicted upward move of +0.05% for Inotiv's stock is likely due to investor anticipation of positive fiscal first-quarter results. This minor increase suggests cautious optimism, which may influence market perceptions of the company's growth potential.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,350,NOTV,2024-01-29 21:05:00+00:00,US/Eastern,"WEST LAFAYETTE, Ind., Jan.  29, 2024  (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.",UP,0.0005196094437483524,en
15172,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/01/29/2819429/0/en/Mineralys-Therapeutics-to-Participate-in-the-Guggenheim-Securities-6th-Annual-Biotechnology-Conference.html,2024-01-29 16:05:00+00:00,Mineralys Therapeutics,conference_call_webinar,The predicted downward move of -0.13% in Mineralys Therapeutics' stock could be due to general market volatility or investor reactions to upcoming events like the biotechnology conference. Minor price shifts like this often have limited immediate market implications.,globenewswire_biotech,biotech,Calendar of Events,283,MLYS,2024-01-29 21:05:00+00:00,US/Eastern,"RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.",UP,-0.0013182948846774361,en
14919,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore Announces Proposed Convertible Senior Notes Offering,https://www.globenewswire.com/news-release/2024/01/29/2819423/0/en/Immunocore-Announces-Proposed-Convertible-Senior-Notes-Offering.html,2024-01-29 16:05:00+00:00,Immunocore,financing_agreements,"The predicted downward move of -2.43% is likely due to potential dilution from issuing convertible senior notes. This move may signal to investors concerns about future equity value, impacting market sentiment negatively and possibly increasing volatility.",globenewswire_biotech,biotech,Press releases,270,IMCR,2024-01-29 21:05:00+00:00,US/Eastern,Immunocore Announces Proposed Convertible Senior Notes Offering,UP,-0.02434155108829493,en
15430,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio,https://www.globenewswire.com/news-release/2024/01/30/2819956/0/en/Annovis-Bio-Announces-the-Filing-of-New-Patent-Application-for-Treatment-of-Mental-Illnesses-Expanding-the-Company-s-Portfolio.html,2024-01-30 08:00:00+00:00,Annovis Bio,patents,"1. The upward move of +0.77% is likely due to Annovis Bio's patent application for using buntanetap in neuropsychiatric treatments. 2. This development could strengthen their intellectual property portfolio, boosting investor confidence and potentially leading to increased market interest.",globenewswire_biotech,biotech,Patents,296,ANVS,2024-01-30 13:00:00+00:00,US/Eastern,"MALVERN, Pa., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63/440,890 which was filed on January 24, 2023.",UP,0.0077156149099002706,en
16537,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/01/30/2820007/0/en/Entera-Bio-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-01-30 08:30:00+00:00,Entera Bio,conference_call_webinar,The predicted downward move of -1.52% could be due to market skepticism about Entera Bio's virtual conference participation impact. This may indicate investor concerns over the effectiveness of virtual formats in generating interest and fostering partnerships.,globenewswire_biotech,biotech,Calendar of Events,353,ENTX,2024-01-30 13:30:00+00:00,US/Eastern,"JERUSALEM, Jan.  30, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held February 13 – 14, 2024 in a virtual format.",UP,-0.015175535026797624,en
15699,ALERS.PA,https://www.google.com/finance/quote/ALERS.PA:NASDAQ,"Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP",https://www.globenewswire.com/news-release/2024/01/30/2820322/0/en/Eurobio-Scientific-FISCAL-YEAR-2023-STRATEGIC-TRANSFORMATION-OF-THE-GROUP.html,2024-01-30 11:45:00+00:00,Alers,earnings_releases_and_operating_results,"1. The predicted upward move of +0.20% is likely due to confidence in the group's strategic transformation plans for fiscal year 2023. 2. This could improve investor sentiment, supporting stock price stability and attracting long-term investment interest.",globenewswire_biotech,biotech,European Regulatory News,310,ALERS.PA,2024-01-30 16:45:00+00:00,US/Eastern,"FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP",UP,0.0020462157072783176,en
16440,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants,https://www.globenewswire.com/news-release/2024/01/30/2820492/0/en/Vaxcyte-Announces-Commencement-of-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html,2024-01-30 16:01:00+00:00,Vaxcyte,shares_issue,"The predicted upward move of +1.00% for Vaxcyte's stock is likely due to investor optimism about the capital raise. This could enhance financial stability, potentially leading to increased investor interest and improved liquidity, positively impacting market sentiment.",globenewswire_biotech,biotech,Financing Agreements,348,PCVX,2024-01-30 21:01:00+00:00,US/Eastern,"SAN CARLOS, Calif., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",DOWN,0.010010859556190063,en
16503,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals Announces Proposed Public Offering,https://www.globenewswire.com/news-release/2024/01/30/2820599/0/en/Corbus-Pharmaceuticals-Announces-Proposed-Public-Offering.html,2024-01-30 18:55:00+00:00,Corbus Pharmaceuticals,shares_issue,"The predicted upward move of +0.38% is likely driven by Corbus Pharmaceuticals' announcement of a public offering, signaling investor confidence and potential capital for growth. This could enhance liquidity and bolster future developments in their precision oncology portfolio.",globenewswire_biotech,biotech,Warrants and Certificates,351,CRBP,2024-01-30 23:55:00+00:00,US/Eastern,"NORWOOD, Mass., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.",DOWN,0.0037546412275842322,en
14918,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore Prices Upsized Convertible Senior Notes Offering,https://www.globenewswire.com/news-release/2024/01/31/2820694/0/en/Immunocore-Prices-Upsized-Convertible-Senior-Notes-Offering.html,2024-01-30 23:30:00+00:00,Immunocore,financing_agreements,The predicted downward move of -2.42% likely stems from investor concerns over dilution due to the upsized convertible senior notes offering. Market implications may include decreased share demand and increased volatility for Immunocore's stock.,globenewswire_biotech,biotech,Press releases,270,IMCR,2024-01-31 04:30:00+00:00,US/Eastern,Immunocore Prices Upsized Convertible Senior Notes Offering ,UP,-0.024214512346079284,en
16439,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Announces Pricing of $750 Million Public Offering,https://www.globenewswire.com/news-release/2024/01/31/2820695/0/en/Vaxcyte-Announces-Pricing-of-750-Million-Public-Offering.html,2024-01-30 23:37:00+00:00,Vaxcyte,shares_issue,1. The predicted downward move of -1.70% is likely caused by market dilution concerns due to Vaxcyte's large public offering of shares. 2. This could pressure existing shareholders and lead to short-term price volatility.,globenewswire_biotech,biotech,Stock Market News,348,PCVX,2024-01-31 04:37:00+00:00,US/Eastern,"SAN CARLOS, Calif., Jan.  30, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,757,812 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.",DOWN,-0.01696841521673488,en
14817,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.,https://www.globenewswire.com/news-release/2024/01/31/2820703/0/en/Addex-Enters-into-At-The-Market-ADS-Offering-Agreement-with-H-C-Wainwright-Co-LLC.html,2024-01-31 01:00:00+00:00,Addex Therapeutics,financing_agreements,The predicted downward move of -1.96% likely stems from negative news or financial performance disclosed in the ad hoc announcement. Market implications may include decreased investor confidence and potential bearish sentiment towards the asset.,globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-01-31 06:00:00+00:00,US/Eastern,Ad Hoc Announcement Pursuant to Art. 53 LR,UP,-0.01956018098915382,en
14693,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,"PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024",https://www.globenewswire.com/news-release/2024/01/31/2820936/0/en/PolyPid-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights-on-February-14-2024.html,2024-01-31 07:00:00+00:00,PolyPid,earnings_releases_and_operating_results,"The predicted upward move of +1.15% for PolyPid likely stems from anticipation of positive financial results and operational highlights. Positive perceptions can boost investor confidence, potentially leading to increased stock demand and valuation in the market.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,258,PYPD,2024-01-31 12:00:00+00:00,US/Eastern,"PETACH TIKVA, Israel, Jan.  31, 2024  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.",UP,0.011470942077311603,en
15593,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework,https://www.globenewswire.com/news-release/2024/01/31/2820960/0/en/InspireMD-Receives-CE-Mark-Recertification-Under-EU-s-New-Medical-Device-Regulation-MDR-Regulatory-Framework.html,2024-01-31 07:00:00+00:00,InspireMD,regulatory_filings,"The predicted downward move of -0.39% in InspireMD's stock may be due to market uncertainty about adapting to the new EU MDR framework. This could impact costs and timelines, affecting investor sentiment and potential future revenue streams.",globenewswire_biotech,biotech,Regulatory information,304,NSPR,2024-01-31 12:00:00+00:00,US/Eastern,"TEL AVIV, Israel and MIAMI, Jan.  31, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework. MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.",UP,-0.003927627719970607,en
15533,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives,https://www.globenewswire.com/news-release/2024/01/31/2821047/0/en/Windtree-Therapeutics-Announces-Engagement-of-Strategic-Advisor-to-Support-Assessment-of-Strategic-Alternatives.html,2024-01-31 08:00:00+00:00,Windtree Therapeutics,licensing_agreements,"The predicted upward move of +2.01% is likely due to Windtree Therapeutics engaging Ladenburg to explore strategic alternatives. This indicates potential value-enhancing activities, suggesting positive market sentiment and investor optimism for future company growth.",globenewswire_biotech,biotech,Major shareholder announcements,301,WINT,2024-01-31 13:00:00+00:00,US/Eastern,"WARRINGTON, Pa., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.",UP,0.020136224489801152,en
16671,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/01/31/2821068/0/en/RAPT-Therapeutics-to-Participate-in-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html,2024-01-31 08:00:00+00:00,RAPT Therapeutics,conference_call_webinar,The predicted downward move of -0.23% for RAPT Therapeutics may stem from investor uncertainty surrounding their participation in the Biotechnology Conference. This could signal increased scrutiny on their development pipeline. Market implications include potential reduced investor confidence and hesitancy in biotechnology sector engagement.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,360,RAPT,2024-01-31 13:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Jan.  31, 2024  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 2:00 p.m. ET .",UP,-0.0022664397715134997,en
19247,MBX,,MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/01/31/2821074/0/en/MBX-Biosciences-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-01-31 08:00:00+00:00,MBX Biosciences,conference_call_webinar,"The predicted upward move of +0.31% is likely due to increased investor interest from MBX Biosciences' participation in the Oppenheimer Conference. This engagement may enhance visibility and attract potential investors, impacting market confidence and possibly increasing share prices slightly.",globenewswire_biotech,biotech,Calendar of Events,749,MBX,2024-01-31 13:00:00+00:00,US/Eastern,"CARMEL, Ind., Jan.  31, 2024  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th, 2024, at 12:40 p.m. ET and the company will host one-on-one investor meetings during the conference.",DOWN,0.30763507210001,en
16378,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/01/31/2821218/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html,2024-01-31 09:00:00+00:00,Editas Medicine,conference_call_webinar,"The predicted upward move of +0.00% suggests stability rather than significant growth. The likely cause is the announcement of Editas Medicine's participation in investor conferences, potentially increasing visibility and investor interest. Market implications could include steady investor confidence but limited immediate impact.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,345,EDIT,2024-01-31 14:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:",UP,2.7280052470991212e-05,en
14578,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/01/31/2821240/0/en/Anaptys-to-Present-at-Guggenheim-s-6th-Annual-Biotechnology-Conference.html,2024-01-31 09:15:00+00:00,AnaptysBio,conference_call_webinar,"1. The predicted downward move of -0.89% for AnaptysBio likely stems from investor concerns about their clinical pipeline's progress or results, which may not meet expectations. 2. This could lead to decreased investor confidence and reduced stock demand.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,252,ANAB,2024-01-31 14:15:00+00:00,US/Eastern,"SAN DIEGO, Jan.  31, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.",DOWN,-0.008891246669149732,en
16502,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals Announces Pricing of Public Offering,https://www.globenewswire.com/news-release/2024/01/31/2821248/0/en/Corbus-Pharmaceuticals-Announces-Pricing-of-Public-Offering.html,2024-01-31 09:19:00+00:00,Corbus Pharmaceuticals,shares_issue,"The predicted downward move of -1.31% is likely due to potential dilution from Corbus Pharmaceuticals' public offering. This may create short-term pressure on share prices, impacting investor sentiment despite raising $82.2 million to support growth.",globenewswire_biotech,biotech,Changes in company's own shares,351,CRBP,2024-01-31 14:19:00+00:00,US/Eastern,"NORWOOD, Mass., Jan.  31, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.",UP,-0.01311791797960361,en
16460,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market,https://www.globenewswire.com/news-release/2024/01/31/2821553/0/en/Nasdaq-Determines-TransCode-Therapeutics-Compliance-with-Minimum-Stockholders-Equity-Requirement-and-Continued-Listing-on-The-Nasdaq-Stock-Market.html,2024-01-31 16:05:00+00:00,TransCode Therapeutics,regulatory_filings,"The predicted upward move of +0.08% likely stems from TransCode Therapeutics meeting Nasdaq's equity requirements, reducing delisting risks. This compliance can boost investor confidence, potentially enhancing market stability and increasing trading activity.",globenewswire_biotech,biotech,Stock Market News,349,RNAZ,2024-01-31 21:05:00+00:00,US/Eastern,"Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market",DOWN,0.00080036075834432,en
15773,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,"Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500",https://www.globenewswire.com/news-release/2024/01/31/2821606/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-First-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-913-500.html,2024-01-31 17:06:00+00:00,Revive Therapeutics,financing_agreements,"The predicted upward move of +0.18% likely stems from favorable market conditions or positive company developments. This minor increase suggests limited immediate impact but may signal growing investor confidence, potentially leading to more significant future gains.",globenewswire_biotech,biotech,Trading information,314,RVVTF,2024-01-31 22:06:00+00:00,US/Eastern,NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN,UP,0.001800962276221431,en
15772,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Explores the Use of Bucillamine for Long COVID,https://www.globenewswire.com/news-release/2024/02/01/2821891/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-for-Long-COVID.html,2024-02-01 07:30:00+00:00,Revive Therapeutics,clinical_study,"The predicted upward move of +17.97% is likely due to Revive Therapeutics' focus on Bucillamine for long COVID, signaling potential market expansion. This initiative could boost investor confidence and increase competitive dynamics in the specialty pharma sector.",globenewswire_biotech,biotech,Clinical Study,314,RVVTF,2024-02-01 12:30:00+00:00,US/Eastern,"TORONTO, Feb.  01, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by leveraging the published research and existing data from its previous Phase 3 clinical trial (the “Study”) and is preparing a clinical package that includes a proposed Phase 2/3 clinical protocol for long COVID to present to the FDA and international health regulatory bodies.",UP,0.17974197056760224,en
14728,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/02/01/2821941/0/en/Tourmaline-Bio-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html,2024-02-01 08:00:00+00:00,Talaris Therapeutics,conference_call_webinar,"The predicted downward move of -0.59% for Tourmaline Bio, Inc. may be due to investor skepticism surrounding clinical trial progress or broader market conditions affecting biotech stocks. This could potentially impact investor confidence and stock liquidity.",globenewswire_biotech,biotech,Calendar of Events,260,TALS,2024-02-01 13:00:00+00:00,US/Eastern,"NEW YORK, Feb.  01, 2024  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference:",DOWN,-0.005943644766748541,en
15532,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research,https://www.globenewswire.com/news-release/2024/02/01/2821921/0/en/Windtree-Renews-Agreement-with-Chang-Gung-University-for-Scientific-Collaboration-to-Further-SERCA2a-Research.html,2024-02-01 08:00:00+00:00,Windtree Therapeutics,partnerships,"The predicted downward move of -0.26% might be due to investor concerns over Windtree's ongoing investment in the SERCA2a research partnership. This could signal delays or additional costs, affecting short-term profitability and impacting market perception.",globenewswire_biotech,biotech,Product / Services Announcement,301,WINT,2024-02-01 13:00:00+00:00,US/Eastern,"WARRINGTON, Pa., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration.",UP,-0.002606728751335398,en
15357,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Announces Participation in February Investor Conferences,https://www.globenewswire.com/news-release/2024/02/01/2821914/0/en/Immuneering-Announces-Participation-in-February-Investor-Conferences.html,2024-02-01 08:00:00+00:00,Immuneering,conference_call_webinar,"1. The predicted upward move of +0.13% is likely due to anticipated positive investor sentiment from Immuneering's participation in investor conferences, which could boost confidence in their oncology pipeline and business strategy. 2. This might enhance interest and potentially increase investment in the company, strengthening market presence.",globenewswire_biotech,biotech,Health,292,IMRX,2024-02-01 13:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company’s pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.",UP,0.001293768103043859,en
16647,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,"Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline",https://www.globenewswire.com/news-release/2024/02/01/2822062/0/en/Celularity-Announces-Net-Sales-Expectations-for-First-Quarter-2024-and-Full-Year-2024-Reiterates-Advanced-Biomaterial-Product-Commercial-and-Development-Pipeline.html,2024-02-01 09:00:00+00:00,Celularity,earnings_releases_and_operating_results,"The predicted upward move of +0.49% for Celularity is likely driven by expected strong sales growth. This could enhance investor confidence and potentially attract more investments, positively impacting the stock's valuation and market perception.",globenewswire_biotech,biotech,Health,359,CELU,2024-02-01 14:00:00+00:00,US/Eastern," Continuing the substantial growth trajectory that began during 2023, for the first quarter 2024 and the full year 2024, Celularity expects triple-digit percentage increases in combined net sales of its advanced biomaterial product and biobanking businesses compared to the first quarter 2023 and the full year 2023.",UP,0.004939008436962648,en
15014,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/02/01/2822037/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-02-01 09:00:00+00:00,Oncternal Therapeutics,management_changes,"The predicted upward move of +0.12% is likely due to the appointment of Damien Bresson, signaling confidence in Oncternal's scientific capabilities. Market implications may include increased investor optimism and potential advancements in oncology therapies.",globenewswire_biotech,biotech,Clinical Study,275,ONCT,2024-02-01 14:00:00+00:00,US/Eastern,"SAN DIEGO, Feb.  01, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.",DOWN,0.001168855336421617,en
16438,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/02/01/2822450/0/en/Vaxcyte-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html,2024-02-01 16:05:00+00:00,Vaxcyte,conference_call_webinar,The predicted downward move of -0.73% for Vaxcyte may stem from investor anticipation or uncertainty ahead of the company's presentation. This could imply cautious sentiment or skepticism about their developments. Prolonged negativity might affect stock performance and investor confidence.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,348,PCVX,2024-02-01 21:05:00+00:00,US/Eastern,"SAN CARLOS, Calif., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.",DOWN,-0.007283909264192105,en
15655,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,"Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference",https://www.globenewswire.com/news-release/2024/02/01/2822481/0/en/Certara-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-29th-2024-and-Participate-in-the-Barclays-26th-Annual-Global-Healthcare-Conference.html,2024-02-01 16:30:00+00:00,Certara,earnings_releases_and_operating_results,"Certara's predicted upward move of +0.45% may be driven by positive market expectations for their upcoming financial results. This suggests potential investor confidence, possibly increasing stock demand and influencing broader sector sentiment positively.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,308,CERT,2024-02-01 21:30:00+00:00,US/Eastern,"PRINCETON, N.J., Feb.  01, 2024  (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.",UP,0.004468325765979967,en
16605,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2024/02/02/2823027/0/en/NexImmune-Announces-3-67-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2024-02-02 14:00:00+00:00,NexImmune,financing_agreements,"The likely cause of the predicted downward move of -6.08% is dilution from the $3.67 million registered direct offering. This can decrease investor confidence, impacting market capitalization and share value. Market implications may include reduced buying interest and increased volatility.",globenewswire_biotech,biotech,Warrants and Certificates,357,NEXI,2024-02-02 19:00:00+00:00,US/Eastern,NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,DOWN,-0.06081743974596308,en
16501,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares,https://www.globenewswire.com/news-release/2024/02/02/2823041/0/en/Corbus-Pharmaceuticals-Announces-Closing-of-94-5-Million-Public-Offering-of-Common-Stock-including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,2024-02-02 16:01:00+00:00,Corbus Pharmaceuticals,shares_issue,"The predicted upward move of +1.17% is likely due to positive investor sentiment following Corbus Pharmaceuticals' successful closing of its public offering. This could enhance liquidity and investor confidence, potentially leading to increased market interest in the company.",globenewswire_biotech,biotech,Stock Market News,351,CRBP,2024-02-02 21:01:00+00:00,US/Eastern,"NORWOOD, Mass., Feb.  02, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.",DOWN,0.01174755403267987,en
15601,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Announces Director Resignation,https://www.globenewswire.com/news-release/2024/02/02/2823050/0/en/Mydecine-Innovations-Group-Announces-Director-Resignation.html,2024-02-02 16:05:00+00:00,Mydecine Innovations Group,management_changes,"The predicted upward move of +0.11% for Mydecine stock may result from investors seeing potential positive changes in the company’s governance with Neil Stevenson-Moore’s resignation. This could signal fresh strategic directions or leadership, positively impacting market perception.",globenewswire_biotech,biotech,Directors and Officers,306,MYCO.CN,2024-02-02 21:05:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Feb.  02, 2024  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors.",UP,0.0011393778891782957,en
16437,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares,https://www.globenewswire.com/news-release/2024/02/02/2823089/0/en/Vaxcyte-Announces-Closing-of-862-5-Million-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,2024-02-02 18:39:00+00:00,Vaxcyte,shares_issue,"1. The predicted upward move of +0.63% is likely due to Vaxcyte's successful public offering, raising approximately $862.5 million. 2. This capital influx could enhance their R&D capabilities, potentially boosting investor confidence and market interest.",globenewswire_biotech,biotech,Warrants and Certificates,348,PCVX,2024-02-02 23:39:00+00:00,US/Eastern,"SAN CARLOS, Calif., Feb.  02, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.",DOWN,0.00631989492952269,en
14877,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,"Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference",https://www.globenewswire.com/news-release/2024/02/05/2823457/0/en/Ocuphire-Pharma-Announces-Presentation-on-APX3330-at-the-Annual-Angiogenesis-Exudation-and-Degeneration-2024-Conference.html,2024-02-05 08:00:00+00:00,Ocuphire Pharma,clinical_study,The predicted downward move of -0.11% for Ocuphire Pharma may be due to investors' lukewarm reception to the clinical data presentation at the conference. Potential market implications include tempered enthusiasm regarding the commercial prospects of APX3330 in diabetic retinopathy.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,268,OCUP,2024-02-05 13:00:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., Feb.  05, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation, titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint, was delivered by Veeral Sheth, M.D., M.B.A., a practicing retina specialist at University Retina, and Clinical Assistant Professor at the University of Illinois. ",UP,-0.0011085636228567457,en
15078,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,"Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP",https://www.globenewswire.com/news-release/2024/02/05/2823475/33333/en/Coherus-Amends-Term-Loan-Agreement-with-Pharmakon-Advisors-LP.html,2024-02-05 08:00:00+00:00,Coherus BioSciences,financing_agreements,1. The predicted downward move of -0.04% may be due to reduced revenue projections linked to the $125 million covenant. 2. Market implications could include reduced investor confidence and possible reassessment of asset quality and valuations.,globenewswire_biotech,biotech,Financing Agreements,278,CHRS,2024-02-05 13:00:00+00:00,US/Eastern,- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduced by ~70% -,DOWN,-0.00041803293139822687,en
19246,MBX,,"MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors",https://www.globenewswire.com/news-release/2024/02/05/2823481/0/en/MBX-Biosciences-Appoints-Steven-Ryder-M-D-to-Board-of-Directors.html,2024-02-05 08:00:00+00:00,MBX Biosciences,management_changes,The predicted downward move of -0.77% could be due to investor concerns about management changes overshadowing strategic direction. This minor decline suggests limited immediate confidence but may stabilize with future positive developments or successful product advancements.,globenewswire_biotech,biotech,Directors and Officers,749,MBX,2024-02-05 13:00:00+00:00,US/Eastern,"CARMEL, Ind., Feb.  05, 2024  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors. Dr. Ryder is an accomplished biopharmaceutical executive with over 35 years of global drug development experience and industry leadership.",UP,-0.7706622808644077,en
14644,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound to Participate in Two Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/02/05/2823453/30505/en/MediWound-to-Participate-in-Two-Upcoming-Investor-Conferences.html,2024-02-05 08:00:00+00:00,MediWound,conference_call_webinar,"Participation in notable conferences like Oppenheimer and TD Cowen signals increased visibility for MediWound Ltd., contributing to the predicted upward move of +0.21%. This may enhance investor interest and potentially boost market confidence in the company's growth prospects.",globenewswire_biotech,biotech,Calendar of Events,255,MDWD,2024-02-05 13:00:00+00:00,US/Eastern,"YAVNE, Israel, Feb.  05, 2024  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.",DOWN,0.002140747658265008,en
16641,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts,https://www.globenewswire.com/news-release/2024/02/05/2823461/0/en/Candel-Therapeutics-Sets-Path-to-Success-Recent-Achievements-Pave-the-Way-for-a-Promising-2024-Propelled-by-Key-Value-Drivers-and-Catalysts.html,2024-02-05 08:00:00+00:00,Candel Therapeutics,clinical_study,"Candel Therapeutics' recent achievements likely drive the predicted upward move of +2.68%, suggesting positive investor sentiment. This could enhance market credibility, potentially attracting more investment and increasing stock liquidity.",globenewswire_biotech,biotech,Product / Services Announcement,358,CADL,2024-02-05 13:00:00+00:00,US/Eastern,Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts,UP,0.026845668294522392,en
16217,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge,https://www.globenewswire.com/news-release/2024/02/05/2823462/25416/en/Vaxart-Announces-Publication-in-Vaccines-of-Non-Human-Primate-Preclinical-Data-Demonstrating-Its-Next-Generation-Vaccine-Candidates-Elicit-Mucosal-and-Systemic-Immunogenicity-and-R.html,2024-02-05 08:00:00+00:00,Vaxart,clinical_study,"1. The predicted upward move of +11.80% is likely due to positive sentiment around the vaccine candidate's progression to Phase 2 research. 2. This could increase investor confidence and lead to further investment, positively impacting the stock's valuation.",globenewswire_biotech,biotech,Health,336,VXRT,2024-02-05 13:00:00+00:00,US/Eastern,—  Data served as foundation for current vaccine candidate for planned Phase 2 research,UP,0.11800789987376467,en
15828,ELTX,https://www.google.com/finance/quote/ELTX:NASDAQ,Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/05/2823522/0/en/Elicio-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-02-05 08:30:00+00:00,Elicio Therapeutics,conference_call_webinar,"The predicted downward move of -1.23% for Elicio Therapeutics likely stems from market skepticism about the impact of the presentation. Investors may doubt significant news will emerge, leading to decreased stock interest, potentially affecting investor sentiment and trading volume.",globenewswire_biotech,biotech,Calendar of Events,317,ELTX,2024-02-05 13:30:00+00:00,US/Eastern,"BOSTON, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.",UP,-0.0123098216288781,en
14837,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting,https://www.globenewswire.com/news-release/2024/02/05/2823584/0/en/ARS-Pharmaceuticals-to-Present-Positive-Clinical-Efficacy-Data-for-neffy-epinephrine-nasal-spray-at-2024-AAAAI-Annual-Meeting.html,2024-02-05 09:01:00+00:00,ARS Pharmaceuticals,clinical_study,The predicted downward move of -0.22% may be due to investor anticipation rather than immediate positive outcomes. Potential market implications include cautious optimism reflecting uncertainty about the new clinical data's impact on ARS Pharmaceuticals' future earnings.,globenewswire_biotech,biotech,Calendar of Events,265,SPRY,2024-02-05 14:01:00+00:00,US/Eastern,"SAN DIEGO, Feb.  05, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that new clinical data, including efficacy outcomes supporting neffy (epinephrine nasal spray), will be presented during the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI). The meeting will be held February 23-26, 2024, in Washington, DC.",UP,-0.0021782427343223993,en
16236,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces Proposed Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/02/05/2823822/0/en/Immix-Biopharma-Announces-Proposed-Public-Offering-of-Common-Stock.html,2024-02-05 15:20:00+00:00,Immix Biopharma,shares_issue,"The predicted upward move of +0.90% likely results from investor optimism about Immix Biopharma's potential capital influx from its public offering. This could enhance funding for development, potentially boosting market confidence and attracting increased attention from investors.",globenewswire_biotech,biotech,Company Announcement,337,IMMX,2024-02-05 20:20:00+00:00,US/Eastern,"LOS ANGELES, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.    ",DOWN,0.009025718235636934,en
16235,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/02/06/2823945/0/en/Immix-Biopharma-Announces-Pricing-of-15-Million-Public-Offering-of-Common-Stock.html,2024-02-05 22:30:00+00:00,Immix Biopharma,shares_issue,The predicted downward move of -0.49% is likely due to dilution concerns from Immix Biopharma's public offering. This increased supply of shares may pressure stock prices. Market implications include potential investor caution and short-term volatility.,globenewswire_biotech,biotech,Initial Public Offerings,337,IMMX,2024-02-06 03:30:00+00:00,US/Eastern,"LOS ANGELES, CA, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on February 8, 2024, subject to the satisfaction of customary closing conditions.",DOWN,-0.004865052303591561,en
15995,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/06/2824229/0/en/Ovid-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-02-06 08:00:00+00:00,Ovid Therapeutics,conference_call_webinar,"The predicted downward move of -1.23% for Ovid Therapeutics could be due to investor uncertainty surrounding upcoming presentations. Market implications may include decreased investor confidence and temporary stock volatility, affecting overall market perception of the company.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,325,OVID,2024-02-06 13:00:00+00:00,US/Eastern,"NEW YORK, Feb.  06, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.",DOWN,-0.0123098216288781,en
14569,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock,https://www.globenewswire.com/news-release/2024/02/06/2824392/0/en/Jasper-Therapeutics-Announces-Pricing-of-50-Million-Underwritten-Offering-of-Common-Stock.html,2024-02-06 08:59:00+00:00,Jasper Therapeutics,shares_issue,"1. The predicted downward move of -1.64% is likely due to dilution concerns from the sale of 3.9 million shares. 2. Market implications include potential investor caution, impacting Jasper's stock liquidity and valuation.",globenewswire_biotech,biotech,Financing Agreements,251,JSPR,2024-02-06 13:59:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU), as well as general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.",UP,-0.016385393607588193,en
16500,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/06/2824475/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-02-06 09:50:00+00:00,Corbus Pharmaceuticals,conference_call_webinar,"1. The predicted downward move of -1.72% could be due to investor uncertainty surrounding the corporate update. 2. This could imply potential investor skepticism and impact stock performance negatively, possibly influencing broader sector sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,351,CRBP,2024-02-06 14:50:00+00:00,US/Eastern,"NORWOOD, Mass., Feb.  06, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.",DOWN,-0.01719463720707482,en
15013,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/06/2824764/0/en/Oncternal-Therapeutics-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,2024-02-06 16:30:00+00:00,Oncternal Therapeutics,conference_call_webinar,"The predicted downward move of -0.73% for Oncternal Therapeutics may stem from market skepticism about the fireside chat, possibly lacking groundbreaking updates. This could imply reduced investor confidence, impacting short-term trading sentiment and the stock's perceived growth prospects.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,275,ONCT,2024-02-06 21:30:00+00:00,US/Eastern,"SAN DIEGO, Feb.  06, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.",DOWN,-0.007254516729975935,en
16604,NEXI,https://www.google.com/finance/quote/NEXI:NASDAQ,NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2024/02/06/2824768/0/en/NexImmune-Announces-Closing-of-3-67-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2024-02-06 16:42:00+00:00,NexImmune,shares_issue,"The predicted upward move of +0.07% is likely due to increased investor confidence following NexImmune's successful $3.67 million funding. This capital boost may enhance operational capacity, potentially improving market perception and attracting further investment interest.",globenewswire_biotech,biotech,Financing Agreements,357,NEXI,2024-02-06 21:42:00+00:00,US/Eastern,NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,DOWN,0.0007362896085390844,en
15566,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock,https://www.globenewswire.com/news-release/2024/02/07/2825084/0/en/PepGen-Announces-Pricing-of-80-1-Million-Underwritten-Offering-of-Common-Stock.html,2024-02-07 07:30:00+00:00,PepGen,shares_issue,"The predicted downward move of -0.44% is likely due to market dilution from PepGen's new stock offering. This could lead to reduced earnings per share and investor concerns, impacting stock performance and market sentiment negatively.",globenewswire_biotech,biotech,Changes in company's own shares,303,PEPG,2024-02-07 12:30:00+00:00,US/Eastern,"BOSTON, Feb.  07, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share. The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about February 9, 2024, subject to customary closing conditions.",UP,-0.004363639646912506,en
14568,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference,https://www.globenewswire.com/news-release/2024/02/07/2825163/0/en/Jasper-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Conference.html,2024-02-07 08:00:00+00:00,Jasper Therapeutics,conference_call_webinar,"The predicted downward move of -0.01% could be due to investor anticipation of new information from Jasper Therapeutics' conference presentation. Minimal market impact is expected, indicating low investor concern about short-term developments.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,251,JSPR,2024-02-07 13:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Feb.  07, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024. The conference is being held in a virtual format.",UP,-0.00013501586228788928,en
15499,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,"Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.",https://www.globenewswire.com/news-release/2024/02/07/2825137/0/en/Pacira-BioSciences-Awarded-Brand-Pharmaceuticals-Agreement-With-Premier-Inc.html,2024-02-07 08:00:00+00:00,Pacira BioSciences,business_contracts,"The predicted upward move of +0.34% for Pacira BioSciences is likely due to the new group purchasing agreement with Premier, potentially increasing sales of EXPAREL. This may enhance market confidence and expand its customer base.",globenewswire_biotech,biotech,Product / Services Announcement,299,PCRX,2024-02-07 13:00:00+00:00,US/Eastern,"TAMPA, Fla., Feb.  07, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc. Effective January 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for EXPAREL® (bupivacaine liposome injectable suspension).",DOWN,0.0034214528632600756,en
14501,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series,https://www.globenewswire.com/news-release/2024/02/07/2825204/0/en/Kineta-to-Participate-in-H-C-Wainwright-Virtual-Home-Fireside-Chat-Series.html,2024-02-07 08:30:00+00:00,Kineta,clinical_study,1. The upward move of +17.08% is likely due to positive anticipation surrounding Kineta's presentation on KVA12123's clinical results. 2. The predicted upward move of +17.08% could boost investor confidence and increase market interest in Kineta's stock.,globenewswire_biotech,biotech,Calendar of Events,248,KA,2024-02-07 13:30:00+00:00,US/Eastern,"SEATTLE, Feb.  07, 2024  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024. Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta and Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present an overview of recent clinical results of KVA12123, the company’s VISTA blocking immunotherapy in development for patients with advanced solid tumors.",UP,0.17075228942025725,en
16234,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis,https://www.globenewswire.com/news-release/2024/02/07/2825304/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-AL-Amyloidosis.html,2024-02-07 09:37:00+00:00,Immix Biopharma,clinical_study,"1. The European Orphan Drug Designation likely causes the predicted upward move of +11.67% due to anticipated regulatory benefits, market exclusivity, and increased investor interest. 2. Market implications include enhanced visibility and potential partner collaborations.",globenewswire_biotech,biotech,Company Announcement,337,IMMX,2024-02-07 14:37:00+00:00,US/Eastern,European Orphan Drug Designation (“ODD”) qualifies NXC-201 for:,UP,0.11674866304005428,en
16475,NOTV,https://www.google.com/finance/quote/NOTV:NASDAQ,Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update,https://www.globenewswire.com/news-release/2024/02/07/2825561/0/en/Inotiv-Reports-First-Quarter-Financial-Results-for-Fiscal-2024-and-Provides-Business-Update.html,2024-02-07 16:05:00+00:00,Inotiv,earnings_releases_and_operating_results,"Despite a 10.3% revenue increase to $135.5 million, the predicted downward move of -0.13% may result from profit-taking or future growth concerns. This slight decline suggests limited immediate market impact, with investors potentially reassessing valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,350,NOTV,2024-02-07 21:05:00+00:00,US/Eastern,- First quarter fiscal 2024 revenue up 10.3% to $135.5 million,UP,-0.0012640016854889137,en
15600,MYCO.CN,https://www.google.com/finance/quote/MYCO.CN:NASDAQ,Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds,https://www.globenewswire.com/news-release/2024/02/07/2825615/0/en/Mydecine-Innovations-Group-Receives-Two-Notice-of-Allowances-from-USPTO-for-its-MYCO-005-and-MYCO-006-Family-of-Compounds.html,2024-02-07 17:01:00+00:00,Mydecine Innovations Group,patents,"The predicted upward move of +2.07% is likely due to Mydecine receiving Notice of Allowances from the USPTO, boosting investor confidence. This could enhance the company's competitive edge in mental health treatment, potentially attracting further investment.",globenewswire_biotech,biotech,Product / Services Announcement,306,MYCO.CN,2024-02-07 22:01:00+00:00,US/Eastern,"VANCOUVER, British Columbia, Feb.  07, 2024  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families.",UP,0.020702359327047778,en
15793,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program,https://www.globenewswire.com/news-release/2024/02/07/2825625/34378/en/Yield10-Bioscience-Provides-an-Update-on-its-Omega-3-Camelina-Program.html,2024-02-07 17:40:00+00:00,Yield10 Bioscience,press_releases,"1. The prioritization of the Omega-3 Camelina program likely boosts investor confidence, driving the predicted upward move of +0.79%. 2. This may attract increased investment and higher market visibility, positively affecting related agricultural biotech sectors.",globenewswire_biotech,biotech,Management statements,315,YTEN,2024-02-07 22:40:00+00:00,US/Eastern,-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024,UP,0.00790002782362556,en
15171,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics Announces $120 Million Private Placement Financing,https://www.globenewswire.com/news-release/2024/02/08/2825968/0/en/Mineralys-Therapeutics-Announces-120-Million-Private-Placement-Financing.html,2024-02-08 08:00:00+00:00,Mineralys Therapeutics,financing_agreements,Mineralys Therapeutics' predicted upward move of +1.20% is likely due to positive investor sentiment following their $120 million private placement. This influx of capital may boost development prospects and enhance market confidence in their pipeline's potential.,globenewswire_biotech,biotech,Financing Agreements,283,MLYS,2024-02-08 13:00:00+00:00,US/Eastern,"RADNOR, Pa., Feb.  08, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.",UP,0.011989590802493257,en
15670,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,"Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference",https://www.globenewswire.com/news-release/2024/02/08/2826431/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4th-2024-and-Participate-at-an-Upcoming-Investor-Conference.html,2024-02-08 16:05:00+00:00,Akoya Biosciences,earnings_releases_and_operating_results,"The predicted upward move of +0.58% likely stems from anticipated positive financial results from Akoya Biosciences. This could boost investor confidence, potentially increasing stock demand and impacting the broader spatial biology market positively.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,309,AKYA,2024-02-08 21:05:00+00:00,US/Eastern,"MARLBOROUGH, Mass., Feb.  08, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.",UP,0.005803909152583223,en
16233,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/02/08/2826486/0/en/Immix-Biopharma-Announces-Closing-of-15-Million-Public-Offering-of-Common-Stock.html,2024-02-08 16:45:00+00:00,Immix Biopharma,shares_issue,"The predicted upward move of +1.30% is likely driven by Immix Biopharma's successful public offering, providing $15 million for trials and operations. This capital infusion may boost investor confidence, potentially enhancing market perception and stock attractiveness.",globenewswire_biotech,biotech,Initial Public Offerings,337,IMMX,2024-02-08 21:45:00+00:00,US/Eastern,"LOS ANGELES, CA, Feb.  08, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ImmixBio. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes.",DOWN,0.012999386257889507,en
15448,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)",https://www.globenewswire.com/news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html,2024-02-09 06:00:00+00:00,Adagene,clinical_study,1. The likely cause of the predicted upward move of +0.36% is positive interim data anticipation. 2. Market implications could include increased investor confidence and potential partnerships. 3. The predicted upward move of +0.36% reflects optimism about treatment efficacy with pembrolizumab.,globenewswire_biotech,biotech,Product / Services Announcement,297,ADAG,2024-02-09 11:00:00+00:00,US/Eastern, - Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -,DOWN,0.0035818842856692474,en
15308,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech: Invitation to second half interim 2023 results presentation,https://www.globenewswire.com/news-release/2024/02/12/2827225/0/en/PCI-Biotech-Invitation-to-second-half-interim-2023-results-presentation.html,2024-02-12 03:26:00+00:00,PCI Biotech Holding,interim_information,"The predicted downward move of +nan% for PCI Biotech may stem from negative expectations regarding their second half 2023 interim report, indicating potential financial underperformance. This could lead to reduced investor confidence and a decline in stock value.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2024-02-12 08:26:00+00:00,US/Eastern,"Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time).",DOWN,0.8429669655156867,en
15592,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System,https://www.globenewswire.com/news-release/2024/02/12/2827400/0/en/InspireMD-Appoints-Principal-Investigators-for-C-GUARDIANS-II-Clinical-Trial-of-the-SwitchGuard-Neuroprotection-System.html,2024-02-12 07:00:00+00:00,InspireMD,clinical_study,"The predicted upward move of +1.66% is likely due to positive investor sentiment around SwitchGuard's innovation, aligning with the company's mission. This could enhance its market competitiveness, potentially increasing investor confidence and market share in CAS and TCAR procedures.",globenewswire_biotech,biotech,Clinical Study,304,NSPR,2024-02-12 12:00:00+00:00,US/Eastern,Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform,DOWN,0.016615113500893158,en
14643,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study,https://www.globenewswire.com/news-release/2024/02/12/2827407/30505/en/MediWound-Announces-Positive-Results-in-Head-to-Head-Comparison-of-EscharEx-vs-SANTYL-within-the-ChronEx-Phase-II-Randomized-Controlled-Study.html,2024-02-12 07:00:00+00:00,MediWound,clinical_study,"The predicted upward move of +3.88% is likely due to EscharEx® demonstrating superior efficacy over SANTYL® for venous leg ulcers. This could increase market share and revenue prospects, positively influencing investor sentiment and boosting the stock's attractiveness.",globenewswire_biotech,biotech,Health,255,MDWD,2024-02-12 12:00:00+00:00,US/Eastern,"Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU) Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU)",UP,0.038781962179525856,en
14692,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial,https://www.globenewswire.com/news-release/2024/02/12/2827386/0/en/PolyPid-Announces-Enrollment-of-the-100th-Patient-in-the-Ongoing-SHIELD-II-Phase-3-Trial.html,2024-02-12 07:00:00+00:00,PolyPid,clinical_study,"The upward move of +0.25% is likely due to positive sentiment from 40 centers reopening. Increased operational capacity can boost revenues, enhancing investor confidence. This predicted upward move may attract more investment, slightly shifting market dynamics toward optimism.",globenewswire_biotech,biotech,Clinical Study,258,PYPD,2024-02-12 12:00:00+00:00,US/Eastern,Approximately 40 Centers Currently Open,DOWN,0.0024641444801630835,en
16039,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC),https://www.globenewswire.com/news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html,2024-02-12 07:14:00+00:00,BioXcel Therapeutics,clinical_study,"1. The upward movement is likely due to positive designation news for BXCL701 with a CPI for treating metastatic SCNC, which enhances its clinical potential. 2. The predicted upward move of +11.60% could boost investor confidence and increase market demand for the asset.",globenewswire_biotech,biotech,Health,327,BTAI,2024-02-12 12:14:00+00:00,US/Eastern,Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability,UP,0.11600409475759883,en
15259,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO,https://www.globenewswire.com/news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html,2024-02-12 08:00:00+00:00,Cidara Therapeutics,regulatory_filings,The likely cause of the predicted upward move of +14.65% is the receipt of an $11.14 million milestone payment following the European approval of REZZAYO™. This approval boosts investor confidence and may enhance Cidara's market position in antifungal treatments.,globenewswire_biotech,biotech,Health,287,CDTX,2024-02-12 13:00:00+00:00,US/Eastern,"SAN DIEGO, Feb.  12, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.",UP,0.14645220377148924,en
16337,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,"European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)",https://www.globenewswire.com/news-release/2024/02/13/2827965/0/en/European-Commission-Approves-First-CRISPR-Cas9-Gene-Edited-Therapy-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Sickle-Cell-Disease-SCD-and-Transfusion-Dependent-Beta-Thal.html,2024-02-13 02:30:00+00:00,CRISPR Therapeutics,product_services_announcement,"The predicted upward move of +4.17% likely stems from increased investor confidence due to the potential treatment market for over 8,000 patients with severe SCD or TDT. This could lead to higher revenue projections and increased market interest.",globenewswire_biotech,biotech,Clinical Study,343,CRSP,2024-02-13 07:30:00+00:00,US/Eastern," —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment—",DOWN,0.04170664740469179,en
16640,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma,https://www.globenewswire.com/news-release/2024/02/13/2828140/0/en/CAN-3110-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Recurrent-High-Grade-Glioma.html,2024-02-13 07:30:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +9.65% is likely due to the FDA granting Fast Track Designation to Candel's CAN-3110, potentially accelerating its approval process. This can lead to increased investor confidence and heightened interest in Candel Therapeutics.",globenewswire_biotech,biotech,Health,358,CADL,2024-02-13 12:30:00+00:00,US/Eastern,"NEEDHAM, Mass., Feb.  13, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of patients with recurrent high-grade glioma (HGG) to improve overall survival.",UP,0.09646220095495048,en
16670,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,"RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations",https://www.globenewswire.com/news-release/2024/02/13/2828209/0/en/RAPT-Therapeutics-Bolsters-Leadership-Team-with-the-Appointment-of-Nipun-Davar-Ph-D-as-Senior-Vice-President-of-Technical-Operations.html,2024-02-13 08:00:00+00:00,RAPT Therapeutics,management_changes,"The predicted downward move of -1.11% might be due to uncertainties surrounding leadership changes. Market participants could perceive risks in strategic shifts. This appointment could influence investor sentiment, impacting RAPT's stock performance in the short term.",globenewswire_biotech,biotech,Product / Services Announcement,360,RAPT,2024-02-13 13:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Feb.  13, 2024  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.",DOWN,-0.011126323064430194,en
16336,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Announces $280 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2024/02/13/2828258/0/en/CRISPR-Therapeutics-Announces-280-Million-Registered-Direct-Offering.html,2024-02-13 08:30:00+00:00,CRISPR Therapeutics,financing_agreements,The predicted downward move of -3.84% likely stems from investor concerns over potential dilution or strategic uncertainties. Market implications could include cautious sentiment and short-term volatility as investors reassess the asset's valuation and growth trajectory.,globenewswire_biotech,biotech,Changes in company's own shares,343,CRSP,2024-02-13 13:30:00+00:00,US/Eastern,- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors -,DOWN,-0.038444136732033736,en
16038,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Announces Termination of Proposed Public Offering,https://www.globenewswire.com/news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html,2024-02-13 09:00:00+00:00,BioXcel Therapeutics,corporate_action,"The upward movement of +2.17% is likely due to positive investor sentiment following the termination of the offering, which may be perceived as a signal of strategic decision-making. This could lead to increased investor confidence and potential volatility.",globenewswire_biotech,biotech,Financing Agreements,327,BTAI,2024-02-13 14:00:00+00:00,US/Eastern,"NEW HAVEN, Conn., Feb.  13, 2024  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As a result of such termination, no securities of the Company are being sold pursuant to the offering.",UP,0.021680617113790386,en
15752,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine,https://www.globenewswire.com/news-release/2024/02/13/2828372/0/en/AI-Pioneer-GEDi-Cube-and-Biotech-Innovator-Renovaro-Biosciences-Combine-Forces-to-Accelerate-Personalized-Medicine.html,2024-02-13 09:31:00+00:00,Renovacor,mergers_acquisitions,1. The predicted downward move of -1.64% likely stems from investor skepticism about Renovaro Inc.'s integration risks following the GEDiCube acquisition. 2. This decline may reflect concerns about execution challenges affecting short-term profitability and market confidence.,globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2024-02-13 14:31:00+00:00,US/Eastern,"LOS ANGELES, Feb.  13, 2024  (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) announced today that it completed its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, and a new era in healthcare innovation. The two subsidiaries will be under the parent organization, which was renamed Renovaro Inc.",DOWN,-0.016422716743322123,en
15751,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace,https://www.globenewswire.com/news-release/2024/02/13/2828380/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html,2024-02-13 09:46:00+00:00,Renovacor,mergers_acquisitions,"The predicted downward move of -0.52% may stem from initial skepticism regarding execution risks in disrupting cancer diagnosis. This could lead to short-term market volatility, impacting investor confidence despite long-term potential in personalized therapy advancements.",globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2024-02-13 14:46:00+00:00,US/Eastern,"The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. ",DOWN,-0.005226442693071189,en
15814,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/02/13/2828647/0/en/Rezolute-Reports-Second-Quarter-Fiscal-2024-Results-and-Provides-Business-Update.html,2024-02-13 16:05:00+00:00,Rezolute,clinical_study,The predicted downward move of -4.89% likely stems from investor concerns about risks or delays associated with drug development. Market implications could include decreased stock momentum and potential reassessment of valuation until successful study results are confirmed.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,316,RZLT,2024-02-13 21:05:00+00:00,US/Eastern,Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025,UP,-0.04891321559031012,en
15307,PCIB.OL,https://www.google.com/finance/quote/PCIB.OL:NASDAQ,PCI Biotech second half 2023 interim results,https://www.globenewswire.com/news-release/2024/02/14/2828767/0/en/PCI-Biotech-second-half-2023-interim-results.html,2024-02-14 01:00:00+00:00,PCI Biotech Holding,earnings_releases_and_operating_results,"The predicted downward move of -1.05% likely stems from underwhelming interim second half 2023 results. This may undermine investor confidence, potentially decreasing investment appeal and resulting in lower short-term stock liquidity for PCI Biotech.",globenewswire_biotech,biotech,European Regulatory News,290,PCIB.OL,2024-02-14 06:00:00+00:00,US/Eastern,"Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation.",UP,-0.01052451289789539,en
14691,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/14/2828967/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-02-14 07:00:00+00:00,PolyPid,clinical_study,"The predicted upward move of +8.25% is likely due to positive sentiment around the Phase 3 trial progress of D-PLEX100 for preventing infections. Successful trials could enhance asset value and investor confidence, potentially boosting stock performance.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,258,PYPD,2024-02-14 12:00:00+00:00,US/Eastern,More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,UP,0.08253541942565533,en
15279,NTLA,https://www.google.com/finance/quote/NTLA:NASDAQ,Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates,https://www.globenewswire.com/news-release/2024/02/14/2828990/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Earnings-and-Company-Updates.html,2024-02-14 07:30:00+00:00,Intellia Therapeutics,conference_call_webinar,"The predicted upward move of +0.34% for Intellia Therapeutics is likely due to anticipated positive financial results and operational highlights in the upcoming conference call. This could boost investor confidence, potentially increasing demand for NTLA shares.",globenewswire_biotech,biotech,Calendar of Events,288,NTLA,2024-02-14 12:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Feb.  14, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET.",UP,0.0034199496939468776,en
15429,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease,https://www.globenewswire.com/news-release/2024/02/14/2828993/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html,2024-02-14 07:30:00+00:00,Annovis Bio,clinical_study,The likely cause of the predicted downward move of -4.54% is market skepticism about trial outcomes or challenges in drug approval. This move could impact investor confidence and lead to decreased funding or valuation concerns for Annovis Bio.,globenewswire_biotech,biotech,Clinical Study,296,ANVS,2024-02-14 12:30:00+00:00,US/Eastern,"MALVERN, Pa., Feb.  14, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). ",UP,-0.04538648439183117,en
14876,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Strengthens Leadership Team with Key Appointments,https://www.globenewswire.com/news-release/2024/02/14/2829026/0/en/Ocuphire-Pharma-Strengthens-Leadership-Team-with-Key-Appointments.html,2024-02-14 08:00:00+00:00,Ocuphire Pharma,management_changes,"The predicted upward move of +0.40% likely results from Ash Jayagopal's appointment, suggesting confidence in enhanced scientific leadership. Market implications include potential innovations and increased investor interest in strategic developments. This optimism may positively impact the asset’s perceived value.",globenewswire_biotech,biotech,Directors and Officers,268,OCUP,2024-02-14 13:00:00+00:00,US/Eastern,"Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer",UP,0.00395534606099339,en
15479,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology,https://www.globenewswire.com/news-release/2024/02/14/2829025/0/en/IN8bio-Announces-Publication-on-Novel-Gamma-Delta-T-Cell-Therapy-for-Glioblastoma-in-Frontiers-in-Immunology.html,2024-02-14 08:00:00+00:00,IN8bio,clinical_study,"The predicted upward move of +14.93% is likely driven by promising peer-reviewed research on gamma-delta T cell therapy for glioblastoma, signaling innovation and potential in biotech, attracting investor interest and funding opportunities. Market confidence in cutting-edge treatments could rise.",globenewswire_biotech,biotech,Clinical Study,298,INAB,2024-02-14 13:00:00+00:00,US/Eastern,Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy,UP,0.14931671332923732,en
14500,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/02/14/2829081/0/en/Kineta-to-Present-at-Upcoming-Investor-Conferences.html,2024-02-14 08:30:00+00:00,Kineta,press_releases,"The predicted downward move of -0.15% for Kineta, Inc. may be due to investor concerns about presentation outcomes at investor conferences. If presentations don't impress, it could hinder investor confidence, potentially leading to reduced stock demand.",globenewswire_biotech,biotech,Calendar of Events,248,KA,2024-02-14 13:30:00+00:00,US/Eastern,"SEATTLE, Feb.  14, 2024  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:",DOWN,-0.0014637301334973264,en
15792,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock,https://www.globenewswire.com/news-release/2024/02/14/2829136/34378/en/Yield10-Bioscience-Grants-Global-License-to-VISION-Bioenergy-Oilseeds-for-Herbicide-Tolerant-Camelina-Cultivated-for-the-Production-of-Biofuel-Feedstock.html,2024-02-14 09:00:00+00:00,Yield10 Bioscience,licensing_agreements,"1. The upward move is likely caused by increased biofuel feedstock production from the herbicide-tolerant camelina license. 2. This predicted upward move of +3.05% could boost investor confidence in biofuel-related assets, potentially leading to further investment in sustainable agriculture technologies.",globenewswire_biotech,biotech,Partnerships,315,YTEN,2024-02-14 14:00:00+00:00,US/Eastern,Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production,UP,0.03051209097858002,en
15750,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Statement of Renovaro Inc,https://www.globenewswire.com/news-release/2024/02/14/2829209/0/en/Statement-of-Renovaro-Inc.html,2024-02-14 10:01:00+00:00,Renovacor,management_statements,1. The likely cause of the predicted downward move of +nan% in Renovaro's stock could be attributed to negative sentiment from Hindenburg's opinion piece. 2. This may lead to increased volatility and decreased investor confidence in the market.,globenewswire_biotech,biotech,Advisory,313,RENB,2024-02-14 15:01:00+00:00,US/Eastern,"LOS ANGELES, Feb.  14, 2024  (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:",UP,5.361920037194666,en
16646,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,"Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease",https://www.globenewswire.com/news-release/2024/02/14/2829457/0/en/Celularity-s-Tri-layer-Decellularized-Dehydrated-Human-Amniotic-Membrane-Product-Investigated-as-a-Carrier-of-Induced-Pluripotent-Stem-Cell-Derived-Limbal-Stem-Cells-in-the-Treatme.html,2024-02-14 16:05:00+00:00,Celularity,trade_show,The predicted downward move of -0.51% may be due to market uncertainty regarding the integration of Celularity biomaterials in regenerative medicine. This could affect investor confidence and lead to decreased short-term asset value in related biotech sectors.,globenewswire_biotech,biotech,Health,359,CELU,2024-02-14 21:05:00+00:00,US/Eastern,-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery,UP,-0.005095560287286352,en
14778,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit,https://www.globenewswire.com/news-release/2024/02/14/2829482/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html,2024-02-14 16:30:00+00:00,ORIC Pharmaceuticals,conference_call_webinar,The predicted downward move of -1.84% for ORIC Pharmaceuticals may be due to investor skepticism about the impact of their participation in the Citi Oncology Summit. Market implications include potential reduced investor confidence in short-term growth prospects and increased volatility.,globenewswire_biotech,biotech,Calendar of Events,262,ORIC,2024-02-14 21:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO and SAN DIEGO, Feb.  14, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 3:00 p.m. ET.",DOWN,-0.01838060603721378,en
15278,NTLA,https://www.google.com/finance/quote/NTLA:NASDAQ,Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis,https://www.globenewswire.com/news-release/2024/02/15/2829852/0/en/Intellia-Therapeutics-and-ReCode-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Novel-Gene-Editing-Therapies-for-Cystic-Fibrosis.html,2024-02-15 07:30:00+00:00,Intellia Therapeutics,partnerships,"The predicted upward move of +8.16% likely results from Intellia Therapeutics' strategic partnership with ReCode Therapeutics, seen as a significant advancement in cystic fibrosis treatment. This collaboration may enhance investor confidence and spur interest in gene therapy markets.",globenewswire_biotech,biotech,Partnerships,288,NTLA,2024-02-15 12:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and MENLO PARK, Calif., Feb.  15, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications.",UP,0.0815811931905246,en
16335,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit,https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html,2024-02-15 08:30:00+00:00,CRISPR Therapeutics,conference_call_webinar,The predicted downward move of -1.65% could be due to investor expectations falling short as CRISPR presents at the Citi Virtual Oncology Summit. Market implications might include reduced investor confidence and potential sector-wide reevaluation.,globenewswire_biotech,biotech,Calendar of Events,343,CRSP,2024-02-15 13:30:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, Feb.  15, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET.",UP,-0.016484666143838166,en
15498,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy,https://www.globenewswire.com/news-release/2024/02/15/2829981/0/en/Pacira-Announces-Publication-of-Pivotal-Study-of-EXPAREL-as-a-Sciatic-Nerve-Block-in-the-Popliteal-Fossa-for-Patients-After-Bunionectomy.html,2024-02-15 08:36:00+00:00,Pacira BioSciences,clinical_study,"The predicted upward move of +5.76% is likely due to the findings showing reduced pain and opioid use, indicating efficacy. This could boost investor confidence, potentially increasing demand and revenue expectations. Positive clinical results often attract market interest.",globenewswire_biotech,biotech,Clinical Study,299,PCRX,2024-02-15 13:36:00+00:00,US/Eastern,– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –,UP,0.057592342289409265,en
15749,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace,https://www.globenewswire.com/news-release/2024/02/15/2830059/0/en/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace.html,2024-02-15 09:25:00+00:00,Renovacor,mergers_acquisitions,"The predicted downward move of -0.52% could stem from high competition in cancer diagnostics, regulatory hurdles, or market skepticism about execution. This might cause investor caution, affecting the stock's short-term performance despite long-term potential.",globenewswire_biotech,biotech,Mergers and Acquisitions,313,RENB,2024-02-15 14:25:00+00:00,US/Eastern,"The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. ",DOWN,-0.005226442693071189,en
16436,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,"Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024",https://www.globenewswire.com/news-release/2024/02/15/2830367/0/en/Vaxcyte-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-27-2024.html,2024-02-15 16:05:00+00:00,Vaxcyte,earnings_releases_and_operating_results,"The predicted upward move of +0.46% is likely due to investor anticipation of positive financial results or business updates from Vaxcyte. If results exceed expectations, it could boost investor confidence and potentially lead to further stock appreciation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,348,PCVX,2024-02-15 21:05:00+00:00,US/Eastern,"SAN CARLOS, Calif., Feb.  15, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.",UP,0.004596502814178519,en
14875,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/02/15/2830386/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-02-15 16:10:00+00:00,Ocuphire Pharma,management_changes,"The predicted upward move of +0.17% is likely due to investor confidence in Ocuphire's new executive appointments, expected to drive strategic growth. This could enhance the company's competitive edge and attract further investor interest, potentially boosting stock performance.",globenewswire_biotech,biotech,Product / Services Announcement,268,OCUP,2024-02-15 21:10:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., Feb.  15, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to Ashwath Jayagopal, Ph.D., M.B.A., the Company’s newly appointed Chief Scientific and Development Officer and to Nirav Jhaveri, C.F.A.., M.B.A., the Company’s newly appointed Chief Financial Officer in connection with their employment with the Company effective on February 12, 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.",UP,0.0016542818155456998,en
16191,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,Mdxhealth Announces Resignation of Board Member,https://www.globenewswire.com/news-release/2024/02/16/2830770/0/en/Mdxhealth-Announces-Resignation-of-Board-Member.html,2024-02-16 08:45:00+00:00,MDxHealth,management_changes,"The predicted upward move of +0.04% in Mdxhealth's asset may be linked to investor confidence in refreshed corporate governance. This minimal increase suggests limited immediate impact, but potential positive sentiment for strategic shifts in the long term.",globenewswire_biotech,biotech,Directors and Officers,335,MDXH,2024-02-16 13:45:00+00:00,US/Eastern,Mdxhealth Announces Resignation of Board Member,UP,0.00038703485305396494,en
14989,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023",https://www.globenewswire.com/news-release/2024/02/16/2830814/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-and-Year-Ended-December-31-2023.html,2024-02-16 09:30:00+00:00,ImmuCell Corporation,conference_call_webinar,"The predicted upward move of +0.52% likely results from anticipated positive news during the conference call. Market implications include increased investor confidence and potential stock price growth, possibly attracting more buyers and increasing trading volumes.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,274,ICCC,2024-02-16 14:30:00+00:00,US/Eastern,"Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET",DOWN,0.005177747454176565,en
16300,PHIL.MI,https://www.google.com/finance/quote/PHIL.MI:NASDAQ,Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma,https://www.globenewswire.com/news-release/2024/02/20/2831505/0/en/Philogen-provides-update-on-pre-planned-interim-analysis-of-the-Phase-III-FIBROSARC-trial-investigating-Onfekafusp-alfa-L19TNF-in-patients-with-first-line-advanced-or-metastatic-So.html,2024-02-20 01:30:00+00:00,PharmaNutra,clinical_study,"1. The likely cause of the predicted downward move of -10.46% is disappointing interim results in the Phase III FIBROSARC trial for L19TNF, leading to concerns about effectiveness. 2. This may diminish investor confidence, impacting related stocks and funding.",globenewswire_biotech,biotech,Research Analysis and Reports,341,PHIL.MI,2024-02-20 06:30:00+00:00,US/Eastern,Interim analysis of the Phase III FIBROSARC trial investigating L19TNF in patients with first-line Soft Tissue Sarcoma,UP,-0.1046176326863773,en
16669,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon,https://www.globenewswire.com/news-release/2024/02/20/2831721/0/en/RAPT-Therapeutics-Announces-Clinical-Hold-on-Studies-Evaluating-Zelnecirnon.html,2024-02-20 07:30:00+00:00,RAPT Therapeutics,clinical_study,"1. The predicted upward move of +7.93% likely reflects investor optimism ahead of RAPT's conference call, expecting positive announcements. 2. This could boost investor confidence, potentially increasing demand and improving the stock's market valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,360,RAPT,2024-02-20 12:30:00+00:00,US/Eastern,- RAPT to host a conference call today at 8:30 am ET -,DOWN,0.07925077313251926,en
15565,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1,https://www.globenewswire.com/news-release/2024/02/20/2831795/0/en/PepGen-Receives-U-S-FDA-Fast-Track-Designation-for-PGN-EDODM1-for-the-Treatment-of-Myotonic-Dystrophy-Type-1.html,2024-02-20 08:00:00+00:00,PepGen,clinical_study,"The predicted upward move of +11.58% is likely due to the FDA granting Fast Track designation to PepGen's PGN-EDODM1, signaling its potential impact in treating DM1. This could boost investor confidence and attract increased market interest in PepGen.",globenewswire_biotech,biotech,Product / Services Announcement,303,PEPG,2024-02-20 13:00:00+00:00,US/Eastern,"BOSTON, Feb.  20, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1 (DM1). “Receiving Fast Track designation from the FDA for PGN-EDODM1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the DM1 community,” said James McArthur, Ph.D., President and CEO of PepGen. “Patients with DM1 currently have no available treatment options that target the root cause of the disease, which leads to progressive neuromuscular symptoms and reduction in life expectancy. Following robust preclinical data, we are now evaluating PGN-EDODM1 in the ongoing FREEDOM-DM1 Phase 1 trial and expect to report preliminary data later this year. We believe that PGN-EDODM1 has the potential to be disease-modifying and improve outcomes for patients living with DM1.”",DOWN,0.11583887425950716,en
16459,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic,https://www.globenewswire.com/news-release/2024/02/20/2831781/0/en/TransCode-Therapeutics-Reports-Publication-of-United-States-Patent-Application-Covering-TransCode-s-RIG-I-Agonist-Immunotherapeutic.html,2024-02-20 08:00:00+00:00,TransCode Therapeutics,patents,"The predicted upward move of +2.05% is likely due to the positive patent news, which could enhance TransCode's competitive position. Market implications include increased investor confidence and potential for expanded market opportunities.",globenewswire_biotech,biotech,Health,349,RNAZ,2024-02-20 13:00:00+00:00,US/Eastern,TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic,UP,0.020505135371761782,en
15356,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer,https://www.globenewswire.com/news-release/2024/02/20/2831754/0/en/Immuneering-Receives-FDA-Fast-Track-Designation-for-IMM-1-104-in-Pancreatic-Cancer.html,2024-02-20 08:00:00+00:00,Immuneering,clinical_study,"The predicted upward move of +10.45% likely results from the Fast Track designation, which accelerates FDA submission for IMM-1-104. This boosts investor confidence, potentially increasing investment and market interest in the biotech firm.",globenewswire_biotech,biotech,Clinical Study,292,IMRX,2024-02-20 13:00:00+00:00,US/Eastern,– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma –,UP,0.10445738768028055,en
14836,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,"ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter",https://www.globenewswire.com/news-release/2024/02/20/2831938/0/en/ARS-Pharma-Announces-Favorable-Topline-Results-from-Repeat-Dosing-Study-of-neffy-Epinephrine-Nasal-Spray-Under-Nasal-Allergen-Challenge-Conditions-Readies-Data-for-Response-to-FDA-.html,2024-02-20 09:01:00+00:00,ARS Pharmaceuticals,clinical_study,"The predicted upward move of +6.10% is likely due to neffy's favorable pharmacokinetic and pharmacodynamic profiles compared to injections, indicating enhanced effectiveness. This could boost investor confidence, potentially increasing demand and market share for the company.",globenewswire_biotech,biotech,Health,265,SPRY,2024-02-20 14:01:00+00:00,US/Eastern,"Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection",DOWN,0.06097431084973084,en
14917,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,"Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024",https://www.globenewswire.com/news-release/2024/02/21/2832598/0/en/Immunocore-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-call-on-February-28-2024.html,2024-02-21 07:00:00+00:00,Immunocore,earnings_releases_and_operating_results,"The predicted upward move of +0.44% may be due to anticipated positive financial results or strategic announcements. This could enhance investor confidence, potentially boosting stock value. Such movements might signal broader market interest in biotechnology.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,270,IMCR,2024-02-21 12:00:00+00:00,US/Eastern,"Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 ",UP,0.0044360365493694535,en
16377,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events,https://www.globenewswire.com/news-release/2024/02/21/2832602/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2023-Results-Conference-Call-and-Upcoming-Investor-Events.html,2024-02-21 07:00:00+00:00,Editas Medicine,conference_call_webinar,The predicted downward move of -0.07% for Editas Medicine might be due to anticipated lackluster financial results or minimal updates during the conference call. Its impact could slightly erode investor confidence and cause mild short-term stock sell-offs.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,345,EDIT,2024-02-21 12:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Feb.  21, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.",UP,-0.0007194136357855943,en
16334,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/21/2832665/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-02-21 07:30:00+00:00,CRISPR Therapeutics,product_services_announcement,"The predicted downward move of -0.16% may be due to market expectations already pricing in CASGEVY's approvals, leading to limited short-term upside. Market implications include cautious investor sentiment and potential re-evaluation of growth prospects.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,343,CRSP,2024-02-21 12:30:00+00:00,US/Eastern,"— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —",UP,-0.0016453812232543699,en
15099,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy,https://www.globenewswire.com/news-release/2024/02/21/2832730/0/en/Mainz-Biomed-Establishes-Strategic-Partnership-with-TomaLab-to-Expand-Availability-of-ColoAlert-in-Italy.html,2024-02-21 08:01:00+00:00,Mainz Biomed,partnerships,"The predicted upward move of +1.74% for Mainz Biomed is likely due to the strategic partnership with TomaLab, expanding ColoAlert® availability in Italy, potentially increasing market penetration and revenue. This could enhance investor confidence and market presence in Europe.",globenewswire_biotech,biotech,Partnerships,279,MYNZ,2024-02-21 13:01:00+00:00,US/Eastern,Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy,UP,0.01744291654052037,en
15208,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board,https://www.globenewswire.com/news-release/2024/02/21/2832740/0/en/Diagnostics-Industry-Leader-Gary-Huff-Appointed-to-Biomerica-Strategic-Advisory-Board.html,2024-02-21 08:19:00+00:00,Biomerica,advisory,The predicted downward move of +nan% could be due to uncertain investor sentiment despite Mr. Huff's experience. Potential market implications include decreased investor confidence and possible reevaluation of related stocks within medical diagnostics and healthcare sectors.,globenewswire_biotech,biotech,Management statements,285,BMRA,2024-02-21 13:19:00+00:00,US/Eastern,Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare,UP,0.5828634986267043,en
15077,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv,https://www.globenewswire.com/news-release/2024/02/21/2832750/33333/en/Coherus-Announces-U-S-Launch-of-UDENYCA-ONBODY-a-Novel-and-Proprietary-State-of-the-Art-Delivery-System-for-pegfilgrastim-cbqv.html,2024-02-21 08:30:00+00:00,Coherus BioSciences,product_services_announcement,The predicted downward move of -2.52% is likely due to perceived limitations or competition concerns despite the innovation. Market implications may include investor skepticism about impact on sales or increased competition affecting the company's market position.,globenewswire_biotech,biotech,Product / Services Announcement,278,CHRS,2024-02-21 13:30:00+00:00,US/Eastern,– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –,DOWN,-0.025239522657612885,en
16232,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma 12 Month Review Progress Update,https://www.globenewswire.com/news-release/2024/02/21/2832855/0/en/Immix-Biopharma-12-Month-Review-Progress-Update.html,2024-02-21 09:31:00+00:00,Immix Biopharma,clinical_study,"The predicted upward move of +7.83% could be due to positive advancements in Immix Biopharma's cell therapies for autoimmune diseases. This progress may boost investor confidence, potentially increasing the company's stock demand and enhancing market perception of its long-term growth prospects.",globenewswire_biotech,biotech,Clinical Study,337,IMMX,2024-02-21 14:31:00+00:00,US/Eastern,"LOS ANGELES, Feb.  21, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.",UP,0.07830774736445828,en
16190,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results  and Corporate Update on March 6,https://www.globenewswire.com/news-release/2024/02/21/2833183/0/en/MDxHealth-to-Present-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Update-on-March-6.html,2024-02-21 17:00:00+00:00,MDxHealth,financial_results,"1. The predicted upward move of +0.74% is likely due to anticipated positive financial results and updates. 2. This could boost investor confidence, enhancing demand and price. 3. Potential market implications include increased trading volume and stock interest.",globenewswire_biotech,biotech,Company Announcement,335,MDXH,2024-02-21 22:00:00+00:00,US/Eastern,MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6,UP,0.007353764329432275,en
14916,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial,https://www.globenewswire.com/news-release/2024/02/22/2833534/0/en/Immunocore-announces-clinical-trial-collaboration-and-supply-agreement-with-Bristol-Myers-Squibb-to-evaluate-IMC-F106C-PRAME-HLA-A02-in-combination-with-nivolumab-in-its-registrati.html,2024-02-22 07:00:00+00:00,Immunocore,clinical_study,"1. The predicted upward move of +1.04% is likely caused by the strategic collaboration between Immunocore and Bristol Myers Squibb, enhancing trial prospects. 2. This could boost investor confidence, indicating potential growth and competitive advantage in melanoma treatment.",globenewswire_biotech,biotech,Other News,270,IMCR,2024-02-22 12:00:00+00:00,US/Eastern,Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial,UP,0.010411196586536362,en
15897,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2024/02/22/2833515/0/en/C4-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html,2024-02-22 07:00:00+00:00,C4 Therapeutics,clinical_study,"The predicted upward move of +17.25% for CFT1946 is likely due to positive response from the acceptance of its preclinical data at the AACR meeting. This suggests market optimism for potential advancements in cancer treatment, possibly increasing investor interest and valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,320,CCCC,2024-02-22 12:00:00+00:00,US/Eastern,CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024,UP,0.1725229466646415,en
15277,NTLA,https://www.google.com/finance/quote/NTLA:NASDAQ,Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress,https://www.globenewswire.com/news-release/2024/02/22/2833580/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,2024-02-22 07:30:00+00:00,Intellia Therapeutics,financial_results,"1. The upward movement is likely caused by positive operational highlights and financial results reported by Intellia. 2. The predicted upward move of +0.73% could boost investor confidence, attracting more investments in the gene editing sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,288,NTLA,2024-02-22 12:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass., Feb.  22, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023.",UP,0.007251756149444971,en
15497,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,"Pacira to Report 2023 Financial Results on Thursday February 29, 2024",https://www.globenewswire.com/news-release/2024/02/22/2833636/0/en/Pacira-to-Report-2023-Financial-Results-on-Thursday-February-29-2024.html,2024-02-22 08:00:00+00:00,Pacira BioSciences,earnings_releases_and_operating_results,"The predicted upward move of +0.28% is likely due to investor anticipation ahead of Pacira BioSciences' financial results announcement. This signals market confidence, potentially increasing investor interest and trading volume in NASDAQ:PCRX on earnings news.",globenewswire_biotech,biotech,Calendar of Events,299,PCRX,2024-02-22 13:00:00+00:00,US/Eastern,"TAMPA, Fla., Feb.  22, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.",UP,0.002843607847658226,en
15098,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®,https://www.globenewswire.com/news-release/2024/02/22/2833655/0/en/Mainz-Biomed-Announces-Distribution-Partnership-with-Praxisdienst-for-ColoAlert.html,2024-02-22 08:01:00+00:00,Mainz Biomed,partnerships,"The predicted upward move of +2.33% is likely due to increased distribution reach for ColoAlert® through the partnership with Praxisdienst, potentially boosting sales. This expansion could strengthen Mainz Biomed's market position and attract investor interest.",globenewswire_biotech,biotech,Partnerships,279,MYNZ,2024-02-22 13:01:00+00:00,US/Eastern,Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®,UP,0.023309857488808188,en
14499,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium,https://www.globenewswire.com/news-release/2024/02/22/2833675/0/en/Kineta-to-Present-New-Preclinical-Data-on-its-Anti-VISTA-Antibody-KVA12123-in-Acute-Myeloid-Leukemia-at-the-AACR-Blood-Cancer-Discovery-Symposium.html,2024-02-22 08:30:00+00:00,Kineta,clinical_study,"The likely cause of the predicted upward move of +8.20% is the announcement of new preclinical data on Kineta's anti-VISTA antibody in AML. This could generate investor optimism and increase visibility at the AACR symposium, potentially boosting investment interest.",globenewswire_biotech,biotech,Product / Services Announcement,248,KA,2024-02-22 13:30:00+00:00,US/Eastern,"SEATTLE, Feb.  22, 2024  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.",UP,0.08204693364177705,en
16323,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,"Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024",https://www.globenewswire.com/news-release/2024/02/22/2833711/0/en/Iovance-Biotherapeutics-to-Host-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Conference-Call-and-Webcast-on-Wednesday-February-28-2024.html,2024-02-22 08:45:00+00:00,Iovance Biotherapeutics,earnings_releases_and_operating_results,"The predicted upward move of +0.27% is likely due to investor anticipation of positive financial results and updates during the conference call. This could boost investor confidence and lead to increased stock buying, potentially enhancing market valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,342,IOVA,2024-02-22 13:45:00+00:00,US/Eastern,"SAN CARLOS, Calif., Feb.  22, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.",UP,0.002696840965318105,en
14835,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,"ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024",https://www.globenewswire.com/news-release/2024/02/22/2833758/0/en/ARS-Pharmaceuticals-to-Host-Virtual-neffy-Investor-Day-on-March-7-2024.html,2024-02-22 09:01:00+00:00,ARS Pharmaceuticals,conference_call_webinar,The predicted upward move of +1.86% for ARS Pharmaceuticals likely stems from investor optimism about the virtual event showcasing the neffy® nasal spray. Positive market implications could include increased investor interest and enhanced company valuation if product potential is favorably viewed.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,265,SPRY,2024-02-22 14:01:00+00:00,US/Eastern,"SAN DIEGO, Feb.  22, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that it will host a virtual investor day highlighting neffy® (epinephrine nasal spray) on Thursday, March 7, 2024, at 1:00 p.m. ET. To participate in the event, please register here.",UP,0.01856409513618744,en
16552,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics to Present at the 2024 BIO CEO & Investor Conference,https://www.globenewswire.com/news-release/2024/02/22/2834124/0/en/Bionomics-to-Present-at-the-2024-BIO-CEO-Investor-Conference.html,2024-02-22 16:30:00+00:00,Bionomics,conference_call_webinar,"The predicted upward move of +0.49% for Bionomics' asset is likely due to their upcoming presentation at the BIO CEO & Investor Conference, signaling positive developments. This could increase investor interest and confidence in their CNS disorder treatments.",globenewswire_biotech,biotech,Calendar of Events,354,BNOX,2024-02-22 21:30:00+00:00,US/Eastern,"ADELAIDE, Australia and CAMBRIDGE, Mass., Feb.  22, 2024  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.",UP,0.004867905448462891,en
14549,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic מקדמת שיתוף פעולה עם המכון הביולוגי הישראלי (IIBR) להתמקדות באיומים ביולוגיים ופתרונות למחלות מתפתחות,https://www.globenewswire.com/news-release/2024/02/23/2834238/0/he/Dyadic-%D7%9E%D7%A7%D7%93%D7%9E%D7%AA-%D7%A9%D7%99%D7%AA%D7%95%D7%A3-%D7%A4%D7%A2%D7%95%D7%9C%D7%94-%D7%A2%D7%9D-%D7%94%D7%9E%D7%9B%D7%95%D7%9F-%D7%94%D7%91%D7%99%D7%95%D7%9C%D7%95%D7%92%D7%99-%D7%94%D7%99%D7%A9%D7%A8%D7%90%D7%9C%D7%99-IIBR-%D7%9C%D7%94%D7%AA%D7%9E%D7%A7%D7%93%D7%95%D7%AA-%D7%91%D7%90%D7%99%D7%95%D7%9E%D7%99%D7%9D-%D7%91%D7%99%D7%95%D7%9C%D7%95%D7%92%D7%99%D7%99%D7%9D-%D7%95%D7%A4%D7%AA%D7%A8%D7%95%D7%A0%D7%95%D7%AA-%D7%9C%D7%9E%D7%97%D7%9C%D7%95%D7%AA-%D7%9E%D7%AA%D7%A4%D7%AA%D7%97%D7%95%D7%AA.html,2024-02-23 02:00:00+00:00,Dyadic International,partnerships,"The predicted upward move of +0.70% for Dyadic International is likely due to its new collaboration with the Israeli Institute for Biological Research, focusing on advanced disease solutions. This could enhance market confidence and lead to increased interest in biotechnological innovations.",globenewswire_biotech,biotech,Partnerships,250,DYAI,2024-02-23 07:00:00+00:00,US/Eastern,"יופיטר, פלורידה ונס-ציונה, ישראל, Feb.  23, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc (""דיאדיק"" או ""החברה"") (נאסד""ק: DYAI), חברת ביוטכנולוגיה גלובלית המתמחה בפלטפורמות מיקרוביאליות מתקדמות לפיתוח חלבונים וייצור ביולוגי ומתן מענה לצרכים קליניים, והמכון למחקר ביולוגי (IIBR) הודיעו כי קידמו את שיתוף הפעולה עם המכון למחקר ביולוגי (IIBR) והזרוע המסחרית שלו Life Science Research Israel (LSRI), כדי להתמקד בפתרונות מתפתחים למחלות. שותפות זו נועדה למנף את המומחיות של Dyadic בפלטפורמות מיקרוביאליות לייצור ביולוגי של חלבונים בקנה מידה גמיש ואת יכולות גילוי הנוגדנים והאנטיגנים של המכון כדי לפתח ולייצר פתרונות חדשניים לטיפול במחלות מתפתחות ובאיומים ביולוגיים פוטנציאליים. באמצעות שיתוף פעולה זה, שני הצדדים פועלים לפיתוח טיפולים וחיסונים יעילים למאבק באתגרי הבריאות העולמיים מתוך כוונה למסחור עתידי (נכון להיום, המסגרת אינה מחייבת וכפופה לביצוע הסכם מחייב שיידון על ידי הצדדים) באמצעות יוזמות שיתוף פעולה של רישוי חוץ.",UP,0.006951794797894057,he
14548,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions,https://www.globenewswire.com/news-release/2024/02/23/2834238/0/en/Dyadic-Advances-Collaboration-with-Israel-Institute-for-Biological-Research-IIBR-Targeting-Bio-Threats-and-Emerging-Disease-Solutions.html,2024-02-23 02:00:00+00:00,Dyadic International,partnerships,"1. The predicted upward move of +0.17% is likely due to Dyadic's partnership with IIBR, enhancing its potential in addressing emerging diseases and bio-threats. 2. This collaboration may increase investor confidence, potentially boosting stock interest and market value.",globenewswire_biotech,biotech,Partnerships,250,DYAI,2024-02-23 07:00:00+00:00,US/Eastern,"JUPITER, Fla. and NES-ZIONA, Israel, Feb.  23, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"" or the ""Company"") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.",UP,0.001674731786800291,en
15399,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update,https://www.globenewswire.com/news-release/2024/02/23/2834408/8790/en/TG-Therapeutics-to-Host-Conference-Call-on-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Business-Update.html,2024-02-23 07:30:00+00:00,TG Therapeutics,conference_call_webinar,"The predicted upward move of +0.47% is likely due to positive expectations from the conference call. This could enhance investor confidence, potentially leading to increased buying activity and a short-term rise in the asset's market value.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,294,TGTX,2024-02-23 12:30:00+00:00,US/Eastern,"Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET",DOWN,0.004738993250741439,en
14567,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,"Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting",https://www.globenewswire.com/news-release/2024/02/23/2834438/0/en/Jasper-Therapeutics-Presents-Data-from-Preclinical-Briquilimab-Studies-at-the-American-Academy-of-Allergy-Asthma-and-Immunology-AAAAI-Annual-Meeting.html,2024-02-23 08:00:00+00:00,Jasper Therapeutics,clinical_study,The predicted upward move of +9.65% for Jasper Therapeutics is likely due to positive sentiment around its presentation of preclinical results for briquilimab at the AAAAI Annual Meeting. This could enhance investor confidence and increase interest in the biotechnology sector.,globenewswire_biotech,biotech,Clinical Study,251,JSPR,2024-02-23 13:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.",UP,0.09650815036427059,en
14874,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma to Present in the BIO CEO & Investor Conference,https://www.globenewswire.com/news-release/2024/02/23/2834435/0/en/Ocuphire-Pharma-to-Present-in-the-BIO-CEO-Investor-Conference.html,2024-02-23 08:00:00+00:00,Ocuphire Pharma,conference_call_webinar,"The predicted upward move of +0.06% is likely due to investor optimism from Ocuphire's participation in the BIO CEO & Investor Conference. This engagement could enhance visibility and attract interest, potentially leading to increased investment in the company.",globenewswire_biotech,biotech,Calendar of Events,268,OCUP,2024-02-23 13:00:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.",UP,0.0006214329946284964,en
16645,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity Announces 1-for-10 Reverse Stock Split,https://www.globenewswire.com/news-release/2024/02/23/2834655/0/en/Celularity-Announces-1-for-10-Reverse-Stock-Split.html,2024-02-23 16:10:00+00:00,Celularity,corporate_action,"The predicted downward move of -4.05% likely stems from investor concern about the 1-for-10 reverse stock split, which can signal financial instability. Market implications include potential reduced liquidity and cautious investor sentiment.",globenewswire_biotech,biotech,Changes in company's own shares,359,CELU,2024-02-23 21:10:00+00:00,US/Eastern,"FLORHAM PARK, N.J., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.",UP,-0.04053694191072232,en
15076,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,Coherus BioSciences Announces New Employment Inducement Grants,https://www.globenewswire.com/news-release/2024/02/23/2834681/33333/en/Coherus-BioSciences-Announces-New-Employment-Inducement-Grants.html,2024-02-23 17:33:00+00:00,Coherus BioSciences,changes_in_companys_own_shares,"The predicted upward move of +0.41% is likely due to investor confidence from Coherus BioSciences' executive appointments and stock option grants, signaling potential growth. Market implications include increased interest and potential valuation gains for Coherus.",globenewswire_biotech,biotech,Changes in company's own shares,278,CHRS,2024-02-23 22:33:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Feb.  23, 2024  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.",UP,0.00411416785467805,en
15398,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy),https://www.globenewswire.com/news-release/2024/02/26/2835010/8790/en/TG-Therapeutics-Announces-European-Launch-of-BRIUMVI-ublituximab-xiiy.html,2024-02-26 07:00:00+00:00,TG Therapeutics,geographic_expansion,"The predicted downward move of -0.42% likely stems from market saturation concerns in Germany following Neuraxpharm's launch of BRIUMVI. This may affect competition dynamics, potentially pressuring local pharmaceutical stocks and impacting future strategic deployments.",globenewswire_biotech,biotech,Product / Services Announcement,294,TGTX,2024-02-26 12:00:00+00:00,US/Eastern,"Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country",UP,-0.004173475801754166,en
15729,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS),https://www.globenewswire.com/news-release/2024/02/26/2835058/0/en/MoonLake-Immunotherapeutics-Announces-Positive-Feedback-from-both-FDA-and-EMA-on-Regulatory-Path-for-the-Phase-3-Program-of-the-Nanobody-sonelokimab-SLK-in-Hidradenitis-Suppurativa.html,2024-02-26 08:00:00+00:00,MoonLake Immunotherapeutics,clinical_study,"Positive regulatory feedback from FDA and EMA on MoonLake's Nanobody® sonelokimab creates investor optimism, driving a predicted upward move of +4.27%. This could enhance market confidence in the drug's potential success in treating Hidradenitis Suppurativa.",globenewswire_biotech,biotech,Press releases,312,MLTX,2024-02-26 13:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS),UP,0.04272850980315509,en
14834,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study,https://www.globenewswire.com/news-release/2024/02/26/2835180/0/en/ARS-Pharmaceuticals-announces-neffy-meets-primary-endpoints-and-shows-rapid-symptom-control-in-Phase-2-urticaria-clinical-study.html,2024-02-26 09:01:00+00:00,ARS Pharmaceuticals,clinical_study,"1. The predicted upward move of +1.50% is likely due to the positive phase 2 trial results of ARS Pharmaceuticals' drug, neffy, which showed significant improvements in treating chronic spontaneous urticaria. 2. This success could increase investor confidence and future market value for ARS Pharmaceuticals, enhancing interest in its stock.",globenewswire_biotech,biotech,Clinical Study,265,SPRY,2024-02-26 14:01:00+00:00,US/Eastern,"SAN DIEGO, Feb.  26, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray), an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.",UP,0.01496691213485921,en
15771,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,"Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110",https://www.globenewswire.com/news-release/2024/02/26/2835487/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-Second-and-Final-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-1-187-110.html,2024-02-26 16:05:00+00:00,Revive Therapeutics,financing_agreements,The predicted upward move of +0.18% likely stems from favorable economic indicators or positive corporate news. This modest increase suggests cautious optimism among investors. Market implications could include slight boosts in sector confidence and increased trading volumes.,globenewswire_biotech,biotech,Financing Agreements,314,RVVTF,2024-02-26 21:05:00+00:00,US/Eastern,NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN,UP,0.0018191351709918163,en
14566,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference,https://www.globenewswire.com/news-release/2024/02/26/2835529/0/en/Jasper-Therapeutics-to-Present-at-the-43rd-Annual-TD-Cowen-Healthcare-Conference.html,2024-02-26 16:30:00+00:00,Jasper Therapeutics,conference_call_webinar,"The predicted downward move of -0.20% may stem from investor anticipation of potential challenges Jasper Therapeutics might face in clinical trials or market adoption. This could lead to cautious trading, impacting short-term stock value and investor sentiment.",globenewswire_biotech,biotech,Calendar of Events,251,JSPR,2024-02-26 21:30:00+00:00,US/Eastern,"REDWOOD CITY, Calif., Feb.  26, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.",UP,-0.0019616698046744925,en
14727,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/02/27/2835888/0/en/Tourmaline-Bio-to-Present-at-Upcoming-Investor-Conferences.html,2024-02-27 07:30:00+00:00,Talaris Therapeutics,conference_call_webinar,"The predicted upward move of +0.14% for Tourmaline Bio may result from increased investor interest as the CEO participates in upcoming conferences, potentially boosting visibility. This can enhance market sentiment and attract potential investment, positively impacting stock performance.",globenewswire_biotech,biotech,Calendar of Events,260,TALS,2024-02-27 12:30:00+00:00,US/Eastern,"NEW YORK, Feb.  27, 2024  (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in March.",DOWN,0.0013869549798464814,en
15397,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy),https://www.globenewswire.com/news-release/2024/02/27/2835897/8790/en/TG-Therapeutics-Announces-Issuance-of-Additional-Patents-for-BRIUMVI-ublituximab-xiiy.html,2024-02-27 07:30:00+00:00,TG Therapeutics,patents,"The predicted upward move of +2.20% for ublituximab is likely due to patent extensions securing market exclusivity until 2042. This could increase investor confidence, ensuring long-term revenue and competitive advantage for the asset's stakeholders.",globenewswire_biotech,biotech,Patents,294,TGTX,2024-02-27 12:30:00+00:00,US/Eastern,Newly issued patents extend exclusivity of ublituximab through 2042 Newly issued patents extend exclusivity of ublituximab through 2042,UP,0.02204533034461886,en
15447,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene to Present at the Leerink Partners Global Biopharma Conference 2024,https://www.globenewswire.com/news-release/2024/02/27/2835951/0/en/Adagene-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference-2024.html,2024-02-27 08:00:00+00:00,Adagene,conference_call_webinar,The predicted downward move of -0.21% for Adagene could be due to anticipated market reactions to their participation in the Leerink Partners Global Biopharma Conference. This might imply cautious investor sentiment or lack of significant news expected.,globenewswire_biotech,biotech,Calendar of Events,297,ADAG,2024-02-27 13:00:00+00:00,US/Eastern,"SAN DIEGO and SUZHOU, China, Feb.  27, 2024  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.",UP,-0.0021036690542755596,en
15428,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024,https://www.globenewswire.com/news-release/2024/02/27/2835978/0/en/Annovis-Bio-Announces-Participation-in-Forum-Discussion-at-AD-PD-2024.html,2024-02-27 08:00:00+00:00,Annovis Bio,conference_call_webinar,"Annovis Bio's predicted upward move of +0.11% is likely due to their panel participation at AD/PD 2024, which may increase visibility and investor interest in their neurodegenerative therapies. This could enhance market confidence and potentially attract new investments.",globenewswire_biotech,biotech,Health,296,ANVS,2024-02-27 13:00:00+00:00,US/Eastern,"MALVERN, Pa., Feb.  27, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. ",DOWN,0.001146903740894675,en
15097,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,"Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community",https://www.globenewswire.com/news-release/2024/02/27/2835993/0/en/Mainz-Biomed-to-Showcase-at-the-Gynecology-Conference-in-Stuttgart-Germany-Strengthening-Connections-within-the-Medical-Community.html,2024-02-27 08:01:00+00:00,Mainz Biomed,trade_show,"The predicted downward move of -0.24% for Mainz Biomed may stem from limited short-term benefits anticipated from the conference. Market implications could include cautious investor sentiment, potentially impacting share prices temporarily despite strengthening medical community ties.",globenewswire_biotech,biotech,Health,279,MYNZ,2024-02-27 13:01:00+00:00,US/Eastern,"Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community",UP,-0.002422524001050603,en
16435,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/02/27/2836415/0/en/Vaxcyte-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,2024-02-27 16:01:00+00:00,Vaxcyte,clinical_study,The predicted upward move of +8.38% likely results from completed enrollments in VAX-31's Phase 1/2 study and VAX-24's readiness for Phase 3. This progress suggests increased optimism and potential for enhanced market positioning and future revenues.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,348,PCVX,2024-02-27 21:01:00+00:00,US/Eastern,"-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults --",UP,0.08382349947007989,en
14988,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023",https://www.globenewswire.com/news-release/2024/02/27/2836441/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-and-Year-Ended-December-31-2023.html,2024-02-27 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"1. The predicted downward move of -0.65% is likely due to weaker-than-expected financial results. 2. This could signal to investors potential challenges in growth, affecting market confidence and possibly leading to reduced investment interest.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,274,ICCC,2024-02-27 21:05:00+00:00,US/Eastern,"PORTLAND, Maine, Feb.  27, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023.",UP,-0.0064849818716017586,en
15233,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference,https://www.globenewswire.com/news-release/2024/02/27/2836438/0/en/Kronos-Bio-Announces-Participation-in-44th-Annual-Cowen-Health-Care-Conference.html,2024-02-27 16:05:00+00:00,Kronos Bio,conference_call_webinar,The predicted downward move of -0.52% in Kronos Bio's asset might be due to skepticism over the upcoming conference's impact. Market implications could include reduced investor confidence or profit-taking ahead of the event.,globenewswire_biotech,biotech,Calendar of Events,286,KRON,2024-02-27 21:05:00+00:00,US/Eastern,"SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb.  27, 2024  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.",UP,-0.00516347011838521,en
16092,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing,https://www.globenewswire.com/news-release/2024/02/28/2836759/0/en/CENTOGENE-Announces-Receipt-of-Nasdaq-Notice-of-Delisting-and-Intention-to-Request-a-Hearing.html,2024-02-28 06:30:00+00:00,Centogene,exchange_announcement,"The predicted downward move of -0.68% likely stems from investor concern over potential future delisting. Market implications include increased volatility and investor caution, as uncertainty surrounding the company’s securities may lead to reduced trading volume and liquidity.",globenewswire_biotech,biotech,Management statements,330,CNTG,2024-02-28 11:30:00+00:00,US/Eastern,Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities,UP,-0.0068367935248318246,en
16093,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Explores Strategic Alternatives,https://www.globenewswire.com/news-release/2024/02/28/2836749/0/en/CENTOGENE-Explores-Strategic-Alternatives.html,2024-02-28 06:30:00+00:00,Centogene,joint_venture,"The predicted downward move of +nan% likely stems from Centogene's exploration of strategic alternatives, which may indicate financial instability or operational challenges. This can create uncertainty, potentially leading investors to sell and impacting market confidence.",globenewswire_biotech,biotech,Product / Services Announcement,330,CNTG,2024-02-28 11:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb.  28, 2024  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.",UP,-0.03899542878008967,en
15591,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,"InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th",https://www.globenewswire.com/news-release/2024/02/28/2836813/0/en/InspireMD-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Corporate-Business-Update-on-Wednesday-March-6th.html,2024-02-28 07:00:00+00:00,InspireMD,conference_call_webinar,"The predicted downward move of -0.03% may result from anticipated negative news or poor financial performance discussed in the call. This small decline suggests muted market reaction, with minimal implications for broader market sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,304,NSPR,2024-02-28 12:00:00+00:00,US/Eastern,-Conference call and webcast to be held at 8:30 a.m. EST-,DOWN,-0.00025817608440743595,en
15396,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/28/2836785/8790/en/TG-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results.html,2024-02-28 07:00:00+00:00,TG Therapeutics,financial_results,"The predicted upward move of +0.78% likely stems from strong fourth-quarter and full-year BRIUMVI U.S. net revenue. This could boost investor confidence and improve company valuation, potentially attracting more investments and enhancing market positioning.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,294,TGTX,2024-02-28 12:00:00+00:00,US/Eastern,"Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively",UP,0.007781659500488495,en
14690,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference,https://www.globenewswire.com/news-release/2024/02/28/2836793/0/en/PolyPid-to-Participate-in-Barclays-26th-Annual-Global-Healthcare-Conference.html,2024-02-28 07:00:00+00:00,PolyPid,conference_call_webinar,"The predicted upward move of +1.43% for PolyPid Ltd. is likely due to positive investor sentiment from their participation in the Barclays Global Healthcare Conference. This could enhance visibility and investor interest, potentially increasing market valuation and liquidity.",globenewswire_biotech,biotech,Calendar of Events,258,PYPD,2024-02-28 12:00:00+00:00,US/Eastern,"PETACH TIKVA, Israel, Feb.  28, 2024  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.",UP,0.014336939671583624,en
16376,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2024/02/28/2836806/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2023-Results-and-Business-Updates.html,2024-02-28 07:00:00+00:00,Editas Medicine,clinical_study,"1. The company aligning with the FDA on a streamlined RUBY trial suggests regulatory efficiency and potential expedited approval, fueling investor optimism. 2. This predicted upward move of +28.19% may increase investor interest and boost sector confidence.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,345,EDIT,2024-02-28 12:00:00+00:00,US/Eastern,Company aligned with FDA that RUBY is a single Phase 1/2/3 trial,UP,0.28188779276269676,en
14915,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore reports fourth quarter and full year 2023 financial results and provides a business update,https://www.globenewswire.com/news-release/2024/02/28/2836870/0/en/Immunocore-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-business-update.html,2024-02-28 07:34:00+00:00,Immunocore,financial_results,"1. The predicted upward move of +0.49% is likely due to positive financial results or business updates. 2. This could boost investor confidence, possibly leading to increased stock demand.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,270,IMCR,2024-02-28 12:34:00+00:00,US/Eastern,Immunocore reports fourth quarter and full year 2023 financial results and provides a business update,UP,0.004894946069717587,en
15994,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference,https://www.globenewswire.com/news-release/2024/02/28/2836903/0/en/Ovid-Therapeutics-to-Present-at-the-TD-Cowen-44th-Annual-Health-Care-Conference.html,2024-02-28 08:00:00+00:00,Ovid Therapeutics,conference_call_webinar,"The predicted downward move of -0.43% for Ovid Therapeutics may stem from investor anticipation of limited immediate impact from the conference participation. This suggests cautious market sentiment, possibly affecting short-term trading volumes and investor confidence.",globenewswire_biotech,biotech,Calendar of Events,325,OVID,2024-02-28 13:00:00+00:00,US/Eastern,"NEW YORK, Feb.  28, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.",DOWN,-0.0042555998227648,en
16499,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer,https://www.globenewswire.com/news-release/2024/02/28/2836900/0/en/Corbus-Pharmaceuticals-Appoints-Dr-Dominic-Smethurst-as-Chief-Medical-Officer.html,2024-02-28 08:00:00+00:00,Corbus Pharmaceuticals,management_changes,1. The predicted downward move of -0.49% likely reflects cautious investor response to leadership changes. 2. Market implications may include concerns about execution risk during the transition period under new CMO. 3. This can affect short-term stock performance.,globenewswire_biotech,biotech,Directors and Officers,351,CRBP,2024-02-28 13:00:00+00:00,US/Eastern,"NORWOOD, Mass., Feb.  28, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company’s investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.",DOWN,-0.004891328978650816,en
14547,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform,https://www.globenewswire.com/news-release/2024/02/28/2836955/0/en/Dyadic-Announces-Strategic-Partnership-Agreement-to-Develop-Affordable-Rabies-Prophylactics-and-Vaccines-Using-its-Proprietary-C1-Cell-Microbial-Protein-Production-Platform.html,2024-02-28 08:30:00+00:00,Dyadic International,partnerships,"The predicted upward move of +3.50% is likely due to Dyadic's strategic partnership with Rabian to develop cost-effective rabies vaccines using its C1 platform. This could enhance Dyadic's market position and revenue potential, boosting investor confidence.",globenewswire_biotech,biotech,Partnerships,250,DYAI,2024-02-28 13:30:00+00:00,US/Eastern,"JUPITER, Fla. and BUNNIK, the Netherlands, Feb.  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV (“Rabian”), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform. This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.",DOWN,0.03500430628568579,en
16322,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates,https://www.globenewswire.com/news-release/2024/02/28/2837400/0/en/Iovance-Biotherapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Updates.html,2024-02-28 16:01:00+00:00,Iovance Biotherapeutics,product_services_announcement,"The predicted downward move of -0.18% for Amtagvi™ may result from initial market skepticism following its launch. Potential market implications include slower initial adoption or pricing concerns, affecting short-term investor confidence in biotech stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,342,IOVA,2024-02-28 21:01:00+00:00,US/Eastern,"Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer",UP,-0.00177270389167028,en
15116,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,scPharmaceuticals to Participate in Two Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/02/28/2837392/0/en/scPharmaceuticals-to-Participate-in-Two-Upcoming-Investor-Conferences.html,2024-02-28 16:01:00+00:00,scPharmaceuticals,press_releases,The predicted downward move of -0.03% could be due to market uncertainty regarding scPharmaceuticals' strategic direction after John Tucker's participation in investor conferences. This minor decline suggests limited immediate impact on investor sentiment or market confidence.,globenewswire_biotech,biotech,Calendar of Events,280,SCPH,2024-02-28 21:01:00+00:00,US/Eastern,"BURLINGTON, Mass., Feb.  28, 2024  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.",UP,-0.00025466786343806967,en
16056,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/02/29/2837838/0/en/Akero-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,2024-02-29 07:00:00+00:00,Akero Therapeutics,clinical_study,"The predicted upward move of +8.31% is likely due to positive financial results reported by Akero Therapeutics. This can boost investor confidence, potentially increasing stock purchasing and valuation, affecting the broader biotech sector with heightened interest.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,328,AKRO,2024-02-29 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., Feb.  29, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2023.",UP,0.08307932991709162,en
16019,TSHA,https://www.google.com/finance/quote/TSHA:NASDAQ,Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome,https://www.globenewswire.com/news-release/2024/02/29/2837908/0/en/Taysha-Gene-Therapies-Announces-Updates-to-TSHA-102-Clinical-Program-in-Rett-Syndrome.html,2024-02-29 08:00:00+00:00,Taysha Gene Therapies,clinical_study,"The predicted upward move of +3.61% likely stems from positive sentiment on dose escalation approval, indicating trial progress. This could boost investor confidence and attract attention, potentially increasing the asset's perceived future value and market interest.",globenewswire_biotech,biotech,Clinical Study,326,TSHA,2024-02-29 13:00:00+00:00,US/Eastern,"REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in Q2 2024",UP,0.0361428261365987,en
15496,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/29/2837899/0/en/Pacira-BioSciences-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-02-29 08:00:00+00:00,Pacira BioSciences,earnings_releases_and_operating_results,"Despite record revenues of $675 million in 2023, the predicted downward move of -0.13% might result from higher costs or market saturation. This could lead investors to reassess growth prospects and prompt cautious trading behavior.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,299,PCRX,2024-02-29 13:00:00+00:00,US/Eastern,— Record revenues of $675 million in 2023 —,DOWN,-0.0012598307073312023,en
15728,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,"MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10",https://www.globenewswire.com/news-release/2024/02/29/2837932/0/en/MoonLake-Immunotherapeutics-Reports-Full-Year-2023-Financial-Results-Recent-Business-Highlights-and-Announces-an-R-D-Day-on-March-10.html,2024-02-29 08:00:00+00:00,MoonLake Immunotherapeutics,financial_results,"MoonLake Immunotherapeutics' predicted upward move of +0.74% is likely due to positive financial results and anticipation of new developments. This can attract investors, signaling potential growth and increased market confidence in the company's future initiatives.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2024-02-29 13:00:00+00:00,US/Eastern,"MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10",UP,0.007366338117463774,en
16055,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH,https://www.globenewswire.com/news-release/2024/02/29/2837913/0/en/Akero-Therapeutics-to-Present-Topline-Week-96-Results-from-Phase-2b-HARMONY-Study-Investigating-Efruxifermin-in-Patients-with-Pre-Cirrhotic-MASH.html,2024-02-29 08:00:00+00:00,Akero Therapeutics,clinical_study,"The predicted upward move of +2.84% is likely due to positive clinical data being presented, which can enhance investor confidence. This may increase investor interest and trading volume, potentially raising the asset's market value.",globenewswire_biotech,biotech,Clinical Study,328,AKRO,2024-02-29 13:00:00+00:00,US/Eastern,"Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data",UP,0.028388072198533912,en
14498,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Announces Restructuring and Exploration of Strategic Alternatives,https://www.globenewswire.com/news-release/2024/02/29/2837995/0/en/Kineta-Announces-Restructuring-and-Exploration-of-Strategic-Alternatives.html,2024-02-29 08:30:00+00:00,Kineta,corporate_action,"1. The predicted upward move of +0.29% is likely due to Kineta's restructuring efforts to cut costs and preserve cash, signaling financial prudence. 2. This restructuring could strengthen the company's financial stability, boosting investor confidence slightly.",globenewswire_biotech,biotech,Financing Agreements,248,KA,2024-02-29 13:30:00+00:00,US/Eastern,"SEATTLE, Feb.  29, 2024  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed a review of its business, including the status of its programs, resources and capabilities. Following this review, Kineta is implementing a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring includes a significant workforce reduction and the termination of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Patients currently enrolled in the trial will be permitted to continue to participate. The company has made this decision, in part, because certain investors have indicated they will not fulfill their funding obligations pursuant the previously disclosed second tranche of the company’s contemplated private placement later this year.",DOWN,0.0028725303786646455,en
15791,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests,https://www.globenewswire.com/news-release/2024/02/29/2838003/34378/en/Yield10-Bioscience-Reports-that-Proprietary-Varieties-of-Winter-Camelina-Show-Tolerance-to-Commonly-Used-Herbicides-in-First-Field-Tests.html,2024-02-29 08:31:00+00:00,Yield10 Bioscience,product_services_announcement,"The predicted downward move of -0.49% likely stems from concerns about herbicide tolerance challenges. This could affect Camelina production at scale, potentially limiting biofuel and omega-3 oil supply, impacting market growth expectations negatively.",globenewswire_biotech,biotech,Product / Services Announcement,315,YTEN,2024-02-29 13:31:00+00:00,US/Eastern,-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets -Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets,DOWN,-0.004918742615986554,en
14577,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference  and 2024 AAD Annual Meeting,https://www.globenewswire.com/news-release/2024/02/29/2838079/0/en/Anaptys-to-Present-at-TD-Cowen-s-44th-Annual-Health-Care-Conference-and-2024-AAD-Annual-Meeting.html,2024-02-29 09:15:00+00:00,AnaptysBio,conference_call_webinar,1. The predicted downward move of -0.04% could be due to lack of significant new developments from AnaptysBio's conference participation. 2. This minor change suggests limited immediate impact on investor sentiment and market dynamics.,globenewswire_biotech,biotech,Calendar of Events,252,ANAB,2024-02-29 14:15:00+00:00,US/Eastern,"SAN DIEGO, Feb.  29, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.",UP,-0.0004195638001660984,en
15012,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/29/2838399/0/en/Oncternal-Therapeutics-to-Provide-Business-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-02-29 16:05:00+00:00,Oncternal Therapeutics,earnings_releases_and_operating_results,"The predicted upward move of +0.05% likely stems from investor anticipation of Oncternal's upcoming financial results and business update. This slight optimism suggests stable expectations, with minimal immediate market impact anticipated post-announcement.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,275,ONCT,2024-02-29 21:05:00+00:00,US/Eastern,"SAN DIEGO, Feb.  29, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results.",UP,0.0005371969930878264,en
15979,CAPR,https://www.google.com/finance/quote/CAPR:NASDAQ,Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/02/29/2838398/0/en/Capricor-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-02-29 16:05:00+00:00,Capricor Therapeutics,clinical_study,"The predicted upward move of +8.32% is likely due to the successful interim futility analysis and enrollment completion in the Phase 3 HOPE-3 trial for CAP-1002. This may boost investor confidence, potentially increasing stock value and interest in Duchenne Muscular Dystrophy treatments.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,324,CAPR,2024-02-29 21:05:00+00:00,US/Eastern,"-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024-",UP,0.08315650397875998,en
15654,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,Certara Reports Fourth Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/29/2838415/0/en/Certara-Reports-Fourth-Quarter-2023-Financial-Results.html,2024-02-29 16:10:00+00:00,Certara,financial_results,"The predicted upward move of +0.71% likely results from positive investor sentiment due to optimistic full-year 2024 financial guidance. This may enhance market confidence, potentially attracting more investments and leading to further asset appreciation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,308,CERT,2024-02-29 21:10:00+00:00,US/Eastern,Provides Full Year 2024 Financial Guidance Provides Full Year 2024 Financial Guidance,UP,0.00712181198100722,en
16091,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency,https://www.globenewswire.com/news-release/2024/02/29/2838463/0/en/CENTOGENE-Collaborates-on-Research-Published-in-Science-Showing-Immunopathological-Landscape-of-Human-Pre-TCR%CE%B1-Deficiency.html,2024-02-29 17:00:00+00:00,Centogene,research_analysis_and_reports,"1. The predicted downward move of +nan% could be due to investor concern over unexpected findings in rare disease incidence impacting biotech valuations. 2. This could lead to decreased investments and volatility, especially in biotech stocks focused on related research or therapies.",globenewswire_biotech,biotech,Health,330,CNTG,2024-02-29 22:00:00+00:00,US/Eastern,"Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected",DOWN,-6.5432079198838835,en
14914,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2024/03/01/2838739/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,2024-03-01 07:00:00+00:00,Immunocore,conference_call_webinar,The predicted downward move of -0.01% for Immunocore could be due to market anticipation of neutral or underwhelming presentations at investor conferences. This minor decline suggests limited immediate impact on investor sentiment and overall market position.,globenewswire_biotech,biotech,Other News,270,IMCR,2024-03-01 12:00:00+00:00,US/Eastern,Immunocore to present at upcoming investor conferences ,UP,-0.00012664986722225313,en
16037,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,"BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024",https://www.globenewswire.com/news-release/2024/03/01/2838717/0/en/BioXcel-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-12-2024.html,2024-03-01 07:00:00+00:00,BioXcel Therapeutics,earnings_releases_and_operating_results,"The predicted upward move of +0.47% likely stems from investor anticipation of positive 2023 financial results. This could enhance investor confidence and market valuation, potentially boosting stock demand and influencing broader sector sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,327,BTAI,2024-03-01 12:00:00+00:00,US/Eastern,"NEW HAVEN, Conn., March  01, 2024  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s financial results and provide a general business update.",UP,0.004697156080125505,en
15395,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum,https://www.globenewswire.com/news-release/2024/03/01/2838758/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-in-Multiple-Sclerosis-at-the-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Forum.html,2024-03-01 07:30:00+00:00,TG Therapeutics,clinical_study,"The likely cause of the predicted upward move of +1.38% is the positive presentation of clinical trial data for BRIUMVI. This could enhance investor confidence in TG Therapeutics, potentially increasing its market valuation and interest in its stock.",globenewswire_biotech,biotech,Clinical Study,294,TGTX,2024-03-01 12:30:00+00:00,US/Eastern,"NEW YORK, March  01, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below.",UP,0.013792612751560341,en
15355,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2024/03/01/2838793/0/en/Immuneering-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Updates.html,2024-03-01 08:00:00+00:00,Immuneering,clinical_study,"The predicted upward move of +17.02% is likely due to positive expectations for the Phase 1 trial data of IMM-1-104, suggesting potential efficacy and safety. If proven successful, this could enhance investor confidence and spur interest in the asset.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,292,IMRX,2024-03-01 13:00:00+00:00,US/Eastern,- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -,DOWN,0.17018116910326114,en
14546,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic to Attend Industry Events in March,https://www.globenewswire.com/news-release/2024/03/01/2838801/0/en/Dyadic-to-Attend-Industry-Events-in-March.html,2024-03-01 08:30:00+00:00,Dyadic International,trade_show,"1. The predicted downward move of -0.56% may result from investor uncertainty about Dyadic's future performance or industry challenges. 2. This could signal reduced investor confidence, potentially dampening short-term trading activity or influencing peer sentiment.",globenewswire_biotech,biotech,Calendar of Events,250,DYAI,2024-03-01 13:30:00+00:00,US/Eastern,"JUPITER, Fla. , March  01, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following industry events during the month of March 2024.",UP,-0.00555354949106882,en
16723,XFOR,https://www.google.com/finance/quote/XFOR:NASDAQ,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/03/01/2839064/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-03-01 16:05:00+00:00,X4 Pharmaceuticals,shares_issue,"The predicted upward move of +0.31% is likely due to the strategic issuance of inducement awards, signaling company growth and attracting new talent. This could improve investor confidence, potentially leading to a positive market reaction for X4 Pharmaceuticals.",globenewswire_biotech,biotech,Stock Market News,362,XFOR,2024-03-01 21:05:00+00:00,US/Eastern,"BOSTON, March  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on February 29, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,524,112 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",DOWN,0.0030808032542239063,en
16259,GTHX,https://www.google.com/finance/quote/GTHX:NASDAQ,G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/03/01/2839075/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-03-01 16:20:00+00:00,G1 Therapeutics,corporate_action,"The predicted upward move of +0.37% likely stems from positive investor sentiment following the inducement grants announcement, signaling confidence in company leadership. This could attract more investors, potentially leading to increased market interest and activity.",globenewswire_biotech,biotech,Stock Market News,338,GTHX,2024-03-01 21:20:00+00:00,US/Eastern,G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),UP,0.0037159476787624753,en
14777,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/03/01/2839078/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,2024-03-01 16:30:00+00:00,ORIC Pharmaceuticals,corporate_action,"The predicted upward move of +0.23% likely stems from ORIC Pharmaceuticals' announcement of granting stock options and restricted stock units, suggesting investor optimism about new talent acquisition. This could signal positive growth prospects and enhance shareholder confidence.",globenewswire_biotech,biotech,Stock Market News,262,ORIC,2024-03-01 21:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  01, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 1, 2024 (the “Grant Date”), ORIC granted a total of 3,600 non-qualified stock options and 600 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2024.",UP,0.002310372947825854,en
16321,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,Iovance Biotherapeutics to Present at Upcoming Conferences,https://www.globenewswire.com/news-release/2024/03/01/2839091/0/en/Iovance-Biotherapeutics-to-Present-at-Upcoming-Conferences.html,2024-03-01 17:00:00+00:00,Iovance Biotherapeutics,conference_call_webinar,"The predicted upward move of +0.13% for Iovance Biotherapeutics is likely due to increased investor interest ahead of upcoming conference presentations by senior leadership. This may signal potential positive developments in their TIL therapy pipeline, boosting market sentiment.",globenewswire_biotech,biotech,Health,342,IOVA,2024-03-01 22:00:00+00:00,US/Eastern,"SAN CARLOS, Calif., March  01, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:",DOWN,0.0013472097518205316,en
16018,TSHA,https://www.google.com/finance/quote/TSHA:NASDAQ,Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/03/01/2839099/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-03-01 17:08:00+00:00,Taysha Gene Therapies,corporate_action,"The predicted upward move of +0.28% is likely due to investor optimism around Taysha's new employee stock option grants, indicating confidence in future talent and growth. This move may signal positive expectations for the company's strategic initiatives and innovation.",globenewswire_biotech,biotech,Changes in company's own shares,326,TSHA,2024-03-01 22:08:00+00:00,US/Eastern,"DALLAS, March  01, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on March 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 347,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",DOWN,0.002763863686752333,en
15075,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,Coherus Completes Divestiture of Ophthalmology Franchise,https://www.globenewswire.com/news-release/2024/03/04/2839218/33333/en/Coherus-Completes-Divestiture-of-Ophthalmology-Franchise.html,2024-03-04 01:00:00+00:00,Coherus BioSciences,divestiture,1. The predicted downward move of +nan% likely stems from investor skepticism despite the cash infusion. 2. Market implications may include reduced investor confidence and potential volatility as stakeholders reassess financial health despite strengthened capital structure.,globenewswire_biotech,biotech,Other News,278,CHRS,2024-03-04 06:00:00+00:00,US/Eastern,– Upfront cash payment of $170 million strengthens capital structure –,UP,-3.6502971894473486,en
16054,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study,https://www.globenewswire.com/news-release/2024/03/04/2839329/0/en/Akero-Therapeutics-Reports-Statistically-Significant-Histological-Improvements-at-Week-96-in-Phase-2b-HARMONY-Study.html,2024-03-04 06:00:00+00:00,Akero Therapeutics,clinical_study,"The predicted upward move of +6.55% is likely due to impressive clinical trial results showing significant fibrosis improvement with EFX treatment. This may increase investor confidence and attract heightened interest, potentially boosting the asset's market value.",globenewswire_biotech,biotech,Clinical Study,328,AKRO,2024-03-04 11:00:00+00:00,US/Eastern,"      50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%)",DOWN,0.06552808196199526,en
16320,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer,https://www.globenewswire.com/news-release/2024/03/04/2839362/0/en/Iovance-Biotherapeutics-Announces-FDA-has-Lifted-Clinical-Hold-on-the-IOV-LUN-202-Registrational-Trial-in-Non-Small-Cell-Lung-Cancer.html,2024-03-04 06:30:00+00:00,Iovance Biotherapeutics,clinical_study,"The predicted upward move of +1.42% is likely due to the FDA lifting the partial clinical hold on Iovance's trial, signaling regulatory confidence. Market implications include increased investor optimism and potential advancement in cancer therapy offerings.",globenewswire_biotech,biotech,Health,342,IOVA,2024-03-04 11:30:00+00:00,US/Eastern,"SAN CARLOS, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC).   In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring. Upon reviewing this proposal, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202.",UP,0.014158425790603526,en
15896,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,"C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins",https://www.globenewswire.com/news-release/2024/03/04/2839392/0/en/C4-Therapeutics-Announces-Strategic-Discovery-Research-Collaboration-with-Merck-KGaA-Darmstadt-Germany-Against-Critical-Oncogenic-Proteins.html,2024-03-04 07:00:00+00:00,C4 Therapeutics,licensing_agreements,The predicted upward move of +2.89% likely stems from optimism around the collaboration enhancing C4T's drug development pipeline. Potential market implications include increased investor confidence and potential valuation boosts for C4T.,globenewswire_biotech,biotech,Licensing Agreements,320,CCCC,2024-03-04 12:00:00+00:00,US/Eastern,Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline,UP,0.02885713185715052,en
15564,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,"PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy",https://www.globenewswire.com/news-release/2024/03/04/2839407/0/en/PepGen-Announces-Clearance-of-CTA-by-UK-Medicines-Healthcare-Products-Regulatory-Agency-to-Begin-CONNECT2-EDO51-a-Phase-2-Clinical-Trial-designed-to-support-potential-accelerated-a.html,2024-03-04 07:00:00+00:00,PepGen,clinical_study,"The likely cause of the predicted upward move of +3.04% is the authorization of PepGen's Phase 2 trial for its DMD treatment, signaling potential therapeutic advancements. This could boost investor confidence and enhance the company's market position.",globenewswire_biotech,biotech,Clinical Study,303,PEPG,2024-03-04 12:00:00+00:00,US/Eastern,"BOSTON, March  04, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has authorized its Clinical Trial Application (CTA) to initiate the CONNECT2-EDO51 Phase 2 clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51-skipping approach.",UP,0.03040884425271625,en
14565,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments,https://www.globenewswire.com/news-release/2024/03/04/2839472/0/en/Jasper-Therapeutics-Reports-Fiscal-2023-Financial-Results-and-Recent-Corporate-Developments.html,2024-03-04 07:30:00+00:00,Jasper Therapeutics,earnings_releases_and_operating_results,"The predicted downward move of -0.38% for Jasper Therapeutics may stem from investor concerns over recent financial results or corporate developments. This movement could signal caution among investors, potentially impacting short-term trading volume and stock price volatility.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,251,JSPR,2024-03-04 12:30:00+00:00,US/Eastern,"REDWOOD CITY, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter and year ended December 31, 2023, and reported recent corporate developments.",UP,-0.0037782310157321343,en
15354,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering to Participate in the Cowen 44th Annual Health Care Conference,https://www.globenewswire.com/news-release/2024/03/04/2839526/0/en/Immuneering-to-Participate-in-the-Cowen-44th-Annual-Health-Care-Conference.html,2024-03-04 08:00:00+00:00,Immuneering,conference_call_webinar,"The predicted downward move of -0.21% for Immuneering may result from investor anticipation of conference discussions not meeting expectations. Market implications may include caution towards biotech, affecting similar stocks if sentiment weakens after presentations.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,292,IMRX,2024-03-04 13:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., March  04, 2024  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, Chief Accounting Officer, Treasurer.",UP,-0.002148497932841085,en
15851,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference,https://www.globenewswire.com/news-release/2024/03/04/2839534/0/en/NKGen-Biotech-Announces-Upcoming-Presentation-on-SNK01-in-Alzheimer-s-Disease-at-the-Tau2024-Global-Conference.html,2024-03-04 08:00:00+00:00,NKGen Biotech,clinical_study,"The predicted upward move of +17.69% for NKGen Biotech is likely due to their innovative presentation on SNK01 NK cell therapy at a prominent conference. This may enhance investor interest, potentially increasing funding and collaboration opportunities in Alzheimer's therapeutic development.",globenewswire_biotech,biotech,Health,318,NKGN,2024-03-04 13:00:00+00:00,US/Eastern,"SANTA ANA, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics, today announced the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease. The data will be presented at the Tau2024 Global Conference, held March 25-26, 2024, virtually and at The Westin Washington, DC Downtown in Washington, D.C.",UP,0.17686120075103104,en
15727,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/03/04/2839499/0/en/MoonLake-Immunotherapeutics-to-present-MIRA-trial-data-of-Nanobody-sonelokimab-in-hidradenitis-suppurativa-as-a-late-breaker-at-the-AAD-Annual-Meeting-2024.html,2024-03-04 08:00:00+00:00,MoonLake Immunotherapeutics,clinical_study,"MoonLake's predicted upward move of +1.95% is likely due to positive expectations for the MIRA trial data presentation on sonelokimab. Successful results could boost investor confidence, impact future profitability, and enhance market position in treating hidradenitis suppurativa.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2024-03-04 13:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024,UP,0.019482845137686992,en
14481,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease,https://www.globenewswire.com/news-release/2024/03/04/2839612/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-4-1-Million-Grant-from-NINDS-to-Further-Development-of-AAV-ATP7A-Gene-Therapy-for-Menkes-Disease.html,2024-03-04 08:30:00+00:00,Fortress Biotech,clinical_study,"The predicted upward move of +0.76% is likely due to promising preclinical study results. Market implications could include increased investor interest and potential FDA approval anticipation, boosting confidence in treatment options for Menkes disease.",globenewswire_biotech,biotech,Financing Agreements,247,FBIO,2024-03-04 13:30:00+00:00,US/Eastern,"Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease",UP,0.007553042893646214,en
16536,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement,https://www.globenewswire.com/news-release/2024/03/04/2839586/0/en/Entera-Bio-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html,2024-03-04 08:30:00+00:00,Entera Bio,exchange_announcement,"The likely cause of Entera Bio's predicted upward move of +0.45% is regaining NASDAQ compliance, boosting investor confidence. This may improve market perception of the company's stability, potentially attracting more investment and enhancing stock liquidity.",globenewswire_biotech,biotech,Exchange News,353,ENTX,2024-03-04 13:30:00+00:00,US/Eastern,"JERUSALEM, March  04, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 1, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The NASDAQ Capital Market and the matter is now closed.",UP,0.00450768364772905,en
16434,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants,https://www.globenewswire.com/news-release/2024/03/04/2839584/0/en/Vaxcyte-Completes-Enrollment-of-Phase-2-Study-Evaluating-VAX-24-for-the-Prevention-of-Invasive-Pneumococcal-Disease-IPD-in-Infants.html,2024-03-04 08:30:00+00:00,Vaxcyte,clinical_study,"The predicted upward move of +3.46% likely stems from anticipated positive data on VAX-24's safety and effectiveness. If successful, this vaccine could lead to increased market share by covering more serotypes, thereby boosting investor confidence and company valuation.",globenewswire_biotech,biotech,Product / Services Announcement,348,PCVX,2024-03-04 13:30:00+00:00,US/Eastern,"-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 -- -- VAX-24, a 24-Valent Pneumococcal Conjugate Vaccine (PCV), is Designed to Cover More Serotypes Than Any Infant Pneumococcal Vaccine On-Market or in U.S. Clinics Today --",UP,0.034605866123039807,en
15669,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook,https://www.globenewswire.com/news-release/2024/03/04/2839962/0/en/Akoya-Reports-Record-Revenue-in-the-Fourth-Quarter-of-2023-and-Provides-Full-Year-2024-Financial-Outlook.html,2024-03-04 16:05:00+00:00,Akoya Biosciences,earnings_releases_and_operating_results,"The predicted downward move of -0.52% is likely due to conservative FY 2024 revenue guidance despite growth projections. This may imply investor concerns over future profit margins or market volatility, impacting confidence in the asset's short-term performance.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,309,AKYA,2024-03-04 21:05:00+00:00,US/Eastern,Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024,UP,-0.005198818173550604,en
16053,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Announces Proposed Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/03/04/2839994/0/en/Akero-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html,2024-03-04 16:21:00+00:00,Akero Therapeutics,shares_issue,"The predicted downward move of -0.25% is likely caused by potential dilution concerns due to Akero Therapeutics' $300 million stock offering. This might temporarily pressure the stock price, though raising capital may support future growth and development initiatives.",globenewswire_biotech,biotech,Changes in company's own shares,328,AKRO,2024-03-04 21:21:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., March  04, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",DOWN,-0.0025455088370532415,en
15297,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease,https://www.globenewswire.com/news-release/2024/03/05/2840273/0/en/Tiziana-Life-Sciences-Announces-Podium-Presentation-at-AD-PD-of-Nasal-Anti-CD3-in-Alzheimer-s-Disease.html,2024-03-05 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The predicted upward move of +11.01% is likely due to positive data from Tiziana Life Sciences' intranasal anti-CD3 therapy for Alzheimer's and Parkinson's. This could boost investor confidence, potentially leading to increased funding and partnerships in neurotherapeutics.",globenewswire_biotech,biotech,Calendar of Events,289,TLSA,2024-03-05 12:00:00+00:00,US/Eastern,"NEW YORK, March  05, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.",DOWN,0.11010426355865283,en
15096,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic,https://www.globenewswire.com/news-release/2024/03/05/2840418/0/en/Mainz-Biomed-Partners-with-Trusted-Health-Advisors-to-Support-U-S-Go-To-Market-Strategy-for-Next-Generation-Early-Colorectal-Cancer-Diagnostic.html,2024-03-05 08:01:00+00:00,Mainz Biomed,partnerships,"1. The partnership enhances Mainz Biomed's market strategy, boosting investor confidence. 2. This could increase competition and innovation in colorectal cancer diagnostics. Predicted upward move of +2.24% reflects anticipated positive impact on market presence.",globenewswire_biotech,biotech,Health,279,MYNZ,2024-03-05 13:01:00+00:00,US/Eastern,Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic,UP,0.022385413433655917,en
16231,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative,https://www.globenewswire.com/news-release/2024/03/05/2840587/0/en/Immix-Biopharma-Announces-Be-Proactive-in-AL-AL-Amyloidosis-Awareness-Initiative.html,2024-03-05 09:35:00+00:00,Immix Biopharma,press_releases,The likely cause of the predicted downward move of -0.58% is negative sentiment surrounding AL Amyloidosis treatment efficacy or market concerns. Potential market implications include decreased investor confidence and possible impact on related biotech firms.,globenewswire_biotech,biotech,Advisory,337,IMMX,2024-03-05 14:35:00+00:00,US/Eastern,"Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words",UP,-0.005836774288760872,en
15074,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,"Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024",https://www.globenewswire.com/news-release/2024/03/05/2840881/33333/en/Coherus-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-13-2024.html,2024-03-05 16:01:00+00:00,Coherus BioSciences,conference_call_webinar,The predicted upward move of +1.53% likely stems from anticipated positive financial results or favorable business updates from Coherus. This could boost investor confidence and potentially enhance market perception and valuation of the company's stock.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,278,CHRS,2024-03-05 21:01:00+00:00,US/Eastern,"REDWOOD CITY, Calif., March  05, 2024  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.",UP,0.015283432976669514,en
14913,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore presented two posters at CROI 2024,https://www.globenewswire.com/news-release/2024/03/05/2840934/0/en/Immunocore-presented-two-posters-at-CROI-2024.html,2024-03-05 16:30:00+00:00,Immunocore,conference_call_webinar,"The predicted upward move of +0.47% likely results from positive data or innovative research in Immunocore's CROI 2024 presentations. This could enhance investor confidence and potentially increase demand for the asset, boosting market valuation.",globenewswire_biotech,biotech,Press releases,270,IMCR,2024-03-05 21:30:00+00:00,US/Eastern,Immunocore presented two posters at CROI 2024,UP,0.004738489493702299,en
15895,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/03/05/2840942/0/en/C4-Therapeutics-to-Present-New-Preclinical-Data-on-Highly-Selective-Orally-Bioavailable-BiDAC-Degraders-at-the-American-Association-for-Cancer-Research-Annual-Meeting-2024.html,2024-03-05 16:30:00+00:00,C4 Therapeutics,clinical_study,"1. The predicted upward move of +3.11% is likely due to promising preclinical results for CFT1946 in treating BRAF V600X related cancers. 2. This could increase investor confidence and attract more funding, benefiting the company's market position.",globenewswire_biotech,biotech,Product / Services Announcement,320,CCCC,2024-03-05 21:30:00+00:00,US/Eastern,"CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis",UP,0.03106679636411394,en
15478,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/03/05/2840932/0/en/IN8bio-to-Present-New-Preclinical-Data-on-Novel-Gamma-Delta-CAR-Platform-Candidate-at-AACR-Annual-Meeting-2024.html,2024-03-05 16:30:00+00:00,IN8bio,clinical_study,"1. The predicted downward move of -2.88% might stem from investor skepticism about the preclinical data's impact on IN8bio's future prospects. 2. This may indicate uncertainty about the candidate's market viability, potentially affecting investor confidence and investment inflow.",globenewswire_biotech,biotech,Health,298,INAB,2024-03-05 21:30:00+00:00,US/Eastern,IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024,UP,-0.028823177524647123,en
14776,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting,https://www.globenewswire.com/news-release/2024/03/05/2840945/0/en/ORIC-Pharmaceuticals-Announces-Multiple-Presentations-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,2024-03-05 16:30:00+00:00,ORIC Pharmaceuticals,clinical_study,"The upward move of +1.70% is likely due to positive sentiment from ORIC Pharmaceuticals' announcement of multiple presentations, including key oral presentations for ORIC-944, at a major cancer research conference. This could increase investor confidence and attention towards ORIC's innovative oncology treatments.",globenewswire_biotech,biotech,Health,262,ORIC,2024-03-05 21:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  05, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted for presentation, including two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA.",UP,0.0169520821842086,en
16639,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate,https://www.globenewswire.com/news-release/2024/03/05/2840948/0/en/Candel-Therapeutics-Announces-an-Upcoming-Presentation-at-the-AACR-Annual-Meeting-Unveiling-New-Cancer-Immunotherapy-Candidate.html,2024-03-05 16:30:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +4.62% is likely due to Candel Therapeutics' advancement in cancer immunotherapy, announced via the AACR presentation. This can enhance investor confidence, suggesting potential growth and stronger market positioning in cancer treatment innovations.",globenewswire_biotech,biotech,Calendar of Events,358,CADL,2024-03-05 21:30:00+00:00,US/Eastern,"NEEDHAM, Mass., March  05, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA. The presentation will describe the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors. This abstract presentation at AACR accelerates the milestone associated with the unveiling of the second enLIGHTEN™ program, which was originally planned for the third quarter of 2024.",UP,0.04623710001314908,en
16668,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting,https://www.globenewswire.com/news-release/2024/03/05/2840939/0/en/RAPT-Therapeutics-Announces-Multiple-Late-Breaking-Presentations-at-the-Upcoming-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,2024-03-05 16:30:00+00:00,RAPT Therapeutics,clinical_study,"The predicted upward move of +5.56% is likely due to positive phase 2 clinical data for tivumecirnon in head and neck cancer. This can boost investor confidence, potentially increasing market interest and valuation of the asset.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,360,RAPT,2024-03-05 21:30:00+00:00,US/Eastern,Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer,UP,0.055620399589209016,en
15232,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/03/05/2840963/0/en/Kronos-Bio-To-Present-Three-Posters-at-AACR-2024-Annual-Meeting.html,2024-03-05 16:44:00+00:00,Kronos Bio,clinical_study,The predicted upward move of +3.14% for Kronos Bio likely stems from increased investor confidence after news of abstract selections for AACR. Successful presentations could enhance Kronos Bio's reputation and lead to potential collaborations or investments.,globenewswire_biotech,biotech,Clinical Study,286,KRON,2024-03-05 21:44:00+00:00,US/Eastern,"SAN MATEO, Calif. and CAMBRIDGE, Mass., March  05, 2024  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.",UP,0.031420558417333176,en
15353,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/03/05/2840973/0/en/Immuneering-to-Present-Preclinical-Data-on-Universal-RAS-Program-IMM-1-104-at-American-Association-for-Cancer-Research-Annual-Meeting-2024.html,2024-03-05 17:00:00+00:00,Immuneering,clinical_study,"The predicted downward move of -0.69% may stem from investor concerns about the preclinical stage of Immuneering's lead program, potentially indicating uncertainty about its market readiness. This slight dip suggests cautious optimism but suggests possible volatility ahead.",globenewswire_biotech,biotech,Health,292,IMRX,2024-03-05 22:00:00+00:00,US/Eastern,"CAMBRIDGE, Mass., March  05, 2024  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.",UP,-0.006881652161245121,en
16052,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Announces Pricing of Public Offering of Common Stock,https://www.globenewswire.com/news-release/2024/03/06/2841024/0/en/Akero-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html,2024-03-05 21:13:00+00:00,Akero Therapeutics,shares_issue,"The predicted downward move of -1.55% is likely due to the stock dilution from Akero Therapeutics' new share offering. This may lead to short-term pressure on share prices, affecting investor sentiment and possibly altering market perceptions of company value.",globenewswire_biotech,biotech,Trading information,328,AKRO,2024-03-06 02:13:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., March  05, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $319.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions.",DOWN,-0.015508102635992702,en
15590,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/03/06/2841249/0/en/InspireMD-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,2024-03-06 07:00:00+00:00,InspireMD,earnings_releases_and_operating_results,"Despite a 71.6% revenue increase, the predicted downward move of -0.06% may stem from market concerns over profitability or future growth. This slight decline could impact investor confidence, potentially affecting short-term stock performance.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,304,NSPR,2024-03-06 12:00:00+00:00,US/Eastern,- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 -,DOWN,-0.0006316703961057726,en
15813,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH),https://www.globenewswire.com/news-release/2024/03/06/2841293/0/en/Rezolute-Reports-Validation-of-the-Potential-Use-of-RZ358-for-Treatment-of-Non-Islet-Cell-Tumor-Hypoglycemia-NICTH.html,2024-03-06 07:30:00+00:00,Rezolute,clinical_study,1. The upward movement is likely due to the expanded addressable patient population for treating hypoglycemia related to tumor hyperinsulinism. 2. This predicted upward move of +3.47% suggests increased market opportunities and revenue potential for relevant healthcare companies.,globenewswire_biotech,biotech,Clinical Study,316,RZLT,2024-03-06 12:30:00+00:00,US/Eastern,Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism),UP,0.034743549843202284,en
15495,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference,https://www.globenewswire.com/news-release/2024/03/06/2841365/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-Barclays-26th-Annual-Global-Healthcare-Conference.html,2024-03-06 08:00:00+00:00,Pacira BioSciences,conference_call_webinar,The predicted upward move of +1.17% for Pacira BioSciences may result from increased investor interest due to the company's participation in the high-profile Barclays Healthcare Conference. This visibility can enhance investor confidence and potentially influence broader market perception positively.,globenewswire_biotech,biotech,Calendar of Events,299,PCRX,2024-03-06 13:00:00+00:00,US/Eastern,"TAMPA, Fla., March  06, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.",UP,0.011694448454320454,en
15258,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/03/06/2841387/0/en/Cidara-Therapeutics-to-Present-Preclincal-Data-on-Multiple-Novel-Drug-Fc-Conjugate-Candidates-at-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024.html,2024-03-06 08:00:00+00:00,Cidara Therapeutics,annual_general_meeting,1. The predicted downward move of -1.01% is likely due to underwhelming preclinical data or market skepticism about the drug-Fc conjugate candidates' effectiveness. 2. This could lead to reduced investor confidence and potential delays in development timelines.,globenewswire_biotech,biotech,Health,287,CDTX,2024-03-06 13:00:00+00:00,US/Eastern,"Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC) Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)",DOWN,-0.010114957585798286,en
16216,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,"Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director",https://www.globenewswire.com/news-release/2024/03/06/2841361/25416/en/Vaxart-Inc-Appoints-Steven-Lo-as-President-Chief-Executive-Officer-and-Director.html,2024-03-06 08:00:00+00:00,Vaxart,management_changes,1. The predicted upward move of +0.32% likely results from investor confidence in Michael J. Finney's continued leadership. 2. Market implications could include increased stability and potential long-term growth as strategic directions are maintained.,globenewswire_biotech,biotech,Directors and Officers,336,VXRT,2024-03-06 13:00:00+00:00,US/Eastern,"Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors",DOWN,0.0031814171741007973,en
16498,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit,https://www.globenewswire.com/news-release/2024/03/06/2841358/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BMO-Capital-Markets-Inaugural-Obesity-Summit.html,2024-03-06 08:00:00+00:00,Corbus Pharmaceuticals,conference_call_webinar,"1. The predicted upward move of +4.73% is likely due to positive investor sentiment from Corbus's participation in the BMO Obesity Summit. 2. This could enhance market visibility and boost investor confidence, potentially affecting stock demand positively.",globenewswire_biotech,biotech,Calendar of Events,351,CRBP,2024-03-06 13:00:00+00:00,US/Eastern,"NORWOOD, Mass., March  06, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.",UP,0.04732958819355759,en
15978,CAPR,https://www.google.com/finance/quote/CAPR:NASDAQ,Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference,https://www.globenewswire.com/news-release/2024/03/06/2841425/0/en/Capricor-Therapeutics-Presents-at-2024-Muscular-Dystrophy-Association-MDA-Clinical-Scientific-Conference.html,2024-03-06 08:30:00+00:00,Capricor Therapeutics,clinical_study,"The likely cause of the predicted upward move of +0.41% is positive 24-month results from the HOPE-2 study of CAP-1002 in Duchenne Muscular Dystrophy. This could enhance investor confidence, potentially leading to increased investment and valuation of the asset.",globenewswire_biotech,biotech,Clinical Study,324,CAPR,2024-03-06 13:30:00+00:00,US/Eastern,Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy,UP,0.004122599994289808,en
14833,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024,https://www.globenewswire.com/news-release/2024/03/06/2841498/0/en/ARS-Pharmaceuticals-to-Participate-in-the-Leerink-Partners-Global-Biopharma-Conference-2024.html,2024-03-06 09:01:00+00:00,ARS Pharmaceuticals,conference_call_webinar,"1. The predicted downward move of -0.02% is likely due to limited new information provided by ARS Pharmaceuticals' conference participation announcement. 2. This minimal shift suggests stable investor sentiment, potentially implying no significant change in market perception.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,265,SPRY,2024-03-06 14:01:00+00:00,US/Eastern,"SAN DIEGO, March  06, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 being held March 11-13, 2024 in Miami, Florida.",UP,-0.0002232178020783513,en
16189,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/06/2841752/0/en/Mdxhealth-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-06 16:00:00+00:00,MDxHealth,financial_results,"The predicted upward move of +0.35% is likely due to positive financial results from Mdxhealth. This uplift can increase investor confidence, potentially leading to higher stock demand and improved valuation in the market.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,335,MDXH,2024-03-06 21:00:00+00:00,US/Eastern,Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results,UP,0.0035486372713811644,en
15563,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments,https://www.globenewswire.com/news-release/2024/03/06/2841759/0/en/PepGen-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Corporate-Developments.html,2024-03-06 16:01:00+00:00,PepGen,clinical_study,The predicted upward move of +16.92% is likely due to positive expectations surrounding the successful enrollment and progress of the PGN-EDO51 trial. Market implications could include increased investor confidence in the company's potential breakthrough in treating DMD.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,303,PEPG,2024-03-06 21:01:00+00:00,US/Eastern,- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 –,DOWN,0.16922575719973676,en
15115,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,"scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024",https://www.globenewswire.com/news-release/2024/03/06/2841762/0/en/scPharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Wednesday-March-13-2024.html,2024-03-06 16:01:00+00:00,scPharmaceuticals,conference_call_webinar,"The predicted upward move of +2.23% suggests positive expectations from the conference call. Investors anticipate favorable announcements or strong financial performance. This could lead to increased investor confidence and potentially higher stock demand, influencing market dynamics positively.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,280,SCPH,2024-03-06 21:01:00+00:00,US/Eastern,Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,DOWN,0.02230273940192748,en
16458,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress,https://www.globenewswire.com/news-release/2024/03/06/2841789/0/en/TransCode-Therapeutics-To-Present-At-2024-RNA-Leaders-Europe-Congress.html,2024-03-06 16:15:00+00:00,TransCode Therapeutics,clinical_study,"The predicted upward move of +1.80% for TransCode Therapeutics is likely due to increased investor confidence from presenting at the 2024 RNA Leaders Europe Congress, which may attract attention to their innovations. This could enhance market visibility and potential investment interest.",globenewswire_biotech,biotech,Product / Services Announcement,349,RNAZ,2024-03-06 21:15:00+00:00,US/Eastern,TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress,UP,0.018041956019047723,en
14775,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference,https://www.globenewswire.com/news-release/2024/03/06/2841802/0/en/ORIC-Pharmaceuticals-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference.html,2024-03-06 16:30:00+00:00,ORIC Pharmaceuticals,conference_call_webinar,"The predicted downward move of -0.22% may be due to market anticipation that the presentation lacks significant new developments or catalysts. This minor drop suggests limited immediate impact on ORIC's stock, reflecting cautious investor sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,262,ORIC,2024-03-06 21:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March  06, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company overview at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 a.m. ET.",DOWN,-0.0021876485463240038,en
15519,BCAB,https://www.google.com/finance/quote/BCAB:NASDAQ,BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting,https://www.globenewswire.com/news-release/2024/03/07/2842190/0/en/BioAtla-Announces-Poster-Presentations-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,2024-03-07 08:00:00+00:00,BioAtla,press_releases,"The predicted downward move of -0.31% for BioAtla may be due to investor caution ahead of preclinical data, highlighting risks associated with early-stage biotechnology developments. This could result in increased volatility and cautious sentiment in biotech stocks in the short term.",globenewswire_biotech,biotech,Calendar of Events,300,BCAB,2024-03-07 13:00:00+00:00,US/Eastern,"SAN DIEGO, March  07, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024. ",DOWN,-0.003101500334108912,en
16215,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14,https://www.globenewswire.com/news-release/2024/03/07/2842178/25416/en/Vaxart-to-Host-Full-Year-2023-Business-Update-and-Financial-Results-Conference-Call-on-March-14.html,2024-03-07 08:00:00+00:00,Vaxart,conference_call_webinar,"The predicted upward move of +2.25% is likely due to positive expectations from the scheduled conference call, potentially signaling good earnings or strategy updates. This could boost investor confidence, driving higher demand and positively impacting market sentiment.",globenewswire_biotech,biotech,Calendar of Events,336,VXRT,2024-03-07 13:00:00+00:00,US/Eastern,Conference call to begin at 4:30 p.m. ET Conference call to begin at 4:30 p.m. ET,DOWN,0.02245788997313379,en
16667,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/07/2842189/0/en/RAPT-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-07 08:00:00+00:00,RAPT Therapeutics,financial_results,"The predicted upward move of +0.70% is likely due to the company's solid cash position of $158.9 million, indicating strong financial health. This may attract investors, potentially boosting stock demand and positive market sentiment.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,360,RAPT,2024-03-07 13:00:00+00:00,US/Eastern,Company maintains solid cash position of $158.9 million Company maintains solid cash position of $158.9 million,UP,0.006974889102766999,en
16644,CELU,https://www.google.com/finance/quote/CELU:NASDAQ,Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells,https://www.globenewswire.com/news-release/2024/03/07/2842357/0/en/Celularity-to-Present-Data-Showing-Cancer-Tumor-Reduction-by-Off-the-Shelf-Cell-Therapy-Derived-from-Human-Placental-Cells.html,2024-03-07 09:35:00+00:00,Celularity,clinical_study,"The predicted upward move of +2.65% is likely due to anticipation of positive results from the in vivo study at the AACR Annual Meeting. This could enhance investor confidence, boost investor interest, and potentially increase the company’s valuation in the biotechnology sector.",globenewswire_biotech,biotech,Product / Services Announcement,359,CELU,2024-03-07 14:35:00+00:00,US/Eastern,"Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024 Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024",UP,0.026506160158621558,en
15011,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/07/2842710/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-07 16:01:00+00:00,Oncternal Therapeutics,financial_results,"The predicted upward move of +0.21% is likely due to positive financial results or strategic business updates from Oncternal Therapeutics. This could enhance investor confidence, potentially signaling growth prospects and increased interest in the biopharmaceutical sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,275,ONCT,2024-03-07 21:01:00+00:00,US/Eastern,"SAN DIEGO, March  07, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.",UP,0.0020742651518186658,en
16051,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology,https://www.globenewswire.com/news-release/2024/03/07/2842721/0/en/Akero-Therapeutics-Announces-Publication-of-Phase-2b-SYMMETRY-Cohort-D-Study-in-Clinical-Gastroenterology-and-Hepatology.html,2024-03-07 16:01:00+00:00,Akero Therapeutics,clinical_study,"The predicted upward move of +0.97% is likely due to positive safety and efficacy results for EFX in combination with GLP-1 therapy. This may enhance market optimism and increase investor interest, potentially boosting asset value.",globenewswire_biotech,biotech,Clinical Study,328,AKRO,2024-03-07 21:01:00+00:00,US/Eastern,"As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health",UP,0.009733796311614782,en
15446,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,"Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board",https://www.globenewswire.com/news-release/2024/03/07/2842715/0/en/Adagene-Appoints-Heinz-Josef-Lenz-M-D-FACP-to-Scientific-and-Strategic-Advisory-Board.html,2024-03-07 16:01:00+00:00,Adagene,management_changes,"1. The predicted upward move of +0.12% is likely due to increased optimism from advancements in colorectal cancer treatment using CTLA-4 therapy. 2. Market implications may include enhanced investor confidence in oncology-related assets, potentially driving further interest and investment.",globenewswire_biotech,biotech,Directors and Officers,297,ADAG,2024-03-07 21:01:00+00:00,US/Eastern,- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy -,DOWN,0.0011509661317139286,en
14832,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day,https://www.globenewswire.com/news-release/2024/03/07/2842745/0/en/ARS-Pharmaceuticals-Reviews-Recent-Clinical-Updates-and-Commercial-Opportunity-at-neffy-Investor-Day.html,2024-03-07 16:05:00+00:00,ARS Pharmaceuticals,product_services_announcement,"The predicted upward move of +0.21% for ARS Pharmaceuticals likely stems from positive investor sentiment due to the investor event showcasing neffy®, a promising treatment for Type I allergic reactions. Market implications could include increased investor interest and potential future stock appreciation if neffy® receives approval.",globenewswire_biotech,biotech,Calendar of Events,265,SPRY,2024-03-07 21:05:00+00:00,US/Eastern,"SAN DIEGO, March  07, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today hosted an investor event highlighting neffy® (epinephrine nasal spray), an investigational new drug, for the treatment of Type I allergic reactions. The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.",UP,0.002133222821424492,en
15231,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway,https://www.globenewswire.com/news-release/2024/03/07/2842738/0/en/Kronos-Bio-Announces-Restructuring-to-Focus-Resources-on-Clinical-Development-with-Extended-Cash-Runway.html,2024-03-07 16:05:00+00:00,Kronos Bio,clinical_study,The predicted upward move of +5.36% is likely due to optimistic expectations for the new dose schedule in the KB-0742 study. Market implications include potential increased investor confidence and enhanced valuation of the company's drug pipeline.,globenewswire_biotech,biotech,Clinical Study,286,KRON,2024-03-07 21:05:00+00:00,US/Eastern,Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025,UP,0.053619306967407354,en
15394,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/03/08/2843057/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html,2024-03-08 07:30:00+00:00,TG Therapeutics,clinical_study,"The predicted upward move of +2.49% is likely due to positive anticipation surrounding TG Therapeutics' data presentations on BRIUMVI® at the AAN meeting. This could boost investor confidence, potentially increasing demand for TGTX shares.",globenewswire_biotech,biotech,Health,294,TGTX,2024-03-08 12:30:00+00:00,US/Eastern,"NEW YORK, March  08, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49. Details of the upcoming presentations are outlined below.",UP,0.024913051921049353,en
15993,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,"Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results",https://www.globenewswire.com/news-release/2024/03/08/2843091/0/en/Ovid-Therapeutics-Reports-Business-Updates-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-08 08:00:00+00:00,Ovid Therapeutics,financial_results,"The predicted upward move of +0.57% for Ovid Therapeutics is likely due to positive business updates and financial results. This modest increase may boost investor confidence, potentially attracting more interest and investment in the biopharmaceutical sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,325,OVID,2024-03-08 13:00:00+00:00,US/Eastern,"NEW YORK, March  08, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.",DOWN,0.005674810693487114,en
14873,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/08/2843088/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023-and-Provides-Corporate-Update.html,2024-03-08 08:00:00+00:00,Ocuphire Pharma,financial_results,The predicted upward move of +0.50% is likely due to positive financial results and a promising corporate update from Ocuphire Pharma. Market implications may include increased investor confidence and potential investment interest in the biopharmaceutical sector.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,268,OCUP,2024-03-08 13:00:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., March  08, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.",UP,0.0049886012153183105,en
16050,AKRO,https://www.google.com/finance/quote/AKRO:NASDAQ,Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares,https://www.globenewswire.com/news-release/2024/03/08/2843312/0/en/Akero-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,2024-03-08 16:02:00+00:00,Akero Therapeutics,shares_issue,"The predicted upward move of +1.02% is likely due to Akero Therapeutics raising approximately $366.9 million, signaling investor confidence. This capital injection could enhance the company's research and development, potentially attracting more investors and boosting market sentiment.",globenewswire_biotech,biotech,Financing Agreements,328,AKRO,2024-03-08 21:02:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., March  08, 2024  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.",DOWN,0.010170279532449289,en
16535,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2024/03/08/2843316/0/en/Entera-Bio-Announces-Full-Year-2023-Financial-Results-and-Provides-Business-Updates.html,2024-03-08 16:05:00+00:00,Entera Bio,earnings_releases_and_operating_results,"The predicted upward move of +0.01% likely stems from Entera Bio's favorable financial results or developments in its orally delivered peptides. This minimal increase could strengthen investor confidence, though immediate market implications would be limited due to the small change.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,353,ENTX,2024-03-08 21:05:00+00:00,US/Eastern,"JERUSALEM, March  08, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.",UP,0.00014215650755345868,en
15726,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day,https://www.globenewswire.com/news-release/2024/03/10/2843427/0/en/MoonLake-announces-significant-improvements-with-Nanobody-sonelokimab-over-24-weeks-in-active-psoriatic-arthritis-PsA-and-other-important-updates-at-its-R-D-Day.html,2024-03-10 12:00:00+00:00,MoonLake Immunotherapeutics,clinical_study,"The predicted upward move of +11.54% is likely due to MoonLake's positive announcement on its Nanobody sonelokimab showing significant improvements in psoriatic arthritis. This boosts investor confidence, potentially increasing stock value and attracting more investments in similar biotechnologies.",globenewswire_biotech,biotech,Company Announcement,312,MLTX,2024-03-10 16:00:00+00:00,US/Eastern,MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day,DOWN,0.11536613295244035,en
15352,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors,https://www.globenewswire.com/news-release/2024/03/11/2843713/0/en/Immuneering-Doses-First-Patient-in-Phase-2a-Clinical-Trial-of-IMM-1-104-in-RAS-mutant-Solid-Tumors.html,2024-03-11 08:00:00+00:00,Immuneering,clinical_study,"The predicted upward move of +0.66% likely stems from positive market sentiment regarding the innovative combination treatment for PDAC, suggesting improved patient outcomes. This could elevate investor confidence and increase the biotech firm's valuation and influence.",globenewswire_biotech,biotech,Clinical Study,292,IMRX,2024-03-11 12:00:00+00:00,US/Eastern,- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -,UP,0.006562832665950909,en
14545,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization,https://www.globenewswire.com/news-release/2024/03/11/2843773/0/en/Dyadic-Announces-Closing-of-Private-Placement-of-6-0-Million-Convertible-Notes-to-Accelerate-Near-Term-Revenue-Growth-and-Commercialization.html,2024-03-11 08:30:00+00:00,Dyadic International,financing_agreements,"The predicted upward move of +0.89% is likely driven by investor confidence following Dyadic's $6 million securities purchase agreement with significant insider participation. This suggests strong internal belief in the company's potential, potentially boosting market sentiment and attracting further investment interest.",globenewswire_biotech,biotech,Financing Agreements,250,DYAI,2024-03-11 12:30:00+00:00,US/Eastern,"JUNIPER, Fla., March  11, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"" or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, announced today that it entered into a securities purchase agreement on March 8, 2024, pursuant to which, the Company has sold and issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the “Convertible Notes”) in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock, (collectively, the “Purchasers”).",UP,0.008866296941239436,en
16457,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment,https://www.globenewswire.com/news-release/2024/03/11/2843809/0/en/TransCode-Therapeutics-and-Akribion-Genomics-Report-Progress-Developing-CRISPR-Derived-Technology-for-Cancer-Treatment.html,2024-03-11 09:00:00+00:00,TransCode Therapeutics,partnerships,"The likely cause of the predicted upward move of +1.14% is positive progress in developing CRISPR-derived cancer treatments. This advancement could boost investor confidence, potentially leading to increased investment and interest in therapeutic biotech stocks.",globenewswire_biotech,biotech,Product / Services Announcement,349,RNAZ,2024-03-11 13:00:00+00:00,US/Eastern,TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment,UP,0.01136085631328022,en
14544,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization,https://www.globenewswire.com/news-release/2024/03/11/2843873/0/en/CORRECTION-Dyadic-Announces-Closing-of-Private-Placement-of-6-0-Million-Convertible-Notes-to-Accelerate-Near-Term-Revenue-Growth-and-Commercialization.html,2024-03-11 09:57:00+00:00,Dyadic International,financing_agreements,"1. The predicted upward move of +0.89% is likely due to increased investor attention following the correction of the company's press release, enhancing credibility. 2. This may improve market sentiment, potentially attracting more investors and increasing stock demand.",globenewswire_biotech,biotech,Financing Agreements,250,DYAI,2024-03-11 13:57:00+00:00,US/Eastern,"In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows:",UP,0.008866296941239436,en
14774,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates,https://www.globenewswire.com/news-release/2024/03/11/2844147/0/en/ORIC-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Updates.html,2024-03-11 16:05:00+00:00,ORIC Pharmaceuticals,clinical_study,"The predicted upward move of +17.02% is likely due to positive Phase 1b data from ORIC-944 and ORIC-114, suggesting best in class potential. This could enhance investor confidence and increase the potential for future market capitalization.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,262,ORIC,2024-03-11 20:05:00+00:00,US/Eastern,"Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies",UP,0.17018116910326114,en
14576,ANAB,https://www.google.com/finance/quote/ANAB:NASDAQ,Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/03/11/2844161/0/en/Anaptys-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,2024-03-11 16:15:00+00:00,AnaptysBio,earnings_releases_and_operating_results,"The predicted downward move of -0.08% is likely due to unmet market expectations in AnaptysBio's operating results or business update. This minor decrease suggests limited immediate impact on investor sentiment, potentially signaling cautious market optimism.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,252,ANAB,2024-03-11 20:15:00+00:00,US/Eastern,"SAN DIEGO, March  11, 2024  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.",UP,-0.000757047264041287,en
15934,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology,https://www.globenewswire.com/news-release/2024/03/12/2844366/7767/en/MediciNova-Announces-New-Data-and-Results-of-MN-166-ibudilast-in-Chlorine-Gas-induced-Acute-Lung-Injury-Presented-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html,2024-03-12 06:30:00+00:00,MediciNova,clinical_study,"1. The predicted upward move of +5.20% is likely due to positive nonclinical study results for MN-166, boosting investor confidence. 2. This could increase interest in MediciNova's stock, potentially attracting more investors and enhancing market valuation.",globenewswire_biotech,biotech,Clinical Study,322,MNOV,2024-03-12 10:30:00+00:00,US/Eastern,"LA JOLLA, Calif., March  12, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury (CIALI) model at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.",UP,0.05200084988438523,en
16036,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023,https://www.globenewswire.com/news-release/2024/03/12/2844387/0/en/BioXcel-Therapeutics-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023.html,2024-03-12 07:00:00+00:00,BioXcel Therapeutics,clinical_study,"The predicted upward move of +17.17% likely stems from positive updates on BXCL501's late-stage trials, suggesting potential market success. This could increase investor confidence and boost interest in the healthcare sector, possibly influencing related biotech companies.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,327,BTAI,2024-03-12 11:00:00+00:00,US/Eastern,Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation,UP,0.17165054366482607,en
15770,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/12/2844382/0/en/Revive-Therapeutics-Provides-Corporate-Update.html,2024-03-12 07:00:00+00:00,Revive Therapeutics,press_releases,The predicted upward move of +0.79% likely stems from Revive Therapeutics' update on promising developments in Bucillamine research and its long COVID diagnostic product. This could increase investor confidence and potentially boost market interest in their stock.,globenewswire_biotech,biotech,Product / Services Announcement,314,RVVTF,2024-03-12 11:00:00+00:00,US/Eastern,"TORONTO, March  12, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.",UP,0.007948770827785735,en
16497,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/12/2844478/0/en/Corbus-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-03-12 08:00:00+00:00,Corbus Pharmaceuticals,financial_results,"The predicted upward move of +1.18% is likely due to positive corporate updates or better-than-expected financial results. This could boost investor confidence, potentially increasing demand for Corbus Pharmaceuticals' stock. Positive sentiment may enhance portfolio visibility and attract new investors.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,351,CRBP,2024-03-12 12:00:00+00:00,US/Eastern,"NORWOOD, Mass., March  12, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.",UP,0.011796920844213875,en
16722,XFOR,https://www.google.com/finance/quote/XFOR:NASDAQ,"X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024",https://www.globenewswire.com/news-release/2024/03/12/2844468/0/en/X4-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-a-Conference-Call-and-Webcast-on-March-21-2024.html,2024-03-12 08:00:00+00:00,X4 Pharmaceuticals,earnings_releases_and_operating_results,"The predicted upward move of +0.32% for X4 Pharmaceuticals likely stems from investor anticipation of positive financial results and corporate updates. This movement suggests market optimism, potentially boosting investor confidence and increasing stock demand.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,362,XFOR,2024-03-12 12:00:00+00:00,US/Eastern,"BOSTON, March  12, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.",DOWN,0.0032141357541025516,en
14497,KA,https://www.google.com/finance/quote/KA:NASDAQ,KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported,https://www.globenewswire.com/news-release/2024/03/12/2844483/0/en/KVA12123-Clears-Additional-Cohorts-in-Monotherapy-and-in-Combination-Therapy-Arms-in-the-Phase-1-2-VISTA-101-Clinical-Trial-Initial-Clinical-Response-Data-Reported.html,2024-03-12 08:00:00+00:00,Kineta,clinical_study,"The predicted upward move of +2.33% is likely due to positive clinical trial results, including stable disease without dose limiting toxicities. Market implications could include increased investor confidence, potentially enhancing stakeholder value.",globenewswire_biotech,biotech,Clinical Study,248,KA,2024-03-12 12:00:00+00:00,US/Eastern,"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of six monotherapy cohorts and second of four combination cohortsKineta is actively exploring strategic alternatives to maximize value for all stakeholders",UP,0.023276929394466638,en
15351,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,"Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors",https://www.globenewswire.com/news-release/2024/03/12/2844480/0/en/Immuneering-Appoints-Thomas-J-Schall-Ph-D-to-its-Board-of-Directors.html,2024-03-12 08:00:00+00:00,Immuneering,management_changes,"The predicted downward move of -0.35% could stem from leadership changes or concerns over strategic direction at ChemoCentryx. This slight decline might affect investor sentiment, potentially influencing similar biotech stocks.",globenewswire_biotech,biotech,Mergers and Acquisitions,292,IMRX,2024-03-12 12:00:00+00:00,US/Eastern,"Former Chairman, CEO and Founder of ChemoCentryx, Inc. Former Chairman, CEO and Founder of ChemoCentryx, Inc.",DOWN,-0.003493558314805748,en
15095,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations,https://www.globenewswire.com/news-release/2024/03/12/2844494/0/en/Mainz-Biomed-Presents-ColoAlert-at-UDH-Congress-2024-Leading-the-Way-in-Evidence-Based-Cancer-Screening-Innovations.html,2024-03-12 08:01:00+00:00,Mainz Biomed,trade_show,"1. The likely cause of the predicted upward move of +1.80% is positive reception of ColoAlert® at the UDH Congress, showcasing innovation in cancer screening. 2. This may increase investor confidence, driving further interest and investment in Mainz Biomed.",globenewswire_biotech,biotech,Product / Services Announcement,279,MYNZ,2024-03-12 12:01:00+00:00,US/Eastern,Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations,UP,0.017981487708250535,en
14480,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech to Participate in 36th Annual ROTH Conference,https://www.globenewswire.com/news-release/2024/03/12/2844540/28889/en/Fortress-Biotech-to-Participate-in-36th-Annual-ROTH-Conference.html,2024-03-12 08:30:00+00:00,Fortress Biotech,conference_call_webinar,"1. The predicted downward move of -0.38% could be due to investor expectations for Fortress Biotech's presentation, which may lack significant new developments. 2. This might imply cautious market sentiment or limited short-term catalysts for growth.",globenewswire_biotech,biotech,Calendar of Events,247,FBIO,2024-03-12 12:30:00+00:00,US/Eastern,"MIAMI, March  12, 2024  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the 36th Annual ROTH Conference on Monday, March 18, 2024, at 2:00 p.m. PT in Dana Point, California. The Company will also attend one-on-one meetings during the conference.",UP,-0.0037664746844267988,en
16188,MDXH,https://www.google.com/finance/quote/MDXH:NASDAQ,Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering,https://www.globenewswire.com/news-release/2024/03/12/2844983/0/en/Mdxhealth-Adds-Hereditary-Prostate-Cancer-Genetic-Test-to-Prostate-Cancer-Offering.html,2024-03-12 16:00:00+00:00,MDxHealth,product_services_announcement,"The predicted upward move of +1.51% likely stems from Mdxhealth enhancing its prostate cancer portfolio with a new genetic test. The expansion could boost market position and revenues, increasing investor confidence and attracting interest in healthcare innovations.",globenewswire_biotech,biotech,Company Announcement,335,MDXH,2024-03-12 20:00:00+00:00,US/Eastern,Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering ,UP,0.015099863398852394,en
15864,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,"Faron’s Financial Statement Release January 1 to December 31, 2023",https://www.globenewswire.com/news-release/2024/03/13/2845159/0/en/Faron-s-Financial-Statement-Release-January-1-to-December-31-2023.html,2024-03-13 03:00:00+00:00,Faron Pharmaceuticals,financial_results,"The predicted downward move of -0.11% for Faron Pharmaceuticals may result from less-than-expected financial performance in their 2023 results. This could lead to reduced investor confidence, potentially influencing broader sentiment in the biotech sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,319,FARON.HE,2024-03-13 07:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, March  13, 2024  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (""Faron"" or ""the Company"") (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced audited full-year financial results for January 1 to December 31, 2023 (the ""Period"") and provided an overview of recent corporate developments.",DOWN,-0.0010611635276912672,en
15494,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee,https://www.globenewswire.com/news-release/2024/03/13/2845287/0/en/Pacira-BioSciences-Announces-PCRX-201-Granted-Regenerative-Medicine-Advance-Therapy-RMAT-Designation-for-the-Treatment-of-Osteoarthritis-of-the-Knee.html,2024-03-13 07:00:00+00:00,Pacira BioSciences,clinical_study,"The predicted upward move of +38.10% is likely due to PCRX-201 receiving RMAT designation, backed by positive Phase 1 data. This could enhance investor confidence, increase funding opportunities, and accelerate development, impacting market dynamics favorably.",globenewswire_biotech,biotech,Product / Services Announcement,299,PCRX,2024-03-13 11:00:00+00:00,US/Eastern,-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --,UP,0.3810085618643473,en
15919,BCDA,https://www.google.com/finance/quote/BCDA:NASDAQ,BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership,https://www.globenewswire.com/news-release/2024/03/13/2845293/0/en/BioCardia-and-StemCardia-Announce-Biotherapeutic-Delivery-Partnership.html,2024-03-13 07:00:00+00:00,BioCardia,partnerships,"The partnership between BioCardia and StemCardia targets heart failure, increasing interest due to limited treatments, driving demand. The predicted upward move of +4.26% reflects investor optimism, potentially enhancing biotech market innovation and investments.",globenewswire_biotech,biotech,Partnerships,321,BCDA,2024-03-13 11:00:00+00:00,US/Eastern,"BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options",UP,0.04264233124976784,en
15562,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy,https://www.globenewswire.com/news-release/2024/03/13/2845286/0/en/PepGen-Receives-U-S-FDA-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-for-PGN-EDO51-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html,2024-03-13 07:00:00+00:00,PepGen,clinical_study,The predicted upward move of +0.71% is likely due to the FDA granting orphan drug and rare pediatric disease designations to PepGen's PGN-EDO51. This recognition can boost investor confidence and potentially increase funding opportunities.,globenewswire_biotech,biotech,Product / Services Announcement,303,PEPG,2024-03-13 11:00:00+00:00,US/Eastern,"BOSTON, March  13, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.",UP,0.007091812625292071,en
14858,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,IMUNON Files IND Application to Begin Human Testing of IMNN-101,https://www.globenewswire.com/news-release/2024/03/13/2845364/0/en/IMUNON-Files-IND-Application-to-Begin-Human-Testing-of-IMNN-101.html,2024-03-13 08:00:00+00:00,Imunon,clinical_study,The predicted upward move of +60.12% is likely due to investor optimism surrounding the novel DNA-based vaccine technology entering Phase 1 trials. Potential market implications include increased investor interest and valuation if clinical progress and FDA interactions prove favorable.,globenewswire_biotech,biotech,Press releases,266,IMNN,2024-03-13 12:00:00+00:00,US/Eastern,Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA ,UP,0.6011949041028692,en
16333,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics Proposes New Appointment to the Board of Directors,https://www.globenewswire.com/news-release/2024/03/13/2845431/0/en/CRISPR-Therapeutics-Proposes-New-Appointment-to-the-Board-of-Directors.html,2024-03-13 08:30:00+00:00,CRISPR Therapeutics,management_changes,"The likely cause of the predicted upward move of +0.19% is the proposed election of Christian Rommel, Ph.D., to CRISPR Therapeutics' Board, suggesting confidence in leadership. This could enhance investor sentiment, potentially boosting market perceptions of future innovation.",globenewswire_biotech,biotech,Directors and Officers,343,CRSP,2024-03-13 12:30:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, March  13, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year.",DOWN,0.0019130418391981444,en
14612,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases,https://www.globenewswire.com/news-release/2024/03/13/2845650/0/en/Almirall-and-Eloxx-Pharmaceuticals-Enter-into-Exclusive-Agreement-to-license-ZKN-013-for-rare-dermatological-diseases.html,2024-03-13 11:42:00+00:00,Eloxx Pharmaceuticals,licensing_agreements,"The predicted upward move of +1.84% is likely due to Almirall acquiring global rights for ZKN-013, signaling potential revenue growth. This deal enhances Almirall's portfolio in rare dermatological diseases, possibly leading to increased investor interest.",globenewswire_biotech,biotech,Product / Services Announcement,254,ELOX,2024-03-13 15:42:00+00:00,US/Eastern,"BARCELONA, Spain and WATERTOWN, Mass., March  13, 2024  (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.",UP,0.01844746254575365,en
15073,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,"Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update",https://www.globenewswire.com/news-release/2024/03/13/2845826/33333/en/Coherus-BioSciences-Reports-Fourth-Quarter-Full-Year-2023-Financial-Results-and-Provides-Current-Business-Update.html,2024-03-13 16:01:00+00:00,Coherus BioSciences,financial_results,"The predicted upward move of +0.34% is likely due to strong quarterly and annual revenue figures. This could boost investor confidence, potentially increasing stock value and market interest in the company's growth prospects.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,278,CHRS,2024-03-13 20:01:00+00:00,US/Eastern,– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – ,UP,0.0034106707297402454,en
15114,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/03/13/2845823/0/en/scPharmaceuticals-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,2024-03-13 16:01:00+00:00,scPharmaceuticals,earnings_releases_and_operating_results,"The slight predicted downward move of -0.03% likely stems from profit-taking after strong sequential revenue growth. Market implications might include short-term volatility but confidence in sustained performance, maintaining investor interest in the company's growth trajectory.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,280,SCPH,2024-03-13 20:01:00+00:00,US/Eastern,"Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023",UP,-0.0003432336573879065,en
15561,PEPG,https://www.google.com/finance/quote/PEPG:NASDAQ,PepGen to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/03/13/2845838/0/en/PepGen-to-Participate-in-Upcoming-Investor-Conferences.html,2024-03-13 16:05:00+00:00,PepGen,conference_call_webinar,"The predicted upward move of +0.21% for PepGen Inc. is likely due to its active participation in investor conferences, which can boost visibility and investor confidence. This may enhance interest and potentially increase stock demand in the market.",globenewswire_biotech,biotech,Calendar of Events,303,PEPG,2024-03-13 20:05:00+00:00,US/Eastern,"BOSTON, March  13, 2024  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:",DOWN,0.002140747658265008,en
14609,ECOR,https://www.google.com/finance/quote/ECOR:NASDAQ,electroCore Announces Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/13/2845835/0/en/electroCore-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-13 16:05:00+00:00,electroCore,earnings_releases_and_operating_results,"Despite strong sales growth, the predicted downward move of -0.18% likely stems from unmet investor expectations or concerns about profitability. This could dampen investor sentiment and suggest caution in the broader market regarding earnings quality.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,253,ECOR,2024-03-13 20:05:00+00:00,US/Eastern,Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022,DOWN,-0.0017595355566612956,en
15170,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,"Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024",https://www.globenewswire.com/news-release/2024/03/13/2845834/0/en/Mineralys-Therapeutics-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-Call-on-Thursday-March-21-2024.html,2024-03-13 16:05:00+00:00,Mineralys Therapeutics,earnings_releases_and_operating_results,"The predicted upward move of +0.39% likely results from investor anticipation of positive financial results. This might boost shareholder confidence and potentially increase trading volume, impacting MLYS’s market valuation favorably as more investors seek to buy.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,283,MLYS,2024-03-13 20:05:00+00:00,US/Eastern,"RADNOR, Pa., March  13, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.",UP,0.00385324808332029,en
14816,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex to Present at the Bio-Europe Spring 2024 Conference,https://www.globenewswire.com/news-release/2024/03/14/2845974/0/en/Addex-to-Present-at-the-Bio-Europe-Spring-2024-Conference.html,2024-03-14 02:00:00+00:00,Addex Therapeutics,conference_call_webinar,Addex Therapeutics' predicted upward move of +0.16% is likely due to increased visibility and networking opportunities from CEO Tim Dyer's presentation at the Bio-Europe Spring 2024 conference. This may enhance investor interest and lead to strategic partnerships.,globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-03-14 06:00:00+00:00,US/Eastern,"Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event.",UP,0.001552979334087252,en
15863,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab,https://www.globenewswire.com/news-release/2024/03/14/2845984/0/en/Faron-to-Host-Webcast-to-Discuss-latest-data-from-Phase-1-part-of-the-BEXMAB-Study-of-Bexmarilimab.html,2024-03-14 03:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted upward move of +0.34% for Faron Pharmaceuticals is likely caused by investor optimism ahead of the BEXMAB update event. Positive data could enhance market confidence, potentially leading to increased investor interest and higher trading volumes.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,319,FARON.HE,2024-03-14 07:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, March  14, 2024  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis.",DOWN,0.0033751758068598175,en
15350,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors,https://www.globenewswire.com/news-release/2024/03/14/2846143/0/en/Immuneering-Announces-Positive-Topline-Results-from-Phase-1-Portion-of-its-Phase-1-2a-Clinical-Trial-of-IMM-1-104-in-RAS-Mutant-Solid-Tumors.html,2024-03-14 07:00:00+00:00,Immuneering,clinical_study,"The predicted downward move of -0.48% may be due to market skepticism about the future efficacy or commercial viability of IMM-1-104 despite its safety profile. This could lead to cautious investor sentiment, potentially affecting share prices and trading volumes.",globenewswire_biotech,biotech,Clinical Study,292,IMRX,2024-03-14 11:00:00+00:00,US/Eastern,"- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile -",DOWN,-0.004772966119309369,en
14642,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound to Report Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/14/2846241/30505/en/MediWound-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-14 08:00:00+00:00,MediWound,earnings_releases_and_operating_results,"The predicted upward move of +0.09% is likely due to positive anticipation ahead of the conference call and webcast. Investors may expect favorable announcements, potentially boosting investor confidence and leading to slight asset price appreciation.",globenewswire_biotech,biotech,Health,255,MDWD,2024-03-14 12:00:00+00:00,US/Eastern,"Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time",UP,0.0009154274076616272,en
15477,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2024/03/14/2846670/0/en/IN8bio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html,2024-03-14 16:00:00+00:00,IN8bio,financial_results,"The predicted upward move of +0.61% is likely due to strong financial results and positive business highlights from IN8bio. This can increase investor confidence, potentially attracting new investments and boosting market valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,298,INAB,2024-03-14 20:00:00+00:00,US/Eastern,IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights,UP,0.006090755868429545,en
16214,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart Provides Business Update and Reports Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/14/2846672/25416/en/Vaxart-Provides-Business-Update-and-Reports-Full-Year-2023-Financial-Results.html,2024-03-14 16:01:00+00:00,Vaxart,financial_results,"The predicted downward move of -0.08% likely stems from skepticism about Vaxart's oral pill XBB COVID-19 vaccine outperforming mRNA comparators. This minor decline suggests the market anticipates challenges, possibly affecting investor confidence and funding for new vaccine technologies.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,336,VXRT,2024-03-14 20:01:00+00:00,US/Eastern,Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator,UP,-0.0007503528815643215,en
16017,TSHA,https://www.google.com/finance/quote/TSHA:NASDAQ,"Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19",https://www.globenewswire.com/news-release/2024/03/14/2846713/0/en/Taysha-Gene-Therapies-to-Release-Full-Year-2023-Financial-Results-Provide-Corporate-and-Clinical-Updates-and-Host-Conference-Call-on-March-19.html,2024-03-14 16:26:00+00:00,Taysha Gene Therapies,financial_results,"The predicted downward move of -0.41% for Taysha Gene Therapies could be due to market anticipation of unimpressive financial results or clinical updates. This might signal investor caution, potentially impacting stock valuations and investor confidence.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,326,TSHA,2024-03-14 20:26:00+00:00,US/Eastern,"DALLAS, March  14, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.",UP,-0.0041288068423360556,en
14543,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,"Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024",https://www.globenewswire.com/news-release/2024/03/14/2846716/0/en/Dyadic-to-Report-Full-Year-2023-Financial-Results-and-Host-Conference-call-on-Thursday-March-28-2024.html,2024-03-14 16:30:00+00:00,Dyadic International,conference_call_webinar,"The predicted upward move of +0.87% is likely driven by anticipation surrounding Dyadic's upcoming financial results announcement and corporate update. Positive results could boost investor confidence, potentially increasing interest in the biotechnology sector as a whole.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,250,DYAI,2024-03-14 20:30:00+00:00,US/Eastern,"JUPITER, Fla., March  14, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.",UP,0.008717407869641218,en
16035,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine,https://www.globenewswire.com/news-release/2024/03/15/2846944/0/en/BioXcel-Therapeutics-Announces-European-Patent-Office-s-Grant-of-Patent-for-Method-of-Treating-Agitation-in-Dementia-Using-Sublingual-Dexmedetomidine.html,2024-03-15 07:00:00+00:00,BioXcel Therapeutics,patents,The recent patent grant likely causes the predicted upward move of +0.67% as it enhances the company's intellectual property and expands its market reach. This could improve competitive positioning and attract investor interest in the company's prospects.,globenewswire_biotech,biotech,Patents,327,BTAI,2024-03-15 11:00:00+00:00,US/Eastern,Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501,UP,0.006695057788978267,en
14564,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia,https://www.globenewswire.com/news-release/2024/03/15/2847004/0/en/New-Positive-Data-Presented-on-Briquilimab-Conditioning-in-Patients-with-Fanconi-Anemia.html,2024-03-15 08:00:00+00:00,Jasper Therapeutics,clinical_study,"The likely cause of the predicted upward move of +0.31% in Jasper Therapeutics' stock is positive data from their Phase 1b/2a trial of briquilimab. This enhances investor confidence, potentially leading to increased valuation, interest, and investment in the company's pipeline.",globenewswire_biotech,biotech,Clinical Study,251,JSPR,2024-03-15 12:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., March  15, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).",DOWN,0.0031085901508073432,en
15010,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer,https://www.globenewswire.com/news-release/2024/03/15/2847056/0/en/Oncternal-Participating-in-Virtual-Fireside-Chat-with-Key-Opinion-Leader-on-Treatment-Landscape-New-Treatment-Options-for-Prostate-Cancer.html,2024-03-15 09:00:00+00:00,Oncternal Therapeutics,clinical_study,"The predicted upward move of +3.07% is likely due to investor optimism from Oncternal's participation in the prostate cancer treatment discussion. This could enhance their visibility, potentially attracting investment and partnerships, positively impacting market perception.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,275,ONCT,2024-03-15 13:00:00+00:00,US/Eastern,"SAN DIEGO, March  15, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.",DOWN,0.03067149506050091,en
15276,NTLA,https://www.google.com/finance/quote/NTLA:NASDAQ,Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy,https://www.globenewswire.com/news-release/2024/03/18/2847698/0/en/Intellia-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-3-MAGNITUDE-Study-of-NTLA-2001-as-a-Single-Dose-CRISPR-Based-Treatment-for-Transthyretin-Amyloidosis-with-Cardiomyo.html,2024-03-18 07:30:00+00:00,Intellia Therapeutics,clinical_study,"The predicted upward move of +1.23% for Intellia Therapeutics is likely due to the advancement of their NTLA-2001 therapy into Phase 3 trials, indicating progress in treating ATTR amyloidosis. This increases investor confidence and can lead to market optimism.",globenewswire_biotech,biotech,Clinical Study,288,NTLA,2024-03-18 11:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass., March  18, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis. The MAGNITUDE trial is evaluating the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.",DOWN,0.012309605456051167,en
16298,HUMA,https://www.google.com/finance/quote/HUMA:NASDAQ,"Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024",https://www.globenewswire.com/news-release/2024/03/18/2847721/0/en/Humacyte-to-Present-2023-Fourth-Quarter-and-Year-End-Financial-Results-and-Provide-Corporate-Update-on-March-22-2024.html,2024-03-18 08:00:00+00:00,Humacyte,financial_results,"The likely cause of the predicted upward move of +0.15% is anticipation of positive financial results or updates from Humacyte's webcast. This could improve investor confidence, potentially boosting stock demand and positively influencing the biotechnology sector's market sentiment.",globenewswire_biotech,biotech,Calendar of Events,340,HUMA,2024-03-18 12:00:00+00:00,US/Eastern,"DURHAM, N.C., March  18, 2024  (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.",UP,0.0015423230682907495,en
16695,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,"Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors",https://www.globenewswire.com/news-release/2024/03/18/2847762/36989/en/Checkpoint-Therapeutics-Announces-Appointment-of-Accomplished-Life-Sciences-Executive-Amit-Sharma-M-D-to-Board-of-Directors.html,2024-03-18 08:00:00+00:00,Checkpoint Therapeutics,management_changes,"The predicted upward move of +0.36% is likely due to the market's positive reaction to Dr. Amit Sharma's board appointment, increasing investor confidence. This strategic addition might enhance Checkpoint's leadership, potentially boosting long-term growth prospects.",globenewswire_biotech,biotech,Directors and Officers,361,CKPT,2024-03-18 12:00:00+00:00,US/Eastern,"WALTHAM, Mass., March  18, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.",UP,0.0035744021355346178,en
15094,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options,https://www.globenewswire.com/news-release/2024/03/18/2847763/0/en/Mainz-Biomed-Webinar-on-Early-Detection-of-Colorectal-Cancer-Exploring-New-Laboratory-Diagnostic-Options.html,2024-03-18 08:01:00+00:00,Mainz Biomed,conference_call_webinar,1. The likely cause of the predicted downward move of -3.44% could be weak webinar reception or negative investor sentiment about the discussed diagnostic options. 2. Market implications might include decreased investor confidence and potential reevaluation of the company's future growth prospects.,globenewswire_biotech,biotech,Health,279,MYNZ,2024-03-18 12:01:00+00:00,US/Eastern,Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options,UP,-0.03437197012115998,en
15862,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML,https://www.globenewswire.com/news-release/2024/03/18/2847836/0/en/Inside-Information-Additional-Positive-Data-from-the-Phase-1-Part-of-the-BEXMAB-Study-in-Both-Higher-Risk-HMA-Failed-MDS-and-r-r-AML.html,2024-03-18 09:00:00+00:00,Faron Pharmaceuticals,clinical_study,"The predicted downward move of -0.82% may be due to weaker financial performance or negative market sentiment. This could lead to decreased investor confidence, increased selling pressure, and possibly lower market valuations for related assets.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,319,FARON.HE,2024-03-18 13:00:00+00:00,US/Eastern,Key highlights,UP,-0.008181166378054206,en
16090,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders,https://www.globenewswire.com/news-release/2024/03/19/2848395/0/en/CENTOGENE-Extends-Strategic-Partnership-With-Takeda-to-Continue-Providing-Access-to-Genetic-Testing-for-Patients-With-Lysosomal-Storage-Disorders.html,2024-03-19 06:30:00+00:00,Centogene,partnerships,"The predicted upward move of +0.71% likely results from Centogene's extended partnership with Takeda, enhancing diagnostic capabilities in Lysosomal Storage Disorders. This collaboration could boost Centogene's market position and investor confidence, possibly benefiting both companies' stock values.",globenewswire_biotech,biotech,Partnerships,330,CNTG,2024-03-19 10:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March  19, 2024  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs).",UP,0.007111786273765182,en
15769,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID,https://www.globenewswire.com/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html,2024-03-19 07:00:00+00:00,Revive Therapeutics,clinical_study,"The predicted upward move of +8.58% is likely due to Revive announcing FDA feedback on its drug Bucillamine for long COVID. Market implications include increased investor interest, reflecting optimism about the company's drug development progress.",globenewswire_biotech,biotech,Regulatory information,314,RVVTF,2024-03-19 11:00:00+00:00,US/Eastern,"TORONTO, March  19, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company expects to submit the Type C meeting request by next week.",DOWN,0.08581520534284769,en
14726,TALS,https://www.google.com/finance/quote/TALS:NASDAQ,Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2024/03/19/2848416/0/en/Tourmaline-Bio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html,2024-03-19 07:00:00+00:00,Talaris Therapeutics,clinical_study,1. The predicted upward move of +17.26% is likely due to initiating the pivotal Phase 2b trial and accelerating the Phase 3 trial for Thyroid Eye Disease. 2. This may boost investor confidence and drive increased interest in the asset.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,260,TALS,2024-03-19 11:00:00+00:00,US/Eastern,"– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 –",DOWN,0.172621862234616,en
15518,BCAB,https://www.google.com/finance/quote/BCAB:NASDAQ,"BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024",https://www.globenewswire.com/news-release/2024/03/19/2848514/0/en/BioAtla-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Business-Highlights-on-March-26-2024.html,2024-03-19 08:00:00+00:00,BioAtla,conference_call_webinar,"The predicted upward move of +1.61% likely stems from anticipation around BioAtla's upcoming financial results and business highlights announcement. Positive news could enhance investor confidence, potentially increasing stock interest and market valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,300,BCAB,2024-03-19 12:00:00+00:00,US/Eastern,"SAN DIEGO, March  19, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.",UP,0.016142323899578762,en
14563,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria,https://www.globenewswire.com/news-release/2024/03/19/2848524/0/en/Jasper-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-2a-SPOTLIGHT-Clinical-Study-of-Briquilimab-in-Chronic-Inducible-Urticaria.html,2024-03-19 08:00:00+00:00,Jasper Therapeutics,clinical_study,"1. The predicted upward move of +1.24% is likely due to the initiation of Jasper's Phase 1b/2a clinical study, indicating progress in their drug development process. 2. Success in trials could lead to significant growth opportunities and increased investor interest.",globenewswire_biotech,biotech,Clinical Study,251,JSPR,2024-03-19 12:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., March  19, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).",DOWN,0.012391468564523748,en
15093,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment,https://www.globenewswire.com/news-release/2024/03/19/2848525/0/en/Mainz-Biomed-Organizes-HALLO-DOC-Event-to-Highlight-Innovations-in-Colorectal-Cancer-Treatment.html,2024-03-19 08:01:00+00:00,Mainz Biomed,press_releases,1. The likely cause of the predicted upward move of +1.70% is market optimism about innovative colorectal cancer treatments presented at the event. 2. This could enhance investor confidence and potentially drive further investment in Mainz Biomed's assets.,globenewswire_biotech,biotech,Health,279,MYNZ,2024-03-19 12:01:00+00:00,US/Eastern,Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment,UP,0.017024504718149407,en
16016,TSHA,https://www.google.com/finance/quote/TSHA:NASDAQ,Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates,https://www.globenewswire.com/news-release/2024/03/19/2848955/0/en/Taysha-Gene-Therapies-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-and-Clinical-Updates.html,2024-03-19 16:01:00+00:00,Taysha Gene Therapies,clinical_study,The predicted upward move of +7.28% is likely due to positive trial results showing TSHA-102's tolerability and efficacy. Market implications could include increased investor confidence and potential competitive advantage for the company in therapeutic solutions.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,326,TSHA,2024-03-19 20:01:00+00:00,US/Eastern,"Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six",UP,0.072776401757753,en
15918,BCDA,https://www.google.com/finance/quote/BCDA:NASDAQ,"BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024",https://www.globenewswire.com/news-release/2024/03/20/2849210/0/en/BioCardia-to-Host-2023-Financial-Results-and-Corporate-Update-Conference-Call-on-March-27-2024.html,2024-03-20 07:00:00+00:00,BioCardia,conference_call_webinar,"The predicted upward move of +1.87% is likely due to investor anticipation of positive financial results and strategic updates. This could enhance market confidence, potentially boosting investor interest and elevating BioCardia's stock value.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,321,BCDA,2024-03-20 11:00:00+00:00,US/Eastern,"BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024",UP,0.01872949864744274,en
15427,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease,https://www.globenewswire.com/news-release/2024/03/20/2849275/0/en/Annovis-Bio-Provides-Data-Announcement-Update-for-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html,2024-03-20 07:30:00+00:00,Annovis Bio,clinical_study,"The predicted downward move of -5.54% could be due to investor skepticism about the upcoming efficacy data for buntanetap, raising concerns over its approval potential. This uncertainty may affect market confidence, impacting Annovis Bio’s stock performance negatively.",globenewswire_biotech,biotech,Clinical Study,296,ANVS,2024-03-20 11:30:00+00:00,US/Eastern,"MALVERN, Pa., March  20, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.",UP,-0.055360759984811866,en
16213,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,"Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",https://www.globenewswire.com/news-release/2024/03/20/2849335/25416/en/Vaxart-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-03-20 08:00:00+00:00,Vaxart,management_changes,"The likely cause of the predicted upward move of +0.26% is the market's positive response to the strategic appointment of Steven Lo as CEO. This leadership change could enhance investor confidence, potentially improving Vaxart's market position and future performance.",globenewswire_biotech,biotech,Directors and Officers,336,VXRT,2024-03-20 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., March  20, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. The awards were made pursuant to the Company’s previously disclosed offer letter with Mr. Lo, and as a material inducement to his joining the Company as President and Chief Executive Officer and a member of the Board of Directors.",UP,0.0026438396147461297,en
16534,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome,https://www.globenewswire.com/news-release/2024/03/20/2849325/0/en/Entera-Bio-Announces-Robust-Pharmacokinetic-Data-for-First-in-Class-Oral-GLP-2-Peptide-Tablet-Treatment-for-Patients-with-Short-Bowel-Syndrome.html,2024-03-20 08:00:00+00:00,Entera Bio,clinical_study,The predicted upward move of +4.44% for Entera Bio Ltd. is likely due to positive pharmacokinetic results from its collaboration with OPKO Health. This could enhance investor confidence and potentially boost both companies' market valuations.,globenewswire_biotech,biotech,Clinical Study,353,ENTX,2024-03-20 12:00:00+00:00,US/Eastern,"JERUSALEM, March  20, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with Entera’s proprietary N-Tab™ technology.",UP,0.044380393717551925,en
16230,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial,https://www.globenewswire.com/news-release/2024/03/20/2849459/0/en/Immix-Biopharma-Announces-Major-Comprehensive-Cancer-Center-as-Lead-Site-for-NXC-201-AL-Amyloidosis-Clinical-Trial.html,2024-03-20 09:46:00+00:00,Immix Biopharma,clinical_study,"The predicted upward move of +2.45% is likely due to Immix Biopharma's announcement of Memorial Sloan Kettering as the lead site for its clinical trial, indicating strong research backing. This strengthens investor confidence and could enhance market credibility.",globenewswire_biotech,biotech,Advisory,337,IMMX,2024-03-20 13:46:00+00:00,US/Eastern,"LOS ANGELES, CA, March  20, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.",UP,0.024529043713206175,en
15933,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,"MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society",https://www.globenewswire.com/news-release/2024/03/20/2849862/7767/en/MediciNova-Announces-Two-Abstracts-regarding-MN-001-tipelukast-and-MN-002-Accepted-for-Presentation-at-the-92nd-EAS-2024-Congress-the-Annual-Meeting-of-the-European-Atherosclerosis.html,2024-03-20 19:00:00+00:00,MediciNova,clinical_study,"1. The predicted upward move of +0.93% likely results from MediciNova’s abstracts being selected for presentation, highlighting promising research. 2. This could boost investor confidence and increase visibility within the biopharmaceutical sector, potentially attracting more interest and investment.",globenewswire_biotech,biotech,Product / Services Announcement,322,MNOV,2024-03-20 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., March  20, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled “STUDY PROTOCOL TO EVALUATE MN-001’S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)” and “MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX” have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.",UP,0.009338957749137837,en
16551,BNOX,https://www.google.com/finance/quote/BNOX:NASDAQ,Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder,https://www.globenewswire.com/news-release/2024/03/21/2850042/0/en/Bionomics-Reports-Results-of-the-Full-Dataset-Analysis-from-ATTUNE-Phase-2b-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder.html,2024-03-21 06:00:00+00:00,Bionomics,clinical_study,"The predicted upward move of +2.86% is likely due to BNC210's efficacy in reducing PTSD symptoms, suggesting it may outperform existing treatments. This development could increase investor interest, positively impacting market dynamics and competitive positioning.",globenewswire_biotech,biotech,Clinical Study,354,BNOX,2024-03-21 10:00:00+00:00,US/Eastern,BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.,UP,0.028576836406278172,en
16721,XFOR,https://www.google.com/finance/quote/XFOR:NASDAQ,X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/21/2850047/0/en/X4-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-03-21 06:01:00+00:00,X4 Pharmaceuticals,clinical_study,"1. Approval anticipation for mavorixafor in WHIM syndrome likely drives the predicted upward move of +11.16%. 2. Market implications include increased investor confidence and potential revenue growth if approved, boosting company valuation.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,362,XFOR,2024-03-21 10:01:00+00:00,US/Eastern,"Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024",UP,0.11163075879146117,en
14641,MDWD,https://www.google.com/finance/quote/MDWD:NASDAQ,MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update,https://www.globenewswire.com/news-release/2024/03/21/2850096/30505/en/MediWound-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Company-Update.html,2024-03-21 07:00:00+00:00,MediWound,financial_results,"The predicted upward move of +0.41% is likely due to strong revenue growth projections and NexoBrid®'s commercial launches in major markets. This could boost investor confidence, improving market perception and potentially increasing asset value.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,255,MDWD,2024-03-21 11:00:00+00:00,US/Eastern,"$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42 million cash runway through profitability",UP,0.004119550012501874,en
15169,MLYS,https://www.google.com/finance/quote/MLYS:NASDAQ,Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/21/2850111/0/en/Mineralys-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-03-21 07:00:00+00:00,Mineralys Therapeutics,clinical_study,"The predicted upward move of +8.32% likely stems from successful enrollment in pivotal trials indicating confidence in lorundrostat’s progress. This could increase investor interest and potential market share in treating hypertension, boosting the company’s valuation.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,283,MLYS,2024-03-21 11:00:00+00:00,US/Eastern," – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 –",UP,0.08315650397875998,en
15230,KRON,https://www.google.com/finance/quote/KRON:NASDAQ,Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/21/2850114/0/en/Kronos-Bio-Reports-Recent-Business-Progress-and-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-21 07:05:00+00:00,Kronos Bio,clinical_study,"The predicted upward move of +17.24% likely stems from positive expectations around KB-0742's Phase 1/2 study progress, boosting investor confidence. Market implications could include increased stock interest and potential future funding opportunities, positively influencing the asset's valuation trajectory.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,286,KRON,2024-03-21 11:05:00+00:00,US/Eastern,"Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025",UP,0.1724417574902503,en
15790,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States,https://www.globenewswire.com/news-release/2024/03/21/2850208/34378/en/USDA-APHIS-Determines-that-Yield10-Bioscience-s-Omega-3-Camelina-Varieties-May-Be-Planted-and-Bred-in-the-United-States.html,2024-03-21 08:29:00+00:00,Yield10 Bioscience,regulatory_filings,"Yield10 Bioscience's milestone in omega-3 fatty acid production in Camelina likely drives the predicted upward move of +28.89% by enhancing commercial scalability. This could boost revenue prospects and investor interest, impacting the agricultural biotech market positively.",globenewswire_biotech,biotech,Product / Services Announcement,315,YTEN,2024-03-21 12:29:00+00:00,US/Eastern,Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.,DOWN,0.28889568231637097,en
14542,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,"Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California",https://www.globenewswire.com/news-release/2024/03/21/2850218/0/en/Dyadic-to-Attend-Future-Food-Tech-Event-March-21-22-2024-in-San-Francisco-California.html,2024-03-21 08:30:00+00:00,Dyadic International,trade_show,"The predicted upward move of +0.27% for Dyadic International may be due to increased investor interest in its participation at a prominent industry event. This exposure could enhance the company's visibility, potentially driving future investments and partnerships.",globenewswire_biotech,biotech,Food,250,DYAI,2024-03-21 12:30:00+00:00,US/Eastern,"JUPITER, Fla., March  21, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California.",UP,0.0027451331689545815,en
15977,CAPR,https://www.google.com/finance/quote/CAPR:NASDAQ,Capricor Therapeutics to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/03/21/2850220/0/en/Capricor-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html,2024-03-21 08:30:00+00:00,Capricor Therapeutics,conference_call_webinar,"1. The predicted upward move of +0.38% is likely due to Capricor Therapeutics announcing presentations at two investor conferences. 2. This could increase investor interest and confidence, potentially boosting the stock's visibility and attracting more investment.",globenewswire_biotech,biotech,Calendar of Events,324,CAPR,2024-03-21 12:30:00+00:00,US/Eastern,"SAN DIEGO, March  21, 2024  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.",UP,0.003839845943299829,en
14496,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/21/2850608/0/en/Kineta-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-03-21 16:02:00+00:00,Kineta,clinical_study,"The predicted upward move of +9.72% is likely due to promising trial results in VISTA-101, showing partial responses and stable diseases. This can increase investor confidence, potentially boosting the asset's market value and attracting more interest.",globenewswire_biotech,biotech,Clinical Study,248,KA,2024-03-21 20:02:00+00:00,US/Eastern,"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial",UP,0.09717428288426806,en
14831,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/03/21/2850618/0/en/ARS-Pharmaceuticals-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-03-21 16:05:00+00:00,ARS Pharmaceuticals,clinical_study,"The predicted upward move of +8.38% is likely due to positive outcomes from the nasal allergen challenge study and nitrosamine assessments for neffy®, suggesting favorable FDA response potential. This could increase investor confidence and market valuation for the company.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,265,SPRY,2024-03-21 20:05:00+00:00,US/Eastern,"Preparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period",UP,0.08382349947007989,en
14562,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference,https://www.globenewswire.com/news-release/2024/03/21/2850645/0/en/Jasper-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-Autoimmune-Inflammatory-Disease-Virtual-Conference.html,2024-03-21 16:30:00+00:00,Jasper Therapeutics,conference_call_webinar,"The predicted upward move of +0.23% is likely due to investor optimism surrounding Jasper's participation in the virtual conference, which may provide new insights into their antibody therapy developments. This could enhance investor confidence, potentially boosting the stock's appeal.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,251,JSPR,2024-03-21 20:30:00+00:00,US/Eastern,"REDWOOD CITY, Calif., March  21, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.",UP,0.002295861201125277,en
14857,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,"IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024",https://www.globenewswire.com/news-release/2024/03/21/2850655/0/en/IMUNON-to-Hold-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-March-28-2024.html,2024-03-21 17:00:00+00:00,Imunon,conference_call_webinar,"The predicted upward move of +2.48% is likely due to investor anticipation of positive financial results and progress updates on IMUNON's clinical programs, signaling potential growth. Market implications could include increased investor confidence and higher trading volumes.",globenewswire_biotech,biotech,Press releases,266,IMNN,2024-03-21 21:00:00+00:00,US/Eastern,"LAWRENCEVILLE, N.J., March  21, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.",UP,0.024761427969944596,en
16297,HUMA,https://www.google.com/finance/quote/HUMA:NASDAQ,Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update,https://www.globenewswire.com/news-release/2024/03/22/2850868/0/en/Humacyte-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Business-Update.html,2024-03-22 07:00:00+00:00,Humacyte,financial_results,"The likely cause of the predicted upward move of +0.23% is the FDA's acceptance of the Biologics License Application for HAV™, signaling progress towards product approval. This could boost investor confidence, potentially increasing asset demand and market value.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,340,HUMA,2024-03-22 11:00:00+00:00,US/Eastern,"-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024-",UP,0.0023202967128178485,en
16694,CKPT,https://www.google.com/finance/quote/CKPT:NASDAQ,Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2024/03/22/2850942/36989/en/Checkpoint-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html,2024-03-22 08:30:00+00:00,Checkpoint Therapeutics,financial_results,"The predicted upward move of +0.35% could result from positive financial results or recent corporate achievements. This may boost investor confidence, potentially increasing demand for Checkpoint's stock and potentially impacting similar biotech stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,361,CKPT,2024-03-22 12:30:00+00:00,US/Eastern,"WALTHAM, Mass., March  22, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.",UP,0.0034619738622142533,en
16319,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/03/22/2851164/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html,2024-03-22 17:30:00+00:00,Iovance Biotherapeutics,corporate_action,"The predicted upward move of +0.23% is likely due to optimism around Iovance's strategic expansion by adding new talent, which may enhance their capacity to innovate in cancer therapies. This could positively influence investor confidence and market perception.",globenewswire_biotech,biotech,Financing Agreements,342,IOVA,2024-03-22 21:30:00+00:00,US/Eastern,"SAN CARLOS, Calif., March  22, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (""Iovance"" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-executive employees.",UP,0.002310372947825854,en
16034,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Announces $25 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2024/03/25/2851487/0/en/BioXcel-Therapeutics-Announces-25-Million-Registered-Direct-Offering.html,2024-03-25 07:00:00+00:00,BioXcel Therapeutics,financing_agreements,"The predicted downward move of -4.13% likely stems from shareholder dilution concerns due to BioXcel's securities offering. This may affect investor confidence, potentially increasing stock volatility and impacting short-term market perception of the company's financial health and growth strategy.",globenewswire_biotech,biotech,Changes in company's own shares,327,BTAI,2024-03-25 11:00:00+00:00,US/Eastern,"NEW HAVEN, Conn., March  25, 2024  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share and Accompanying Warrant and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,565,027 shares of Common Stock and Accompanying Warrants to purchase up to 5,565,027 shares of Common Stock at a combined offering price of $2.900 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $0.001 exercise price per share of the Pre-Funded Warrants, for aggregate gross proceeds to the Company of approximately $25 million (excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Accompanying Warrants). The Pre-Funded Warrants have an exercise price of $0.001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Accompanying Warrants have an exercise price of $3.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance.",DOWN,-0.04128952265156838,en
14856,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses,https://www.globenewswire.com/news-release/2024/03/25/2851608/0/en/IMUNON-Receives-1-3-Million-from-Sale-of-its-New-Jersey-Net-Operating-Losses.html,2024-03-25 08:30:00+00:00,Imunon,financing_agreements,The predicted downward move of -0.20% may result from investor concerns over funding terms or market conditions. This slight decline could indicate skepticism or a broader market trend impacting confidence despite the overall balance sheet improvement.,globenewswire_biotech,biotech,Press releases,266,IMNN,2024-03-25 12:30:00+00:00,US/Eastern,Non-dilutive funding strengthens balance sheet and extends current operating runway,DOWN,-0.0020428786459390468,en
15364,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Announces Acquisition of Preferred Stock by David Lazar,https://www.globenewswire.com/news-release/2024/03/25/2851992/35690/en/OpGen-Announces-Acquisition-of-Preferred-Stock-by-David-Lazar.html,2024-03-25 16:05:00+00:00,OpGen,financing_agreements,The likely cause of the predicted upward move of +0.00% is investor confidence from the $3 million investment by David E. Lazar in OpGen's Series E Convertible Preferred Stock. Market implications could include improved liquidity and potential future stock performance improvements.,globenewswire_biotech,biotech,Management Changes,293,OPGN,2024-03-25 20:05:00+00:00,US/Eastern,"ROCKVILLE, Md., March  25, 2024  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.",UP,1.9390400625298854e-05,en
15850,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference,https://www.globenewswire.com/news-release/2024/03/25/2851989/0/en/NKGen-Biotech-Presents-Additional-Phase-1-Clinical-Trial-Data-in-Alzheimer-s-Disease-at-the-Tau2024-Global-Conference.html,2024-03-25 16:05:00+00:00,NKGen Biotech,clinical_study,"The upward move of +4.81% is likely due to positive clinical results for SNK01 in reducing CSF and plasma Tau proteins in Alzheimer’s patients, suggesting therapeutic potential. This could increase market confidence and investment interest in the asset.",globenewswire_biotech,biotech,Clinical Study,318,NKGN,2024-03-25 20:05:00+00:00,US/Eastern,SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.,UP,0.04808745810459278,en
15589,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024,https://www.globenewswire.com/news-release/2024/03/26/2852210/0/en/InspireMD-Announces-Abstract-of-One-Year-Follow-Up-Results-from-the-C-GUARDIANS-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial-Accepted-for-Presentation-at-LINC-2024.html,2024-03-26 07:00:00+00:00,InspireMD,clinical_study,"The predicted downward move of -0.29% may be due to limited short-term impact from the abstract presentation announcement at LINC 2024. Market implications could include investor caution, reflecting a wait-and-see approach pending trial results.",globenewswire_biotech,biotech,Clinical Study,304,NSPR,2024-03-26 11:00:00+00:00,US/Eastern,"TEL AVIV, Israel and MIAMI, March  26, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.",UP,-0.002879268225762895,en
15789,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada,https://www.globenewswire.com/news-release/2024/03/26/2852342/34378/en/Yield10-Bioscience-Announces-that-the-Plant-Biosafety-Office-of-the-Canadian-Food-Inspection-Agency-has-Cleared-Genome-edited-E3902-Camelina-for-Planting-in-Canada.html,2024-03-26 08:29:00+00:00,Yield10 Bioscience,regulatory_filings,"The likely cause of the predicted upward move of +8.57% is the approval by the Canadian Food Inspection Agency which may increase market confidence. Market implications include potential growth in oil production and sales expansion in Canada, positively impacting Yield10's shares.",globenewswire_biotech,biotech,Product / Services Announcement,315,YTEN,2024-03-26 12:29:00+00:00,US/Eastern,"WOBURN, Mass., March  26, 2024  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the Company’s E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10’s E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.",DOWN,0.08565367593776221,en
14541,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications,https://www.globenewswire.com/news-release/2024/03/26/2852344/0/en/Dyadic-Announces-Publication-of-C1-Monoclonal-Antibody-in-Nonhuman-Primate-Study-in-Nature-Communications.html,2024-03-26 08:30:00+00:00,Dyadic International,clinical_study,"The predicted upward move of +7.21% for Dyadic likely stems from the positive reception of their published research on a monoclonal antibody against SARS-CoV-2. This could boost investor confidence and enhance partnerships, impacting biotechnology market dynamics favorably.",globenewswire_biotech,biotech,Product / Services Announcement,250,DYAI,2024-03-26 12:30:00+00:00,US/Eastern,"JUPITER, Fla., March  26, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript ""Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models"" in Nature Communications (“Springer-Nature""), an international journal publishing peer-reviewed research in all fields of science and technology.",UP,0.07206373371547127,en
16533,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months,https://www.globenewswire.com/news-release/2024/03/26/2852347/0/en/Entera-Bio-Announces-Key-Regulatory-Milestone-for-Oral-PTH-1-34-Peptide-EB613-Phase-3-Program-FDA-Ruling-on-Qualifying-BMD-as-a-Surrogate-Endpoint-for-Osteoporosis-Drugs-is-Expecte.html,2024-03-26 08:30:00+00:00,Entera Bio,clinical_study,"1. The likely cause of the predicted upward move of +3.52% is the anticipated FDA ruling which could benefit Entera Bio's future osteoporosis drug trials. 2. This development may increase investor confidence, potentially enhancing market valuation and investment interest.",globenewswire_biotech,biotech,Clinical Study,353,ENTX,2024-03-26 12:30:00+00:00,US/Eastern,"JERUSALEM, March  26, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months.",UP,0.03521521932703586,en
15517,BCAB,https://www.google.com/finance/quote/BCAB:NASDAQ,BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress,https://www.globenewswire.com/news-release/2024/03/26/2852719/0/en/BioAtla-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Progress.html,2024-03-26 16:01:00+00:00,BioAtla,financial_results,"BioAtla's reported financial results and positive updates on clinical programs likely caused the predicted upward move of +0.73%. This could boost investor confidence, potentially increasing stock demand and influencing similar biotech stocks positively.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,300,BCAB,2024-03-26 20:01:00+00:00,US/Eastern,"SAN DIEGO, March  26, 2024  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided highlights on its clinical programs. ",UP,0.007305469044292715,en
16296,HUMA,https://www.google.com/finance/quote/HUMA:NASDAQ,"Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024",https://www.globenewswire.com/news-release/2024/03/26/2852737/0/en/Humacyte-to-Host-Virtual-KOL-Event-Hemodialysis-Access-A-Crossroads-of-Care-on-March-28-2024.html,2024-03-26 16:05:00+00:00,Humacyte,clinical_study,"The predicted upward move of +0.32% likely stems from heightened investor interest due to the upcoming virtual KOL event, showcasing innovations in implantable bioengineered human tissue. This could enhance Humacyte's market position and attract further investment.",globenewswire_biotech,biotech,Calendar of Events,340,HUMA,2024-03-26 20:05:00+00:00,US/Eastern,"DURHAM, N.C., March  26, 2024  (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Thursday, March 28, 2024 at 8:00 AM ET, featuring Timmy Lee, MD, MSPH (University of Alabama at Birmingham) and Prabir Roy-Chaudhury MD, PhD, FRCP (University of North Carolina School of Medicine) who will discuss the profiles of patients receiving an AV Access who have higher rates of complications and the associated costs of treating them. To register, click here.",UP,0.0031642060589126913,en
15932,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan,https://www.globenewswire.com/news-release/2024/03/26/2852845/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-Japan.html,2024-03-26 19:00:00+00:00,MediciNova,patents,"The predicted upward move of +1.64% for MediciNova likely stems from the new patent approval in Japan for MN-166, indicating potential revenue growth. This may boost investor confidence and enhance the company's market position in treating multiple sclerosis.",globenewswire_biotech,biotech,Patents,322,MNOV,2024-03-26 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., March  26, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",UP,0.01638033319348199,en
16212,VXRT,https://www.google.com/finance/quote/VXRT:NASDAQ,Vaxart to Present at World Vaccine Congress Washington 2024 on April 3,https://www.globenewswire.com/news-release/2024/03/27/2853084/25416/en/Vaxart-to-Present-at-World-Vaccine-Congress-Washington-2024-on-April-3.html,2024-03-27 08:00:00+00:00,Vaxart,trade_show,"The predicted upward move of +0.07% is likely due to Vaxart's participation in the World Vaccine Congress, potentially increasing visibility and investor interest. The market might see enhanced attention to biotech developments following the presentation.",globenewswire_biotech,biotech,Calendar of Events,336,VXRT,2024-03-27 12:00:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif., March  27, 2024  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C.",UP,0.0007102398531426679,en
15349,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,https://www.globenewswire.com/news-release/2024/03/27/2853079/0/en/Immuneering-Announces-First-Patient-Dosed-in-its-Phase-1-2a-Trial-of-IMM-6-415-to-Treat-Advanced-Solid-Tumors-with-RAF-or-RAS-Mutations.html,2024-03-27 08:00:00+00:00,Immuneering,clinical_study,"The predicted downward move of -0.21% may result from initial market skepticism regarding Immuneering's clinical trial progress. If adverse trial results surface, investor confidence could waver, potentially depressing the stock further.",globenewswire_biotech,biotech,Clinical Study,292,IMRX,2024-03-27 12:00:00+00:00,US/Eastern,Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations,UP,-0.0021489363380403134,en
14540,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic to Attend Industry Events in April,https://www.globenewswire.com/news-release/2024/03/27/2853162/0/en/Dyadic-to-Attend-Industry-Events-in-April.html,2024-03-27 08:30:00+00:00,Dyadic International,trade_show,"The predicted downward move of -0.55% for Dyadic International may be due to market sentiment regarding the company's announced event attendances lacking immediate revenue impact. This could lead investors to reassess short-term growth expectations, affecting biotech sector sentiment.",globenewswire_biotech,biotech,Calendar of Events,250,DYAI,2024-03-27 12:30:00+00:00,US/Eastern,"JUPITER, Fla., March  27, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry events during the month of April 2024.",UP,-0.005486076454980044,en
15768,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID,https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html,2024-03-27 09:08:00+00:00,Revive Therapeutics,clinical_study,"1. The upward move of +2.45% is likely due to Revive Therapeutics' submission of a meeting request to the FDA, signaling progress in their COVID treatment research. 2. The predicted upward move could boost investor confidence, potentially increasing stock interest.",globenewswire_biotech,biotech,Clinical Study,314,RVVTF,2024-03-27 13:08:00+00:00,US/Eastern,"TORONTO, March  27, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.",UP,0.024489334468618357,en
14939,ORPHA.CO,https://www.nasdaqomxnordic.com/aktier/microsite?Instrument=CSE145804&name=Orphazyme&ISIN=DK0062502894,Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00,https://www.globenewswire.com/news-release/2024/03/27/2853267/0/en/Indkaldelse-Til-Ordin%C3%A6r-Generalforsamling-Den-18-April-2024-Kl-15-00.html,2024-03-27 09:20:00+00:00,Orphazyme,annual_general_meeting,"The predicted upward move of +1.53% for Orphazyme A/S might be due to positive market anticipation of the upcoming general meeting's outcomes. This could enhance investor confidence, potentially boosting stock demand and valuation.",globenewswire_biotech,biotech,European Regulatory News,146,ORPHA.CO,2024-03-27 13:20:00+00:00,US/Eastern,"I henhold til vedtægternes pkt. 4.5 indkaldes hermed til ordinær generalforsamling i              Orphazyme A/S til afholdelse den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende dagsorden:",DOWN,0.015255719253113977,da
15917,BCDA,https://www.google.com/finance/quote/BCDA:NASDAQ,BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results,https://www.globenewswire.com/news-release/2024/03/27/2853582/0/en/BioCardia-Reports-Fourth-Quarter-and-Full-Year-2023-Business-Highlights-and-Financial-Results.html,2024-03-27 16:00:00+00:00,BioCardia,financial_results,"The predicted upward move of +0.58% could be due to positive financial results reported by BioCardia, Inc. This might boost investor confidence, potentially increasing investment in biotechnology, enhancing market interest in related securities.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,321,BCDA,2024-03-27 20:00:00+00:00,US/Eastern,"BioCardia®, Inc. today reported financial results for the year ended December 31, 2023",UP,0.005752228304245941,en
14855,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,IMUNON Reports 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2024/03/28/2853938/0/en/IMUNON-Reports-2023-Financial-Results-and-Provides-Business-Update.html,2024-03-28 08:00:00+00:00,Imunon,financial_results,"The predicted downward move of -0.04% suggests investor concerns over anticipated underwhelming information from the conference call. This minor decline indicates limited market impact, potentially reflecting cautious sentiment without significant shifts in asset valuation.",globenewswire_biotech,biotech,Press releases,266,IMNN,2024-03-28 12:00:00+00:00,US/Eastern,Conference Call Begins Today at 10:00 a.m. Eastern Time,UP,-0.0003655724575084801,en
16638,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2024/03/28/2853970/0/en/Candel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html,2024-03-28 08:05:00+00:00,Candel Therapeutics,financial_results,"The predicted upward move of +0.76% for Candel Therapeutics may result from positive financial results for Q4 2023. This could boost investor confidence, potentially increasing market interest and valuation, thereby reinforcing the company's growth prospects in the biopharmaceutical sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,358,CADL,2024-03-28 12:05:00+00:00,US/Eastern,"NEEDHAM, Mass., March  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.",UP,0.007589572603287359,en
15207,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference,https://www.globenewswire.com/news-release/2024/03/28/2853981/0/en/Biomerica-InFoods-IBS-Data-to-be-Presented-at-the-Upcoming-Digestive-Disease-Week-DDW-2024-Conference.html,2024-03-28 08:19:00+00:00,Biomerica,clinical_study,"The predicted upward move of +7.81% is likely due to positive exposure from presenting at the prestigious DDW Annual Meeting. This could enhance Biomerica's reputation, attract more investors, and potentially lead to increased demand for their IBS technologies.",globenewswire_biotech,biotech,Product / Services Announcement,285,BMRA,2024-03-28 12:19:00+00:00,US/Eastern,"IRVINE, Calif., March  28, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.",UP,0.07806631426273093,en
16456,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,"TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2024/03/28/2853993/0/en/TransCode-Therapeutics-Announces-Appointment-of-Daniel-Vlock-M-D-as-Chief-Medical-Officer.html,2024-03-28 08:30:00+00:00,TransCode Therapeutics,management_changes,The predicted downward move of -0.11% could be due to uncertainty about leadership changes. Market implications may include investor cautiousness and short-term volatility.,globenewswire_biotech,biotech,Directors and Officers,349,RNAZ,2024-03-28 12:30:00+00:00,US/Eastern,"TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer",UP,-0.0010857665433943531,en
14539,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Announces Change in Board and Management Leadership Roles,https://www.globenewswire.com/news-release/2024/03/28/2854006/0/en/Dyadic-Announces-Change-in-Board-and-Management-Leadership-Roles.html,2024-03-28 08:30:00+00:00,Dyadic International,management_changes,"1. Leadership changes, including the chairman stepping down and board member retirements, likely caused concern. 2. Potential market implications include investor uncertainty impacting company strategy perception. 3. The predicted downward move of -0.87% reflects apprehension about these changes.",globenewswire_biotech,biotech,Management Changes,250,DYAI,2024-03-28 12:30:00+00:00,US/Eastern,"JUPITER, Fla., March  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael Tarnok is stepping down as Chairman of Dyadic’s board of directors (the “Board”) and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Mr. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company’s annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company’s annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland’s retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.",UP,-0.008738556207545985,en
14538,DYAI,https://www.google.com/finance/quote/DYAI:NASDAQ,Dyadic Reports 2023 Full Year Results and Recent Company Progress,https://www.globenewswire.com/news-release/2024/03/28/2854430/0/en/Dyadic-Reports-2023-Full-Year-Results-and-Recent-Company-Progress.html,2024-03-28 16:00:00+00:00,Dyadic International,financial_results,"The predicted upward move of +0.07% likely stems from strong financial results and recent progress by Dyadic. This modest increase suggests market confidence in their biotechnology applications, potentially leading to increased investor interest and market stability for the company.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,250,DYAI,2024-03-28 20:00:00+00:00,US/Eastern,"JUPITER, Fla., March  28, 2024  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent Company progress.",UP,0.0006952753948697614,en
16279,INMB,https://www.google.com/finance/quote/INMB:NASDAQ,INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update,https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html,2024-03-28 16:01:00+00:00,INmune Bio,earnings_releases_and_operating_results,"The predicted downward move of -0.07% may result from market anticipation of disappointing updates during the conference call. This could signal weakened investor confidence, leading to minor selling pressure and possibly impacting overall market sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,339,INMB,2024-03-28 20:01:00+00:00,US/Eastern,"Company to Host Conference Call Today, March 28, at 4:30pm ET Company to Host Conference Call Today, March 28, at 4:30pm ET",UP,-0.000710547439563169,en
15788,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,"Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024",https://www.globenewswire.com/news-release/2024/03/28/2854445/34378/en/Yield10-Bioscience-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-a-Conference-Call-on-Monday-April-1-2024.html,2024-03-28 16:01:00+00:00,Yield10 Bioscience,earnings_releases_and_operating_results,"The predicted upward move of +0.35% for Yield10 Bioscience likely stems from anticipated positive financial results and corporate updates. This optimism could boost investor confidence, potentially increasing trading volume and share value in the bioscience sector.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,315,YTEN,2024-03-28 20:01:00+00:00,US/Eastern,"WOBURN, Mass., March  28, 2024  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.",UP,0.003484549558439725,en
14479,FBIO,https://www.google.com/finance/quote/FBIO:NASDAQ,Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2024/03/28/2854477/28889/en/Fortress-Biotech-Reports-2023-Financial-Results-and-Recent-Corporate-Highlights.html,2024-03-28 16:05:00+00:00,Fortress Biotech,financial_results,"The upward movement is likely due to strong financial performance, reflecting investor confidence. A predicted upward move of +0.61% suggests positive market sentiment, potentially boosting stock value and attracting further investment interest.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,247,FBIO,2024-03-28 20:05:00+00:00,US/Eastern,Record consolidated net revenue of $84.5 million for full-year 2023,UP,0.0061382380329643845,en
16637,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma,https://www.globenewswire.com/news-release/2024/03/28/2854466/0/en/Candel-Therapeutics-Announces-Oral-Presentation-During-the-5th-Glioblastoma-Drug-Development-Summit-with-Update-on-Phase-1b-Clinical-Trial-of-CAN-3110-in-Recurrent-High-Grade-Gliom.html,2024-03-28 16:05:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +1.21% for Candel Therapeutics is likely due to positive data from its phase 1b trial of CAN-3110 in rHGG patients. This could enhance investor confidence and potentially increase interest in their viral immunotherapy platform, impacting future valuations.",globenewswire_biotech,biotech,Clinical Study,358,CADL,2024-03-28 20:05:00+00:00,US/Eastern,"NEEDHAM, Mass., March  28, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with rHGG that has recurred after standard of care (SoC) treatment. The data were presented today during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts.",UP,0.012059685325742335,en
15445,ADAG,https://www.google.com/finance/quote/ADAG:NASDAQ,Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/03/29/2854733/0/en/Adagene-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-03-29 09:00:00+00:00,Adagene,clinical_study,"1. Positive trial results for ADG126 in MSS CRC likely fuel the predicted upward move of +9.72%. 2. This could enhance investor confidence and lead to increased investment in similar therapies, potentially boosting biotech stock performance.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,297,ADAG,2024-03-29 13:00:00+00:00,US/Eastern,"- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 -",UP,0.09717428288426806,en
14872,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris,https://www.globenewswire.com/news-release/2024/04/01/2855095/0/en/Ocuphire-Announces-the-U-S-Commercial-Launch-of-RYZUMVl-Phentolamine-Ophthalmic-Solution-0-75-by-its-Partner-Viatris.html,2024-04-01 07:14:00+00:00,Ocuphire Pharma,product_services_announcement,The predicted downward move of -1.58% for Ocuphire Pharma may be due to potential market skepticism surrounding the commercial success of RYZUMVI. This could imply investor uncertainty about future revenue growth and impact share prices negatively.,globenewswire_biotech,biotech,Health,268,OCUP,2024-04-01 11:14:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., April  01, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).",UP,-0.015836645926050483,en
16720,XFOR,https://www.google.com/finance/quote/XFOR:NASDAQ,X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences,https://www.globenewswire.com/news-release/2024/04/01/2855122/0/en/X4-Pharmaceuticals-to-Participate-in-Upcoming-April-Investor-Conferences.html,2024-04-01 08:00:00+00:00,X4 Pharmaceuticals,conference_call_webinar,"The predicted upward move of +0.21% for X4 Pharmaceuticals is likely due to increased visibility from participating in upcoming healthcare conferences. This may boost investor confidence, potentially leading to positive sentiment and increased interest in the stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,362,XFOR,2024-04-01 12:00:00+00:00,US/Eastern,"BOSTON, April  01, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.",UP,0.0021326100904266302,en
16332,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/01/2855148/0/en/CRISPR-Therapeutics-to-Present-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html,2024-04-01 08:00:00+00:00,CRISPR Therapeutics,clinical_study,"The predicted upward move of +2.04% for CRISPR Therapeutics likely results from anticipation surrounding their ASGCT 2024 presentation. This suggests increased investor optimism in their gene-based therapies, potentially boosting interest and stock value in the biotech sector.",globenewswire_biotech,biotech,Calendar of Events,343,CRSP,2024-04-01 12:00:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, April  01, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.",DOWN,0.020362546503391563,en
15426,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans,https://www.globenewswire.com/news-release/2024/04/01/2855138/0/en/Annovis-Announces-Publication-That-Supports-Understanding-of-Buntanetap-s-Mechanism-of-Action-in-Humans.html,2024-04-01 08:00:00+00:00,Annovis Bio,clinical_study,"The predicted upward move of +17.37% is likely due to the positive results from the ADCS Phase 1b study, increasing investor confidence in the asset. This could lead to heightened market interest and potential investment inflow.",globenewswire_biotech,biotech,Clinical Study,296,ANVS,2024-04-01 12:00:00+00:00,US/Eastern,Further look at earlier Phase 1b study by ADCS unveils confirmatory data,UP,0.17372480418213854,en
15787,YTEN,https://www.google.com/finance/quote/YTEN:NASDAQ,Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/04/01/2855414/34378/en/Yield10-Bioscience-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-04-01 16:01:00+00:00,Yield10 Bioscience,financial_results,The predicted upward move of +0.51% is likely due to the global license for Vision Bioenergy and regulatory clearance for omega-3 Camelina. Market implications include increased investor confidence and potential growth in biofuel and omega-3 markets.,globenewswire_biotech,biotech,Earnings Releases and Operating Results,315,YTEN,2024-04-01 20:01:00+00:00,US/Eastern,-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update,UP,0.00506387334105919,en
16258,GTHX,https://www.google.com/finance/quote/GTHX:NASDAQ,G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/04/01/2855473/0/en/G1-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-04-01 16:20:00+00:00,G1 Therapeutics,corporate_action,"The likely cause of the predicted upward move of +0.37% is investor optimism about G1 Therapeutics' recent inducement grants approval, signaling potential future growth. This may increase investor confidence and attract more buyers to the market.",globenewswire_biotech,biotech,Financing Agreements,338,GTHX,2024-04-01 20:20:00+00:00,US/Eastern,G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),UP,0.0037159476787624753,en
15767,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder,https://www.globenewswire.com/news-release/2024/04/02/2855836/0/en/Revive-Therapeutics-Provides-Update-on-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder.html,2024-04-02 07:30:00+00:00,Revive Therapeutics,clinical_study,The predicted downward move of -2.26% may result from negative investor sentiment regarding the clinical study's progress or results. Market implications could include reduced investor confidence in Revive's research capabilities and future therapeutic potential.,globenewswire_biotech,biotech,Clinical Study,314,RVVTF,2024-04-02 11:30:00+00:00,US/Eastern,"TORONTO, April  02, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.",DOWN,-0.022580184856019606,en
15425,ANVS,https://www.google.com/finance/quote/ANVS:NASDAQ,Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/04/02/2855841/0/en/Annovis-Bio-Provides-Corporate-Updates-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-04-02 07:30:00+00:00,Annovis Bio,clinical_study,"The predicted upward move of +17.14% may be due to positive clinical trial results or promising corporate updates. This could enhance investor confidence and attract more investment, potentially increasing market valuation and interest in related biotech stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,296,ANVS,2024-04-02 11:30:00+00:00,US/Eastern,"MALVERN, Pa., April  02, 2024  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.",UP,0.17136006944217538,en
14608,ECOR,https://www.google.com/finance/quote/ECOR:NASDAQ,electroCore Expands Intellectual Property Portfolio,https://www.globenewswire.com/news-release/2024/04/02/2855874/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html,2024-04-02 08:00:00+00:00,electroCore,patents,"The predicted upward move of +1.93% is likely due to investor optimism following electroCore's new U.S. patents, which indicate potential growth and innovation. This could increase interest in the company's assets, potentially boosting market valuation and share price.",globenewswire_biotech,biotech,Patents,253,ECOR,2024-04-02 12:00:00+00:00,US/Eastern,electroCore Granted Two New U.S. Patents electroCore Granted Two New U.S. Patents,UP,0.019264450419636328,en
16496,CRBP,https://www.google.com/finance/quote/CRBP:NASDAQ,Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC,https://www.globenewswire.com/news-release/2024/04/02/2855883/0/en/Corbus-Announces-Dosing-of-First-Patient-in-U-S-Phase-1-Clinical-Trial-of-Its-Next-Generation-Nectin-4-Targeting-ADC.html,2024-04-02 08:00:00+00:00,Corbus Pharmaceuticals,clinical_study,The predicted upward move of +0.92% for Corbus Pharmaceuticals likely stems from positive investor sentiment due to dosing the first U.S. patient in its CRB-701 Phase 1 trial. This could enhance interest in its oncology innovations and bolster investor confidence.,globenewswire_biotech,biotech,Clinical Study,351,CRBP,2024-04-02 12:00:00+00:00,US/Eastern,"NORWOOD, Mass., April  02, 2024  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.",DOWN,0.009185096063030307,en
15493,PCRX,https://www.google.com/finance/quote/PCRX:NASDAQ,Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/02/2855915/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-02 08:00:00+00:00,Pacira BioSciences,conference_call_webinar,"The predicted downward move of -0.03% may be due to minimal investor excitement regarding the fireside chat participation, suggesting limited immediate impact. Market implications include lukewarm sentiment and minor short-term trading adjustments for Pacira BioSciences.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,299,PCRX,2024-04-02 12:00:00+00:00,US/Eastern,"TAMPA, Fla., April  02, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.",DOWN,-0.00026664372603458255,en
16719,XFOR,https://www.google.com/finance/quote/XFOR:NASDAQ,X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/04/02/2856457/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-04-02 16:05:00+00:00,X4 Pharmaceuticals,corporate_action,"The predicted upward move of +0.17% for X4 Pharmaceuticals is likely due to investor optimism about attracting new talent through the inducement awards. This could enhance innovation and productivity, potentially boosting future company performance and market value.",globenewswire_biotech,biotech,Changes in company's own shares,362,XFOR,2024-04-02 20:05:00+00:00,US/Eastern,"BOSTON, April  02, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 1,164,470 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.",UP,0.0017189704090564643,en
16433,PCVX,https://www.google.com/finance/quote/PCVX:NASDAQ,Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/02/2856469/0/en/Vaxcyte-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-02 16:05:00+00:00,Vaxcyte,conference_call_webinar,"The predicted upward move of +0.11% for Vaxcyte may result from increased investor interest due to their participation in a high-profile healthcare conference. This could indicate potential strategic developments, possibly increasing market confidence in their pipeline progress.",globenewswire_biotech,biotech,Calendar of Events,348,PCVX,2024-04-02 20:05:00+00:00,US/Eastern,"SAN CARLOS, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.",DOWN,0.0011074043602069363,en
14561,JSPR,https://www.google.com/finance/quote/JSPR:NASDAQ,Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/02/2856491/0/en/Jasper-Therapeutics-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-02 16:30:00+00:00,Jasper Therapeutics,conference_call_webinar,"The predicted upward move of +0.24% is likely due to anticipation of positive updates from Jasper's presentation at the healthcare conference. This could boost investor confidence and increase interest in their innovative antibody therapy, potentially driving modest stock gains.",globenewswire_biotech,biotech,Calendar of Events,251,JSPR,2024-04-02 20:30:00+00:00,US/Eastern,"REDWOOD CITY, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.",UP,0.0024161599142820526,en
16089,CNTG,https://www.google.com/finance/quote/CNTG:NASDAQ,CENTOGENE Receives Nasdaq Non-Compliance Notice,https://www.globenewswire.com/news-release/2024/04/02/2856492/0/en/CENTOGENE-Receives-Nasdaq-Non-Compliance-Notice.html,2024-04-02 16:30:00+00:00,Centogene,observation_status,"1. The likely cause of the predicted downward move of +nan% is Centogene's non-compliance with Nasdaq's minimum bid price rule. 2. This could lead to reduced investor confidence and potential delisting from Nasdaq, affecting market perception and liquidity.",globenewswire_biotech,biotech,Regulatory information,330,CNTG,2024-04-02 20:30:00+00:00,US/Eastern,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April  02, 2024  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.",UP,-6.946643570649935,en
15931,MNOV,https://www.google.com/finance/quote/MNOV:NASDAQ,MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO),https://www.globenewswire.com/news-release/2024/04/02/2856544/7767/en/MediciNova-Announces-Abstract-Regarding-Results-of-a-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-.html,2024-04-02 19:00:00+00:00,MediciNova,clinical_study,The predicted upward move of +1.17% is likely due to MediciNova's announcement of their clinical trial results for MN-166 being highlighted at a prestigious oncology conference. This recognition may enhance investor confidence and improve the company's market perception.,globenewswire_biotech,biotech,Health,322,MNOV,2024-04-02 23:00:00+00:00,US/Eastern,"LA JOLLA, Calif., April  02, 2024  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago. The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.",UP,0.011695865997052399,en
14815,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders,https://www.globenewswire.com/news-release/2024/04/03/2856583/0/en/Addex-and-Perceptive-Launch-Neurosterix-with-63-Million-to-Accelerate-Development-of-Allosteric-Modulator-Therapeutics-for-Neurological-Disorders.html,2024-04-03 01:00:00+00:00,Addex Therapeutics,financing_agreements,"The likely cause of the predicted upward move of +1.90% is Addex receiving CHF5M and a 20% share of Neurosterix, enhancing its financial position and growth potential. This may increase investor confidence, leading to potential market gains for Addex.",globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-04-03 05:00:00+00:00,US/Eastern,Addex receives CHF5M and 20% share of Neurosterix,UP,0.018995356197763064,en
14678,EYEN,https://www.google.com/finance/quote/EYEN:NASDAQ,Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings,https://www.globenewswire.com/news-release/2024/04/03/2856771/0/en/Eyenovia-to-Feature-its-Suite-of-Commercial-Products-and-the-Optejet-Dispenser-at-Upcoming-National-Eyecare-Meetings.html,2024-04-03 07:00:00+00:00,Eyenovia,trade_show,"1. The predicted downward move of -0.59% is likely due to investor concerns about the competitiveness or reception of the products showcased. 2. This could lead to cautious market sentiment, impacting investment decisions in related stocks.",globenewswire_biotech,biotech,Product / Services Announcement,257,EYEN,2024-04-03 11:00:00+00:00,US/Eastern,"Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston",DOWN,-0.005907245108651117,en
16331,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/03/2856862/0/en/CRISPR-Therapeutics-to-Present-at-the-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-03 08:00:00+00:00,CRISPR Therapeutics,conference_call_webinar,1. The predicted upward move of +0.28% is likely due to investor anticipation ahead of CRISPR Therapeutics' presentation at the Needham Virtual Healthcare Conference. 2. This movement suggests positive market sentiment towards the company's upcoming developments and announcements.,globenewswire_biotech,biotech,Calendar of Events,343,CRSP,2024-04-03 12:00:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, April  03, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET.",DOWN,0.00276832518397,en
15588,NSPR,https://www.google.com/finance/quote/NSPR:NASDAQ,InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/03/2856961/0/en/InspireMD-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-03 08:59:00+00:00,InspireMD,conference_call_webinar,"The predicted downward move of -0.74% may be due to investor anticipation ahead of the company's presentation at the Needham Virtual Healthcare Conference. This could imply uncertainty or lack of excitement over InspireMD's upcoming announcements, potentially affecting investor sentiment negatively.",globenewswire_biotech,biotech,Calendar of Events,304,NSPR,2024-04-03 12:59:00+00:00,US/Eastern,"TEL AVIV, Israel and MIAMI, April  03, 2024  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.",UP,-0.007396411762591053,en
14830,SPRY,https://www.google.com/finance/quote/SPRY:NASDAQ,ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray),https://www.globenewswire.com/news-release/2024/04/03/2857016/0/en/ARS-Pharmaceuticals-Submits-Response-to-FDA-Complete-Response-Letter-for-neffy-Epinephrine-Nasal-Spray.html,2024-04-03 09:01:00+00:00,ARS Pharmaceuticals,regulatory_filings,"The predicted upward move of +0.15% is likely due to ARS Pharmaceuticals' submission of their response to the FDA for approval of neffy®. This indicates progress in their drug approval process, potentially enhancing future revenue and investor confidence.",globenewswire_biotech,biotech,Product / Services Announcement,265,SPRY,2024-04-03 13:01:00+00:00,US/Eastern,"SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.",UP,0.0015395506557467189,en
16455,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics Reports 2023 Results; Provides Business Update,https://www.globenewswire.com/news-release/2024/04/03/2857023/0/en/TransCode-Therapeutics-Reports-2023-Results-Provides-Business-Update.html,2024-04-03 09:10:00+00:00,TransCode Therapeutics,financial_results,"1. The likely cause of the predicted upward move of +0.08% is positive financial results or optimistic business developments reported by TransCode Therapeutics. 2. This movement may boost investor confidence, potentially attracting more investment in the biotechnology sector.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,349,RNAZ,2024-04-03 13:10:00+00:00,US/Eastern,TransCode Therapeutics Reports 2023 Results; Provides Business Update,DOWN,0.00084101312412465,en
15159,BIOR,https://www.google.com/finance/quote/BIOR:NASDAQ,Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2024/04/03/2857352/0/en/Biora-Therapeutics-Announces-Closing-of-6-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,2024-04-03 16:05:00+00:00,Biora Therapeutics,financing_agreements,"The predicted downward move of -5.52% likely stems from shareholder dilution concerns due to the new stock issuance and warrants. This may impact investor confidence, leading to potential selling pressure and volatility in Biora's stock price.",globenewswire_biotech,biotech,Financing Agreements,282,BIOR,2024-04-03 20:05:00+00:00,US/Eastern,"SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval.",DOWN,-0.05524381038627544,en
15348,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/03/2857344/0/en/Immuneering-to-Participate-in-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-03 16:05:00+00:00,Immuneering,conference_call_webinar,"Immuneering's participation in the 23rd Annual Needham Virtual Healthcare Conference likely boosts investor confidence, driving the predicted upward move of +0.22%. This could increase investor interest and trading volume, positively influencing the stock's short-term performance.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,292,IMRX,2024-04-03 20:05:00+00:00,US/Eastern,Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference,DOWN,0.0022091798048304843,en
15158,BIOR,https://www.google.com/finance/quote/BIOR:NASDAQ,"Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development",https://www.globenewswire.com/news-release/2024/04/04/2857705/0/en/Biora-Therapeutics-Achieves-Positive-Interim-Results-for-Clinical-Trial-of-BT-600-Advancing-NaviCap-Platform-Development.html,2024-04-04 08:00:00+00:00,Biora Therapeutics,clinical_study,"The upward move of +0.14% is likely due to successful pharmacokinetic outcomes and flawless device performance without safety issues. This positive result may enhance investor confidence, impacting market sentiment and potentially boosting related stocks or assets.",globenewswire_biotech,biotech,Clinical Study,282,BIOR,2024-04-04 12:00:00+00:00,US/Eastern,All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed,UP,0.0013717501519415482,en
16636,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer,https://www.globenewswire.com/news-release/2024/04/04/2857746/0/en/Candel-Therapeutics-Announces-Positive-Interim-Data-from-Randomized-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html,2024-04-04 08:00:00+00:00,Candel Therapeutics,clinical_study,The likely cause of the predicted upward move of +0.95% is the positive interim survival data and Fast Track Designation by the FDA for Candel Therapeutics' treatment. This can boost investor confidence and potentially increase funding opportunities.,globenewswire_biotech,biotech,Clinical Study,358,CADL,2024-04-04 12:00:00+00:00,US/Eastern,"NEEDHAM, Mass., April  04, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023.",UP,0.009538627620172758,en
15992,OVID,https://www.google.com/finance/quote/OVID:NASDAQ,Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/04/2857730/0/en/Ovid-Therapeutics-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-04 08:00:00+00:00,Ovid Therapeutics,conference_call_webinar,"The predicted upward move of +0.30% is likely due to Ovid Therapeutics' participation in the Needham Virtual Healthcare Conference, highlighting strategic developments. This could increase investor interest and market confidence, potentially enhancing stock visibility and value.",globenewswire_biotech,biotech,Calendar of Events,325,OVID,2024-04-04 12:00:00+00:00,US/Eastern,"NEW YORK, April  04, 2024  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET.",DOWN,0.0029717873472750417,en
16257,GTHX,https://www.google.com/finance/quote/GTHX:NASDAQ,G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2024/04/04/2857933/0/en/G1-Therapeutics-to-Participate-in-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html,2024-04-04 10:30:00+00:00,G1 Therapeutics,conference_call_webinar,"The predicted upward move of +0.43% likely stems from investor optimism about G1 Therapeutics presenting positive developments at the conference. This can attract increased investor interest, potentially boosting stock value and enhancing market perception of the company's growth prospects.",globenewswire_biotech,biotech,Calendar of Events,338,GTHX,2024-04-04 14:30:00+00:00,US/Eastern,G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference,DOWN,0.004304183284321555,en
14912,IMCR,https://www.google.com/finance/quote/IMCR:NASDAQ,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2024/04/04/2858173/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,2024-04-04 16:00:00+00:00,Immunocore,conference_call_webinar,The predicted downward move of -0.01% may result from investors having tempered expectations about the presentations. Such minor movement suggests limited market impact but could indicate cautious sentiment or profit-taking ahead of the conferences.,globenewswire_biotech,biotech,Calendar of Events,270,IMCR,2024-04-04 20:00:00+00:00,US/Eastern,Immunocore to present at upcoming investor conferences ,UP,-0.00012664986722225313,en
14773,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/04/04/2858218/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html,2024-04-04 16:30:00+00:00,ORIC Pharmaceuticals,conference_call_webinar,"The upward move of +0.24% in ORIC Pharmaceuticals' asset price is likely due to the announcement of management's participation in investor conferences, which might boost investor confidence. This predicted upward move could enhance market interest and visibility for ORIC.",globenewswire_biotech,biotech,Calendar of Events,262,ORIC,2024-04-04 20:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  04, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:",DOWN,0.0023861382057322952,en
15668,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale,https://www.globenewswire.com/news-release/2024/04/05/2858480/0/en/Akoya-Biosciences-Showcases-Spatial-Biology-2-0-Solutions-at-AACR-Annual-Meeting-with-Case-Studies-Demonstrating-Unprecedented-Speed-and-Scale.html,2024-04-05 08:00:00+00:00,Akoya Biosciences,trade_show,"The predicted downward move of -0.63% is likely due to possible investor concerns over the impact of new product showcases not meeting market expectations. Such moves could imply cautious investor sentiment, potentially affecting short-term liquidity for Akoya Biosciences.",globenewswire_biotech,biotech,Health,309,AKYA,2024-04-05 12:00:00+00:00,US/Eastern,"MARLBOROUGH, Mass., April  05, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya’s platforms.",DOWN,-0.0062864543388741955,en
16015,TSHA,https://www.google.com/finance/quote/TSHA:NASDAQ,Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/04/05/2858478/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,2024-04-05 08:00:00+00:00,Taysha Gene Therapies,corporate_action,"The predicted upward move of +0.28% is likely due to investor confidence in Taysha Gene Therapies' strategic hiring and expansion efforts. This could signal future growth prospects, potentially enhancing the company's ability to advance its CNS disease treatments.",globenewswire_biotech,biotech,Major shareholder announcements,326,TSHA,2024-04-05 12:00:00+00:00,US/Eastern,"DALLAS, April  05, 2024  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).",DOWN,0.002763863686752333,en
15257,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/04/05/2858706/0/en/Cidara-Therapeutics-Presents-Promising-New-Data-on-Novel-Drug-Fc-Conjugate-Candidates-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024.html,2024-04-05 15:00:00+00:00,Cidara Therapeutics,clinical_study,"The predicted upward move of +3.19% is likely due to improved tumor reduction results from the multispecific CD73/PD-1 therapy compared to PD-1 monotherapy, potentially enhancing competitive positioning and increasing investor interest in future drug performance.",globenewswire_biotech,biotech,Health,287,CDTX,2024-04-05 19:00:00+00:00,US/Eastern,- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study,UP,0.031901039989999075,en
14772,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/04/05/2858745/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,2024-04-05 16:30:00+00:00,ORIC Pharmaceuticals,corporate_action,The predicted upward move of +0.23% might be due to investor optimism surrounding new talent acquisition. This could signal future growth. Market implications include increased investor confidence in ORIC's strategic direction and potential enhanced productivity.,globenewswire_biotech,biotech,Stock Market News,262,ORIC,2024-04-05 20:30:00+00:00,US/Eastern,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  05, 2024  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.",UP,0.002310372947825854,en
15058,EVAX,https://www.google.com/finance/quote/EVAX:NASDAQ,Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré,https://www.globenewswire.com/news-release/2024/04/08/2858863/0/fr/Evaxion-et-un-collaborateur-anonyme-annoncent-des-r%C3%A9sultats-encourageants-concernant-les-antig%C3%A8nes-du-vaccin-EVX-B1-contre-l-infection-%C3%A0-staphylocoque-dor%C3%A9.html,2024-04-07 21:28:00+00:00,Evaxion Biotech,clinical_study,"The predicted upward move of +17.67% for Evaxion Biotech is likely driven by successful results in large-scale animal studies of their EVX-B1 vaccine candidate, boosting investor confidence. This success could lead to increased market interest and potential future partnerships.",globenewswire_biotech,biotech,Clinical Study,277,EVAX,2024-04-08 01:28:00+00:00,US/Eastern,"COPENHAGUE, Danemark,  08 avr. 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de puissants vaccins basés sur sa plateforme d’immunologie par l’IA, AI-Immunology™, se réjouit d'annoncer la réussite d'une série d'études à grande échelle portant sur les infections chez les animaux autres que des rongeurs et visant à tester les antigènes de l'EVX-B1, le candidat vaccin préclinique d'Evaxion contre le Staphylocoque doré (S. aureus). Dans les études chez l'animal, les antigènes de l'EVX-B1 ont réduit de manière significative la charge de morbidité. Actuellement, les deux sociétés sont en phase de discussion pour déterminer la marche à suivre.",UP,0.1767331294018187,fr
15059,EVAX,https://www.google.com/finance/quote/EVAX:NASDAQ,Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen,https://www.globenewswire.com/news-release/2024/04/08/2858863/0/de/Evaxion-und-nicht-offengelegter-Kooperationspartner-ver%C3%B6ffentlichen-vielversprechende-Ergebnisse-f%C3%BCr-EVX-B1-Impfstoff-Antigene-gegen-Staphylococcus-aureus-Infektionen.html,2024-04-07 21:28:00+00:00,Evaxion Biotech,clinical_study,"The likely cause of the predicted upward move of +18.15% for Evaxion Biotech is the successful completion of studies showing EVX-B1's effectiveness against S. aureus. This could enhance Evaxion's market position and investor confidence, potentially boosting stock value.",globenewswire_biotech,biotech,Clinical Study,277,EVAX,2024-04-08 01:28:00+00:00,US/Eastern,"KOPENHAGEN, Dänemark, April  08, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein Biotechnologie-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von AI-Immunology™-gestützten Impfstoffen spezialisiert hat, freut sich, den erfolgreichen Abschluss mehrerer umfangreicher Infektionsstudien an Nicht-Nagetieren bekannt zu geben, in deren Rahmen die Antigene des präklinischen Impfstoffkandidaten EVX-B1 von Evaxion gegen Staphylococcus aureus (S. aureus) getestet wurden. In den Tierstudien führten die EVX-B1-Antigene zu einer deutlichen Verringerung der Krankheitslast. Gegenwärtig führen die beiden Unternehmen Gespräche über das weitere Vorgehen.",UP,0.18151410013696107,de
14677,EYEN,https://www.google.com/finance/quote/EYEN:NASDAQ,Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities,https://www.globenewswire.com/news-release/2024/04/08/2859046/0/en/Eyenovia-Announces-Updated-Strategy-and-Corporate-Priorities-to-Focus-on-Shareholder-Value-Generation-and-Immediate-Commercial-Opportunities.html,2024-04-08 07:00:00+00:00,Eyenovia,mergers_acquisitions,The predicted upward move of +0.38% is likely due to Eyenovia's strategic review and potential development acceleration of its MicroPine product. Market implications include increased investor interest and speculation on potential mergers or asset sales.,globenewswire_biotech,biotech,Management statements,257,EYEN,2024-04-08 11:00:00+00:00,US/Eastern,"NEW YORK, April  08, 2024  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value. As part of this process, the Company plans to consider a wide range of options, including potential sale of assets of the Company, a sale of the Company, a merger, or other strategic action. In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.",UP,0.0038419326839701624,en
16278,INMB,https://www.google.com/finance/quote/INMB:NASDAQ,INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024,https://www.globenewswire.com/news-release/2024/04/08/2859126/0/en/INmune-Bio-Inc-Presents-Data-on-INB03-s-Role-as-an-Immune-Check-Point-Modulator-in-the-Treatment-of-High-Risk-Breast-Cancer-at-AACR-2024.html,2024-04-08 08:00:00+00:00,INmune Bio,clinical_study,The predicted upward move of +1.40% is likely due to investor optimism about the novel immunotherapy's potential to improve outcomes in high-risk breast cancer. Market implications may include increased investment in biotech sectors focusing on cancer treatments.,globenewswire_biotech,biotech,Press releases,339,INMB,2024-04-08 12:00:00+00:00,US/Eastern,Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer,DOWN,0.014022966887514315,en
14771,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting,https://www.globenewswire.com/news-release/2024/04/08/2859138/0/en/ORIC-Pharmaceuticals-Presents-Preclinical-Data-on-Two-Programs-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,2024-04-08 08:00:00+00:00,ORIC Pharmaceuticals,clinical_study,"ORIC-944 shows promising preclinical results and superior clinical properties, likely leading to the predicted upward move of +1.32%. This could enhance its competitive position against other PRC2 inhibitors, attracting investor interest. Market confidence may increase accordingly.",globenewswire_biotech,biotech,Clinical Study,262,ORIC,2024-04-08 12:00:00+00:00,US/Eastern,"ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors",UP,0.013212088354368814,en
15894,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024,https://www.globenewswire.com/news-release/2024/04/08/2859100/0/en/C4-Therapeutics-Presents-New-Preclinical-Data-for-CFT1946-Highlighting-Superior-Activity-as-a-Single-Agent-to-Clinically-Approved-BRAF-Inhibitor-Standard-of-Care-Combinations-at-th.html,2024-04-08 08:00:00+00:00,C4 Therapeutics,clinical_study,"The predicted upward move of +5.26% is likely driven by promising new preclinical data for CFT1946 presented by C4 Therapeutics, indicating potential efficacy in various cancer models. This could enhance investor confidence and lead to increased interest in the stock.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,320,CCCC,2024-04-08 12:00:00+00:00,US/Eastern,"WATERTOWN, Mass., April  08, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant melanoma models, and an intracranial model of BRAF V600E metastatic melanoma.",UP,0.05261800858153153,en
15157,BIOR,https://www.google.com/finance/quote/BIOR:NASDAQ,Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology,https://www.globenewswire.com/news-release/2024/04/08/2859129/0/en/Biora-Therapeutics-Announces-New-Patent-Covering-its-BioJet-Liquid-Jet-Delivery-Technology.html,2024-04-08 08:00:00+00:00,Biora Therapeutics,patents,"The predicted upward move of +1.76% is likely due to the patent claims protecting innovative drug delivery methods boosting investor confidence. This could enhance the asset's market position and competitive edge, potentially increasing future revenues.",globenewswire_biotech,biotech,Product / Services Announcement,282,BIOR,2024-04-08 12:00:00+00:00,US/Eastern,Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.,DOWN,0.0175626185053996,en
15072,CHRS,https://www.google.com/finance/quote/CHRS:NASDAQ,"Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting",https://www.globenewswire.com/news-release/2024/04/08/2859185/33333/en/Coherus-Presents-Preclinical-Data-for-CHS-1000-a-Novel-Anti-ILT4-Antibody-at-the-2024-AACR-Annual-Meeting.html,2024-04-08 08:30:00+00:00,Coherus BioSciences,clinical_study,"The predicted upward move of +2.44% is likely due to CHS-1000's promising preclinical results and future IND submission. This suggests strong potential in immunotherapy, potentially boosting Coherus's market position and investor interest in oncology advancements.",globenewswire_biotech,biotech,Product / Services Announcement,278,CHRS,2024-04-08 12:30:00+00:00,US/Eastern,"– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy ––  First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 –",UP,0.024436007782403422,en
14607,ECOR,https://www.google.com/finance/quote/ECOR:NASDAQ,electroCore Announces the Launch of Truvaga Plus® for General Wellness,https://www.globenewswire.com/news-release/2024/04/08/2859191/0/en/electroCore-Announces-the-Launch-of-Truvaga-Plus-for-General-Wellness.html,2024-04-08 08:30:00+00:00,electroCore,product_services_announcement,"The predicted downward move of -1.48% may stem from investor uncertainty regarding the launch of electroCore's Truvaga Plus app. Market implications include potential skepticism about product adoption or revenue impact, possibly affecting stock performance in the short term.",globenewswire_biotech,biotech,Product / Services Announcement,253,ECOR,2024-04-08 12:30:00+00:00,US/Eastern,"ROCKAWAY, N.J., April  08, 2024  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.",UP,-0.014763781017306578,en
16532,ENTX,https://www.google.com/finance/quote/ENTX:NASDAQ,Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research,https://www.globenewswire.com/news-release/2024/04/08/2859187/0/en/Entera-Bio-Announces-Publication-of-Oral-PTH-1-34-Peptide-Tablets-EB613-Phase-2-Trial-Data-in-the-Journal-of-Bone-and-Mineral-Research.html,2024-04-08 08:30:00+00:00,Entera Bio,clinical_study,"The likely cause of the predicted upward move of +2.05% is positive Phase 2 trial data. This could enhance investor confidence in Entera Bio's potential, possibly attracting more investments and increasing share value. Market implications may include heightened interest in biotechnology stocks focused on osteoporosis treatments.",globenewswire_biotech,biotech,Clinical Study,353,ENTX,2024-04-08 12:30:00+00:00,US/Eastern,"JERUSALEM, April  08, 2024  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).",UP,0.020502397642172862,en
14495,KA,https://www.google.com/finance/quote/KA:NASDAQ,Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial,https://www.globenewswire.com/news-release/2024/04/08/2859553/0/en/Kineta-Reports-Initial-Clinical-Response-Data-at-AACR-2024-of-its-Ongoing-Phase-1-2-VISTA-101-Clinical-Trial.html,2024-04-08 16:01:00+00:00,Kineta,clinical_study,"The upward movement of +2.64% is likely due to positive clinical results, with stable disease outcomes boosting investor confidence. This may lead to increased investor interest and potential funding, further enhancing the asset's market position.",globenewswire_biotech,biotech,Clinical Study,248,KA,2024-04-08 20:01:00+00:00,US/Eastern,"Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts",UP,0.026385603842858797,en
15531,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,"Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing",https://www.globenewswire.com/news-release/2024/04/08/2859612/0/en/Windtree-Acquires-Early-Stage-Novel-Oncology-Platform-and-Completes-1-5-Million-Convertible-Note-Bridge-Financing.html,2024-04-08 16:48:00+00:00,Windtree Therapeutics,mergers_acquisitions,"Windtree's acquisition of aPKCi assets and securing $1.5 million financing likely spurred investor optimism, contributing to the predicted upward move of +6.17%. This could enhance Windtree's R&D capabilities, boosting market confidence and potentially attracting further investment.",globenewswire_biotech,biotech,Mergers and Acquisitions,301,WINT,2024-04-08 20:48:00+00:00,US/Eastern,"WARRINGTON, Pa., April  08, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. (“Varian”) to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing.",UP,0.06165954525255068,en
15893,CCCC,https://www.google.com/finance/quote/CCCC:NASDAQ,C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum,https://www.globenewswire.com/news-release/2024/04/09/2859837/0/en/C4-Therapeutics-to-Participate-in-the-Stifel-2024-Targeted-Oncology-Forum.html,2024-04-09 07:00:00+00:00,C4 Therapeutics,conference_call_webinar,"The predicted downward move of -0.18% likely stems from market anticipation or concerns over C4 Therapeutics' messaging at the Stifel 2024 Targeted Oncology Forum. This minor dip may signal investor caution or skepticism, affecting trading volume or short-term stock sentiment.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,320,CCCC,2024-04-09 11:00:00+00:00,US/Eastern,"WATERTOWN, Mass., April  09, 2024  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024.",DOWN,-0.0017623535213035846,en
16635,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors,https://www.globenewswire.com/news-release/2024/04/09/2859909/0/en/Candel-Therapeutics-Presents-Preclinical-Data-at-AACR-on-Immunotherapy-Candidate-for-Induction-of-Tertiary-Lymphoid-Structures-in-Solid-Tumors.html,2024-04-09 08:00:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +7.79% is likely due to Candel's presentation at the AACR highlighting their innovative immunotherapy candidate. This could boost investor confidence, indicating potential advancements in cancer treatment, possibly increasing interest in biotech stocks.",globenewswire_biotech,biotech,Clinical Study,358,CADL,2024-04-09 12:00:00+00:00,US/Eastern,"NEEDHAM, Mass., April  09, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5 through 10 in San Diego, which focused on a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures (TLS), being developed as a novel therapeutic strategy for solid tumors from Candel’s enLIGHTEN™ Discovery Platform.",DOWN,0.07793192039262209,en
15092,MYNZ,https://www.google.com/finance/quote/MYNZ:NASDAQ,Mainz Biomed Reports Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/04/09/2859959/0/en/Mainz-Biomed-Reports-Full-Year-2023-Financial-Results.html,2024-04-09 08:01:00+00:00,Mainz Biomed,financial_results,"The predicted upward move of +0.33% for Mainz Biomed likely stems from positive full-year 2023 financial results. This could boost investor confidence and possibly increase demand for shares, impacting associated biotech market segments.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,279,MYNZ,2024-04-09 12:01:00+00:00,US/Eastern,Mainz Biomed Reports Full Year 2023 Financial Results,UP,0.0032722977688955596,en
15347,IMRX,https://www.google.com/finance/quote/IMRX:NASDAQ,IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models,https://www.globenewswire.com/news-release/2024/04/09/2860240/0/en/IMM-1-104-is-Synergistic-with-Chemotherapy-in-Pancreatic-Cancer-Models.html,2024-04-09 12:00:00+00:00,Immuneering,clinical_study,The predicted upward move of +2.10% is likely due to positive synergy findings between IMM-1-104 and chemotherapy in pancreatic cancer models. Market implications could include increased investor confidence and potential growth in biotech investments.,globenewswire_biotech,biotech,Clinical Study,292,IMRX,2024-04-09 16:00:00+00:00,US/Eastern,IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models,UP,0.021002527015272974,en
16666,RAPT,https://www.google.com/finance/quote/RAPT:NASDAQ,RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients,https://www.globenewswire.com/news-release/2024/04/09/2860241/0/en/RAPT-Therapeutics-Announces-Promising-Results-from-Phase-2-Trial-of-Tivumecirnon-in-Combination-with-Anti-PD-1-Immunotherapy-in-CPI-Experienced-Head-and-Neck-Cancer-Patients.html,2024-04-09 12:00:00+00:00,RAPT Therapeutics,clinical_study,"The predicted upward move of +3.41% likely stems from the positive ORR of 15.6% regardless of PD-L1 or HPV status, indicating broad efficacy. This could boost investor confidence, leading to increased valuations and potential market interest.",globenewswire_biotech,biotech,Clinical Study,360,RAPT,2024-04-09 16:00:00+00:00,US/Eastern,- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status,UP,0.03412208453662435,en
14987,ICCC,https://www.google.com/finance/quote/ICCC:NASDAQ,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024",https://www.globenewswire.com/news-release/2024/04/09/2860349/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q1-2024.html,2024-04-09 16:05:00+00:00,ImmuCell Corporation,earnings_releases_and_operating_results,"The predicted downward move of -1.31% is likely due to disappointing preliminary sales results. This could indicate weaker demand or operational challenges, impacting investor confidence and potentially putting pressure on share prices and profitability expectations in the short term.",globenewswire_biotech,biotech,Stock Market News,274,ICCC,2024-04-09 20:05:00+00:00,US/Eastern,"PORTLAND, Maine, April  09, 2024  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.",UP,-0.013137510261207715,en
15653,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,"Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference",https://www.globenewswire.com/news-release/2024/04/09/2860366/0/en/Certara-to-Report-First-Quarter-2024-Financial-Results-on-May-7th-2024-and-Participate-in-the-BofA-Securities-Healthcare-Conference.html,2024-04-09 16:15:00+00:00,Certara,financial_results,"Certara's predicted upward move of +0.88% is likely due to positive anticipation of their financial results release. This could enhance investor confidence, potentially boosting market valuation and attracting more investments in the biosimulation sector.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,308,CERT,2024-04-09 20:15:00+00:00,US/Eastern,"PRINCETON, N.J., April  09, 2024  (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.",UP,0.00883715814090535,en
15476,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024,https://www.globenewswire.com/news-release/2024/04/09/2860387/0/en/IN8bio-Announces-New-Preclinical-Data-for-Gamma-Delta-nsCAR-T-Cell-Therapy-Platform-at-AACR-2024.html,2024-04-09 16:30:00+00:00,IN8bio,clinical_study,"1. The upward movement is likely due to promising new preclinical data for IN8bio's Gamma-Delta nsCAR-T cell therapy presented at AACR 2024, boosting investor confidence. 2. This predicted upward move of +1.46% could enhance investor interest and funding opportunities.",globenewswire_biotech,biotech,Clinical Study,298,INAB,2024-04-09 20:30:00+00:00,US/Eastern,IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024,UP,0.014630960096984091,en
15725,MLTX,https://www.google.com/finance/quote/MLTX:NASDAQ,MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions,https://www.globenewswire.com/news-release/2024/04/10/2860628/0/en/MoonLake-Immunotherapeutics-inks-three-year-technology-partnership-with-Komodo-Health-to-advance-research-on-inflammatory-skin-and-joint-conditions.html,2024-04-10 07:00:00+00:00,MoonLake Immunotherapeutics,partnerships,The predicted upward move of +0.01% is likely due to the strategic partnership enhancing MoonLake Immunotherapeutics' research capabilities. Market implications could include improved treatment options and competitive advantages in inflammatory skin and joint conditions.,globenewswire_biotech,biotech,Press releases,312,MLTX,2024-04-10 11:00:00+00:00,US/Eastern,MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions ,UP,0.00010394654341082384,en
16033,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia,https://www.globenewswire.com/news-release/2024/04/10/2860623/0/en/BioXcel-Therapeutics-Announces-TRANQUILITY-In-Care-Pivotal-Phase-3-Trial-Plan-With-BXCL501-for-Agitation-Associated-With-Alzheimer-s-Dementia.html,2024-04-10 07:00:00+00:00,BioXcel Therapeutics,clinical_study,"The likely cause of the predicted upward move of +8.93% is positive sentiment around the upcoming trial after the FDA meeting. This could increase investor confidence, potentially boosting stock demand and valuation.",globenewswire_biotech,biotech,Clinical Study,327,BTAI,2024-04-10 11:00:00+00:00,US/Eastern,Company plans to initiate trial following recent meeting with FDA,UP,0.08933378510105645,en
15697,ALERS.PA,https://www.google.com/finance/quote/ALERS.PA:NASDAQ,EUROBIO SCIENTIFIC: RESULTAT ANNUEL 2023,https://www.globenewswire.com/news-release/2024/04/10/2860950/0/fr/EUROBIO-SCIENTIFIC-RESULTAT-ANNUEL-2023.html,2024-04-10 11:40:00+00:00,Alers,earnings_releases_and_operating_results,"The predicted downward move of -0.35% could be due to weaker than expected financial performance or negative market sentiment. This may lead to reduced investor confidence and possible portfolio adjustments, influencing short-term asset valuations across related sectors.",globenewswire_biotech,biotech,European Regulatory News,310,ALERS.PA,2024-04-10 15:40:00+00:00,US/Eastern,RESULTAT ANNUEL 2023,UP,-0.0035458159080307616,fr
15698,ALERS.PA,https://www.google.com/finance/quote/ALERS.PA:NASDAQ,EUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS,https://www.globenewswire.com/news-release/2024/04/10/2860950/0/en/EUROBIO-SCIENTIFIC-2023-ANNUAL-RESULTS.html,2024-04-10 11:40:00+00:00,Alers,earnings_releases_and_operating_results,"The predicted downward move of -0.68% could be caused by weak earnings or negative market sentiment. This may lead to decreased investor confidence, potentially impacting the asset's pricing and market valuation.",globenewswire_biotech,biotech,European Regulatory News,310,ALERS.PA,2024-04-10 15:40:00+00:00,US/Eastern,2023 ANNUAL RESULTS ,UP,-0.006818949379364712,en
15959,OXUR.BR,https://www.google.com/finance/quote/OXUR.BR:NASDAQ,"Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up",https://www.globenewswire.com/news-release/2024/04/10/2861031/0/en/Oxurion-Receives-EUR-450-000-in-the-framework-of-the-Atlas-Funding-Program-Eleventh-tranche-fully-issued-and-paid-up.html,2024-04-10 13:00:00+00:00,Oxurion,financing_agreements,"The predicted upward move of +0.14% is likely due to Oxurion receiving EUR 450,000, boosting investor confidence. This funding can improve liquidity and operational stability, potentially attracting more investors and enhancing Oxurion's market position slightly.",globenewswire_biotech,biotech,Press releases,323,OXUR.BR,2024-04-10 17:00:00+00:00,US/Eastern,"Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up ",UP,0.0013964023836366846,en
14814,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,"Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024",https://www.globenewswire.com/news-release/2024/04/11/2861223/0/en/Addex-Therapeutics-to-Release-Full-Year-2023-Financial-Results-and-Host-Conference-Call-on-April-18-2024.html,2024-04-11 01:00:00+00:00,Addex Therapeutics,earnings_releases_and_operating_results,1. The predicted upward move of +0.08% likely stems from anticipated positive insights in Addex's financial results and product pipeline updates. 2. This minor increase suggests limited immediate impact on market sentiment but may hint at long-term growth potential.,globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-04-11 05:00:00+00:00,US/Eastern,"Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.",UP,0.0008300971570668766,en
15296,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology,https://www.globenewswire.com/news-release/2024/04/11/2861358/0/en/Tiziana-Life-Sciences-Announces-Platform-Presentation-of-New-Quantitative-PET-Imaging-Data-on-Foralumab-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology.html,2024-04-11 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The predicted upward move of +2.36% is likely due to positive reception of new quantitative PET imaging data on Foralumab, signaling potential advancement in neurology. This development might increase investor confidence and drive enthusiasm for Tiziana Life Sciences' prospects.",globenewswire_biotech,biotech,Health,289,TLSA,2024-04-11 11:00:00+00:00,US/Eastern,Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology,UP,0.02356990249002295,en
14854,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,IMUNON Reports Compliance with Nasdaq Listing Requirements,https://www.globenewswire.com/news-release/2024/04/11/2861424/0/en/IMUNON-Reports-Compliance-with-Nasdaq-Listing-Requirements.html,2024-04-11 08:00:00+00:00,Imunon,exchange_announcement,"The likely cause of IMUNON's predicted upward move of +0.22% is regaining compliance with Nasdaq's listing standards. This could improve investor confidence, potentially increasing demand for the stock and ensuring continued liquidity on a reputable exchange.",globenewswire_biotech,biotech,Press releases,266,IMNN,2024-04-11 12:00:00+00:00,US/Eastern,"LAWRENCEVILLE, N.J., April  11, 2024  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.”",UP,0.002231143946515251,en
15849,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs,https://www.globenewswire.com/news-release/2024/04/11/2861470/0/en/NKGen-Biotech-Secures-Additional-Financing-of-5-Million-to-Continue-Advancing-Its-Clinical-Programs.html,2024-04-11 08:05:00+00:00,NKGen Biotech,clinical_study,The predicted upward move of +4.92% is likely due to positive progress in the neurodegenerative clinical program. Advancements in Alzheimer’s and Parkinson’s trials could boost investor confidence and increase the company's perceived future value.,globenewswire_biotech,biotech,Financing Agreements,318,NKGN,2024-04-11 12:05:00+00:00,US/Eastern,"The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation.",UP,0.04923580694034823,en
16634,CADL,https://www.google.com/finance/quote/CADL:NASDAQ,Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer,https://www.globenewswire.com/news-release/2024/04/11/2861549/0/en/Candel-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-CAN-2409-for-the-Treatment-of-Pancreatic-Cancer.html,2024-04-11 09:00:00+00:00,Candel Therapeutics,clinical_study,"The predicted upward move of +13.67% is likely due to the FDA granting Orphan Drug Designation to Candel's CAN-2409 for pancreatic cancer. This designation can boost investor confidence, potentially increasing stock value and attracting further investment.",globenewswire_biotech,biotech,Clinical Study,358,CADL,2024-04-11 13:00:00+00:00,US/Eastern,"NEEDHAM, Mass., April  11, 2024  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.",UP,0.13674009186305697,en
14871,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery,https://www.globenewswire.com/news-release/2024/04/11/2861621/0/en/First-Patient-Enrolled-in-LYNX-2-Phase-3-Study-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-PS-for-the-Treatment-of-Decreased-Visual-Acuity-Under-Low-Light-Conditions-Following.html,2024-04-11 10:03:00+00:00,Ocuphire Pharma,clinical_study,"The predicted downward move of -1.51% likely stems from market concerns over LYNX-2's agreement details with the FDA possibly indicating delays or regulatory hurdles. Investors may anticipate increased costs or extended timelines, potentially affecting short-term market sentiment.",globenewswire_biotech,biotech,Clinical Study,268,OCUP,2024-04-11 14:03:00+00:00,US/Eastern,LYNX-2 Follows SPA Agreement with FDA,DOWN,-0.015059826291657356,en
15958,OXUR.BR,https://www.google.com/finance/quote/OXUR.BR:NASDAQ,Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC,https://www.globenewswire.com/news-release/2024/04/11/2861766/0/en/Oxurion-Receives-Transparency-Notifications-from-Atlas-Special-Opportunities-LLC.html,2024-04-11 13:00:00+00:00,Oxurion,major_shareholder_announcements,"The predicted upward move of +0.40% is likely due to increased investor confidence following transparency notifications from Atlas Special Opportunities LLC. This can enhance market perceptions, potentially attracting more investors and improving liquidity for Oxurion.",globenewswire_biotech,biotech,Press releases,323,OXUR.BR,2024-04-11 17:00:00+00:00,US/Eastern,Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC ,UP,0.003978768282264022,en
14798,TTOO,https://www.google.com/finance/quote/TTOO:NASDAQ,T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity,https://www.globenewswire.com/news-release/2024/04/11/2861869/32489/en/T2-Biosystems-Shareholders-Vote-for-CRG-Debt-Conversion-into-Equity.html,2024-04-11 16:05:00+00:00,T2 Biosystems,changes_in_share_capital_and_votes,"The predicted downward move of +nan% may stem from dilution concerns as $15 million converts into equity, potentially increasing share count. This can lead to weaker per-share metrics and investor apprehension. Market implications include potential reduced demand for shares.",globenewswire_biotech,biotech,Financing Agreements,263,TTOO,2024-04-11 20:05:00+00:00,US/Eastern,"LEXINGTON, Mass., April  11, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for the approval of conversion of $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity.",UP,2.1755540525484314,en
15206,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica Reports Third Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2024/04/12/2862424/0/en/Biomerica-Reports-Third-Quarter-2024-Financial-Results.html,2024-04-12 19:23:00+00:00,Biomerica,financial_results,"The predicted upward move of +0.49% is likely due to positive financial results reported by Biomerica for Q3 fiscal 2024. This could enhance investor confidence and increase market demand for BMRA stock, bolstering the company's market position.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,285,BMRA,2024-04-12 23:23:00+00:00,US/Eastern,"IRVINE, Calif., April  12, 2024  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024.",UP,0.004924496704469272,en
15559,KBLB,https://www.google.com/finance/quote/KBLB:NASDAQ,Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk,https://www.globenewswire.com/news-release/2024/04/15/2862643/0/en/Kraig-Biocraft-Laboratories-Announces-Successful-Launch-of-Spring-Production-Trials-in-Southeast-Asia-for-Spider-Silk.html,2024-04-15 07:05:00+00:00,Kraig Biocraft Laboratories,press_releases,The predicted upward move of +1.84% is likely due to investor optimism about Kraig Biocraft Labs' new BAM-1 hybrid spring production trials meeting expectations and timelines. This can enhance market confidence and potentially attract more investment interest.,globenewswire_biotech,biotech,Product / Services Announcement,302,KBLB,2024-04-15 11:05:00+00:00,US/Eastern,"Kraig Biocraft Labs (OTCQB: KBLB) kicks off new BAM-1 hybrid spring production trials, on track to meet expectations and timeline",UP,0.01844015319487794,en
15393,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/15/2862657/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html,2024-04-15 07:30:00+00:00,TG Therapeutics,clinical_study,"The predicted upward move of +2.04% is likely due to positive data from the ULTIMATE I & II trials for BRIUMVI®, enhancing TG Therapeutics' prospects. This could increase investor confidence and potentially bolster the company's valuation in the biotech sector.",globenewswire_biotech,biotech,Clinical Study,294,TGTX,2024-04-15 11:30:00+00:00,US/Eastern,"NEW YORK, April  15, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024.",DOWN,0.020409250968665114,en
15205,BMRA,https://www.google.com/finance/quote/BMRA:NASDAQ,Biomerica provides update on inFoods® IBS expansion,https://www.globenewswire.com/news-release/2024/04/15/2862677/0/en/Biomerica-provides-update-on-inFoods-IBS-expansion.html,2024-04-15 07:47:00+00:00,Biomerica,geographic_expansion,"1. The predicted downward move of -0.51% likely stems from expansion-related costs. 2. This may lead to temporary investor caution and affect stock value. 3. However, long-term growth opportunities could eventually offset initial market skepticism.",globenewswire_biotech,biotech,Patents,285,BMRA,2024-04-15 11:47:00+00:00,US/Eastern,"- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas.",UP,-0.0050960138210290285,en
16454,RNAZ,https://www.google.com/finance/quote/RNAZ:NASDAQ,TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors,https://www.globenewswire.com/news-release/2024/04/15/2862824/0/en/TransCode-Therapeutics-Announces-FDA-Clearance-To-Initiate-Phase-1-2-Clinical-Trial-with-TTX-MC138-in-Patients-with-Advanced-Solid-Tumors.html,2024-04-15 09:00:00+00:00,TransCode Therapeutics,clinical_study,"The predicted upward move of +1.42% is likely due to FDA clearance for TransCode Therapeutics to begin trials, signaling progress. This could attract investor interest, enhance the company's valuation, and potentially lead to increased funding opportunities.",globenewswire_biotech,biotech,Health,349,RNAZ,2024-04-15 13:00:00+00:00,US/Eastern,TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors,UP,0.01424027460996282,en
16229,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT),https://www.globenewswire.com/news-release/2024/04/15/2862875/0/en/Immix-Biopharma-Announces-Late-Breaking-NXC-201-Clinical-Data-Abstract-Accepted-for-Oral-Presentation-at-the-27th-Annual-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-AS.html,2024-04-15 09:36:00+00:00,Immix Biopharma,clinical_study,"The predicted upward move of +3.97% is likely due to Immix Biopharma's NXC-201 data presentation at ASGCT, signaling potential breakthroughs. This could increase investor confidence, potentially boosting funding and collaborations in autoimmune therapies.",globenewswire_biotech,biotech,Calendar of Events,337,IMMX,2024-04-15 13:36:00+00:00,US/Eastern,"LOS ANGELES, April  15, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore May 7-11, 2024.",UP,0.03974063027642361,en
15957,OXUR.BR,https://www.google.com/finance/quote/OXUR.BR:NASDAQ,Publication Annual Report – Annual Shareholders' Meeting,https://www.globenewswire.com/news-release/2024/04/15/2862993/0/en/Publication-Annual-Report-Annual-Shareholders-Meeting.html,2024-04-15 11:16:00+00:00,Oxurion,annual_report,"The ""predicted downward move of +nan%"" may result from negative sentiment or poor earnings reported in the annual report. This could lead to decreased investor confidence, lowered stock prices, and potential volatility in related markets.",globenewswire_biotech,biotech,Press releases,323,OXUR.BR,2024-04-15 15:16:00+00:00,US/Eastern,Publication Annual Report – Annual Shareholders' Meeting,UP,-1.411039347343647,en
14770,ORIC,https://www.google.com/finance/quote/ORIC:NASDAQ,ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC,https://www.globenewswire.com/news-release/2024/04/15/2863166/0/en/ORIC-Pharmaceuticals-Announces-First-Patients-Dosed-Across-Three-Expansion-Cohorts-in-Phase-1b-Trial-of-ORIC-114-in-Patients-with-Mutated-NSCLC.html,2024-04-15 16:15:00+00:00,ORIC Pharmaceuticals,clinical_study,"The predicted upward move of +1.37% likely stems from optimism about ORIC-114's potential effectiveness in treating specific NSCLC mutations. Market implications could include increased investor interest and potential future collaborations or partnerships, enhancing asset value.",globenewswire_biotech,biotech,Clinical Study,262,ORIC,2024-04-15 20:15:00+00:00,US/Eastern,"Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations",UP,0.013725528339657001,en
15861,FARON.HE,https://www.google.com/finance/quote/FARON.HE:NASDAQ,Faron Confirms Plans for the Coming Months Under New Leadership,https://www.globenewswire.com/news-release/2024/04/16/2863289/0/en/Faron-Confirms-Plans-for-the-Coming-Months-Under-New-Leadership.html,2024-04-16 02:00:00+00:00,Faron Pharmaceuticals,clinical_study,The predicted upward move of +11.95% is likely due to the positive market response to Dr. Juho Jalkanen's CEO appointment. This could enhance investor confidence and potentially boost Faron's strategic growth and innovation in oncology.,globenewswire_biotech,biotech,Clinical Study,319,FARON.HE,2024-04-16 06:00:00+00:00,US/Eastern,"TURKU, Finland and BOSTON, April  16, 2024  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.",UP,0.11945125674926363,en
14611,ELOX,https://www.google.com/finance/quote/ELOX:NASDAQ,Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates,https://www.globenewswire.com/news-release/2024/04/16/2863493/0/en/Eloxx-Pharmaceuticals-Provides-ELX-02-and-ZKN-013-Program-Updates.html,2024-04-16 07:30:00+00:00,Eloxx Pharmaceuticals,licensing_agreements,"The predicted upward move of +2.23% is likely due to the FDA's Orphan Drug Designation, which can enhance investment interest through reduced approval hurdles and potential market exclusivity. This may attract more investors and boost ELX-02's stock value.",globenewswire_biotech,biotech,Clinical Study,254,ELOX,2024-04-16 11:30:00+00:00,US/Eastern,ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome,UP,0.022328070545038256,en
15652,CERT,https://www.google.com/finance/quote/CERT:NASDAQ,Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform,https://www.globenewswire.com/news-release/2024/04/16/2863576/0/en/Certara-Launches-Cloud-Platform-to-Further-Unify-its-End-to-End-Scientific-Software-Platform.html,2024-04-16 08:00:00+00:00,Certara,product_services_announcement,"The predicted upward move of +0.09% is likely due to improved user convenience and efficiency with the integrated Certara Cloud platform. This can enhance client retention and attract new users, positively impacting Certara's market positioning.",globenewswire_biotech,biotech,Product / Services Announcement,308,CERT,2024-04-16 12:00:00+00:00,US/Eastern,Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.,DOWN,0.0008905237471328566,en
15475,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference,https://www.globenewswire.com/news-release/2024/04/16/2864086/0/en/IN8bio-to-Present-at-Noble-Capital-Markets-Emerging-Growth-Virtual-Healthcare-Equity-Conference.html,2024-04-16 16:05:00+00:00,IN8bio,conference_call_webinar,"The predicted upward move of +0.47% is likely due to IN8bio's presentation at the Noble Capital Markets Conference, which may attract investor interest. This could increase market confidence, potentially boosting demand and enhancing the stock's visibility.",globenewswire_biotech,biotech,Calendar of Events,298,INAB,2024-04-16 20:05:00+00:00,US/Eastern,IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference,DOWN,0.004660087830191107,en
15057,EVAX,https://www.google.com/finance/quote/EVAX:NASDAQ,Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01,https://www.globenewswire.com/news-release/2024/04/17/2864434/0/en/Evaxion-Announces-Phase-2-Clinical-Trial-Update-First-Patient-Completed-Dosing-with-Personalized-Cancer-Vaccine-EVX-01.html,2024-04-17 08:00:00+00:00,Evaxion Biotech,clinical_study,"The predicted downward move of -3.30% might be due to investor concerns about trial results or competition. Negative sentiment can affect market confidence, impacting Evaxion's stock. Increased volatility and caution in TechBio investments might follow.",globenewswire_biotech,biotech,Clinical Study,277,EVAX,2024-04-17 12:00:00+00:00,US/Eastern,"COPENHAGEN, Denmark, April  17, 2024  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).",UP,-0.03301400569407153,en
14748,SNCE,https://www.google.com/finance/quote/SNCE:NASDAQ,Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment,https://www.globenewswire.com/news-release/2024/04/17/2864437/0/en/Science-37-Provides-Fully-Consented-Patients-to-Sites-to-Supplement-Enrollment.html,2024-04-17 08:00:00+00:00,Science 37,clinical_study,"Science 37's efficient patient recruitment boosts clinical trial success, likely causing the predicted upward move of +8.99%. This could enhance investor confidence, increasing funding and accelerating drug development timelines.",globenewswire_biotech,biotech,Product / Services Announcement,261,SNCE,2024-04-17 12:00:00+00:00,US/Eastern,Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.,DOWN,0.08992120676182846,en
15530,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates,https://www.globenewswire.com/news-release/2024/04/17/2864452/0/en/Windtree-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Key-Business-Updates.html,2024-04-17 08:00:00+00:00,Windtree Therapeutics,financial_results,"The predicted upward move of +0.97% is likely due to positive financial results and promising business updates from Windtree Therapeutics. This could enhance investor confidence, potentially increasing demand for shares and influencing broader market sentiment positively.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,301,WINT,2024-04-17 12:00:00+00:00,US/Eastern,"WARRINGTON, Pa., April  17, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.",UP,0.009669961207054907,en
16256,GTHX,https://www.google.com/finance/quote/GTHX:NASDAQ,"G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024",https://www.globenewswire.com/news-release/2024/04/17/2864613/0/en/G1-Therapeutics-to-Release-First-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-May-1-2024.html,2024-04-17 09:00:00+00:00,G1 Therapeutics,conference_call_webinar,1. The predicted upward move of +2.20% likely stems from investor optimism about G1 Therapeutics' anticipated positive financial results and business update. 2. It may signal increased confidence in the biotech sector and encourage further investment interest.,globenewswire_biotech,biotech,Conference Calls/ Webcasts,338,GTHX,2024-04-17 13:00:00+00:00,US/Eastern,"G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024",UP,0.022028092629284967,en
14813,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2024/04/18/2865088/0/en/Addex-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,2024-04-18 01:00:00+00:00,Addex Therapeutics,financial_results,1. The predicted upward move of +0.09% is likely due to favorable news or financial results disclosed in the Ad Hoc Announcement Pursuant to Art. 53 LR. 2. Market implications may include positive investor sentiment and slight adjustments in trading strategies.,globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-04-18 05:00:00+00:00,US/Eastern,Ad Hoc Announcement Pursuant to Art. 53 LR,UP,0.0009228061956517608,en
15766,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product,https://www.globenewswire.com/news-release/2024/04/18/2865256/0/en/Revive-Therapeutics-Announces-FDA-Acceptance-of-Meeting-Request-for-Long-COVID-Diagnostic-Product.html,2024-04-18 07:00:00+00:00,Revive Therapeutics,regulatory_filings,"The predicted upward move of +0.70% is likely due to the FDA's acceptance of Revive's meeting request, signaling potential progress in regulatory approval. This development could boost investor confidence, positively impacting Revive's market position and valuation.",globenewswire_biotech,biotech,Product / Services Announcement,314,RVVTF,2024-04-18 11:00:00+00:00,US/Eastern,"TORONTO, April  18, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions. The meeting date assigned by the FDA is June 7, 2024.",UP,0.006987081197211847,en
15392,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis,https://www.globenewswire.com/news-release/2024/04/18/2865236/8790/en/TG-Therapeutics-Awarded-National-Contract-by-the-Department-of-Veterans-Affairs-for-BRIUMVI-as-the-Preferred-Anti-CD20-for-Relapsing-Forms-of-Multiple-Sclerosis.html,2024-04-18 07:00:00+00:00,TG Therapeutics,business_contracts,"The predicted upward move of +1.46% is likely due to TG Therapeutics securing the VA contract, increasing BRIUMVI's market reach. This can enhance revenue, strengthen market position, and potentially boost investor confidence in the company's growth prospects.",globenewswire_biotech,biotech,Product / Services Announcement,294,TGTX,2024-04-18 11:00:00+00:00,US/Eastern,"NEW YORK, April  18, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).",UP,0.014607245292599427,en
15295,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology,https://www.globenewswire.com/news-release/2024/04/18/2865243/0/en/Tiziana-Life-Sciences-Announces-New-Quantitative-PET-Imaging-Data-on-Foralumab-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology.html,2024-04-18 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The likely cause of the predicted upward move of +5.73% is the positive study results showing that intranasal foralumab reduces microglial activation in MS patients. This could enhance investor optimism, potentially boosting market confidence in foralumab's future applications.",globenewswire_biotech,biotech,Health,289,TLSA,2024-04-18 11:00:00+00:00,US/Eastern,Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans,UP,0.0573154741389828,en
15391,TGTX,https://www.google.com/finance/quote/TGTX:NASDAQ,TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/18/2865285/8790/en/TG-Therapeutics-Announces-Additional-Data-Presentations-for-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html,2024-04-18 07:30:00+00:00,TG Therapeutics,clinical_study,"The predicted upward move of +2.55% for TG Therapeutics, Inc. is likely due to positive data presentations from Phase 3 trials of BRIUMVI® in RMS patients. This can enhance investor confidence and potentially boost the company's market position.",globenewswire_biotech,biotech,Clinical Study,294,TGTX,2024-04-18 11:30:00+00:00,US/Eastern,"NEW YORK, April  18, 2024  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below.",UP,0.025531455989386883,en
16523,IMMP,https://www.google.com/finance/quote/IMMP:NASDAQ,Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761,https://www.globenewswire.com/news-release/2024/04/18/2865336/0/en/Immutep-Appoints-Leading-Research-Institute-to-Conduct-First-in-Human-Phase-I-Study-of-IMP761.html,2024-04-18 08:00:00+00:00,Immutep,clinical_study,"The predicted downward move of -1.42% in ""Media Release"" may be due to negative news, poor earnings, or market sentiment shifts. This could lead to reduced investor confidence, lower trading volumes, and potential sector-wide impacts.",globenewswire_biotech,biotech,Press releases,352,IMMP,2024-04-18 12:00:00+00:00,US/Eastern,Media Release,UP,-0.014236987753821732,en
15529,WINT,https://www.google.com/finance/quote/WINT:NASDAQ,Windtree Therapeutics Announces Reverse Stock Split,https://www.globenewswire.com/news-release/2024/04/18/2865312/0/en/Windtree-Therapeutics-Announces-Reverse-Stock-Split.html,2024-04-18 08:00:00+00:00,Windtree Therapeutics,changes_in_share_capital_and_votes,"The reverse stock split may cause the predicted downward move of +nan% due to perceived financial instability. Market implications could include reduced investor confidence and potential liquidity issues, leading to decreased stock demand and volatility concerns.",globenewswire_biotech,biotech,Major shareholder announcements,301,WINT,2024-04-18 12:00:00+00:00,US/Eastern,"WARRINGTON, Pa., April  18, 2024  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time on April 19, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT” on April 22, 2024. At such time, the Company’s common stock will also commence trading under a new CUSIP number, 97382D 501.",UP,-5.145402611947445,en
14853,IMNN,https://www.google.com/finance/quote/IMNN:NASDAQ,IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101,https://www.globenewswire.com/news-release/2024/04/18/2865393/0/en/IMUNON-s-IND-Application-Cleared-to-Begin-Human-Testing-of-IMNN-101.html,2024-04-18 08:30:00+00:00,Imunon,clinical_study,The predicted upward move of +60.12% is likely due to investor optimism surrounding the innovative potential of the DNA-based vaccine technology. Market implications may include increased investor confidence and potential further funding for biotech advancements.,globenewswire_biotech,biotech,Press releases,266,IMNN,2024-04-18 12:30:00+00:00,US/Eastern,Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter,UP,0.6011949041028692,en
15748,RENB,https://www.google.com/finance/quote/RENB:NASDAQ,"Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care",https://www.globenewswire.com/news-release/2024/04/18/2865415/0/en/Renovaro-Inc-Proudly-Announces-the-Appointment-Of-Professor-Dr-Geert-Kazemier-as-the-Chairman-of-its-Scientific-Advisory-Board-A-Move-That-Heralds-a-New-Era-of-Innovation-and-Progr.html,2024-04-18 08:45:00+00:00,Renovacor,management_changes,The predicted downward move of -0.00% likely reflects market indifference or lack of immediate impact from the announcement. Potential market implications include investor skepticism about the immediate financial benefits of new leadership versus long-term innovation prospects.,globenewswire_biotech,biotech,Directors and Officers,313,RENB,2024-04-18 12:45:00+00:00,US/Eastern,"LOS ANGELES and AMSTERDAM, April  18, 2024  (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.",DOWN,-4.25673226620742e-05,en
15009,ONCT,https://www.google.com/finance/quote/ONCT:NASDAQ,Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer,https://www.globenewswire.com/news-release/2024/04/18/2865429/0/en/Oncternal-Announces-First-Patient-Dosed-in-Fourth-Cohort-of-Phase-1-2-Study-of-ONCT-534-for-the-Treatment-of-R-R-Metastatic-Castration-Resistant-Prostate-Cancer.html,2024-04-18 09:00:00+00:00,Oncternal Therapeutics,clinical_study,"The predicted upward move of +0.57% likely stems from positive sentiment around Oncternal dosing its fourth cohort in the prostate cancer study. This may boost investor confidence, potentially enhancing the company's market perception and future valuation prospects.",globenewswire_biotech,biotech,Clinical Study,275,ONCT,2024-04-18 13:00:00+00:00,US/Eastern,"SAN DIEGO, April  18, 2024  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fourth dosing cohort will receive ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the patients treated to date, including the third dose level of 160 mg ONCT-534 daily.",UP,0.0057149291021536056,en
16228,IMMX,https://www.google.com/finance/quote/IMMX:NASDAQ,Immix Biopharma on Track to Dose NXC-201 Patients in United States,https://www.globenewswire.com/news-release/2024/04/18/2865508/0/en/Immix-Biopharma-on-Track-to-Dose-NXC-201-Patients-in-United-States.html,2024-04-18 09:32:00+00:00,Immix Biopharma,clinical_study,"The predicted upward move of +6.35% for the asset could be due to strong earnings reports or favorable economic indicators. This may boost investor confidence and increase demand, potentially leading to broader market optimism and increased trading volumes.",globenewswire_biotech,biotech,Advisory,337,IMMX,2024-04-18 13:32:00+00:00,US/Eastern, ,DOWN,0.06349714450720628,en
14938,ORPHA.CO,https://www.nasdaqomxnordic.com/aktier/microsite?Instrument=CSE145804&name=Orphazyme&ISIN=DK0062502894,Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00,https://www.globenewswire.com/news-release/2024/04/18/2865515/0/en/Referat-Fra-Ordin%C3%A6r-Generalforsamling-Den-18-April-2024-Kl-15-00.html,2024-04-18 09:39:00+00:00,Orphazyme,annual_general_meeting,"The predicted upward move of +1.53% for Orphazyme A/S may be attributed to positive investor sentiment following their general meeting. This could lead to increased investor confidence, potentially boosting stock demand and enhancing market cap stability.",globenewswire_biotech,biotech,European Regulatory News,146,ORPHA.CO,2024-04-18 13:39:00+00:00,US/Eastern,"Orphazyme A/S har afholdt ordinær generalforsamling den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende dagsorden:",UP,0.015255719253113977,da
15848,NKGN,https://www.google.com/finance/quote/NKGN:NASDAQ,NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit,https://www.globenewswire.com/news-release/2024/04/18/2865818/0/en/NKGen-Biotech-Announces-Upcoming-Presentation-on-SNK01-NK-Cell-Therapy-in-Neurodegenerative-Disease-at-the-12th-Annual-Alzheimer-s-Parkinson-s-Drug-Development-Summit.html,2024-04-18 16:05:00+00:00,NKGen Biotech,clinical_study,The predicted upward move of +9.87% is likely due to the promising preclinical and clinical data on NKGen's NK cell therapy in neurodegenerative diseases. Positive trial results could enhance investor confidence and potentially increase market interest in NKGen's stock.,globenewswire_biotech,biotech,Product / Services Announcement,318,NKGN,2024-04-18 20:05:00+00:00,US/Eastern,"SANTA ANA, Calif., April  18, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit to be held in Boston, MA, from April 23–25, 2024.",UP,0.09865047397587577,en
14812,ADXN,https://www.google.com/finance/quote/ADXN:NASDAQ,Addex to Present at the Swiss Biotech Day 2024,https://www.globenewswire.com/news-release/2024/04/19/2865937/0/en/Addex-to-Present-at-the-Swiss-Biotech-Day-2024.html,2024-04-19 01:00:00+00:00,Addex Therapeutics,conference_call_webinar,The predicted upward move of +0.34% is likely due to anticipation of positive developments or partnerships discussed during CEO Tim Dyer's presentation. Potential implications include increased investor confidence and heightened interest in Addex Therapeutics' innovative drug development strategies.,globenewswire_biotech,biotech,European Regulatory News,264,ADXN,2024-04-19 05:00:00+00:00,US/Eastern,"Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.",DOWN,0.0034268168281838037,en
15294,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®,https://www.globenewswire.com/news-release/2024/04/19/2866076/0/en/Tiziana-Life-Sciences-Announces-Study-Results-from-Intranasal-Anti-CD3-Foralumab-in-Multiple-Sclerosis-Patients-with-PIRA-Highlighted-in-Neurology-Today.html,2024-04-19 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The predicted upward move of +7.47% likely results from positive Phase II trial data of intranasal foralumab, indicating efficacy in multiple sclerosis treatment. This could enhance investor confidence and potentially increase funding in similar biotech innovations.",globenewswire_biotech,biotech,Health,289,TLSA,2024-04-19 11:00:00+00:00,US/Eastern,"- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado -",UP,0.07468641540372738,en
16318,IOVA,https://www.google.com/finance/quote/IOVA:NASDAQ,Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2024/04/19/2866395/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html,2024-04-19 17:15:00+00:00,Iovance Biotherapeutics,corporate_action,"The predicted upward move of +0.23% is likely due to new employee stock options enhancing investor confidence in future growth. Market implications include increased trust in company expansion and potential for improved employee performance, benefiting Iovance’s strategic objectives.",globenewswire_biotech,biotech,Major shareholder announcements,342,IOVA,2024-04-19 21:15:00+00:00,US/Eastern,"SAN CARLOS, Calif., April  19, 2024  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees.",UP,0.002310372947825854,en
16032,BTAI,https://www.google.com/finance/quote/BTAI:NASDAQ,BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential,https://www.globenewswire.com/news-release/2024/04/22/2866727/0/en/BioXcel-Therapeutics-Announces-Plan-for-Evaluating-BXCL501-in-the-At-Home-Setting-to-Expand-Its-Market-Potential.html,2024-04-22 07:00:00+00:00,BioXcel Therapeutics,clinical_study,"1. The upward movement is likely due to positive FDA feedback and initiation of the Phase 3 trial, boosting investor confidence. 2. This predicted upward move of +17.28% could lead to increased investment and market interest in the company.",globenewswire_biotech,biotech,Clinical Study,327,BTAI,2024-04-22 11:00:00+00:00,US/Eastern,Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA,UP,0.1728001346885832,en
15293,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program,https://www.globenewswire.com/news-release/2024/04/22/2866733/0/en/Tiziana-Life-Sciences-Announces-Additional-Clinical-Improvements-Among-Multiple-Sclerosis-Patients-in-its-Expanded-Access-Program.html,2024-04-22 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The predicted upward move of +7.27% in Tiziana Life Sciences' stock is likely due to positive clinical trial results for foralumab in treating MS, indicating a promising new therapy. This could increase investor confidence and potentially boost funding or partnerships.",globenewswire_biotech,biotech,Health,289,TLSA,2024-04-22 11:00:00+00:00,US/Eastern,"NEW YORK, April  22, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients. The data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale (MFIS).",UP,0.07265455471573469,en
15558,KBLB,https://www.google.com/finance/quote/KBLB:NASDAQ,Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials,https://www.globenewswire.com/news-release/2024/04/22/2866741/0/en/Kraig-Biocraft-Laboratories-Successfully-Completes-Recombinant-Cocoon-Production-From-Spring-Trials.html,2024-04-22 07:05:00+00:00,Kraig Biocraft Laboratories,press_releases,"1. The likely cause is the completion of BAM-1 strain development exceeding expectations. 2. This achievement may boost investor confidence and market interest, leading to increased demand. 3. The predicted upward move of +1.98% reflects anticipated positive sentiment.",globenewswire_biotech,biotech,Management statements,302,KBLB,2024-04-22 11:05:00+00:00,US/Eastern,Kraig Labs (OTCQB: KBLB) achieves major milestone; completes new BAM-1 1st gen parental strain rearing and cocoons at rates that exceeded expectations,UP,0.01983652033024824,en
16277,INMB,https://www.google.com/finance/quote/INMB:NASDAQ,"INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with  Officers, Employees and Directors Purchasing Approximately 20% of the Offering",https://www.globenewswire.com/news-release/2024/04/22/2866810/0/en/INmune-Bio-Inc-Raises-Approximately-4-8-Million-in-Gross-Proceeds-Through-Registered-Direct-Offering-with-Officers-Employees-and-Directors-Purchasing-Approximately-20-of-the-Offeri.html,2024-04-22 08:00:00+00:00,INmune Bio,warrants_and_certificates,1. The predicted downward move of +nan% could be attributed to dilution concerns as new shares are issued. 2. Market implications may include decreased investor confidence due to the uncertain impact on share value following the offering.,globenewswire_biotech,biotech,Press releases,339,INMB,2024-04-22 12:00:00+00:00,US/Eastern,"Boca Raton, Florida, April  22, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price  that include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzhzimer’s Disease program (as further described  below).  The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”). The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company’s board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and  in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. ",UP,-4.352389160297799,en
14870,OCUP,https://www.google.com/finance/quote/OCUP:NASDAQ,Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/22/2866824/0/en/Ocuphire-Pharma-Announces-APX3330-Presentation-at-ARVO-2024-Annual-Meeting.html,2024-04-22 08:00:00+00:00,Ocuphire Pharma,clinical_study,"The predicted upward move of +1.01% is likely due to anticipation around Ocuphire's presentation on APX3330, potentially signaling positive developments. This could increase investor interest and confidence, impacting Ocuphire's stock and overall biotech sector sentiment positively.",globenewswire_biotech,biotech,Annual Meetings & Shareholder Rights,268,OCUP,2024-04-22 12:00:00+00:00,US/Eastern,"FARMINGTON HILLS, Mich., April  22, 2024  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington.",UP,0.010064026559881202,en
15256,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics Announces Reverse Stock Split,https://www.globenewswire.com/news-release/2024/04/22/2866891/0/en/Cidara-Therapeutics-Announces-Reverse-Stock-Split.html,2024-04-22 08:49:00+00:00,Cidara Therapeutics,corporate_action,"The predicted downward move of -3.80% is likely due to the reverse stock split, which often signals financial instability or attempts to meet listing requirements. Market implications include possible increased volatility and investor skepticism about Cidara's financial health.",globenewswire_biotech,biotech,Stock Market News,287,CDTX,2024-04-22 12:49:00+00:00,US/Eastern,"SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be 5 p.m. ET on April 23, 2024. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on April 24, 2024.",UP,-0.03798697820652341,en
15667,AKYA,https://www.google.com/finance/quote/AKYA:NASDAQ,"Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024",https://www.globenewswire.com/news-release/2024/04/22/2867199/0/en/Akoya-to-Report-First-Quarter-2024-Financial-Results-on-May-13th-2024.html,2024-04-22 16:05:00+00:00,Akoya Biosciences,earnings_releases_and_operating_results,"The predicted upward move of +0.01% is likely due to positive anticipation ahead of Akoya Biosciences' financial results release. This minor increase suggests stable or slightly improving market confidence, but minimal immediate impact on broader market trends is expected.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,309,AKYA,2024-04-22 20:05:00+00:00,US/Eastern,"MARLBOROUGH, Mass., April  22, 2024  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.",UP,7.89741474504378e-05,en
16330,CRSP,https://www.google.com/finance/quote/CRSP:NASDAQ,CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html,2024-04-22 16:30:00+00:00,CRISPR Therapeutics,conference_call_webinar,1. The predicted upward move of +0.67% is likely due to the anticipation of positive reception from CRISPR Therapeutics' presentation on their innovative lipid nanoparticle approach at the ASGCT meeting. 2. This could enhance investor confidence and increase interest in their gene-based therapies.,globenewswire_biotech,biotech,Health,343,CRSP,2024-04-22 20:30:00+00:00,US/Eastern,"ZUG, Switzerland and BOSTON, April  22, 2024  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.",DOWN,0.006671268250843485,en
16375,EDIT,https://www.google.com/finance/quote/EDIT:NASDAQ,Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting,https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html,2024-04-22 16:31:00+00:00,Editas Medicine,clinical_study,"The likely cause of the predicted upward move of +17.91% in Editas Medicine's stock is the acceptance of three abstracts for presentation at a prestigious annual gene therapy meeting, indicating promising pre-clinical data. This development suggests potential advancements in gene editing, possibly boosting investor confidence. Market implications could include increased interest and investment in gene editing technologies, potentially benefiting related biotech stocks.",globenewswire_biotech,biotech,Health,345,EDIT,2024-04-22 20:31:00+00:00,US/Eastern,"CAMBRIDGE, Mass., April  22, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.  ",UP,0.17910757967118598,en
15255,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice,https://www.globenewswire.com/news-release/2024/04/22/2867265/0/en/Cidara-Therapeutics-Announces-Receipt-of-Nasdaq-Delinquency-Notice.html,2024-04-22 17:06:00+00:00,Cidara Therapeutics,regulatory_filings,"The likely cause of the predicted downward move of -0.01% is Cidara's failure to timely file its annual report, raising delisting concerns. This could reduce investor confidence, potentially lowering liquidity and impacting future capital-raising efforts.",globenewswire_biotech,biotech,Stock Market News,287,CDTX,2024-04-22 21:06:00+00:00,US/Eastern,"SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K)  with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.",UP,-9.849036686651391e-05,en
15254,CDTX,https://www.google.com/finance/quote/CDTX:NASDAQ,Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/04/22/2867269/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,2024-04-22 17:10:00+00:00,Cidara Therapeutics,financial_results,"The predicted upward move of +0.49% for Cidara Therapeutics may be linked to their positive financial results and development progress in their drug-Fc conjugate immunotherapies. This can increase investor confidence, potentially leading to more investment in biotechnology stocks.",globenewswire_biotech,biotech,Earnings Releases and Operating Results,287,CDTX,2024-04-22 21:10:00+00:00,US/Eastern,"SAN DIEGO, April  22, 2024  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline.",UP,0.004919931622211439,en
15765,RVVTF,https://www.google.com/finance/quote/RVVTF:NASDAQ,Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID,https://www.globenewswire.com/news-release/2024/04/23/2867498/0/en/Revive-Therapeutics-Announces-Type-C-Meeting-Request-Granted-by-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html,2024-04-23 07:00:00+00:00,Revive Therapeutics,clinical_study,"The predicted upward move of +2.14% likely stems from FDA granting Revive Therapeutics a Type C meeting, signaling regulatory progress for Bucillamine as a long COVID treatment. This could enhance investor confidence and increase the company's valuation.",globenewswire_biotech,biotech,Clinical Study,314,RVVTF,2024-04-23 11:00:00+00:00,US/Eastern,"TORONTO, April  23, 2024  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The meeting date assigned by the FDA is June 9, 2024.",UP,0.02137906204062533,en
15292,TLSA,https://www.google.com/finance/quote/TLSA:NASDAQ,Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program,https://www.globenewswire.com/news-release/2024/04/23/2867512/0/en/Tiziana-Life-Sciences-Announces-FDA-Allowance-for-Additional-Twenty-Patients-to-be-Enrolled-in-the-Intranasal-Foralumab-Multiple-Sclerosis-Expanded-Access-Program.html,2024-04-23 07:00:00+00:00,Tiziana Life Sciences,clinical_study,"The likely cause of the predicted upward move of +8.77% is the FDA's approval to expand Tiziana's patient program, indicating progress in their drug development. This expansion could boost investor confidence, potentially leading to increased stock demand and market valuation.",globenewswire_biotech,biotech,Health,289,TLSA,2024-04-23 11:00:00+00:00,US/Eastern,"NEW YORK, April  23, 2024  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients.",UP,0.087723838451902,en
15812,RZLT,https://www.google.com/finance/quote/RZLT:NASDAQ,Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting,https://www.globenewswire.com/news-release/2024/04/23/2867607/0/en/Phase-2-RIZE-Study-Sub-Analyses-to-be-Presented-at-the-2024-Pediatric-Endocrine-Society-Annual-Meeting.html,2024-04-23 08:00:00+00:00,Rezolute,clinical_study,"The predicted upward move of +0.37% for Rezolute, Inc. likely stems from positive anticipation surrounding the presentation of their study results at a key medical conference, potentially leading to increased investor interest and confidence in their biopharmaceutical advancements.",globenewswire_biotech,biotech,Calendar of Events,316,RZLT,2024-04-23 12:00:00+00:00,US/Eastern,"REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.",UP,0.0037126071128171082,en
16276,INMB,https://www.google.com/finance/quote/INMB:NASDAQ,INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay,https://www.globenewswire.com/news-release/2024/04/23/2867596/0/en/INmune-Bio-Inc-Announces-24-Month-Stability-Validation-of-XPro-for-Phase-III-Readiness-and-Commercial-Supply-Chain-Modeling-Development-of-Novel-Immunogenicity-Assay.html,2024-04-23 08:00:00+00:00,INmune Bio,press_releases,"The predicted downward move of -0.47% for INmune Bio may be due to investor expectations already incorporating positive stability data, resulting in limited stock impact. Market implications include potential reevaluation of the company's market position and supply chain strategy.",globenewswire_biotech,biotech,Press releases,339,INMB,2024-04-23 12:00:00+00:00,US/Eastern,"Boca Raton, Florida, April  23, 2024  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is delighted to announce the successful completion of the extended stability validation for XProTM continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability. The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems. With this data, the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid-formulation drugs at 2-8C, which is routine across the pharmaceutical industry. The 24-month stability data confirms that XProTM can mirror these established supply chain strategies. ",UP,-0.004745255164771709,en
15363,OPGN,https://www.google.com/finance/quote/OPGN:NASDAQ,OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K,https://www.globenewswire.com/news-release/2024/04/23/2868142/35690/en/OpGen-Receives-Nasdaq-Notice-Regarding-Delayed-Form-10-K.html,2024-04-23 16:15:00+00:00,OpGen,regulatory_filings,"The predicted upward move of +0.14% may be due to investors' optimism about OpGen resolving its filing issues. Potential market implications include restored investor confidence if compliance issues are quickly addressed, reducing the risk of delisting concerns.",globenewswire_biotech,biotech,Regulatory information,293,OPGN,2024-04-23 20:15:00+00:00,US/Eastern,"ROCKVILLE, Md., April  23, 2024  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.",UP,0.001427839571188784,en
14689,PYPD,https://www.google.com/finance/quote/PYPD:NASDAQ,"PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024",https://www.globenewswire.com/news-release/2024/04/24/2868439/0/en/PolyPid-to-Report-First-Quarter-2024-Financial-Results-and-Operational-Highlights-on-May-8-2024.html,2024-04-24 07:00:00+00:00,PolyPid,earnings_releases_and_operating_results,"The predicted downward move of -0.01% could be due to anticipated negative sentiment or uncertainty ahead of PolyPid's earnings report. Market implications may include caution among investors, potentially causing minor fluctuations in trading volumes or short-term market responses.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,258,PYPD,2024-04-24 11:00:00+00:00,US/Eastern,"PETACH TIKVA, Israel, April  24, 2024  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.",UP,-8.65391709239566e-05,en
16522,IMMP,https://www.google.com/finance/quote/IMMP:NASDAQ,Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B,https://www.globenewswire.com/news-release/2024/04/24/2868564/0/en/Immutep-Announces-Positive-Preliminary-Topline-Results-from-TACTI-003-Cohort-B.html,2024-04-24 08:00:00+00:00,Immutep,clinical_study,"The predicted upward move of +13.08% for ""Media Release"" may be due to positive news, strong earnings, or strategic partnerships. This could boost investor confidence, increase demand, and potentially attract new investors, impacting market dynamics positively.",globenewswire_biotech,biotech,Press releases,352,IMMP,2024-04-24 12:00:00+00:00,US/Eastern,Media Release,UP,0.13075955432580133,en
15474,INAB,https://www.google.com/finance/quote/INAB:NASDAQ,IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting,https://www.globenewswire.com/news-release/2024/04/24/2868562/0/en/IN8bio-Announces-Oral-Presentation-at-the-Upcoming-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html,2024-04-24 08:00:00+00:00,IN8bio,clinical_study,"The predicted upward move of +2.06% for IN8bio likely stems from investor optimism about the company's advancements in gene and cell therapy, potentially enhancing its market position and leading to increased investor interest and confidence in future growth.",globenewswire_biotech,biotech,Conference Calls/ Webcasts,298,INAB,2024-04-24 12:00:00+00:00,US/Eastern,IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting,UP,0.02059512921165566,en
15113,SCPH,https://www.google.com/finance/quote/SCPH:NASDAQ,scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection,https://www.globenewswire.com/news-release/2024/04/24/2868561/0/en/scPharmaceuticals-Announces-First-Participant-Enrolled-in-Pivotal-Pharmacokinetic-Study-of-FUROSCIX-Auto-Injector-furosemide-80mg-mL-Injection.html,2024-04-24 08:00:00+00:00,scPharmaceuticals,clinical_study,"The predicted upward move of +8.10% likely results from optimism about FUROSCIX’s expanded delivery options enhancing treatment flexibility. This may boost market confidence, potentially increasing demand and positive investor sentiment, impacting healthcare sector dynamics.",globenewswire_biotech,biotech,Clinical Study,280,SCPH,2024-04-24 12:00:00+00:00,US/Eastern,FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor,DOWN,0.08101877015631753,en
